CANADA

COUR D'APPEL

PROVINCE DE QUÉBEC DISTRICT DE MONTRÉAL

C.A. N° :

C.S. N° : 500-06-000484-093

BAYER INC., personne morale ayant une place d'affaire au 1250, boul. René-Lévesque Ouest, bureau 2820, Montréal, district de Montréal, Québec, H3B 4W8, Canada

APPELANTE/Défenderesse

C.

JANIE GUINDON, domiciliée et résidant au 37, impasse Roger-Parizeau, Gatineau, district de Gatineau, Québec, J9H 0B9, Canada

-et-

GENEVIÈVE GLADU, domiciliée et résidant au 124, rue Léo-Gravelle, Vaudreuil-Dorion, district de Beauharnois, Québec, J7V 0B1, Canada

-et-

JULIEN LEBŒUF, domicilié et résidant au 124, rue Léo-Gravelle, Vaudreuil-Dorion, district de Beauharnois, Québec, J7V 0B1, Canada

INTIMÉS/Demandeurs

DEMANDE POUR PERMISSION D'APPELER D'UN JUGEMENT QUI AUTORISE L'EXERCICE D'UNE ACTION COLLECTIVE (Articles 357 et 578 C.p.c.) Partie Appelante Datée du 5 septembre 2018

À L'UN DES HONORABLES JUGES DE LA COUR D'APPEL, LA PARTIE APPELANTE EXPOSE CE QUI SUIT :

- L'appelante Bayer Inc. (« Bayer ») demande la permission d'en appeler d'un jugement de la Cour supérieure rendu le 26 juillet 2018 par l'honorable Guylène Beaugé, J.C.S., siégeant dans et pour le district de Montréal, dans le dossier portant le numéro 500-06-000484-093 (le « Jugement » - Annexe 1)¹.
- 2. Le Jugement accueille en partie la Demande re-re modifiée pour obtenir l'autorisation d'exercer une action collective et pour obtenir le statut de représentants (la « Demande d'autorisation » - Annexe 2) de Janie Guindon, Geneviève Gladu et Julien Leboeuf (les « Intimés ») telle que modifiée verbalement lors de l'audience sur l'autorisation tel qu'il appert du procès-verbal d'audience du 30 janvier 2018 (Annexe 3).
- Plus précisément, le Jugement a autorisé l'exercice d'une action collective sous la forme d'une demande introductive d'instance en dommages et accordé aux Intimés le statut de représentants des personnes faisant partie du groupe suivant :

« Toutes les personnes résidant au Québec, incluant leurs successeurs, ayants droit, membres de leurs familles et personnes à charge, qui se sont fait prescrire et ont utilisé les médicaments YASMIN et/ou YAZ, depuis leur introduction respective sur le marché (10 décembre 2004 dans le cas de Yasmin et 6 janvier 2009 dans le cas de Yaz) et la date du 30 novembre 2011, et qui ont reçu un diagnostic de thrombose veineuse profonde, d'embolie pulmonaire, de thromboembolie artérielle ou de la maladie de la vésicule biliaire. » (le « Groupe »)

- Bayer joint en liasse comme Annexe 4 les pièces suivantes qui sont nécessaires à l'obtention de la permission d'en appeler recherchée :
 - a) déclaration sous serment amendée du Dr André Masse, MD, CSPA, FRCSC datée du 17 juin 2016 (la « Déclaration du Dr Masse ») déposée par Bayer;

¹ L'avis de jugement est daté du 9 août 2018.

- b) déclaration sous serment du Dr Steven A. Grover, MD, datée du 19 août 2016 (la « Déclaration du Dr Grover ») déposée par les Intimés;
- c) transcription de l'interrogatoire du Dr Grover tenu le 13 décembre 2016; et
- d) étude de M. Etminan *et al.* publiée en mai 2011 dans le Canadian Medical Association Journal (l'« étude Etminan ») (Pièce P-12).
- 5. Bayer est justifiée de demander la permission d'en appeler du Jugement puisqu'il comporte à sa face même des erreurs déterminantes concernant l'interprétation des conditions d'exercice de l'action collective et l'appréciation des faits relatifs à ces conditions.
- 6. En effet, Bayer soumet que la juge de première instance a commis des erreurs déterminantes en concluant que les Intimés avaient rencontré leur fardeau de démontrer qu'ils avaient une cause d'action personnelle soutenable et pouvaient donc agir à titre de représentants dans l'action collective proposée.
- 7. Plus particulièrement, les Intimés n'ont pas démontré de manière même *prima facie* que :
 - a) les problèmes de santé allégués de Mme Guindon et de Mme Gladu pouvaient avoir été causés par la prise de YAZ pour la première et de Yasmin pour la seconde, et donc que les faits apparaissaient justifier les conclusions recherchées au sens de l'article 575 (2°) du *Code de procédure civile* (le « *C.p.c.* »), alors que l'examen de leurs dossiers médicaux tant par le Dr Masse que par le Dr Grover ne supporte pas de telles conclusions;
 - b) Bayer avait failli à son devoir d'information à leur égard concernant les risques prétendument accrus de développer des maladies de la vésicule biliaire et donc que les faits apparaissaient justifier les conclusions recherchées au sens de l'article 575 (2°) *C.p.c.*, alors que la seule allégation de faits sur laquelle elles se fondent réfère à une étude publiée plusieurs années <u>après</u> que Mme Guindon et Mme Gladu aient consommé YAZ/Yasmin.

8. De plus, la juge de première instance a également commis des erreurs déterminantes en déclarant que Bayer avait consenti aux questions proposées comme étant identiques, similaires ou connexes (questions communes) portant sur la causalité individuelle et sur les dommages compensatoires, alors que ces questions ont été fortement contestées, et en les autorisant comme des questions appropriées au sens de l'article 575 (1°) *C.p.c.* alors qu'il ne s'agit pas, à leur face même, de questions pouvant être traitées collectivement.

I. CONTEXTE

- 9. La demande d'autorisation initiale dans le dossier portant le numéro 500-06-000484-093 a été déposée le 22 octobre 2009 par Mme Alexandra Paton contre Bayer et Bayer A.G., Berlex Canada Inc., Bayer Schering Pharma A.G., Bayer Corporation, Bayer Healthcare, LLC et Bayer Heatlhcare Pharmaceuticals Inc.
- 10. Cette demande initiale a été amendée une première fois en 2010, notamment afin d'ajouter trois demandeurs/représentants proposés (Mme Guindon, Mme Gladu et M. Serge Bouchard), une deuxième fois le 28 mai 2015 afin de retrancher Mme Paton et afin de retirer toutes les défenderesses à l'exception de Bayer, une troisième fois le 2 février 2017 afin de remplacer M. Bouchard par M. Lebœuf, conjoint de Mme Gladu, à titre de demandeur/représentant proposé, et une quatrième fois de manière verbale le 30 janvier 2018 lors de l'audience sur l'autorisation afin de modifier certaines des questions communes et des conclusions recherchées et d'accepter, de manière subsidiaire, la définition du groupe proposée par Bayer.
- 11. Mme Guindon allègue avoir développé des calculs biliaires en octobre 2009, s'être fait enlever la vésicule biliaire en novembre 2009, avoir subi une thrombose veineuse profonde en décembre 2009 et avoir subi des embolies pulmonaires en janvier 2010. Elle attribue ces problèmes de santé allégués à l'utilisation de YAZ, qu'elle aurait commencé à utiliser en août 2009.

3

- 12. Mme Gladu allègue avoir éprouvé des douleurs abdominales en juin 2009 et avoir été hospitalisée entre le 7 juin 2009 et le 7 juillet 2009 pour des calculs biliaires, pour se faire enlever la vésicule biliaire, pour des pancréatites et pour des embolies pulmonaires. Elle attribue ces problèmes de santé allégués à l'utilisation de Yasmin, qu'elle aurait commencé à utiliser en mars 2008.
- 13. M. Lebœuf, le conjoint de Mme Gladu, allègue quant à lui avoir souffert de dommages suite à l'hospitalisation de cette dernière.
- 14. L'action collective sous la forme d'une demande introductive d'instance en dommages compensatoires et punitifs repose sur la prétention que YAZ/Yasmin causeraient des risques accrus de thrombose artérielle, de thromboembolie veineuse et de maladie de la vésicule biliaire comparativement aux autres contraceptifs oraux (« COs ») disponibles. Les Intimés allèguent que Bayer aurait commis une faute en n'informant pas adéquatement les membres du Groupe et/ou leurs médecins de tels risques et en faisant des représentations trompeuses quant à la nature sécuritaire de YAZ/Yasmin, lesquels auraient causé des préjudices corporels, moraux et matériels aux membres du Groupe.

II. LES MOTIFS JUSTIFIANT D'ACCORDER LA PRÉSENTE DEMANDE

A. L'ABSENCE DE CAUSE D'ACTION PERSONNELLE SOUTENABLE DES INTIMÉS

- 15. À sa face même, le Jugement comporte des erreurs déterminantes quant à l'interprétation de la condition d'exercice d'une action collective prévue à l'article 575 (2°) *C.p.c.*, à savoir que les faits allégués dans la Demande d'autorisation, examinés à la lumière de la situation individuelle des Intimés, paraissent justifier les conclusions recherchées.
- 16. La juge de première instance a correctement reconnu que le critère de l'article 575
 (2°) C.p.c. devait s'examiner à la lumière de la situation individuelle des

représentantes proposées², soit de Mme Guindon et de Mme Gladu³, et que pour satisfaire ce critère, la réclamation des Intimés devait prendre appui sur plus que de simples possibilités. La réclamation ne doit pas non plus reposer sur des allégations erronées à la lumière de la preuve déposée de part et d'autre⁴.

- 17. Toutefois, elle a ensuite ignoré la preuve déposée par les deux parties démontrant clairement que les Intimés n'avaient pas de cause d'action personnelle soutenable, que les allégations ne reposaient que sur de simples possibilités, hypothèses ou soupçons ou encore sur des opinions et non des faits.
- 18. Tel que souligné récemment par cette Cour, au stade de l'autorisation, la partie demanderesse doit présenter une « cause soutenable », donc ayant « une chance de réussite », et pour ce faire, doit présenter en preuve « l'essentiel et l'indispensable » au soutient de cette cause⁵.

i. Quant à la causalité

- 19. En matière de responsabilité de produits pharmaceutiques, simplement alléguer au soutien d'une demande d'autorisation que l'on attribue ses problèmes de santé au produit en question relève de l'opinion et n'est pas un fait qui peut être tenu pour avéré par la Cour.
- 20. De plus, avoir une cause soutenable et présenter en preuve l'essentiel et l'indispensable ne peut respectueusement pas vouloir dire se contenter de déposer une déclaration sous serment d'un expert concluant que le risque de contribuer à certains problèmes de santé associés à la prise d'un médicament ne peut pas être considéré comme étant de <u>zéro</u>.

² Jugement, paragr. 19.

³ En tant que prétendue victime par ricochet, M. Lebœuf n'a quant à lui aucune cause d'action personnelle à faire valoir si Mme Gladu n'en a pas.

⁴ Jugement, paragr. 18.

⁵ Baratto c. Merck Canada inc., 2018 QCCA 1240, paragr. 51.

- 21. Si tel était le cas, toutes les demandes d'autorisation en matière de responsabilité de produits pharmaceutiques ou comportant une question de causalité reposant sur la science seraient nécessairement accordées. En effet, rares sont les cas dans le domaine de la santé où quiconque peut affirmer qu'un risque est de zéro. Une telle conclusion rendrait la nécessité de démontrer avoir une cause soutenable dénuée de tout fondement.
- 22. Or, en l'espèce, en ce qui concerne Mme Guindon, la juge de première instance a complètement écarté la preuve non contredite à l'effet que :
 - Mme Guindon présentait des facteurs de risques importants reliés au développement de calculs biliaires, soit l'obésité et l'usage du tabac⁶;
 - Seulement deux mois après le début de l'utilisation de YAZ, une échographie démontrait que le calcul biliaire de Mme Guindon était de 3,2 cm, de sorte qu'il était en formation bien avant le début de la prise de YAZ⁷;
 - Mme Guindon présentait des facteurs de risques importants de phénomènes thrombo-emboliques, soit des facteurs personnels tels que l'obésité, l'usage du tabac, un taux de cholestérol élevé et le fait d'être porteuse du facteur V de Leiden, lequel, à lui seul, augmente de sept fois le risque de phénomène thrombo-embolique⁸, et des facteurs circonstanciels tels que l'immobilisation, l'hospitalisation et la chirurgie⁹.
- 23. En réponse à la déclaration du Dr Masse, les Intimés ont déposé la déclaration du Dr Grover, un médecin généraliste qui a admis n'avoir aucune expertise clinique ou de recherche en matière de COs ou de maladies de la vésicule biliaire, et qui s'est dit en accord avec le Dr Masse quant aux facteurs de risques importants présentés par Mme Guindon. Il n'a pas conclu qu'il était probable ou même

⁶ Déclaration du Dr Masse, paragr. 7 et 15.

⁷ Déclaration du Dr Masse, paragr. 5 et 8.

⁸ Déclaration du Dr Masse, paragr. 15 à 17.

⁹ Déclaration du Dr Masse, paragr. 15 et 16.

vraisemblable que la prise de YAZ ait contribué aux problèmes de santé allégués par cette dernière. Au contraire, il a affirmé être d'accord que les autres facteurs de risques étaient plus vraisemblablement responsables de ses problèmes.

- 24. En effet, en ce qui concerne les phénomènes thrombo-emboliques de Mme Guindon, il s'est dit d'accord que leur cause première était son immobilisation et sa chirurgie dans les mois précédant leur survenance. Il a toutefois ajouté, sans expliquer pourquoi, qu'il ne pouvait pas conclure que la prise de YAZ n'ait pas contribué du tout (risque de zéro) au risque thrombo-embolique, tout en précisant qu'il ne s'agirait que d'un rôle mineur si c'était le cas¹⁰.
- 25. Il s'est également dit d'accord que Mme Guindon présentait de nombreux facteurs de risques importants associés au développement de calculs biliaires. Cependant, il a encore une fois ajouté qu'il ne pouvait pas conclure que le risque de contribution de YAZ était de zéro. Il n'a fourni aucune explication basée sur les dossiers médicaux de Mme Guindon pour soutenir ce point de vue, mais s'est plutôt appuyé uniquement sur une seule étude, soit l'étude Etminan qui conclut que ledit risque est mineur et non cliniquement significatif¹¹.
- 26. Avec respect, cela ne rencontre pas le fardeau de démonstration si peu élevé soitil de l'article 575 (2°) *C.p.c.* puisque le recours proposé de Madame Guindon fondé sur une telle affirmation n'a aucune chance de réussite. Il ne s'agit pas d'un cas ici où il y a un débat d'expert devant être tranché au mérite mais bien d'un cas où le fardeau minimum de démonstration n'est pas rencontré sur la foi même des allégations et de la preuve des Intimés.
- 27. Quant à Mme Gladu, la juge de première instance a également écarté la preuve non contredite à l'effet que :

¹⁰ Déclaration du Dr Grover, paragr. 7.

¹¹ Déclaration du Dr Grover, paragr. 8-13; étude Etminan (pièce P-12), pages 899 et 902; et interrogatoire du Dr Grover, page 38.

- Mme Gladu présentait des facteurs de risques importants reliés au développement de calculs biliaires, soit l'obésité, l'hypertriglycérédémie et un historique familial, lequel à lui seul double le risque¹²; et
- Mme Gladu présentait des facteurs de risques importants de phénomènes thrombo-emboliques, soit des facteurs personnels comme l'obésité, l'usage de COs depuis longtemps (Yasmin depuis 2008, mais Triphasil puis Alesse depuis 2005) et des facteurs circonstanciels tels que, l'immobilisation, l'hospitalisation et la chirurgie¹³.
- 28. Encore une fois, le Dr Grover s'est dit en accord avec le Dr Masse quant aux facteurs de risques importants présentés par l'historique de Mme Gladu et n'a pas conclu qu'il était probable ou même vraisemblable que la prise de Yasmin ait contribué à ses problèmes de santé allégués. Au contraire, il a conclu que le phénomène thrombo-embolique de Mme Gladu subi pendant son hospitalisation avait vraisemblablement été causé par son immobilisation et son inflammation, mais a ajouté qu'il ne pouvait pas conclure que le risque de développer des calculs biliaires relié à la prise de Yasmin était de <u>zéro</u> dans son cas et ce, toujours en se basant uniquement sur l'étude Etminan¹⁴.
- 29. Encore une fois, avec égard, cela ne rencontre pas le fardeau de démonstration si peu élevé soit-il de l'article 575 (2°) *C.p.c*.

ii. Quant au devoir d'information en ce qui concerne la vésicule biliaire

30. Tel que reconnu par cette Cour, afin de démontrer avoir une cause soutenable relativement à un défaut d'information, encore faut-il avoir une allégation de fait

¹² Déclaration du Dr Masse, paragr. 7 et 22.

¹³ Déclaration du Dr Masse, paragr. 20, 21, 24 et 26.

¹⁴ Déclaration du Dr Grover, paragr. 14 à 16.

pouvant être tenue pour avérée à l'effet que l'information existait et n'a pas été divulguée au moment de la consommation du produit¹⁵.

- 31. Or, la juge de première instance a aussi commis une erreur déterminante en écartant le fait que la seule allégation portant sur le défaut d'information concernant un prétendu risque accru de développer des maladies de la vésicule biliaire en lien avec l'utilisation de YAZ/ Yasmin, comparativement à d'autres COs, réfère à une étude publiée uniquement en mai 2011 (concluant par ailleurs que ce risque n'est pas cliniquement significatif), soit après la prise de YAZ par Mme Guindon en 2009 et de Yasmin par Mme Gladu en 2008 et 2009.
- 32. Il ne peut donc clairement pas y avoir une cause d'action soutenable fondée sur le devoir d'information quant au supposé risque accru de développer des maladies de la vésicule biliaire et ce risque n'aurait donc pas dû être inclus dans la définition du groupe ou les questions communes proposées.
- 33. À tout évènement, la juge n'a pas non plus tenu compte du fait que le risque en soi de développer des maladies de la vésicule biliaire en utilisant un CO était déjà divulgué dans les monographies de YAZ/Yasmin au moment où Mme Guidon et Mme Gladu ont utilisé ces COs, et qu'elles avaient admises toutes les deux avoir lu cette monographie et avoir été informées du risque.

B. L'AUTORISATION DE QUESTIONS QUI, À LEUR FACE MÊME, NE PEUVENT PAS FAIRE L'OBJET DE DÉTERMINATION COMMUNE

34. Le Jugement comporte également des erreurs déterminantes quant à la détermination des questions communes pouvant être autorisées conformément au critère de l'article 575 (1°) *C.p.*c. en identifiant comme questions à être traitées collectivement des questions qui, à leur face même, ne peuvent pas faire l'objet d'une détermination commune.

¹⁵ Baratto c. Merck Canada inc., 2018 QCCA 1240, paragr. 62.

- 35. Le Jugement indique faussement au paragraphe 41 que Bayer a consenti aux questions communes proposées portant sur la causalité individuelle et sur les dommages compensatoires alors que cette proposition a été fortement contestée.
- 36. En se basant sur ce « consentement » erroné, la Juge de première instance, sans procéder à quelqu'analyse que ce soit, a commis une erreur déterminante en les identifiant dans le Jugement comme faisant partie des principales questions de faits et de droits qui seront traitées collectivement.
- 37. Dans une action collective en matière pharmaceutique, il est de jurisprudence constante que l'octroi de dommages compensatoires exige, une fois que la faute et/ou le défaut de sécurité ont été établis, que le dommage et le lien de causalité entre les deux le soient également pour tous les membres du Groupe individuellement, le tout selon la prépondérance des probabilités et selon les règles de preuve habituelles¹⁶. Il n'est tout simplement pas possible d'éviter la tenue de procès individuels pour traiter de la causalité individuelle et des dommages.
- 38. En plus d'être inadéquates, l'identification de la causalité individuelle et des dommages compensatoires comme questions devant être déterminées collectivement à l'étape du procès sur les questions communes dans les avis aux membres induit ceux-ci en erreur. Ces derniers auront l'impression de n'avoir jamais à démontrer que leurs problèmes de santé ont bel et bien été causés par la prise de YAZ/Yasmin, ni à démontrer quels sont les dommages qu'ils ont réellement subis, alors que ce n'est clairement pas le cas.
- 39. Il est dans le meilleur intérêt de la justice que la présente demande soit accueillie.

¹⁶ Il n'y a pas de disposition légale similaire à l'article 15 de la *Loi sur le recouvrement du coût des soins de santé et des dommages-intérêts liés au tabac*, laquelle permet de faire la preuve du lien de causalité sur la base d'un rapport épidémiologique dans une action prise sur une base collective, qui soit applicable en l'espèce.

L'APPELANTE DEMANDERA À LA COUR D'APPEL :

ACCUEILLIR l'appel;

INFIRMER le jugement rendu par la Cour supérieure le 26 juillet 2018;

REJETER la Demande re-re modifiée pour obtenir l'autorisation d'exercer une action collective et pour obtenir le statut de représentants (*Re-Re-Amended Motion to authorize the bringing of a class action & to ascribe the status of representatives*) telle que modifiée verbalement lors de l'audience du 30 janvier 2018;

CONDAMNER les Intimés Janie Guindon, Geneviève Gladu et Julien Lebœuf aux frais de justice tant en première instance qu'en appel.

POUR CES MOTIFS, PLAISE À LA COUR :

ACCUEILLIR la présente demande;

ACCORDER à l'appelante la permission d'en appeler du jugement de la Cour supérieure rendu en date du 26 juillet 2018, par l'honorable Guylène Beaugé, J.C.S., siégeant dans le district de Montréal, dans le dossier portant le numéro 500-06-000484-093.

LE TOUT, frais à suivre selon le sort de l'appel.

MONTRÉAL, le 5 septembre 2018

Societé d'auxat TORYS SENIRL

SOCIÉTÉ D'AVOCATS TORYS S.E.N.C.R.L. AVOCATS DE L'APPELANTE BAYER INC. Me Sylvie Rodrigue srodrigue@torys.com Tél.: 514.868.5601 Me Marie-Ève Gingras mgingras@torys.com Tél.: 514.868.5607 Me Geneviève Bertrand gbertrand@torys.com Tél.: 514.868.5604 1 Place Ville Marie, Suite 2880 Montréal, Québec H3B 4R4 Fax: 514.868-5700 notifications-mtl@torys.com Code d'impliqué : BS-2554 Notre référence : 34506-2039

DÉCLARATION SOUS SERMENT

Datée du 5 septembre 2018

Je, soussignée, Marie-Ève Gingras, avocate, exerçant ma profession au sein de la Société d'avocats Torys S.E.N.C.R.L., au 1, Place Ville Marie, suite 2880, Montréal, district de Montréal, province de Québec, H3B 4R4, affirme solennellement ce qui suit :

- 1. Je suis l'une des procureures de l'Appelante Bayer Inc. dans la présente instance;
- 2. Tous les faits allégués à la présente demande sont vrais.

ET J'AI SIGNÉ

à Montréal, en ce 5^e jour de septembre 2018

minp

MARIE-ÈVE GINGRAS

Affirmé solennellement devant moi, à Montréal, ce 5^e jour de septembre 2018

Commissaire à l'assermentation pour le Québec



AVIS DE PRÉSENTATION

- À : Me Caroline Perreault Me Erika Provencher <u>caroline.perrault@siskindsdesmeules.com</u> <u>erika.provencher@siskindsdesmeules.com</u> <u>notification@siskindsdesmeules.com</u> <u>SISKINDS DESMEULES, AvocATS S.E.N.C.R.L.</u> <u>Avocats des Intimés – Demandeurs</u> 1430, boul. Saint-Martin Ouest. Suite 322 Laval (Québec) H7S 1M9
- Á : Janie Guindon
 Intimée Demanderesse
 37, impasse Roger-Parizeau
 Gatineau (Québec) J9H 0B9
- À: Geneviève Gladu
 Intimée Demanderesse
 124, rue Léo-Gravelle
 Vaudreuil-Dorion (Québec)
 J7V 0B1
- À: Julien Leboeuf
 Intimé Demandeur
 124, rue Léo-Gravelle
 Vaudreuil-Dorion (Québec)
 J7V 0B1

PRENEZ AVIS que la présente *Demande pour permission d'appeler d'un jugement qui autorise l'exercice d'une action collective* sera présentée pour décision le 15 novembre 2018, à 9h30, à l'un des juges de la Cour d'appel siégeant au Palais de Justice de Montréal, situé au 100, rue Notre-Dame Est, à Montréal, H2Y 4B6, dans la salle RC-18.

VEUILLEZ AGIR EN CONSÉQUENCE.

MONTRÉAL, le 5 septembre 2018

Société d'aucats TORYS SENCRL SOCIÉTÉ D'AVOCATS TORYS S.E.N.C.R.L.

AVOCATS DE L'APPELANTE BAYER INC. Me Sylvie Rodrigue srodrigue@torys.com Tél.: 514.868.5601 Me Marie-Ève Gingras mgingras@torys.com Tél.: 514.868.5607 Me Geneviève Bertrand gbertrand@torys.com Tél.: 514.868.5604 1 Place Ville Marie, Suite 2880 Montréal, Québec H3B 4R4 Fax: 514.868-5700 notifications-mtl@torys.com Code d'impliqué : BS-2554 Notre référence : 34506-2039

LISTE DES ANNEXES AU SOUTIEN DE LA DEMANDE POUR PERMISSION D'APPELER D'UN JUGEMENT QUI AUTORISE L'EXERCICE D'UNE ACTION COLLECTIVE

Partie Appelante Datée du 5 septembre 2018

- **ANNEXE 1 :** Jugement daté du 26 juillet 2018 rendu par l'honorable Guylène Beaugé, J.C.S.
- **ANNEXE 2 :** Demande re-re modifiée pour obtenir l'autorisation d'exercer une action collective et pour obtenir le statut de représentants (*Re-Re-Amended Motion to authorize the bringing of a class action & to ascribe the status of representatives*).
- **ANNEXE 3:** Procès verbal d'audience daté du 30 janvier 2018.
- **ANNEXE 4 :** 1. Déclaration sous serment amendée du Dr André Masse, MD, CSPA, (*en liasse*) FRCSC datée du 17 juin 2016;
 - Déclaration sous serment du Dr Steven A. Grover, MD, datée du 19 août 2016;
 - **3.** Transcription de l'interrogatoire du Dr Steven A. Grover tenu le 13 décembre 2016;
 - **4.** L'étude de M. Etminan *et al.* publiée en mai 2011 dans le *Canadian Medical Association Journal* (Pièce P-12).

MONTRÉAL, le 5 septembre 2018

Diete d'aucat TORYS SENCRU

SOCIÉTÉ D'AVOCATS TORYS S.E.N.C.R.L. AVOCATS DE L'APPELANTE BAYER INC. Me Sylvie Rodrigue srodrigue@torys.com Tél.: 514.868.5601 Me Marie-Ève Gingras mgingras@torys.com Tél.: 514.868.5607 Me Geneviève Bertrand gbertrand@torys.com Tél.: 514.868.5604 1 Place Ville Marie, Suite 2880 Montréal, Québec H3B 4R4 Fax: 514.868-5700 notifications-mtl@torys.com Code d'impliqué : BS-2554 Notre référence : 34506-2039

ANNEXE 1

COUR SUPÉRIEURE (Chambre civile)

CANADA PROVINCE DE QUÉBEC DISTRICT DE MONTRÉAL

N°: 500-06-000484-093

DATE : 26 JUILLET 2018

SOUS LA PRÉSIDENCE DE L'HONORABLE GUYLÈNE BEAUGÉ, J.C.S.

JANIE GUINDON -et-GENEVIÈVE GLADU -et-JULIEN BOUCHARD Demandeurs

с.

BAYER INC.

Défenderesse

JUGEMENT

sur une demande re-re-re-modifiée pour autorisation d'exercer une action collective et pour obtenir le statut de représentants

1. CONTEXTE

[1] Mesdames Janie Guindon et Geneviève Gladu, ainsi que monsieur Julien Leboeuf (les **DEMANDEURS**) demandent l'autorisation d'exercer une action collective contre Bayer inc. (**BAYER**) au nom du groupe suivant :

All persons residing in Quebec who were prescribed and ingested the drugs YASMIN and/or YAZ, from the respective introductions of these drugs into the market (December 10, 2004, in respect of Yasmin and January 6, 2009, in respect of YAZ) and the date of November 30, 2011, and their successors,

JB3984

assigns, family members, and dependants or any group to be determined by the Court.

[Traduction de la défenderesse : Toutes les personnes résidant au Québec qui se sont fait prescrire et ont utilisé les médicaments YASMIN et/ou YAZ, depuis leur introduction respective sur le marché (10 décembre 2004 dans le cas de Yasmin et 6 janvier 2009 dans le cas de Yaz) et la date du 30 novembre 2011, et leurs successeurs, ayants droit, membres de leurs familles et personnes à charge, ou tout autre groupe à être déterminé par la Cour.]

[2] Subsidiairement, ils consentiraient à la définition alternative suivante proposée par Bayer :

All persons residing in Quebec, including their successors, assigns, family members, and dependants, who were prescribed and ingested the drugs Yasmin and/or Yaz, from the respective introductions of these drugs into the market (December 10, 2004, in respect of Yasmin and January 6, 2009, in respect of YAZ) and the date of November 30, 2011, and who were diagnosed with deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease.

Toutes les personnes résidant au Québec, incluant leurs successeurs, ayants droit, membres de leurs familles et personnes à charge, qui se sont fait prescrire et ont utilisé les médicaments YASMIN et/ou YAZ, depuis leur introduction respective sur le marché (10 décembre 2004 dans le cas de Yasmin et 6 janvier 2009 dans le cas de Yaz) et la date du 30 novembre 2011, et qui ont reçu un diagnostic de thrombose veineuse profonde, d'embolie pulmonaire, de thromboembolie artérielle ou de la maladie de la vésicule biliaire.

[3] Dans ce recours en matière pharmaceutique, les demandeurs reprochent à Bayer diverses fautes dans la conception, la fabrication, la mise au point de la formule, la préparation, la transformation, l'inspection, les essais, l'emballage, la promotion, la mise en marché, la distribution, l'étiquetage ou la vente des contraceptifs oraux *Yasmin* et *Yaz*. Ils lui imputent des représentations trompeuses auprès de la communauté médicale et du public concernant la sécurité de ces contraceptifs.

[4] En outre, les demandeurs blâment Bayer de ne pas avoir adéquatement mis en garde la communauté médicale et le public contre les risques accrus des conséquences graves suivantes : thromboses, caillots, embolies pulmonaires, crises cardiaques, accidents vasculaires cérébraux, troubles et infections de la vésicule biliaire, insuffisance hépatique, insuffisance rénale, anxiété sévère, dépression, ainsi que mort subite.

- [5] Plus spécifiquement :
 - Mme Guindon allègue avoir développé des calculs biliaires en octobre 2009, et avoir subi une ablation de la vésicule biliaire en novembre 2009, une thrombose

veineuse profonde en décembre 2009, ainsi que des embolies pulmonaires en janvier 2010. Elle attribue ses problèmes de santé à l'utilisation de *Yaz*;

- Mme Gladu allègue avoir éprouvé des douleurs abdominales en juin 2009, et avoir été hospitalisée entre les 7 juin et 7 juillet 2009 pour des calculs biliaires, l'ablation de la vésicule biliaire, des pancréatites et des embolies pulmonaires. Elle attribue ses problèmes de santé à l'utilisation de Yasmin;
- M. Leboeuf, conjoint de Mme Gladu, allègue un préjudice moral comme suite à l'hospitalisation de celle-ci, à savoir le stress, des inquiétudes quant à son état de santé, ainsi que la peur de la perdre.

[6] Les demandeurs définissent comme suit les questions de faits et de droit identiques, similaires ou connexes dont ils recherchent la détermination¹ :

49. The recourses of the members raise identical, similar or related questions of fact or law, namely:

- a. Do Yasmin and/or YAZ cause an increased risk of arterial thromboembolism² (ATE), veneous thromboembolism³ (VTE), or gallbladder disease⁴ (GBD) compared to other available oral contraceptives?
- b. Was Bayer negligent and/or did it commit a fault and/or did it fail in its duty of safety, duty of care, and/or duty to inform imposed upon it as manufacturer, distributer and/or seller of Yaz and Yasmin?
- c. Do Yaz and Yasmin possess a superior efficacy over other contraceptives available on the market?
- d. Did Bayer knowingly, recklessly or negligently breach a duty to warn class members and/or their physicians of the risks of harm from the use of Yaz and Yasmin?
- e. Did Bayer knowingly, recklessly or negligently misrepresent to class members and/or their physicians the risks and benefits from the use of Yaz and Yasmin?
- f. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin were safe?

¹ Les demandeurs ont partiellement modifié les questions proposées le 30 janvier 2018.

² Thromboembolie artérielle (TEA).

³ Thromboembolie veineuse (TEV).

⁴ Maladie de la vésicule biliaire (MVB).

- g. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin had a superior efficacy over other contraceptions?
- h. In the affirmative to any of the above questions, did Bayer conduct engage its liability towards the members of the class?
- i. If the responsibility of the Bayer is established, what is the nature and the extent of damages and other remedies to which the members of the class can claim?
- j. Are members of the class entitled to bodily, moral, and material damages?
- k. Are members of the class entitled to recover the medical costs incurred in the screening, diagnosis and treatment of medical conditions caused by taking Yaz and Yasmin?
- I. Are the members of the class entitled to recover as damages an amount equal to the purchase price of Yaz and Yasmin or any part of the purchase price?
- m. Question retirée
- n. Are members of the class entitled to aggravated or punitive damages?

[7] Puis par jugement final sur l'action en dommages-intérêts, ils recherchent le versement de dommages-intérêts compensatoires et punitifs, ainsi que la restitution des profits tirés par Bayer de la vente de *Yasmin* et *Yaz* :

52. The conclusions that Petitioners wish to introduce by way of a motion to institute proceedings are:

GRANT the class action of Petitioners and each of the members of the class;

DECLARE the Respondent liable for the damages suffered by the Petitioners and each of the members of the class;

CONDEMN the Respondent to pay to each member of the class a sum to be determined in compensation of the damages suffered, and **ORDER** collective recovery of these sums;

CONDEMN the Respondent to reimburse to each of the members of the class, the purchase price of the product, and **ORDER** collective recovery of these sums;

CONDEMN the Respondent to pay to each of the members of the class, punitive damages, and **ORDER** collective recovery of these sums;

RESERVE the right of each of the members of the class to claim future damages related to the use of Yaz and Yasmin;

CONDEMN the Respondent to pay interest and additional indemnity on the above sums according to law from the date of service of the motion to authorize a class action;

ORDER the Respondent to deposit in the office of this court the totality of the sums which forms part of the collective recovery, with interest and costs;

ORDER that the claims of individual class members be the object of collective liquidation if the proof permits and alternately, by individual liquidation;

CONDEMN the Respondent to bear the costs of the present action including expert, notice fees and the fees relating to administering the plan of distribution of the recovery in this action;

RENDER any other order that this Honourable court shall determine and that is in the interest of the members of the class;

[8] Le litige s'étale du 10 décembre 2004 au 30 novembre 2011 dans le cas de *Yasmin*, et du 6 janvier 2009 au 30 novembre 2011 dans le cas de *Yaz*, soit la période écoulée entre d'une part, leur mise en marché respective au Canada, et d'autre part, la modification des monographies desdits contraceptifs oraux.

[9] Notons que deux actions collectives visant *Yaz* et *Yasmin* sont pendantes au Canada : la première certifiée le 15 avril 2013 par la Cour supérieure de justice de l'Ontario⁵, et la seconde, le 4 octobre 2016, par la Cour du Banc de la Reine de la Saskatchewan. Ce dernier recours consiste en une action de classe nationale, à l'exclusion de l'Ontario et du Québec⁶.

2. QUESTIONS EN LITIGE

[10] Le litige consiste à déterminer si la demande d'autorisation d'exercer une action collective satisfait les quatre conditions édictées à l'article 575 du *C.p.c.* :

575. Le tribunal autorise l'exercice de l'action collective et attribue le statut de représentant au membre qu'il désigne s'il est d'avis que: 1° les demandes des membres soulèvent des questions de droit ou de fait identiques, similaires ou connexes; 2° les faits allégués paraissent justifier les conclusions recherchées; 3° la composition du groupe rend difficile ou peu pratique l'application des règles sur le mandat d'ester en justice pour le compte d'autrui ou sur la jonction d'instance; 4° le membre auquel il entend attribuer le statut de représentant est en mesure d'assurer une représentation adéquate des membres.

⁵ Ann Schwoob et al v. Bayer Inc., 2013 ONSC 2207.

⁶ Dembrowski v. Bayer Inc., 2016 SKQB 324.

[11] Il s'agira également de décider, le cas échéant, s'il convient d'attribuer le statut de représentants aux demandeurs, ainsi que de définir le Groupe, les questions communes à traiter collectivement, et les conclusions qui s'y rattachent.

3. ANALYSE

[12] Deux grands principes encadrent l'application de l'article 575 *C.p.c* : 1) la procédure d'autorisation ne constitue pas une préenquête sur le fond; et 2) les critères de l'article 575 *C.p.c.* s'interprètent généreusement, tout doute devant profiter à l'autorisation⁷. Il s'agit en effet de favoriser l'objectif social de l'action collective, soit celui de permettre à des parties aux ressources limitées et aux réclamations souvent modestes d'obtenir réparation.

[13] Au stade de l'autorisation, le fardeau de la partie demanderesse consiste à établir une cause défendable⁸. À cette étape correspondant à un « mécanisme de filtrage et de vérification »⁹, le tribunal, écartant les demandes frivoles ou manifestement mal fondées, rend un jugement « de vérification et de contrôle ». En d'autres termes, la cour s'assure que les parties ne se retrouvent pas inutilement engagées dans un litige portant sur une demande insoutenable. Ainsi, à ce stade, le tribunal tranche une question procédurale, et ne se penche pas sur le fond du litige¹⁰.

[14] Par ce mécanisme de filtrage de l'article 575 *C.p.c.*, le tribunal s'assure de la qualité du syllogisme juridique proposé en demande, tout en gardant à l'esprit que le seuil de preuve qui, bien que peu élevé¹¹, doit néanmoins être franchi. Aussi, les allégations de la demande, tenues pour avérées, ne doivent pas se limiter à des généralités. Elles doivent s'articuler de manière suffisamment précise pour soutenir efficacement la reconnaissance du droit revendiqué¹².

[15] Bayer plaide que les conditions des alinéas 2 et 4 de l'article 575 *C.p.c.* ne sont pas satisfaites. Subsidiairement, elle fait valoir la nécessité de redéfinir le groupe, ainsi que de reformuler les conclusions recherchées.

⁷ Union des consommateurs c. Bell Canada, 2012 QCCA 1287, par. 117 (autorisation de pourvoi à la C.S.C. rejetée). Voir également : Infineon Technologies AG c. Option consommateurs, [2013] 3 R.C.S. 600, par. 60.

⁸ Infineon Technologies AG c. Option consommateurs, précité à la note 7, par. 61-67; Sofio c. Organisme canadien de réglementation du commerce des valeurs mobilières (OCRCVM), 2015 QCCA 1820, par. 26.

⁹ Pharmascience inc. c. Option Consommateurs, 2005 QCCA 437, par. 24.

¹⁰ Vivendi Canada Inc. c. Dell'Aniello, [2014] 1 RCS 3, par. 37.

¹¹ Infineon Technologies AG c. Option consommateurs, précité à la note 7, par. 59.

¹² Fortier c. Meubles Léon Itée, 2014 QCCA 195, par. 68-70. Option Consommateurs c. Bell Mobilité, 2008 QCCA 2201, par. 37-38; Infineon Technologies AG c. Option consommateurs, précité à la note 7, par. 69

PAGE:7

[16] Il convient de commencer l'analyse des critères d'autorisation par l'examen du recours personnel des demandeurs, cela pour vérifier la validité du syllogisme juridique proposé¹³.

3.1 Article 575, al. 2 *C.p.c.:* les faits paraissent justifier les conclusions recherchées

[17] Le paragraphe 2° de l'article 575 *C.p.c.* permet au tribunal d'écarter les actions frivoles ou manifestement mal fondées. Néanmoins, le pouvoir du tribunal demeure limité, s'apparentant au test de l'article 168, al. 2° *C.p.c.*¹⁴. Ainsi, l'expression « paraissent justifier » signifie qu'à l'examen de la demande, le tribunal doit pouvoir conclure à une apparence sérieuse de droit, sans se prononcer sur le fond du litige.

[18] Une apparence sérieuse de droit repose sur des allégations qui *prima facie* semblent bien fondées en regard des faits essentiels. Cette exigence ne sera pas satisfaite si la réclamation prend appui sur la simple probabilité que ces faits existent, ou sur des allégations mensongères ou qui paraissent manifestement mal fondées à la lumière d'une preuve positive au contraire¹⁵.

[19] Enfin, ce critère s'examine à la lumière de la situation individuelle de la personne désignée¹⁶.

[20] Mme Guidon allègue commencer à utiliser Yaz, en août 2009, à l'âge de 22 ans. En octobre suivant, elle est informée avoir développé des calculs biliaires. En novembre, elle subit une résection de la vésicule biliaire, en décembre, souffre d'une thrombose veineuse profonde, et le 1er janvier 2010, fait une embolie pulmonaire. Elle ajoute avoir utilisé Yaz conformément au mode d'emploi, avoir été en bonne santé avant la prise de ce contraceptif, et ne jamais avoir été informée des risques accrus liés à Yaz, un contraceptif de quatrième génération, par rapport aux contraceptifs de deuxième génération.

[21] Mme Gladu allègue commencer l'utilisation de *Yasmin* en 2004, à l'âge de 25 ans. En juin 2009, elle présente des douleurs abdominales, puis entre le 7 juin et le 7 juillet, elle est hospitalisée pour des calculs biliaires, la résection de la vésicule biliaire, une pancréatite et une embolie pulmonaire. Elle ajoute avoir été en bonne santé avant la prise de *Yasmin*, l'avoir consommé selon le mode d'emploi, et ne jamais avoir été informée des risques accrus liés à ce contraceptif de quatrième génération. À la suite de son hospitalisation, son conjoint et père de ses deux enfants, M. Leboeuf, a vécu

¹³ Lambert (Gestion Peggy) c. Écolait Itée, 2016 QCCA 659, par. 27-28.

¹⁴ Paris c. Lafrance, 2011 QCCS 4619, par. 48-49.

¹⁵Tonnelier c. Québec (Procureur général), 2012 QCCA 1654, par. 59.

¹⁶ Option Consommateurs c. Merck & Co. inc., 2013 QCCA 57, par. 25. Voir également : Abicidan c. Bell Canada, 2017 QCCS 1198, par. 11, et Robillard c. Société canadienne des postes, 2017 QCCS 2707, par. 14.

dans la crainte de la perdre, et est demeuré anxieux quant à sa santé à court et long terme.

[22] Bayer plaide que le recours ne satisfait pas le critère de l'apparence sérieuse de droit, car les demandeurs n'ont pas de cause d'action personnelle à faire valoir. Elle soutient qu'il ressort de l'analyse de leurs dossiers médicaux que d'une part, les problèmes de santé de Mmes Guidon et Gladu n'ont pas été causés par la prise de *Yaz* et *Yasmin*, et que d'autre part, celles-ci connaissaient les risques associés à la prise de ces contraceptifs oraux et présentaient des facteurs de risques importants.

[23] Bayer ajoute que les allégations de la demande relatives à des représentations trompeuses quant à l'efficacité ou aux avantages de ces contraceptifs ne sont ni supportées par la preuve *prima facie*, ni ne peuvent être tenues pour avérées en raison de leur imprécision. Enfin, elle argue que les allégations de faute concernant un défaut d'information ne justifient pas les conclusions recherchées, car 1) aucun fait allégué ne peut être tenu pour avéré concernant des prétendus risques accrus de crises cardiaques, accidents vasculaires cérébraux, insuffisance hépatique, insuffisance rénale, anxiété sévère, dépression et mort subite associés à la prise de *Yaz* et *Yasmin*, et 2) les demandeurs ne se sont pas déchargés de leur fardeau de démontrer que la divulgation des risques de thrombose veineuse profonde, caillots sanguins, embolie pulmonaire ou de troubles et infections de la vésicule biliaire était inadéquate.

[24] Le Tribunal a autorisé la production d'une preuve appropriée consistant notamment en des extraits des dossiers médicaux de Mmes Guindon et Gladu, et en leur interrogatoire sur leur situation personnelle, leurs antécédents médicaux, leurs troubles de santé, la nature des effets secondaires et du préjudice allégués, ainsi que les informations reçues concernant les risques et bénéfices respectifs des contraceptifs *Yaz* et *Yasmin*.

[25] Le Tribunal a aussi permis le dépôt des déclarations assermentées des Dr. André Masse et Steven A. Grover, experts respectifs de Bayer et des demandeurs.

[26] Quant à Mme Guindon, à la question de savoir si ses problèmes de santé allégués, soit « les calculs biliaires, la cholécystectomie (résection de la vésicule biliaire), la thrombose veineuse profonde et les embolies pulmonaires auraient été causés par la prise de *Yaz* », le Dr Masse répond ce qui suit:

19. Les contraceptifs oraux estro-progestatifs, quels qu'ils soient, augmentent le risque de base de phénomène thrombo-embolique de 2 à 3 fois. Le contraceptif *Yaz*, utilisé par la patiente, et contenant la drospirénone (progestatif de quatrième génération), ne modifie pas significativement ce risque comparativement aux autres contraceptifs oraux estro-progestatifs. Par ailleurs, tel que discuté, tous les facteurs de risque présents chez madame Guindon et

son historique médical personnel, influencent et augmentent individuellement et collectivement, son risque thrombo-embolique.¹⁷

[27] Pour sa part, le Dr Grover ne peut exclure les risques accrus de complications associés à la prise de *Yaz* :

7. I agree with Dr. Masse that the primary cause of the thrombophlebitis was the immobility and surgery during the previous month for the removal of her gall bladder. I cannot rule out that *Yasmin* (sic) increased the risk of this complication but would consider this a minor factor compared to those associated with the surgery.

[...]

10. While this increased risk may be small compared to the other risk factors this patient had for gallstones, it cannot be considered zero based on the largest study to date.

11. [...] I agree with Dr. Masse that only two months of Yasmin was unlikely to be the sole cause of the gallstones but one cannot rule out that it contributed to the development of symptomatic disease where the existing stones grew larger with the introduction of *Yasmin* (sic) and finally obstructed the gall bladder.¹⁸

[28] Pour ce qui est de Mme Gladu, à la question de savoir si ses problèmes de santé allégués, soit « les calculs biliaires, la pancréatite biliaire, la cholécystectomie (résection de la vésicule biliaire), et les embolies pulmonaires auraient été causés par la prise de *Yasmin* », le Dr Masse conclut comme suit:

26. Les contraceptifs oraux estro-progestatifs, quels qu'ils soient, augmentent le risque de base de phénomène thrombo-embolique de 2 à 3 fois. Tel que discuté, tous les facteurs de risque présents chez madame Gladu et son historique, influencent et augmentent individuellement et collectivement, son risque thrombo-embolique. Le contraceptif Yasmin, utilisé par la patiente, et contenant la drospirénone (progestatif de quatrième génération), ne modifie pas significativement ce risque comparativement aux autres contraceptifs oraux estro-progestatifs.¹⁹

[29] Dans ce cas également, le Dr Grover n'exclut pas les risques accrus par la prise de *Yasmin*:

15. As mentioned in the previous case, the thrombophlebitis that developed during her hospitalization for biliary obstruction and pancreatitis was probably

¹⁷ Déclaration sous serment modifiée du Dr André Masse, MD, CSPQ, FRCSC, datée du 17 juin 2016, à la page 5.

¹⁸ Déclaration sous serment du Dr Steven A. Grover, datée du 19 août 2016, aux pages 2 et 3.

¹⁹ Déclaration sous serment modifiée du Dr André Masse, MD, CSPQ, FRCSC, datée du 17 juin 2016, à la page 6.

due to the immobilization and inflammation associated with these conditions that required her admission in the first place.

16. Accordingly, I cannot agree with Dr. Masse that the choice of Yasmin did not play any role in her admission for gallstones and pancreatitis followed by thrombophlebitis several days later.²⁰

[30] La position de Bayer constitue une invitation à analyser minutieusement la preuve médicale, y compris des recherches et études contradictoires, à tirer des conclusions notamment sur le lien causal, et à considérer la valeur de ses moyens de défense pour rejeter la demande d'autorisation. Or, il faut résister à la tentation de se livrer à un tel exercice qui relève du fond de l'affaire²¹. Au stade de l'autorisation, le léger fardeau des demandeurs se limitait à démontrer le syllogisme juridique pour chacune des causes d'actions alléguées, et non à administrer une preuve prépondérante sur le lien causal²². Or, le Tribunal estime qu'ils ont atteint ce seuil minimal.

[31] La cause des demandeurs est défendable. La preuve déjà volumineuse, établit *prima facie* que Mmes Guindon et Gladu ont présenté un tableau médical qui semble compatible avec les risques accrus associés, dans certaines études, à la prise de *Yaz* ou *Yasmin*, et énoncés dans les monographies du 30 novembre 2011. En outre, leurs allégations voulant qu'elles n'aient pas été informées des risques accrus de développer des problèmes de santé n'apparaissent ni mensongères ni frivoles.

3.2 Article 575, al. 4 *C.p.c.* : la représentation adéquate des membres

[32] De façon générale, la personne qui se propose pour représenter le groupe doit satisfaire trois exigences : posséder un intérêt personnel à rechercher les conclusions proposées, détenir la compétence voulue pour agir comme mandataire, et ne pas se trouver en situation de conflit d'intérêts. Ces critères s'appliquent de manière libérale, le tribunal devant se garder de se montrer trop exigeant concernant la qualité du représentant²³. En effet, aucun représentant ne devrait être exclu à moins que son intérêt ou sa compétence s'avèrent à ce point lacunaires qu'ils mettent en péril la survie de l'action.

[33] Ainsi, le représentant adéquat ne se définit pas comme le « meilleur représentant », mais plutôt comme le justiciable moyen, de bonne foi, dont la réclamation personnelle s'avère valable et suffisamment fondée en droit, et qui agit dans l'intérêt des membres et au meilleur de ses capacités²⁴. L'évaluation de la

²⁰ Déclaration sous serment du Dr Steven A. Grover, datée du 19 août 2016, à la page 4.

²¹ Asselin c. Desjardins Cabinet de services financiers inc., 2017 QCCA 1673. Voir également : Groupe Vision New Look inc. c. Léveillé, 2018 QCCA 819, par. 6.

²² Pfizer inc. c. Sifneos, 2017 QCCA 1050, par 15-22. Voir également : Asselin c. Desjardins Cabinet de services financiers inc., précité à la note 21, par. 34ss.

²³ Infineon Technologies AG c. Option consommateurs, précité à la note 4, par. 149.

²⁴ Lavoie c. Saint-Mathieu-de-Beloeil (Corp. municipale de), J.E. 2002-586 (C.S.), par. 137.

compétence de cette personne ne devrait pas tenir compte de son assiduité aux audiences, de son niveau de connaissance du dossier judiciaire, ou encore de la qualité de ses réponses lors des interrogatoires préalables²⁵.

[34] En sus de son argument selon lequel les demandeurs n'ont pas de cause personnelle à faire valoir – ce qui les disqualifierait d'emblée comme représentants²⁶ – Bayer plaide qu'ils ne présentent pas la compétence requise pour agir à ce titre. En effet, elle reproche à Mme Guindon de n'avoir lu la demande d'autorisation qu'en 2015, soit cinq ans après son ajout comme représentante proposée, de ne pas avoir pris connaissance de sa version modifiée avant sa production à la Cour, et de n'avoir formulé aucun commentaire. Quant à Mme Gladu, elle n'aurait pris connaissance des pièces au soutien de la demande d'autorisation qu'en juillet 2016, peu avant son interrogatoire. De plus, Bayer souligne que les demandeurs n'ont effectué aucune démarche, n'ont pas échangé avec d'autres utilisatrices de *Yaz* ou *Yasmin*, et n'ont pas tenté de trouver d'autres membres du groupe proposé.

[35] De l'avis du Tribunal, les demandeurs se révèlent des représentants adéquats. Ils comprennent leur rôle, ainsi que les tenants et aboutissants de l'action proposée²⁷, se prêtent de bonne foi aux interrogatoires invasifs, dévoilent leur situation personnelle et médicale, se rendent disponibles pour l'audience sur l'autorisation, et ne sont pas en conflit d'intérêts. En outre, le fait que la demande ait été pilotée par leurs avocats, ou que les demandeurs s'en remettent à leur expertise, ne peut leur être reproché²⁸.

3.3 Article 575, al. 3 *C.p.c.* : la non-application des règles sur le mandat d'ester en justice pour le compte d'autrui ou sur la jonction d'instance

[36] L'action collective ne peut servir à contourner les exigences relatives au mandat pour ester en justice pour le compte d'autrui ou à la jonction d'instances. Bayer ne réfute pas le fait que cette condition soit remplie.

[37] La satisfaction de ce critère ne pose ici aucune difficulté. De toute évidence, la nature confidentielle des informations médicales des utilisatrices de *Yaz* et *Yasmin* rend difficile la tâche de trouver leurs noms et coordonnées. L'action collective s'avère donc indiquée dans le présent recours.

3.4 Article 575, al. 1 *C.p.c.*: les questions de droit ou de faits identiques, similaires ou connexes

[38] Décider si l'action soulève « des questions de droit ou de fait identiques, similaires ou connexes » consiste à déterminer si les réclamations des membres du

²⁵ Jasmin c. Société des alcools du Québec, 2015 QCCA 36, par. 43.

²⁶ Option Consommateurs c. Bell Mobilité, précité à la note 12.

²⁷ Lévesque c. Vidéotron, s.e.n.c., 2015 QCCA 205, par. 45.

²⁸ Sibiga c. Fido Solutions Inc., 2016 QCCA 1299, par. 101-102.

groupe présentent un dénominateur commun, soit s'il existe une ou plusieurs questions communes. Le seuil requis pour satisfaire ce critère s'avère peu élevé, et la présence d'une seule question de droit identique, similaire ou connexe suffit, malgré les circonstances variables d'un membre à l'autre, pourvu que son importance soit susceptible d'influencer le sort de l'action. Dans cet esprit, il faut se garder d'évaluer prématurément les moyens de défense.

[39] Connaissant les enseignements de l'arrêt *Vivend*i²⁹, Bayer s'en remet à la discrétion du Tribunal sur l'observance du critère des questions de droit ou de faits identiques, connexes ou similaires.

[40] En l'instance, les questions communes proposées s'attaquent aux prétendues fautes de Bayer d'une part dans la conception, l'élaboration de la formule, la fabrication, la transformation, la commercialisation, la promotion, l'inspection, l'emballage, la préparation, l'étiquetage, les essais, la distribution, la mise en marché et la vente de *Yaz* et *Yasmin*, et d'autre part, dans l'omission d'une mise en garde contre les risques accrus de conséquences graves, comprenant les thromboses, les caillots, les embolies pulmonaires, les crises cardiaques, les accidents vasculaires cérébraux, les troubles et infections de la vésicule biliaire, l'insuffisance hépatique, l'insuffisance rénale, l'anxiété sévère, la dépression, et la mort subite. Le Tribunal conclut, sans hésitation, que la condition des questions de droit ou de faits identiques, connexes ou similaires se trouve amplement satisfaite.

[41] Par ailleurs, Bayer soumet que si le Tribunal autorise l'action collective, les questions communes proposées au paragraphe 49 de la demande doivent être reformulées selon sa propre proposition. Elle fait valoir que :

- les questions sur la causalité générale et les fautes [par. 49a) à 49g) de la demande] sont redondantes, font appel à des notions de *common law*, ou portent sur des éléments non allégués de manière précise à la demande. À cet égard, elle signale les questions portant sur l'efficacité de *Yaz* et *Yasmin*, ainsi que sur les risques accrus concernant sept des onze problèmes de santé mentionnés;
- les questions sur la causalité individuelle et les dommages compensatoires [par. 49h) à 49l) de la demande] : Bayer y consent;
- la question sur la restitution des profits [par. 49m) de la demande] est inadéquate puisque ce remède n'est pas ouvert en droit québécois en matière de responsabilité civile extracontractuelle, comme en l'instance. Les demandeurs en conviennent et retirent cette question;
- la formulation de la question sur les dommages punitifs est inadéquate, parce qu'elle réfère à une notion inutile.

²⁹ Précité, à la note 10.

[42] Le recours des demandeurs se fonde sur la prétendue violation par Bayer de l'article 53 de la *Loi sur la protection du consommateur*³⁰, ainsi que des articles 1457, 1468, 1469 et 1473 *C.c.Q.* Pour l'essentiel, ils lui reprochent le défaut de s'être assurée de la nature sécuritaire de *Yaz* et *Yasmin*, le manque d'information adéquate sur les risques accrus de conséquences graves liées à leur utilisation à la différence d'autres contraceptifs oraux [par. 11, 11.2, 16.6, 16.10 et 20a) de la demande], ainsi que des représentations trompeuses sur leur efficacité et leur nature sécuritaire [par. 17, 19.1 à 19.7 et 20b) de la demande]. Seules les questions qui touchent à la théorie de la cause des demandeurs et qui renvoient à des allégations précises sur la causalité générale, les fautes, la causalité individuelle, ainsi que sur les dommages-intérêts compensatoires et punitifs seront retenues.

[43] Bayer a raison de proposer la radiation totale ou partielle de certaines questions, ou leur reformulation. Ainsi, la mention des caillots, des crises cardiaques, de l'insuffisance hépatique, de l'insuffisance rénale, de l'anxiété sévère, de la dépression, et de la mort subite dans les risques accrus de conséquences graves n'est pas pertinente, car aucune allégation précise de faits pouvant être tenus pour avérés ne supporte cet énoncé. Qui plus est, les demanderesses n'ont pas connu ces conséquences. De plus, la question de l'efficacité de *Yaz* et *Yasmin*, en comparaison avec d'autres contraceptifs oraux, ne fait pas l'objet d'une preuve et n'a pas été discutée.

[44] Aussi, le Tribunal **IDENTIFIE** comme suit les principales questions de faits et de droit qui seront traitées collectivement :

- 1) Est-ce que *Yasmin* ou *Yaz* causent des risques accrus de thrombose artérielle, de thromboembolie veineuse ou de maladie de la vésicule biliaire comparativement aux autres contraceptifs oraux disponibles?
- 2) Dans l'affirmative, Bayer a-t-elle commis une faute génératrice de responsabilité en n'informant pas adéquatement les membres du groupe et/ou leurs médecins des risques accrus liés à l'utilisation de *Yasmin* et/ou *Yaz*? Si oui, quand?
- 3) Bayer a-t-elle commis une faute génératrice de responsabilité en effectuant des représentations trompeuses auprès des membres du groupe et/ou de leurs médecins concernant la nature sécuritaire de *Yasmin* et/ou *Yaz*? Si oui, quand?
- 4) Les fautes reprochées à Bayer ont-elles causé des préjudices aux membres du Groupe?
- 5) Si la responsabilité de Bayer est établie, les membres du groupe ont-ils droit à des dommages-intérêts compensatoires corporels, moraux et matériels?

³⁰ RLRQ, Chapitre P-40.1.

- 6) Les membres du groupe ont-ils le droit de recouvrer les frais médicaux engagés pour le dépistage, le diagnostic et le traitement des problèmes médicaux causés par la prise de *Yasmin* et/ou *Yaz*?
- 7) Les membres du groupe ont-ils le droit de recouvrer à titre de dommages-intérêts un montant égal au prix d'achat de Yasmin et/ou Yaz ou à une partie du prix d'achat?
- 8) Les membres du groupe ont-ils droit à des dommages punitifs?

[45] Quant au groupe proposé, il convient de restreindre sa définition à celle que suggère Bayer, pour préciser que les seules utilisatrices de *Yaz* et *Yasmin* qui en seront membres seront celles qui ont reçu un diagnostic, par opposition à toutes les consommatrices. Les demandeurs consentent à cette précision.

[46] Enfin, quant aux conclusions recherchées, Bayer plaide que celles visant la restitution des profits et le recouvrement collectif de dommages compensatoires sont inadéquates. Les demandeurs répliquent qu'il est prématuré de décider, à ce stade-ci, du type de recouvrement. Ils ont raison³¹. En conséquence, le Tribunal retiendra les conclusions recherchées par les demandeurs, à l'exception de celle visant la restitution des profits.

POUR CES MOTIFS, LE TRIBUNAL :

[47] **ACCUEILLE** en partie la demande re-re-re-modifiée pour autorisation d'exercer une action collective;

[48] **AUTORISE** l'exercice de l'action collective sous la forme d'une demande introductive d'instance en dommages-intérêts;

[49] **ATTRIBUE** aux demandeurs Janie Guindon, Geneviève Gladu et Julien Leboeuf le statut de représentants aux fins d'exercer l'action collective pour le compte des personnes membres du groupe suivant :

Toutes les personnes résidant au Québec, incluant leurs successeurs, ayants droit, membres de leurs familles et personnes à charge, qui se sont fait prescrire et ont utilisé les médicaments *YASMIN* et/ou *YAZ*, depuis leur introduction respective sur le marché (10 décembre 2004 dans le cas de *Yasmin* et 6 janvier 2009 dans le cas de *Yaz*) et la date du 30 novembre 2011, et qui ont reçu un diagnostic de thrombose veineuse profonde, d'embolie pulmonaire, de thromboembolie artérielle ou de la maladie de la vésicule biliaire.

All persons residing in Quebec, including their successors, assigns, family members, and dependants, who were prescribed and ingested the drugs *Yasmin* and/or *Yaz*, from the respective introductions of these drugs into the market

³¹ Vermette c. General Motors du Canada Itée, 2008 QCCA 1793, par. 63.

(December 10, 2004, in respect of *Yasmin* and January 6, 2009, in respect of YAZ) and the date of November 30, 2011, and who were diagnosed with deep vein thrombosis, pulmonary embolism, arterial thromboembolism or gallbladder disease.

[50] **IDENTIFIE** comme suit les principales questions de faits et de droit qui seront traitées collectivement :

1) Est-ce que *Yasmin* ou *Yaz* causent des risques accrus de thrombose artérielle, de thromboembolie veineuse ou de maladie de la vésicule biliaire comparativement aux autres contraceptifs oraux disponibles?

2) Dans l'affirmative, Bayer a-t-elle commis une faute génératrice de responsabilité en n'informant pas adéquatement les membres du groupe et/ou leurs médecins des risques accrus liés à l'utilisation de *Yasmin* et/ou *Yaz*? Si oui, quand?

3) Bayer a-t-elle commis une faute génératrice de responsabilité en effectuant des représentations trompeuses auprès des membres du groupe et/ou de leurs médecins concernant la nature sécuritaire de *Yasmin* et/ou *Yaz*? Si oui, quand?

4) Les fautes reprochées à Bayer ont-elles causé des préjudices aux membres du Groupe?

5) Si la responsabilité de Bayer est établie, les membres du groupe ont-ils droit à des dommages-intérêts compensatoires corporels, moraux et matériels?

6) Les membres du groupe ont-ils le droit de recouvrer les frais médicaux engagés pour le dépistage, le diagnostic et le traitement des problèmes médicaux causés par la prise de *Yasmin* et/ou *Yaz*?

7) Les membres du groupe ont-ils le droit de recouvrer à titre de dommages-intérêts un montant égal au prix d'achat de *Yasmin* et/ou *Yaz* ou à une partie du prix d'achat?

8) Les membres du groupe ont-ils droit à des dommages punitifs?

[51] **IDENTIFIE** comme suit les conclusions recherchées qui s'y rattachent :

GRANT the class action of Petitioners and each of the members of the class;

DECLARE the Respondent liable for the damages suffered by the Petitioners and each of the members of the class;

CONDEMN the Respondent to pay to each member of the class a sum to be determined in compensation of the damages suffered;

CONDEMN the Respondent to reimburse to each of the members of the class, the purchase price of the product;

CONDEMN the Respondent to pay to each of the members of the class punitive damages;

CONDEMN the Respondent to pay interest and additional indemnity on the above sums according to law from the date of service of the motion to authorize a class action;

CONDEMN the Respondent to bear the costs of the present action including expert, notice fees and the fees relating to administering the plan of distribution of the recovery in this action;

RENDER any other order that this Honourable court shall determine and that is in the interest of the members of the class.

[52] **DÉCLARE** qu'à moins de demande d'exclusion, les membres du Groupe seront liés par tout jugement à intervenir sur l'action collective de la manière prévue à la loi;

[53] **FIXE** le délai d'exclusion à soixante (60) jours après la date de publication de l'avis aux membres, délai à l'expiration duquel les membres du Groupe qui ne se seront pas prévalus des moyens d'exclusion seront liés par tout jugement à intervenir sur l'action collective de la manière prévue à la loi;

[54] **DÉTERMINE** que l'action collective sera exercée dans le district judiciaire de Montréal;

[55] **CONVOQUE** les parties à une date à être fixée ultérieurement pour l'approbation de l'avis aux membres devant être publié conformément aux articles 579 *C.p.c.* et 581 *C.p.c.*

[56] FRAIS DE JUSTICE à suivre.

GUYLÈNE BEAUGÉ, j.c.s.

Me Samy Elnemr Ancien avocat des demandeurs Me Caroline Perrault, Me Erika Provencher Siskinds, Desmeules, Avocats, s.e.n.c.r.l Avocategdes demandeurs

Me Sylvie Rodrigue Me Marie-Eve Gingras Société d'avocats Torys, s.e.n.c.r.l. Avocates de la défenderesse

Dates d'audiences : 29 et 30 janvier 2018



CANADA

PROVINCE OF QUEBEC DISTRICT OF MONTREAL

NO: 500-06-000484-093

(Class Action) SUPERIOR COURT

JANIE GUINDON

and

GENEVIÈVE GLADU

and

JULIEN LEBOEUF

Plaintiffs

۷.

BAYER INC.

Defendant

RE-RE-AMENDED MOTION TO AUTHORIZE THE BRINGING OF A CLASS ACTION &TO ASCRIBE THE STATUS OF REPRESENTATIVES (Art. 1002 C.C.P. and following)

TO THE HONOURABLE JUSTICE OF THE SUPERIOR COURT, GUYLÈNE BEAUGÉ, SITTING IN AND FOR THE DISTRICT OF MONTREAL, YOUR PLAINTIFFS STATE AS FOLLOWS:

I. GENERAL PRESENTATION

A) The Action

1. Plaintiffs wish to institute a class action on behalf of the following group, of which they are members, namely:

«All persons residing in Quebec who were prescribed and ingested the drugs YASMIN and/or YAZ, from the respective introductions of these drugs into the market (December 10, 2004, in respect of Yasmin and January 6, 2009, in respect of YAZ) and the date of November 30, 2011 and their successors, assigns, family members, and dependents or any other group to be determined by the Court.»

B) The Defendant

2. [...];

- 3. Bayer Inc. ("Bayer") is a Federal corporation with its head office in Etobicoke, Ontario. Bayer is a wholly owned subsidiary of Bayer A.G. Bayer is involved in marketing, distribution and sale of healthcare and material science products and has a principal establishment in Montreal, the whole as appears from the Information sheet on the Registraire des entreprises du Quebec, a copy of which is produced herewith as Exhibit P-1. At all material times, Bayer was engaged in the business of designing, manufacturing, developing the formula for, preparing, processing, inspecting, testing, packaging, promoting, marketing, distributing, labelling, and/or selling for a profit, either directly or indirectly through an agent, affiliate, predecessor or subsidiary, Yasmin and Yaz in Canada. The development of Yasmin and Yaz for sale in Canada, the conduct of clinical studies, the preparation of regulatory applications, the maintenance of regulatory records, the labelling and promotional activities regarding Yasmin and Yaz, and other actions central to the allegations of this lawsuit, were undertaken by Bayer in Quebec and elsewhere;
- 4. [...];
- 5. [...];
- 5.1[...];
- 5.2[...];
- 5.3[...];
- 5.4[...];
- 5.5[...];
- 5.6[...];
- 6. [...];

C) The Situation

6.1 Yasmin and Yaz are oral contraceptives manufactured by Bayer, indicated in Canada for the prevention of pregnancy and treatment of moderate acne vulgaris in women (16 years of age or older for Yasmin and 14 years of age or older for Yaz) who have no known contraindications to oral contraceptive therapy, desire contraception, and have achieved menarche the whole as appears from the product monographs, copies of which are produced herewith as **Exhibit P-2** (Yasmin) and **Exhibit P-3** (Yaz);

- 6.2 Yasmin was approved by Health Canada on December 10th, 2004 and Yaz was approved by Health Canada in late 2008;
- 6.3 Yasmin and Yaz are two (2) of the largest selling contraceptives worldwide. Yasmin was the third most prescribed oral contraceptive in Canada in 2008. Worldwide sales of Yasmin and Yaz in 2008 were approximately \$1.8 billion;
- Yasmin and Yaz are combination oral contraceptives ("COCs"), meaning that they contain an estrogen component and a progestin component. Together, these steroidal components work together in COCs to suppress ovulation, fertilization, and implantation and thus prevent pregnancy;
- 8. [...];
- The estrogen component in Yasmin and Yaz is known generically as ethinyl estradiol. The progestin component is known as drospirenone. Yasmin contains 0.03 milligrams of ethinyl estradiol and Yaz contains 0.02 milligrams of ethinyl estradiol. Both drugs contain 3 milligrams of drospirenone;
- 10. The difference between Yaz / Yasmin and other birth control pills on the market is that drospirenone is a new type of progestin and is unlike any other on the market. Drospirenone is considered to be a fourth-generation progestin;

C.1) THE RISKS

- 11. Since Yasmin and Yaz contain the progestin drospirenone, they present additional health risks not associated with other birth control pills;
- 11.1 Drospirenone is a spironolactone analog and can cause elevation of potassium levels (hyperkalemia) and a decrease in sodium levels (hyponatremia) due to its potassium-sparing diuretic effects. Potassium is a key control in the electrical system of the heart and elevated levels can cause arrhythmias which can lead to stroke, deep vein thrombosis, pulmonary embolism, heart attack, or sudden death. Because drospirenone can act like a diuretic, it can also cause dehydration which can lead to kidney stones and gall bladder disease and/or removal;
- 11.2 Because drospirenone is used as the progestin component, the risk of suffering from stroke, deep vein thrombosis, pulmonary embolism, heart attack, or gall bladder disease and/or removal, is substantially higher

3

among women who use Yasmin or Yaz compared to women who use second generation oral contraceptives with a first or second generation progestin component;

- 12.[...];
- 13.[...];
- 14.[...];
- 15.[...];
- 16. Further, because of the combination of estrogen and drospirenone found in Yaz and Yasmin, they can affect a woman's hormonal level in a way that previous classes of birth control pills did not, and can also cause bouts of severe anxiety, depression and other mental health issues;
- 16.1 During the brief time that Yasmin and Yaz have been sold, hundreds of reports of injury and death have been reported to health regulatory agencies in association with these products;
- 16.2 On or about April 13th 2002, the British Medical Journal reported that the Dutch College of General Practitioners recommended that second generation birth control pills be prescribed in lieu of Yasmin, due to the adverse event reports of forty (40) women who experienced venous thrombosis associated with their use of Yasmin, the whole as appears from the British Medical Journal article dated April 13th, 2002, a copy of which is produced herewith as **Exhibit P-4**;
- 16.3 On or about February 1st, 2003, the British Medical Journal published a paper entitled *Thromboembolism Associated with the New Contraceptive Yasmin*. This paper stated that the Dutch spontaneous reporting system for adverse drug reactions received five (5) reports of thromboembolism (including death) as a suspected adverse drug reaction to the new oral contraceptive Yasmin, the whole as appears from the British Medical Journal paper dated February 1st, 2003, a copy of which is produced herewith as **Exhibit P-5**;
- 16.4 On or about August 13th 2009, the British Medical Journal published a study stating that oral contraceptives containing drospirenone (Yasmin and Yaz) carry a 6.3 times increased risk of deep vein thrombosis or pulmonary embolism. When compared to women taking some other type of birth control, the increased risk was nearly four (4) times more among users of Yasmin and Yaz, the whole as appears from the British Medical Journal study, a copy of which is produced herewith as **Exhibit P-6**;

- 16.5 Notwithstanding the well documented safety hazards associated with using Yasmin and Yaz, Bayer failed to conduct meaningful post-market surveillance;
- 16.6 Bayer aggressively marketed Yasmin and Yaz without adequately disclosing the increased safety hazards associated with using Yasmin and Yaz as compared to second generation oral contraceptives;
- 16.7 At all materials times, Bayer knew or should have known that the risks of using Yasmin and/or Yaz included severe and life threatening complications and side effects;
- 16.8 At all material times, Bayer, through its servants and agents, failed to adequately warn physicians and consumers, including the Plaintiffs and putative class members, that the risk of developing adverse events including stroke, deep vein thrombosis, pulmonary embolism, heart attack, gall bladder disease and/or removal, liver failure, kidney failure, severe anxiety, depression or sudden death associated with using Yasmin and/or Yaz is significantly higher compared to the risk of developing stroke, deep vein thrombosis, pulmonary embolism, heart attack, gall bladder disease liver failure, kidney failure, severe anxiety, depression or sudden death associated with the use of second generation oral contraceptives;
- 16.9 Bayer did not provide adequate safety data to Health Canada with respect to Yasmin and Yaz. Bayer knew or should have known that Yasmin and Yaz were unsafe, defective, unreasonably dangerous, and not fit for their intended purpose;
- 16.10 At all material times, Bayer, through its servants and agents, negligently and/or carelessly marketed, distributed and/or sold Yasmin and Yaz without adequate warnings of the products' serious side effects and unreasonably dangerous risks;
- 17. In addition, Bayer marketed Yasmin and Yaz as providing the same efficacy as other birth control pills in preventing pregnancy, but with additional benefits;
- 18. Bayer promoted Yaz as an oral contraceptive, which also reduced menstrual symptoms such as headaches, cramps and breast tenderness. In addition, Yaz is promoted as treating acne and counteracting water retention, resulting in less bloating;

19.[...];

SISKINDS, DESMEULES AVOCATS

- 19.1 The Food and Drug Association ("FDA") in the United States sent Bayer warning letters regarding their aggressive and controversial marketing efforts. Bayer has been warned at least three (3) times by the FDA, in 2003, 2008 and 2009, for misleading the public through the use of ads which overstate the efficacy of Yasmin and Yaz, and minimize serious risks associated with the drugs. Most recently, the FDA issued Bayer a warning letter for overstating Yaz' ability to improve womens' moods and clear up acne in television commercial advertisements. In addition, the FDA required Bayer to run a multi-million dollar television advertisement campaign to correct these misleading claims, as well as disclose the risks of hyperkalemia and other health problems associated with Yaz use. The FDA also directed Bayer to address false claims that Yasmin and Yaz were approved to treat Premenstrual Syndrome and all forms of acne, the whole as appears from the Food and Drug Administration letter dated March 26th, 2009, a copy of which is produced herewith as **Exhibit P-7**;
- 19.2 A Bayer press release dated January 20th, 2009, issued in Canada, which targeted "Gen Yers", states that Yaz may help reduce the symptoms experienced around the time of their period, although Yaz is not indicated for that use and has not been shown to be effective for that use. The press release includes a quote from a family physician stating "The availability of this new low-dose pill provides women with the benefits of reduced menstrual symptoms." Similar to the advertising in the U.S. that the FDA took issue with, the Canadian press release also states that Yaz treats acne, but does not specify the type of acne it is indicated to treat. The press release also states that Yaz was found to be safe and well tolerated without warning of the increased risks associated with Yaz use compared to second generation oral contraceptives, the whole as appears from the Bayer press release dated January 20th, 2009, a copy of which is produced herewith as **Exhibit P-8**;
- 19.3 On March 26th, 2010, Bayer announced it would be updating the Yasmin label in the European Union to include the results of recent epidemiological studies with respect to venous thromboembolism, the whole as appears from the Bayer press release dated March 26th, 2010, a copy of which is produced herewith as **Exhibit P-9**;
- 19.4 On April 7th, 2010, the FDA approved new label changes for Yasmin and Yaz in the United States with respect to the risk of blood clots, the whole as appears from the Bayer letter and labels of Yasmin and Yaz, a copy of which is produced herewith as **Exhibit P-10**;
- 19.5 In Bayer's Interim Report First Quarter of 2015, it is stated that as of April 2015, there were about 4,600 pending lawsuits and claims in the United States, excluding claims already settled, the total of which is not indicated, alleging personal injuries, some fatal, related to the use of

SISKINDS, DESMEULES ANOCATS

Yasmin and Yaz, the whole as appears from the Interim Report First Quarter of 2015 dated April 27th, 2015, a copy of which is produced herewith as **Exhibit P-11**;

- 19.6 On May 17th, 2011, a research paper published in the Canadian Medical Association Journal concluded that women using oral contraceptives containing drospirenone had a significantly increased risk of gallbladder disease, the whole as appears from the research paper published in the Canadian Medical Association Journal dated May 17th, 2011, a copy of which is produced herewith as **Exhibit P-12**;
- 19.7 On October 18th, 2012, an article published on the Science Daily web site referred to a Food and Drug Administration-funded study led by the Kaiser Permanente Northern California Division of Research which found an increased risk of arterial thrombotic events associated with drospirenone-containing birth control pills, the whole as appears from the Science Daily article dated October 18th, 2012, a copy of which is produced herewith as **Exhibit P-13**;
- 20. In view of the foregoing, Bayer has:
 - a) misrepresented information concerning the safety and efficacy of Yasmin and Yaz to the medical community and the public; and
 - b) failed to provide adequate warning to the medical community and the public about Yasmin and Yaz's increased risk of serious adverse events, including deep vein thrombosis, blood clots, pulmonary embolism, heart attacks, stroke, gallbladder problems and infections, liver failure, kidney failure, severe anxiety, depression, and sudden death;

II. FACTS GIVING RISE TO AN INDIVIDUAL ACTION BY THE PLAINTIFFS

- 21.[...];
- 22.[...];
- 23.[...];
- 24.[...];
- 25.[...];
- 26.[...];
- 27.[...];

SISKINDS, DESMEULES AVOCATE

28.[...];

29.[...];

- 30.[...];
- 31.[...];

32.[...];

33.[...];

Plaintiff Janie Guindon

- 33.1 On or about August 1st, 2009, Plaintiff Janie Guindon began using the oral contraceptive Yaz;
- 33.2 Plaintiff Janie Guindon was 22 years of age when she began using the oral contraceptive Yaz;
- 33.3 Plaintiff Janie Guindon used the oral contraceptive Yaz in accordance with the manner it was intended to be used;
- 33.4 Shortly after her first use of the oral contraceptive Yaz, on or about October 14th 2009, Plaintiff was told she had developed gallstones;
- 33.5 On or about November 14th, 2009, Plaintiff Janie Guindon had her gallbladder removed;
- 33.6 On or about December 30th, 2009, Plaintiff Janie Guindon suffered from deep vein thrombosis;
- 33.7 On or about January 1st, 2010, Plaintiff Janie Guindon suffered from multiple pulmonary embolism;
- 33.8 On or about January 1st, 2010, Plaintiff Janie Guindon stopped taking Yaz;
- 33.9 Plaintiff Janie Guindon was in good health prior to her use of Yaz;
- 33.10 In the period before and during the use of Yaz by the Plaintiff Janie Guindon, she received no or inadequate warnings about the increased risk of developing stroke, deep vein thrombosis, pulmonary embolism, heart attack, or gall bladder disease and/or removal associated with Yaz use as compared to the use of second generation oral contraceptives;

SISKINDS, DESMEULES AVOCATS

- 33.11 Plaintiff Janie Guindon would not have taken Yaz if Bayer had properly disclosed the true risks and benefits of taking this medication;
- 33.12 Plaintiff's damages are a direct and proximate result of her use of the drug Yaz, Bayer's negligence and/or fault and/or lack of adequate warnings, and Bayer's misrepresentations as to its efficacy;
- 33.13 In consequence of the foregoing, Plaintiff Janie Guindon is justified in claiming damages;

Plaintiffs Geneviève Gladu and Julien Leboeuf

- 33.14 Plaintiff Geneviève Gladu was prescribed the oral contraceptive Yasmin shortly after it was approved by health Canada in 2004;
- 33.15 Plaintiff Geneviève Gladu used the oral contraceptive Yasmin until June of 2009;
- 33.16 Plaintiff Geneviève Gladu used Yasmin in accordance with the manner it was intended to be used;
- 33.17 On or about June 2009, Plaintiff Geneviève Gladu experienced abdominal pains;
- 33.18 Between June 7th, 2009 and July 7th, 2009, when she was 30 years of age, Plaintiff Geneviève Gladu was hospitalized for gallstones, gallbladder removed, pancreatitis and pulmonary embolism;
- 33.19 On or about June 7th 2009, Plaintiff Geneviève Gladu stopped taking Yasmin;
- 33.20 Plaintiff Geneviève Gladu was in excellent health prior to her use of Yasmin;
- 33.21 In the period before and during the use of Yasmin by the Plaintiff Geneviève Gladu, she received no or inadequate warnings about the increased risk of developing stroke, deep vein thrombosis, pulmonary embolism, heart attack, or gall bladder disease and/or removal associated with Yasmin use as compared to use of second generation oral contraceptives;
- 33.22 Plaintiff Geneviève Gladu would not have taken Yasmin if Bayer had properly disclosed the true risks and benefits of taking this medication;

- 33.23 Plaintiff's damages are a direct and proximate result of her use of the drug Yasmin, Bayer's negligence and/or fault and/or lack of adequate warnings, and Bayer's misrepresentations as to its efficacy;
- 33.24 In consequence of the foregoing, Plaintiff Geneviève Gladu is justified in claiming damages;
- 33.24.1. Plaintiff Julien Leboeuf has been the partner of Plaintiff Geneviève Gladu for the past ten years;
- 33.24.2. Plaintiffs Julien Leboeuf and Geneviève Gladu have two children;
- 33.24.3. Following the hospitalization of Plaintiff Geneviève Gladu in 2009, as described above, Plaintiff Julien Leboeuf suffered damages such as stress, fear of losing his partner and worry about the short and long term health of his partner;

[...]

- 33.25 [...];
- 33.26 [...];
- 33.27 [...];
- 33.28 [...];
- 33.29 [...];
- 33.30 [...];
- 33.31 [...];
- 33.32 [...];
- 33.33 [...];
- 33.34 [...];

III. FACTS GIVING RISE TO AN INDIVIDUAL ACTION BY EACH OF THE MEMBERS OF THE GROUP

34. Every member of the class has either ingested and/or purchased Yaz and/or Yasmin or is the successor, family member, assign, and/or dependant of a person who purchased and/or ingested one of the aforementioned drugs;

- 35. The class members' damages would not have occurred but for the acts and/or omissions and/or fault of Bayer in failing to ensure that the drugs Yaz and Yasmin were safe for use, for failing to provide adequate warning of the risks associated with using them, and for over-promoting (and misrepresenting) their efficacy;
- 36. In consequence of the foregoing, each member of the class is justified in claiming at least one or more of the following as damages:
 - a. physical and mental injuries, including pain, suffering, anxiety, fear, loss of quality and enjoyment of life, and increased risk of health problems;
 - b. out-of-pocket expenses incurred or to be incurred, including those connected with hospital stays, medical treatment, life care, medications, medical monitoring services, and the diagnosis and treatment of Yaz and Yasmin side effect services;
 - c. loss of income and loss of future income;
 - d. refund of the purchase price of Yaz and Yasmin or alternately, the incremental costs of Yaz and Yasmin as paid for by class members;
 - e. disgorgement of all profits earned by Bayer from the sale of the drugs Yaz and Yasmin;
 - f. punitive damages;
- 37. As a direct result of the Bayer's conduct and/or fault, the users' family members, and dependants have, had, and/or will suffer damages and loss, including:
 - a. out of pocket expenses, including paying or providing nursing, housekeeping and other services;
 - b. loss of income and loss of future income;
 - c. loss of support, guidance, care, consortium, and companionship that they might reasonably have expected to receive if the injuries had not occurred;
- 38.[...];

SISKINDS, DESMEULES AVOCATS

39. All of these damages to the class members are a direct and proximate result of their use of the drug Yaz and/or Yasmin, Bayer's negligence and/or fault and/or lack of adequate warnings, and Bayer's misrepresentations as to its efficacy;

IV. CONDITIONS REQUIRED TO INSTITUTE A CLASS ACTION

A) The composition of the class renders the application of Articles 59 or 67 C.C.P. difficult or impractical

- 40. Plaintiffs are unaware of the specific number of persons who took and/or purchased these drugs, however, it is safe to estimate that it is in the tens of thousands (if not hundreds of thousands);
- 41. Class members are numerous and are scattered across the entire province;
- 42. Plaintiffs have no way of knowing the names and addresses of potential class members due to the confidential nature of medical and pharmacy records;
- 43. In addition, given the costs and risks inherent in an action before the courts, many people will hesitate to institute an individual action against Bayer. Even if the class members themselves could afford such individual litigation, the court system could not as it would be overloaded. Further, individual litigation of the factual and legal issues raised by the conduct of Bayer would increase delay and expense to all parties and to the court system;
- 44. Also, a multitude of actions instituted in different judicial districts, risks having contradictory judgements on questions of fact and law that are similar or related to all members of the class;
- 45. These facts demonstrate that it would be impractical, if not impossible, to contact each and every member of the class to obtain mandates and to join them in one action;
- 46. In these circumstances, a class action is the only appropriate procedure for all of the members of the class to effectively pursue their respective rights and have access to justice;
- B) The questions of fact and law which are identical, similar, or related with respect to each of the class members with regard to Bayer and that which the Plaintiffs wish to have adjudicated upon by this class action
- 47. Individual questions, if any, pale by comparison to the numerous common questions that predominate;
- 48. The damages sustained by the class members flow, in each instance, from a common nucleus of operative facts, namely, Bayer's misconduct;

- a. Do Yaz and Yasmin cause, exacerbate, or contribute to serious adverse events, including deep vein thrombosis, blood clots, pulmonary embolism, heart attacks, stroke, gallbladder problems and infections, liver failure, kidney failure, severe anxiety, depression, and sudden death?
- b. Was Bayer negligent and/or did it commit a fault and/or did it fail in its duty of safety, duty of care, and/or duty to inform imposed upon it as manufacturer, distributer and/or seller of Yaz and Yasmin?
- c. Do Yaz and Yasmin possess a superior efficacy over other contraceptives available on the market?
- d. Did Bayer knowingly, recklessly or negligently breach a duty to warn class members and/or their physicians of the risks of harm from the use of Yaz and Yasmin?
- e. Did Bayer knowingly, recklessly or negligently misrepresent to class members and/or their physicians the risks and benefits from the use of Yaz and Yasmin?
- f. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin were safe?
- g. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin had a superior efficacy over other contraceptions?
- h. In the affirmative to any of the above questions, did Bayer conduct engage its liability towards the members of the class?
- i. If the responsibility of the Bayer is established, what is the nature and the extent of damages and other remedies to which the members of the class can claim?
- j. Are members of the class entitled to bodily, moral, and material damages?
- k. Are members of the class entitled to recover the medical costs incurred in the screening, diagnosis and treatment of medical conditions caused by taking Yaz and Yasmin?

- I. Are the members of the class entitled to recover as damages an amount equal to the purchase price of Yaz and Yasmin or any part of the purchase price?
- m. Should Bayer be ordered to disgorge all or part of its ill-gotten profits received from the sale of Yaz and Yasmin?
- n. Are members of the class entitled to aggravated or punitive damages?
- 50. The interests of justice favour that this motion be granted in accordance with its conclusions;

V. NATURE OF THE ACTION AND CONCLUSIONS SOUGHT

- 51. The action that Plaintiffs wish to institute on behalf of the members of the class is an action in damages;
- 52. The conclusions that Plaintiffs wish to introduce by way of a motion to institute proceedings are:

GRANT the class action of Plaintiffs and each of the members of the class;

DECLARE the Defendant liable for the damages suffered by the Plaintiffs and each of the members of the class;

CONDEMN the Defendant to pay to each member of the class a sum to be determined in compensation of the damages suffered, and ORDER collective recovery of these sums;

CONDEMN the Defendant to reimburse to each of the members of the class, the purchase price of the product, and ORDER collective recovery of these sums;

CONDEMN the Defendant to pay to each of the members of the class, punitive damages, and ORDER collective recovery of these sums;

RESERVE the right of each of the members of the class to claim future damages related to the use of Yaz and Yasmin;

CONDEMN the Defendant to pay interest and additional indemnity on the above sums according to law from the date of service of the motion to authorize a class action;

ORDER the Defendant to deposit in the office of this court the totality of the sums which forms part of the collective recovery, with interest and costs;

ORDER that the claims of individual class members be the object of collective liquidation if the proof permits and alternately, by individual liquidation;

CONDEMN the Defendant to bear the costs of the present action including expert, notice fees and the fees relating to administering the plan of distribution of the recovery in this action;

RENDER any other order that this Honourable court shall determine and that is in the interest of the members of the class;

A) The Plaintiffs request the status of representative of the Class

- 53. Plaintiffs are members of the class;
- 54. Plaintiffs are ready and available to manage and direct the present action in the interest of the members of the class that they wish to represent and are determined to lead the present dossier until a final resolution of the matter, the whole for the benefit of the class, as well as, to dedicate the time necessary for the present action before the Courts of Quebec and the *Fonds d'aide aux recours collectifs*, as the case may be, and to collaborate with their attorneys;
- 55. Plaintiffs have the capacity and interest to fairly and adequately protect and represent the interest of the members of the class;
- 56. Plaintiffs have given the mandate to their attorneys to obtain all relevant information with respect to the present action and intend to keep informed of all developments;
- 57. Plaintiffs, with the assistance of their attorneys, are ready and available to dedicate the time necessary for this action and to collaborate with other members of the class and to keep them informed;
- 58. Plaintiffs are in good faith and have instituted this action for the sole goal of having their rights, as well as the rights of other class members recognized and protected so that they may be compensated for the damages that they have suffered as a consequence of the Bayer's conduct;
- 59. Plaintiffs understand the nature of the action;
- 60. The interests of the Plaintiffs are not antagonistic to those of other members of the class;

B) The Plaintiff suggests that this class action be exercised before the Superior Court of justice in the district of Montreal

- 61. A great number of the members of the class reside in the judicial district of Montreal and in the appeal district of Montreal;
- 62. Bayer has its principal place of business in the judicial district of Montreal;

63.[...];

64. The Plaintiffs' attorneys practice their profession in the judicial district of Montreal;

65. The present motion is well founded in fact and in law.

FOR THESE REASONS, MAY IT PLEASE THE COURT:

GRANT the present motion;

AUTHORIZE the bringing of a class action in the form of a motion to institute proceedings in damages;

ASCRIBE the Plaintiffs the status of representatives of the persons included in the class herein described as:

«All persons residing in Quebec who were prescribed and ingested the drugs YASMIN and/or YAZ, from the respective introductions of these drugs into the market (December 10, 2004, in respect of Yasmin and January 6, 2009, in respect of YAZ) and the date of November 30, 2011 and their successors, assigns, family members, and dependants or any other group to be determined by the Court.»

IDENTIFY the principle questions of fact and law to be treated collectively as the following:

- a. Do Yaz and Yasmin cause, exacerbate, or contribute to serious adverse events, including deep vein thrombosis, blood clots, pulmonary embolism, heart attacks, stroke, gallbladder problems and infections, liver failure, kidney failure, severe anxiety, depression, and sudden death?
- b. Was Bayer negligent and/or did it commit a fault and/or did it fail in its duty of safety, duty of care, and/or duty to inform imposed upon it as manufacturer, distributer and/or seller of Yaz and Yasmin?

- c. Do Yaz and Yasmin possess a superior efficacy over other contraceptives available on the market?
- d. Did Bayer knowingly, recklessly or negligently breach a duty to warn class members and/or their physicians of the risks of harm from the use of Yaz and Yasmin?
- e. Did Bayer knowingly, recklessly or negligently misrepresent to class members and/or their physicians the risks and benefits from the use of Yaz and Yasmin?
- f. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin were safe?
- g. Did Bayer engage in false advertising when it represented, through advertisements, promotions and other representations, that Yaz and Yasmin had a superior efficacy over other contraceptions?
- h. In the affirmative to any of the above questions, did Bayer conduct engage its liability towards the members of the class?
- i. If the responsibility of the Bayer is established, what is the nature and the extent of damages and other remedies to which the members of the class can claim?
- j. Are members of the class entitled to bodily, moral, and material damages?
- k. Are members of the class entitled to recover the medical costs incurred in the screening, diagnosis and treatment of medical conditions caused by taking Yaz and Yasmin?
- I. Are the members of the class entitled to recover as damages an amount equal to the purchase price of Yaz and Yasmin or any part of the purchase price?
- m. Should Bayer be ordered to disgorge all or part of its ill-gotten profits received from the sale of Yaz and Yasmin?
- n. Are members of the class entitled to aggravated or punitive damages?

IDENTIFY the conclusions sought by the class action to be instituted as being the following:

GRANT the class action of Plaintiffs and each of the members of the class;

DECLARE the Defendant liable for the damages suffered by the PLAINTIFFS and each of the members of the class;

CONDEMN the Defendant to pay to each member of the class a sum to be determined in compensation of the damages suffered, and ORDER collective recovery of these sums;

CONDEMN the Defendant to reimburse to each of the members of the class, the purchase price of the product, and ORDER collective recovery of these sums;

CONDEMN the Defendant to pay to each of the members of the class, punitive damages, and ORDER collective recovery of these sums;

RESERVE the right of each of the members of the class to claim future damages related to the use of Yaz and Yasmin;

CONDEMN the Defendant to pay interest and additional indemnity on the above sums according to law from the date of service of the motion to authorize a class action;

ORDER the Defendant to deposit in the office of this court the totality of the sums which forms part of the collective recovery, with interest and costs;

ORDER that the claims of individual class members be the object of collective liquidation if the proof permits and alternately, by individual liquidation;

CONDEMN the Defendant to bear the costs of the present action including expert, notice fees and the fees relating to administering the plan of distribution of the recovery in this action;

RENDER any other order that this Honourable court shall determine and that is in the interest of the members of the class;

DECLARE that all members of the class that have not requested their exclusion, be bound by any judgement to be rendered on the class action to be instituted in the manner provided for by law;

FIX the delay of exclusion at thirty (30) days from the date of the publication of the notice to the members, date upon which the members of the class that have not exercised their means of exclusion will be bound by any judgement to be rendered herein;

ORDER the publication of a notice to the members of the group in accordance with article 1006 C.C.P. within sixty (60) days from the judgement to be rendered herein in the JOURNAL DE QUÉBEC, the JOURNAL DE MONTRÉAL, LA PRESSE and the NATIONAL POST;

ORDER that said notice be available on the Bayer's website with a link stating "Notice to Yaz and Yasmin users";

RENDER any other order that this Honourable court shall determine and that is in the interest of the members of the class;

THE WHOLE with costs including publications fees.

Montreal, February 2nd, 2017

kinds Desmeules, Avocats, S.E.N.C.R.L.

Maître Samy Elnemr samy.elnemr@siskindsdesmeules.com SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L. Attorneys for the Plaintiffs 480, Saint-Laurent Bureau 501, Montréal, Québec H2Y 3Y7 Telephone : 514-849-1970 Fax : 514-849-7934 Notification: notification@siskindsdesmeules.com

NOTICE OF PRESENTATION

TO: **Me Sylvie Rodrigue, Ad. E.** Société d'avocats Torys s.e.n.c.r.l. 1 place Ville-Marie Suite 1919 Montreal, Quebec H3B 2C3

Attorneys for the Defendant Bayer Inc.

TAKE NOTICE that the Plaintiffs' Motion will be presented for adjudication before The Honourable Justice Guylène Beaugé on a date and time to be determined by the Court at the Montréal Courthouse located at 1, Notre-Dame East, Montreal, Quebec, H2Y 1B6.

Montreal, February 2nd, 2017

skinds, Desmeules, avocats, S.E.N.C.R.L.

Maître Samy Élnemr samy.elnemr@siskindsdesmeules.com SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L. Attorneys for the Plaintiffs 480, Saint-Laurent Bureau 501, Montréal, Québec H2Y 3Y7 Telephone : 514-849-1970 Fax : 514-849-7934 Notification: notification@siskindsdesmeules.com

CANADA

PROVINCE OF QUEBEC DISTRICT OF MONTREAL

NO: 500-06-000484-093

(Class Action) SUPERIOR COURT

JANIE GUINDON

and

GENEVIÈVE GLADU

and

JULIEN LEBOEUF

Plaintiffs

٧.

BAYER INC.

Defendant

LIST OF EXHIBITS

- **EXHIBIT P-1:** Bayer's Information Sheet on the Registraire des entreprises du Québec;
- **EXHIBIT P-2:** Yasmin Product Monographs;
- **EXHIBIT P-3:** Yaz Product Monographs;
- **EXHIBIT P-4:** British Medical Journal Article, dated April 13, 2002;
- **EXHIBIT P-5:** British Medical Journal Paper, dated February 1, 2003;
- **EXHIBIT P-6:** British Medical Journal Study;
- **EXHIBIT P-7:** Food and Drug Administration letter, dated March 26, 2009;
- **EXHIBIT P-8:** Bayer Press Release, dated January 20, 2009;
- **EXHIBIT P-9:** Bayer Press Release, dated March 26, 2010;

- **EXHIBIT P-10:** Bayer letter and labels of Yasmin and Yaz;
- **EXHIBIT P-11:** Interim Report First Quarter of 2015, dated April 27, 2015;
- **EXHIBIT P-12:** Research paper published in the Canadian Medical Association Journal, dated May 17, 2011;
- **EXHIBIT P-13:** Science Daily article, dated October 18, 2012.

Montreal, February 2nd, 2017

skinds, Desmeules, avocats, S.E. N.C.R.L.

Maître Samy Elnemr samy.elnemr@siskindsdesmeules.com SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L. Attorneys for the Plaintiffs 480, Saint-Laurent Bureau 501, Montréal, Québec H2Y 3Y7 Telephone : 514-849-1970 Fax : 514-849-7934 Notification: notification@siskindsdesmeules.com

C A N A D A PROVINCE OF QUÉBEC DISTRICT OF MONTRÉAL SUPERIOR COURT – CLASS ACTION NO: 500-06-000484-093

JANIE GUINDON

ET AL.

Plaintiffs

<u>~</u>

BAYER INC.


Defendant

RE-RE-AMENDED MOTION TO AUTHORIZE THE BRINGING OF A CLASS ACTION &TO ASCRIBE THE STATUS OF REPRESENTATIVES (Art. 1002 C.C.P. and following), NOTICE OF PRESENTATION, LIST OF EXHIBITS

Copy to the Defendant a/s Me Sylvie Rodrigue Société d'avocats Torys 1 Place Ville-Marie, bureau 1919 Montréal (Québec) H3B 2C3

BB-6852

Me Samy Elnemr O/F:67-095



www.siskinds.com

SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L.

SISKINDS



	The second second second	A 1	the state of the second
ique civile		Char	mbre des actions collectives
Référée	Salle		
de	prévue 15.03	Date	Le 30 janvier 2017
	WE COMPANY AND A CONTRACT OF A DESCRIPTION OF	Référée Salle de prévue	ique civile Référée Salle de prévue Date

Partie demanderesse		Procureur(s)	
JANIE GUINDON(absente)et-		Me Samy Elnemr	
GENEVIÈVE GLADUet-		Me Erika Provencher	
JULIEN LEBOEUF	Présents	Siskinds Desmeules	Présents
Partie défenderesse		Procureur(s)	
BAYER INC.		Me Sylvie Rodrigue	
	Présente	Me Marie-Eve Gingras	Présentes
		Société d'avocats Torys	

Nature de la cause	
Recours collectif	

Cote(s)	Requête (s)
43	Demande de ré-réamendée pour autorisation d'exercer une action collective et pour obtenir le statut de
	représentants

Greffier(ière)°	Interprète	Sténographe
Diane Rivest	N/A	N/A

ENREGISTREMENT NUMÉRIQUE

Audition AM :	Début 9h30	Fin 12h16	Audition PM :	Début 14h15	Fin 15h38
Affaires référées au maître de	s rôles		Résultat de l'audition Cause mise en délibéré. Dos	ssier au bureau de	e la juge.

HEURE .

	CAUSE CONTINUÉE DU 29 JANVIER 2018
9h30	OUVERTURE DE L'AUDIENCE IDENTIFICATION DES PROCUREURS
9h30	Suite de l'argumentation de Me Rodrigue
9h30	Me Rodrigue réfère à la page 26 de son plan d'argumentation
9h37	Me Rodrigue réfère à l'interrogatoire du Dr Grover
9h43	Me Rodrigue réfère à la pièce P-12

DISTRICT E No : 500-06-0004	PROCÈS-VERBAL D'AUDIENCE COUR SUPÉRIEURE Chambre des actions collectives DE QUÉBEC Pratique civile Chambre des actions collectives DE MONTRÉAL Référée de Salle prévue 15.03 Date
9h44	Me Rodrigue réfère au paragraphe 7 du rapport du Dr Grover, onglet 6
9h47	Me Rodrigue réfère au paragraphe 11 du rapport du Dr Grover
9h49	Question du Tribunal à Me Rodrigue
9h49	Me Rodrigue remet au Tribunal deux tableaux concernant les termes utilisés pour les contraceptifs oraux Yaz et Yasmin, ainsi qu'une copie de toutes les monographies de ces contraceptifs depuis 2004
9h52	Me Rodrigue réfère au tableau
9h56	Question du Tribunal à Me Rodrigue
9h57	Me Rodrigue réfère à la page 4 du tableau
9h58	Précision de Me Gingras
10h00	Me Rodrigue réfère à la page 8 du tableau
10h02	Me Rodrigue réfère à la page 11 du tableau
10h07	Question du Tribunal à Me Rodrigue
10h08	Question du Tribunal à Me Rodrigue
10h08	Me Rodrigue réfère à l'onglet 3 du compendium (Mme Guindon) et à l'onglet 4, pages 46 et 47 (Mme Gladu)
10h08	Me Rodrigue réfère le Tribunal à son compendium
10h11	Me Rodrigue réfère à la page 32 de son plan d'argumentation
10h13	Me Rodrigue réfère au rapport du Dr Masse, page 50, onglet 6
10h16	Me Rodrigue réfère aux pièces P-11 et P-12
10h20	Me Rodrigue réfère à la page 35 de son plan d'argumentation
10h23	Me Rodrigue réfère au tableau à l'Annexe 3, à la page 17
10h26	Me Rodrigue réfère aux paragraphes 103 et 104 du plan ainsi qu'à 33.12, 33.23, 35 et 39
10h28	Me Rodrigue réfère à l'allégation dans la demande au paragraphe 19.1 ainsi qu'à la pièce P-7
10h32	Me Rodrigue réfère à la pièce P-8
10h33	Me Rodrigue réfère à la note de bas de page no 5 de la pièce P-8

DISTRICT E No : 500-06-0004	PROCÈS-VERBAL D'AUDIENCE COUR SUPÉRIEURE DE QUÉBEC Pratique civile Chambre des actions collectives DE MONTRÉAL Référée de prévue des actions Date 484-093 15.03 Le 30 janvier 2017 3LE GUYLÈNE BEAUGÉ, J.C.S. JB3984
10h39	Me Rodrigue réfère au paragraphe 122 de son plan
10h41	Me Rodrigue réfère à l'Annexe 4 du plan d'argumentation
10h47	Me Rodrigue réfère à la page 40 du plan d'argumentation
10h49	Question du Tribunal là Me Rodrigue quant au risque accru
10h51	Me Rodrigue réfère à l'onglet 8 de ses autorités
10h54	Me Rodrigue réfère aux paragraphes 135 et 137 de son plan d'argumentation
10h57	Me Rodrigue réfère au paragraphe 142 de son plan d'argumentation
10h58	Me Rodrigue réfère à la pièce P-4
11h00	Me Rodrigue réfère à la pièce P-5
11h02	Me Rodrigue réfère à la pièce P-6
11h04	Me Rodrigue réfère à la pièce P-9
11h06	Me Rodrigue réfère à la pièce P-13
11h09	Me Rodrigue réfère à la pièce P-10
11h10	Me Rodrigue réfère à la pièce P-19
11h13	Me Rodrigue réfère au paragraphe 156 de son plan d'argumentation
11h13	Me Rodrigue réfère au paragraphe 19.1 de la demande
11h14	Suspension
11h36	Reprise
11h36	Suite de l'argumentation de Me Rodrigue
11h38	Me Rodrigue réfère à l'article 575.4 C.p.c.
11h39	Me Rodrigue réfère au paragraphe 166 du plan
11h41	Me Rodrigue réfère aux pages 70 et 71 de l'interrogatoire de Mme Guindon
11h41	Me Rodrigue réfère à l'affaire <i>Caron</i>
11h44	Question du Tribunal à Me Rodrigue

•	PROCÈS-VERBAL D'AUDIENCE COUR SUPÉRIEURE DE QUÉBEC Pratique civile chambre des actions DE MONTRÉAL Référée Salle de Date 484-093 Le 30 janvier 2017
L'HONORAL	BLE GUYLÈNE BEAUGÉ, J.C.S. JB3984
11h46	PIÈCE BD-5 : Ordonnance de l'Ontario, dossier 52030/10
11h47	PIÈCE BD-6 : Ordonnance de la Saskatchewan Q.B. No. 1611 of 2009
11h48	Question du Tribunal
11h48	Me Elnemr réfère le Tribunal à l'onglet 11 pour le dossier de l'Ontario et à l'onglet 12 en liasse pour le dossier de la Saskatchewan
11h49	Me Rodrigue réfère le Tribunal à la page 53 de son plan pour l'informer qu'elle substituera cette page pour y apporter des changements
11h54	Me Rodrigue réfère au paragraphe 178 de son plan d'argumentation
11h56	Me Rodrigue réfère le Tribunal à l'onglet 12
12h00	Me Rodrigue réfère au paragraphe 189 de son plan d'argumentation
12h01	Me Rodrigue réfère à la page 59 de son plan d'argumentation
12h02	Me Rodrigue réfère au paragraphe 194 de son plan d'argumentation
12h04	Me Rodrigue réfère à l'onglet 23 de son cahier d'autorités, paragraphe 102
12h06	Me Rodrigue réfère le Tribunal aux pages 61 et 62 de son plan d'argumentation, et l'informe qu'elle substituera cette page pour y apporter des changements
12h08	Me Rodrigue remet au Tribunal une feuille affichant trois décisions jurisprudentielles
12h09	Me Rodrigue réfère à l'onglet 28 du cahier d'autorités de la partie demanderesse
12h14	Suspension
14h16	Reprise
14h16	Me Rodrigue remet au Tribunal une page remplaçant les questions communes aux pages 53 et 61, ainsi que la définition du groupe à la page 63
14h16	Réplique de Me Elnemr
14h19	Me Elnemer réfère le Tribunal à la demande, page 14
14h20	 La partie demanderesse amende la demande ré-ré-amendée aux paragraphes suivants : le paragraphe 49 a) est remplacé par le libellé de la question commune 1 proposée par la partie défenderesse; le paragraphe 49 m) est retiré; au paragraphe 49 n), le mot « aggravated » est retiré; au paragraphe 52, la conclusion suivante est retirée : « RESERVE the right of each of the members of the class to claim future damages related to the use of Yaz and Yasmin; » à la 3^e conclusion (ASCRIBE), SUBSIDIAIREMENT, les demandeurs acceptent la définition proposée par la partie défenderesse.

CANADA	PROCÈS-VERBAL D'AUDIENCE		a second a second second	COUR SUPÉRIEURE	
PROVINCE DE QUÉBEC	Pratique civile		Chi	Chambre des actions collectives	
DISTRICT DE MONTRÉAL	Référi	ée Salle			
No : 500-06-000484-093	de	prévue 15.03	Date	Le 30 janvier 2017	
L'HONORABLE GUYLÈNE BEAUGÉ, J.	C.S.			JB3984	

14h26	Me Elnemr remet au Tribunal deux décisions jurisprudentielles : Vermette et JTI-MacDonald
14h27	Me Elnemr réfère à la décision <i>Vermette</i> , paragraphe 63
14h29	Me Elnemr réfère à la décision <i>JTI-McDonald</i> aux paragraphes 21 à 32
14h30	Question du Tribunal à Me Elnemr
14h33	Me Elnemr réfère à la déclaration assermentée du Dr Grover
14h34	Me Elnemr réfère le Tribunal à l'onglet 23 de ses autorités, paragraphe 42
14h36	Me Elnemr réfère le Tribunal à l'onglet 24 de ses autorités
14h36	Me Elnemr réfère le Tribunal à l'onglet 28 de ses autorités, paragraphes 39 et 66
14h38	Me Elnemr réfère à la pièce P-6, page 4
14h40	Me Elnemr réfère à la pièce P-2, page 587
14h41	Me Elnemr réfère à la pièce P-17
14h44	Me Elnemr réfère à l'onglet 10, paragraphes 34, 38, 45
14h47	Question du Tribunal à Me Elnemr
14h47	Me Elnemr réfère à l'article 53 et à l'onglet 27 de son cahier d'autorités, paragraphes 17 et 58
14h49	Question du Tribual à Me Elnemr
14h50	Me Elnemr remet au Tribunal une décision jurisprudentielle
14h54	Me Elnemr réfère à l'onglet 28 au paragraphe 70
14h57	Me Elnemr réfère à l'onglet 23, paragraphes 27 et 52
15h00	Me Elnemr réfère à l'onglet 24, paragraphes 41 à 43
15h02	Le Tribunal s'adresse à Me Elnemr
15h06	Me Einemr réfère à l'onglet 25, paragraphe 39
15h07	Me Elnemr réfère à l'onglet 26, paragraphes 64 et 65
15h10	. Me Elnemr réfère à l'onglet 27, paragraphe 37

ANADA PROCÈS-VERBAL D'AUDIENCE ROVINCE DE QUÉBEC Pratique civile ISTRICT DE MONTRÉAL Référée Salle		COUR SUPÉRIEURE Chambre des actions	
		collectives	
; 0-06-000484-093	prévue 15.03	Date	Le 30 janvier 2017
2.S .			JB3984
28, paragraphe 71			
je 17 de la demande, questions h), i), j). I	k), et l)		
exe 5, page 2 de son plan d'argumentatio	n		
ts à la pièce P-2			
Rodrigue			
ts à la pièce P-12			
t Me Rodrigue			
ossier au bureau de la juge.			
g e a F	Pratique civile Référée de C.S. 28, paragraphe 71 ge 17 de la demande, questions h), i), j). I exe 5, page 2 de son plan d'argumentation ats à la pièce P-2 Rodrigue ats à la pièce P-12 et Me Rodrigue	Pratique civile Référée de Salle prévue 15.03 C.S. C.S. 28, paragraphe 71 ge 17 de la demande, questions h), i), j). k), et l) exe 5, page 2 de son plan d'argumentation ats à la pièce P-2 Rodrigue ats à la pièce P-12 et Me Rodrigue	Pratique civile Salle prévue 15.03 Date Référée de Son plan d'argumentation Date c.S. 28, paragraphe 71 ge 17 de la demande, questions h), i), j). k), et l) exe 5, page 2 de son plan d'argumentation ats à la pièce P-2 Rodrigue ats à la pièce P-12 et Me Rodrigue

Diane Rivest, g.a.c.s.



CANADA

PROVINCE DE QUÉBEC DISTRICT DE MONTRÉAL

NO: 500-06-000484-093

COUR SUPÉRIEURE (Recours collectif)

JANIE GUINDON -et-GENEVIÈVE GLADU -et-SERGE BOUCHARD

Requérants

C.

BAYER INC.

Intimée

DÉCLARATION SOUS SERMENT <u>AMENDÉE</u> DU DR ANDRÉ MASSE MD, CSPQ, FRCSC

Je, soussigné, docteur André Masse, obstétricien-gynécologue, pratiquant à l'hôpital St-Luc du Centre hospitalier de l'Université de Montréal, situé au 1058, rue Saint-Denis, Montréal (Québec) H2X 3J4, déclare solennellement ce qui suit :

- Cette déclaration sous serment est produite suite à une demande par la Société d'avocats Torys s.e.n.c.r.l., représentant l'intimée Bayer inc. (« Bayer ») dans le cadre d'une Requête pour autorisation d'intenter un recours collectif contre elle par les requérants Janie Guindon, Geneviève Gladu et Serge Bouchard relativement aux médicaments commercialisés sous les noms de Yaz® et Yasmin®, contraceptifs oraux combinés estro-progestatif, composés d'éthinyl-oestradiol et de drospirénone.
- 2. Je ne connais pas et je n'ai jamais été impliqué dans le traitement ou le suivi des patientes ci-haut mentionnées. Je n'ai jamais travaillé à titre de consultant, ni participé à aucune étude clinique pour le compte de la compagnie Bayer.

QUALIFICATIONS

 Je suis obstétricien gynécologue de formation et professeur titulaire de clinique au département d'Obstétrique Gynécologie de l'Université de Montréal et de l'Hôpital St-Luc du CHUM. Mon curriculum vitae est joint en annexe A.

DOCUMENTS ET DOSSIERS MÉDICAUX CONSULTÉS

4. Pour émettre cette opinion sur dossiers, j'ai consulté plusieurs dossiers et documents qui sont énoncés en **annexe B**. Je joins également copie des monographies concernant le Yaz® et le Yasmin® pour la période pertinente au recours en **annexe C** et **annexe D**, respectivement.

CAS DE MADAME JANIE GUINDON

- 5. Madame Janie Guindon débute l'usage de Yaz® (Éthinyl-estradiol 20 mcg et Drospirénone 3 mg), le 10 août 2009, à l'âge de 22 ans. Notons que le dossier mentionne l'usage de contraception orale en 2003 (Triquilar), à l'âge de 16 ans. Deux mois plus tard, le 14 octobre 2009, elle se présente à l'urgence avec une histoire compatible de colique biliaire et une échographie abdominale démontre alors une macrolithiase de 3,2 cm. Elle subit une cholécystectomie (exérèse de la vésicule biliaire), le 3 novembre 2009. Les notes au dossier ne mentionnent pas si les contraceptifs oraux ont été cessés avant la chirurgie.
- 6. En décembre 2009, peu après sa chirurgie, madame Guindon se rend de Gatineau à Québec, où le 26 décembre, elle consulte à l'urgence pour une douleur à la cheville. Le médecin diagnostique une entorse. Elle consulte à nouveau le 31 décembre. Un diagnostic de thrombophlébite de la veine fémorale superficielle est posé et une anticoagulation est débutée. Quelques jours plus tard, elle consulte une troisième fois pour difficulté respiratoire et douleur pleurale. Une embolie pulmonaire est confirmée à la scintigraphie ventilation perfusion.

Question et opinion

Les problèmes de santé allégués à l'égard de madame Guindon, soit les calculs biliaires, la cholécystectomie (résection de la vésicule biliaire), la thrombose veineuse profonde et les embolies pulmonaires auraient-ils été causés par la prise de Yaz® ?

Lithiase (calcul) biliaire/cholécystectomie

- 7. La prévalence de lithiase vésiculaire chez la femme caucasienne nord-américaine est de l'ordre de 15%. Une histoire familiale double ce risque. L'obésité est également un facteur de risque bien établi de lithiase vésiculaire, dû à l'augmentation de la synthèse et de l'excrétion de cholestérol. Il en est de même pour la grossesse, en lien avec une quantité imposante d'œstrogène produite.
- 8. La composante oestrogénique des contraceptifs oraux estro-progestatif, pourrait augmenter légèrement le risque de formation de lithiase. Il y existe encore controverse dans la littérature à ce sujet. Les comprimés de moins de 50 mcg d'œstrogène,

presque toujours utilisés aujourd'hui, (dont le Yaz® fait partie à seulement 20 mcg d'éthinyl estradiol), n'ont probablement pas d'effet significatif sur la formation de lithiase vésiculaire. À noter que seulement 2 mois après le début de Yaz®, l'échographie chez madame Guindon démontrait un calcul de 3,2 cm, lequel était vraisemblablement en formation depuis longtemps, soit bien avant la prise de Yaz® dans ce cas-ci. [...]

Phénomène thrombo-embolique

- 9. Sans aucun facteur de risque, l'incidence de base de thrombo-embolie est de l'ordre de 4 incidents sur 10 000 personnes par année (soit 0,04%). L'usage des contraceptifs oraux estro-progestatifs quels qu'ils soient, augmente le risque de base de 2 à 3 fois (soit 0,08% à 0,12%). Il est important de souligner que ce risque est à son maximum dans les 3- 4 premiers mois de l'usage. Il n'est pas augmenté par la durée d'utilisation, de fait il diminue graduellement et retourne au risque de base, 3 mois après l'arrêt. Ce risque diminue également en fonction de la dose d'œstrogène. Rappelons que Yaz® contient 20 mcg d'œstrogène.
- 10. De nombreuses études ont tenté de comparer le risque thrombo-embolique en fonction du progestatif associé à l'œstrogène (levonorgestrel, desogestrel, gestodene, norgestimate, drospirénone) dans les différentes marques de contraceptifs oraux. Ces études sont souvent controversées et arrivent à des conclusions divergentes, ce qui s'explique par la diversité des études et de leur qualité scientifique inégale.
- 11. Les études de meilleure qualité scientifique, sont des études prospectives, qui sont expressément conçues pour évaluer un risque déterminé. Elles doivent avoir une puissance statistique suffisante, lorsque l'effet indésirable est peu fréquent. Les facteurs de risque sont compilés de façon prospective par un suivi adéquat pour identifier et confirmer les évènements indésirables et exclure les variables confondantes.
- 12. Les études rétrospectives faites à partir de bases de données comportent souvent de nombreux biais et présentent davantage de faiblesses méthodologiques qui peuvent invalider les résultats et les conclusions et ont des limites importantes.
- 13. Conscient de la controverse dans les études des dernières années quant aux risques associés à l'usage des différents progestatifs dans les contraceptifs oraux, l'Institut National de Santé publique du Québec (INSPQ), a réuni un groupe d'experts de différentes spécialités pour évaluer ces études récentes sur ce sujet, et a émis un consensus en juin 2011. En résumé, ce groupe de travail conclut que, toutes les études disponibles comportent des faiblesses méthodologiques et que s'il existe une différence de risque de thrombo-embolie entre les contraceptifs contenant le progestatif drospirénone (progestatif de quatrième génération) et ceux contenant le progestatif lévonorgestrel (progestatif de deuxième génération), cette différence est faible, de l'ordre de 1-2 cas de plus par 10 000 femmes années et elle ne nécessite pas, dans l'état actuel des connaissances, de changer les pratiques cliniques. La

Société des Obstétriciens et Gynécologues du Canada, a émis une déclaration de principe en février 2013 qui supporte les mêmes conclusions. Il n'y a donc pas de risque significatif accru à l'utilisation du Yaz®, comparativement à d'autres contraceptifs oraux estro-progestatifs.

- 14. Il est du rôle du médecin d'individualiser le traitement, d'évaluer l'état de santé des patientes et de discuter des avantages et des risques associés à l'usage de la contraception orale. Sous contraceptifs oraux, le risque absolu de thrombo-embolie demeure très faible chez les patientes en bonne santé et beaucoup moins élevé que les risques associés à une grossesse non planifiée. À titre comparatif, en grossesse et en période péri partum en raison de la compression veineuse et de l'état d'hypercoagulabilité associée à cet état, l'incidence de thrombo-embolie augmente de 5 à 50 fois par rapport au risque de base, selon l'âge maternel et l'âge gestationnel. Les chances de développer un phénomène thrombo-embolique sont donc beaucoup plus grandes en grossesse que sous contraceptifs oraux estro-progestatifs (5 à 50 fois vs 2 à 3 fois).
- 15. Nous devons considérer que madame Guindon mesure 5 pieds 7 pouces et pèse 266 livres : son indice de masse corporelle, (IMC) est à 41,4 kg/m2. L'obésité (IMC>30kg/ m2) en soi, augmente le risque thrombo-embolique de 2 à 3 fois et la prise de contraceptifs oraux, chez les patientes obèses, augmente ce risque de 2 à 24 fois de plus, proportionnellement au poids. La patiente est également fumeuse. L'usage du tabac est un autre facteur de risque, si bien que les contraceptifs oraux sont déconseillés chez les fumeuses de plus de 35 ans. Une période postopératoire, l'immobilisation, le voyage en position assise prolongée, l'obésité et l'usage de la cigarette sont tous des facteurs prédisposant aux phénomènes thrombo-emboliques. De plus, l'investigation a démontré que madame Guindon est porteuse du facteur V de Leiden. Cette condition génétique augmente en elle seule de 7 fois le risque de phénomène thrombo-embolique. Le bilan lipidique de madame, en août 2008, démontrait également un cholestérol total élevé, autre facteur de risque vasculaire.
- 16. Les patientes avec phénomène thrombo-embolique présentent souvent plusieurs facteurs de risque, dont les plus prévalants dans les études populationnelles sont : 48 heures ou plus d'immobilisation dans le dernier mois, une hospitalisation, une chirurgie, ou un processus infectieux dans les 3 derniers mois. Presque tous ces facteurs de risque, sauf le processus infectieux, sont retrouvés ici à l'histoire de madame Guindon, en plus de ses facteurs personnels, l'obésité, la cigarette, l'hypercholestérolémie et le facteur V de Leiden.
- 17. Les contraceptifs oraux estro-progestatifs, quels qu'ils soient, augmentent le risque de base de phénomène thrombo-embolique de 2 à 3 fois. Tel que discuté, tous les facteurs de risque présents chez madame Guindon et son historique médicale personnelle (obésité, tabagisme, période postopératoire, immobilisation, voyage, facteur V de Leiden, hypercholestérolémie), influencent et augmentent individuellement et collectivement, son risque thrombo-embolique. Le contraceptif Yaz®, utilisé par la patiente, et contenant la drospirénone (progestatif de quatrième

génération), ne modifie pas significativement ce risque comparativement aux autres contraceptifs oraux estro-progestatifs.

Conclusion

18.**[...]**

19. Les contraceptifs oraux estro-progestatifs, quels qu'ils soient, augmentent le risque de base de phénomène thrombo-embolique de 2 à 3 fois. Le contraceptif Yaz®, utilisé par la patiente, et contenant la drospirénone (progestatif de quatrième génération), ne modifie pas significativement ce risque comparativement aux autres contraceptifs oraux estro-progestatifs. Par ailleurs, tel que discuté, tous les facteurs de risque présents chez madame Guindon et son historique médicale personnelle, influencent et augmentent individuellement et collectivement, son risque thrombo-embolique.

CAS DE MADAME GENEVIÈVE GLADU

- 20. Madame Geneviève Gladu, née en juin 1979, utilisait la contraception orale estroprogestative depuis quelques années, au moins depuis l'année 2005, où le dossier mentionne la reprise de contraceptifs oraux (Triphasil®, Alesse®). Ceux-ci sont modifiés pour Yasmin® (Éthinyl-estradiol 30 mcg et drospirénone 3mg) en 2008, entre le mois de mars et le mois de septembre. En juin 2009, âgée de 30 ans, madame Gladu se présente à l'urgence pour nausées et douleurs abdominales. Un diagnostic de colique biliaire avec pancréatite est l'hypothèse de travail de l'équipe médicale.
- 21. L'évaluation en gastro-entérologie précise un phénomène de pancréatite biliaire. Le scan abdominal démontre de nombreux calculs, une stéatose hépatique et un phénomène compatible avec une pancréatite. Elle est hospitalisée et mise sous antibiotiques. En cours d'hospitalisation, quelques jours plus tard, la patiente présente une dyspnée, qui une fois investiguée, s'avère secondaire à la présence d'une embolie pulmonaire. Une anticoagulation est débutée et un filtre est mis en place dans la veine cave en attendant la sphinctérotomie qui a lieu le 26 juin et une cholécystectomie éventuelle. Celle-ci est pratiquée dans un second temps le 4 juillet 2009.

Question et opinion

Les problèmes de santé allégués à l'égard de madame Gladu, soit les calculs biliaires, la pancréatite biliaire, la cholécystectomie (résection de la vésicule biliaire), et les embolies pulmonaires auraient-ils été causés par la prise de Yasmin ®?

Lithiases (calculs) biliaires/pancréatite biliaire/cholécystectomie

22. Madame Gladu est une femme de petite taille (5 pieds 2) mais elle pèse 178 livres (IMC : 37,2 kg/m2). Lors de son hospitalisation, on lui diagnostique aussi une hyper triglycéridémie. L'obstruction de l'ampoule pancréatique par un calcul ou le reflux de bile dans le canal pancréatique sont probablement les causes les plus fréquentes de pancréatite. Toutefois seulement 3 à 7% des patientes porteuses de lithiases développeront une pancréatite. La femme étant plus à risque de lithiase que l'homme, elles sont plus à risque de pancréatite. L'hypertriglycéridémie est également associée à la pancréatite, mais plus rarement.

23.<u>[...]</u>

Phénomène thrombo-embolique

24. Quant au phénomène thrombo-embolique, de nombreux facteurs de risque prédisposants, tels que notés antérieurement, sont également ici présents chez madame Gladu. Elle utilisait la contraception orale depuis plusieurs années. Hospitalisation, immobilisation, obésité, processus infectieux sont tous présents. Les commentaires déjà émis dans l'analyse du dossier de madame Guidon quant au risque thrombo-embolique associés aux contraceptifs oraux, sont aussi justes dans le cas de madame Gladu. Les contraceptifs oraux estro-progestatifs augmentent le risque de base de phénomène thrombo-embolique de 2 à 3 fois. Le contraceptif Yasmin®, utilisé par la patiente, et contenant la drospirénone (progestatif de quatrième génération), ne modifie pas significativement ce risque comparativement aux autres contraceptifs oraux estro-progestatifs. Par ailleurs, tel que discuté, tous les facteurs de risque présents chez madame Gladu et son historique, (obésité, hospitalisation, immobilisation, processus infectieux), influencent et augmentent significativement, individuellement et collectivement, son risque thrombo-embolique.

Conclusion

- 25.<u>[...]</u>
- 26. Les contraceptifs oraux estro-progestatifs quels qu'ils soient, augmentent le risque de base de phénomène thrombo-embolique de 2 à 3 fois. Tel que discuté, tous les facteurs de risque présents chez madame Gladu et son historique, influencent et augmentent individuellement et collectivement, son risque thrombo-embolique. Le contraceptif Yasmin®, utilisé par la patiente, et contenant la drospirénone (progestatif de quatrième génération), ne modifie pas significativement ce risque comparativement aux autres contraceptifs oraux estro-progestatifs.

CAS DE MADAME JULIE BOUCHARD

- 27. Madame Julie Bouchard est née en avril 1981. Il s'agit d'une patiente de petite taille (4 pieds 11, 125 livres, IMC 25,2 kg/m2), atteinte d'un syndrome de Turner (anomalie chromosomique) en 2008. Elle est aussi porteuse d'une anomalie rénale, pour laquelle elle fut opérée en très bas âge. Elle présente un léger surplus de poids, une hypertension artérielle sous médication, un syndrome métabolique, un diabète de type 2, une dyslipidémie et une ostéopénie. L'auscultation cardiaque laisse aussi entendre un souffle. Elle est suivie en endocrinologie et néphrologie.
- 28. Le contraceptif Yasmin®, (éthinyl-estradiol 30 mcg et drospirénone 3mg) est prescrit en mars 2009 par l'endocrinologue pour améliorer la masse osseuse. Le 5 août 2009, alors âgée de 28 ans, madame Bouchard se présente à l'urgence pour une paresthésie du visage, trouble de langage et paralysie de l'hémiface droit. La présentation clinique laisse présumer à un diagnostic d'accident vasculaire cérébral gauche. À son arrivée à l'hôpital, la liste des médicaments utilisés par la patiente est notée et on n'y retrouve pas de contraceptif oral.

Question et opinion

Les problèmes de santé allégués à l'égard de madame Bouchard, soit les AVC auraient-ils été causés par la prise de Yazmin®?

29. Mme Bouchard présente également plusieurs facteurs de risque vasculaire dont l'hypertension et le diabète. Elle ne prenait plus le Yasmin® au moment des évènements en cause. Le docteur Stéphane Charest, neurologue, mentionne dans son résumé de dossier du 14 août 2009 que « des contraceptifs oraux avaient été donnés dans le temps mais cessés en raison d'effets secondaires bien avant cet événement neurologique <u>qui n'a aucun lien avec cette médication prise dans le passé</u> ».

30.[...]

Conclusion

31.**[...]**

May

André Masse MD, CSPQ, FRCSC Obstétricien-gynécologue Professeur titulaire de clinique Département d'obstétrique-gynécologie Université de Montréal Hôpital Saint-Luc du CHUM Membre de la Société d'experts en évaluation médicolégale du Québec (SEEMLQ)

COPIE CONFORME

Société d'avocats Torys S.E.N.C.R.L.

Déclaré solennellement devant moi à Montréal, le 17 juin 2016

Commissaire à l'assermentation



NO : 500-06-000484-093	COUR SUPÉRIEURE (Action collective) DISTRICT DE MONTRÉAL	JANIE GUINDON -et- GENEVIÈVE GLADU -et- SERGE BOUCHARD Requérants	c. BAYER INC. Intimée	DÉCLARATION SOUS SERMENT <u>AMENDÉE</u> DU DR ANDRÉ MASSE MD, CSPQ, FRCSC	COPIE POUR LA COUR	Maître Geneviève Bertrand Courriel : <u>gbertrand@torys.com</u> SociÉrÉ D'AvocATS TorYS s.E.N.C.R.L. 1, Place Ville Marie, bureau 2880 Montréal (Québec) H3B 4R4 Téléphone : (514) 868-5604 Télécopieur : 514.868.5700	BS-2554 # 34506-2039
------------------------	--	--	-----------------------------	---	---------------------------	--	----------------------

CANADA

PROVINCE OF QUEBEC DISTRICT OF MONTREAL

NO: 500-06-000484-093

(Class Action) SUPERIOR COURT

JANIE GUINDON

and

GENEVIÈVE GLADU

and

SERGE BOUCHARD

Plaintiffs

۷.

BAYER INC.

Defendant

AFFIDAVIT OF DR. STEVEN A. GROVER, M.D.

I, the undersigned, **Steven A. Grover**, M.D., Professor of Medicine at McGill University, having a place of practice at the McGill Comprehensive Health Improvement Program (CHIP), located at 430 Rue Saint Pierre, in the City of Montréal, Province of Québec H2Y 2M5, duly sworn do depose and say:

1. This Affidavit is produced as a review of the Affidavit provided by Dr. Andre Masse, M.D., CSPQ, FRCSC and the associated medical files for Janie Guindon, Genevieve Gladu, and Julie Bouchard as part of an Application for Authorization to Institute a Class Action against the Defendant Bayer Inc., in relation to oral contraceptives marketed under the names Yaz and Yasmin.

QUALIFICATIONS

2. I am a board certified specialist (Canada and USA) in Internal Medicine and a Professor of Medicine at McGill University. I have also been on staff at the Montreal General Hospital (now part of the McGill University Health Center) since 1986. Beyond my clinical practice, I have also been a member of the Division of Clinical Epidemiology at the Montreal General Hospital since 1986 and was the Director of this division from 1995-2007. A copy of my C.V. is attached.

DOCUMENTS AND MEDICAL RECORDS CONSULTED

3. I have reviewed the declaration provided by Dr. Andre Masse, M.D., CSPQ, FRCSC and the medical files provided to me for Janie Guindon, Geneviève Gladu, and Julie Bouchard. I also reviewed the expert opinion provided by Dr. David Sackett, which was filed in the Ontario proceeding, and reviewed the published literature on the risk of gall bladder stones associated with the use of specific oral contraceptives.

CASE OF JULIE BOUCHARD

- 4. I reviewed the file of Julie Bouchard and agree with Dr. Masse's opinion that Ms. Bouchard suffered repeated strokes as a result of a vasculitis affecting the arterial circulation of the brain. Vasculitis is a much rarer cause of stroke than the thrombo-embolic causes that have been associated with some oral contraceptives (OC). There is no convincing evidence that I am aware of that vasculitic strokes are associated with the taking of any OC, including Yasmin. As a rare condition it is unlikely that an association could be made convincingly given the few cases of vasculitic strokes among OC users that would be available for study.
- 5. Accordingly, I agree with Dr. Masse that it is unlikely that Yasmin was a cause of these vasculitic strokes.

CASE OF JANIE GUINDON

- 6. Ms. Guindon suffered from two medical problems, acute cholecystitis requiring the removal of her gall bladder in November 2009, followed by the diagnosis of thrombophlebitis one month later. Both of these conditions have been associated with the taking of OC including Yasmin.
- 7. I agree with Dr. Masse that the primary cause of the thrombophlebitis was the immobility and surgery during the previous month for the removal of her gall bladder. I cannot rule out that Yasmin increased the risk of this complication but would consider this a minor factor compared to those associated with the surgery.
- 8. Regarding the cause of the gallstones, I agree with Dr. Masse that this patient had many important risk factors associated with gall stones. In the

largest study to date examining the risks of gall stones associated with different OC, (Etiminian et al) the most important risk factors associated with gall stones that were present in this patient were obesity and smoking. In this study of 2.7 million women including over 27,000 who developed gall stones, those with obesity had an increased in risk of 141% to 187% and smokers had an increased the risk of 99% to 114%.

- 9. However, this study also compared the risk of specific OC after statistically adjusting for risk factors such as obesity and smoking. Seven different OC drugs were available for comparison based on the progestin compound that they contained. Levonorgestrel was selected as the reference progestin as it was one of the most commonly used. After statistically adjusting for 13 other factors associated with gall stones, only two OC were associated with a small but measurable increase risk in gallstones compared to levonorgestrol; norethinderone (6% to 14% increased risk) and drospirenone (16% to 26% increased risk). Drospirenone is the progestin compound used in Yasmin.
- 10. While this increased risk may be small compared to the other risk factors this patient had for gallstones, it cannot be considered zero based on the largest study to date.
- 11. Dr. Masse also argues that the patient had only been on Yasmin for two months making this an unlikely cause of the gallstones. This patient was at increased risk of gallstones due to her weight and smoking habit and the fact that she had used OC of various forms since 2003. I agree with Dr. Masse that only two months of Yasmin was unlikely to be the sole cause of the gallstones but one cannot rule out that it contributed to the development of symptomatic disease where the existing stones grew larger with the introduction of Yasmin and finally obstructed the gall bladder.
- 12. I therefore disagree with Dr. Masse that Yasmin could not have played a role in the gall bladder stones. One could in fact argue that in a patient at increased risk of gallstones like Ms. Guidon, Yasmin, with a small but measurable increased risk for gallstones, should be considered a secondary choice compared to other OC.
- 13. Accordingly, I cannot agree with Dr. Masse that Yasmin did not have any significant effect in the formation of the gallstones. The risk associated with Yasmin may have indeed been small compared to the other factors that were present in this patient but it was not insignificant given the data from this study.

CASE OF GENEVIÈVE GLADU

- 14. This case is very similar to that of Janie Guindon. The formation of gallstones was the cause of her biliary obstruction and pancreatitis. The critical issue is could the use of Yasmin increase the risk of developing gallstones in a women with other risk factors including obesity and hypertriglyceridemia. The results of the previously mentioned study by Etimian et al suggest that while the increased risk (16% to 26%) associated with Yasmin is small compared to major risk factors like obesity (141% to 187%), it is not zero.
- 15. As mentioned in the previous case, the thrombophlebitis that developed during her hospitalization for biliary obstruction and pancreatitis was probably due to the immobilization and inflammation associated with these conditions that required her admission in the first place.
- 16. Accordingly, I cannot agree with Dr. Masse that the choice of Yasmin did not play any role in her admission for gallstones and pancreatitis followed by thrombophlebitis several days later.

AND I HAVE SIGNED ON THIS 19TH DAY OF AUGUST 2016.

Steven A. Grover, M.D. Professor of Medicine McGill University McGill Comprehensive Health Improvement Program (CHIP)

SIGNED AND SWORN TO BEFORE ME ON THE 19TH DAY OF AUGUST 2016.

Varlen iichaela

COMMISSIONER FOR OATHS For all Judicial Districts of Québec



PROVINCE DE QUÉBEC DISTRICT DE MONTRÉAL CANADA

COUR SUPÉRIEURE – ACTION COLLECTIVE NO : 500-06-000484-093

JANIE GUINDON
ET ALS.
Demandeurs
ü
BAYER INC.
Défenderesse
AFFIDAVIT OF DR. STEVEN A. GROVER, M.D.
Copie à la Défenderesse a/s Mes Sylvie Rodrigue Société d'avocats Torys 1 Place Ville-Marie, bureau 1919 Montréal (Québec) H3B 2C3

480, Saint-Laurent, Suite 501 Montréal, Québec H2Y 3Y7 Tel. : (514) 849-1970 Fax : (514) 849-7934 www.siskinds.com SISKINDS, DESMEULES, AVOCATS, S.E.N.C.R.L.



BS-2497 Me Samy Elnemr O/F : 67-095

C A N A D A PROVINCE OF QUEBEC DISTRICT OF MONTREAL N°: 500-06-000484-093

SUPERIOR COURT (Class Action)

JANINE GUINDON

-and-

GENEVIEVE GLADU

-and-

SERGE BOUCHARD Petitioners

-VS-

BAYER INC.

Respondent

EXAMINATION OF STEVEN GROVER

<u>APPEARANCES:</u> **Me SAMY ELNEMR** for Petitioners

Me GENEVIEVE BERTRAND Me SYLVIE RODRIGUE for Respondent

DECEMBER 13, 2016

AZ161213.

ASTRIDA AUZA, o. c. r.

		•
		2
	INDEX	
		PAGE
	STEVEN GROVER	_
	Examination by Me Geneviève Bertrand	.5
Astrida Auza	0.C.r.	Steno Exact MAX

		3	
	LIST OF UNDERTAKINGS		
		PAGE	
#U-1:	Grover consulted. And if he cannot come up with a complete list of the literature reviewed, then confirm whether or not he the Jick Study in the course of his literature review (page	61	
	61)	01	
strida Auza o.c.	r	Steno Exact	MAXIN

			4
		LIST OF EXHIBITS	
			PAGE
I-1:	A copy of the Jick Study - three pages		 59
I-2:	A copy of the Etminan Study .		

				, (118), (11
		5		7
1 In the	e year of Our Lord, two thousand and sixteen		1 A-	And I guess that's a good description of what I
	6), on this thirteenth (13th) day of December;		2	do.
3			3 Q-	Okay, and what about the clinical epidemiology?
	SONALLY CAME AND APPEARED;		4 A-	Clinical epidemiology is basically a research
5			5	training. Usually people spend two (2) or more
	VEN GROVER, born the twenty-ninth (29th) day of		6	years training to become a clinical
	ember, nineteen hundred and fifty-three (1953),		7	epidemiologist, and really clinical epidemiology
	sician, residing at six four four (644) Argyle		8	is a combination of it's largely a
	nue, Westmount, Province of Quebec;		9	familiarity with biostatistics, but it's also
10			10	developing an expertise on study, design, the
	D, after having made a Solemn Affirmation, doth		11	strengths and the weaknesses of a study.
	se and say as follows;		12	In layman's terms, I would sort of say
13			13	clinical epidemiology is is developing the
14 EXA	MINATION BY Me GENEVIEVE BERTRAND,		14	skills to understand research data that's
	ehalf of Respondent:		15	developed and published in clinical medicine.
16 Q-	Hello, Dr. Grover, my name is Geneviève		16 Q-	Okay. And what proportion do you practise in
17	Bertrand, I represent Bayer Inc. in the Class		17	the clinical epidemiology portion versus
18	Action concerning Yaz and Yasmin that was filed		18	internal medicine?
19	in Quebec. My colleague, Sylvie Rodrigue, is		19 A-	My time is about seventy-five percent (75%)
20	also present here today.		20	clinical epidemiology, twenty-five percent (25%)
21	I'm going to ask you a series of questions,		21	internal medicine.
22	if you don't understand the questions, simply		22 Q-	Okay, and in terms of the internal medicine,
23	let me know and I will reformulate the question.		23	where do you practise?
24	Also, it's important to answer verbally, because		24 A-	Montreal General Hospital, and McGill
25	the Stenographer won't be able to transcribe,		25	Comprehensive Health Improvement Program, which
		_		· · · · ·
		6		8
1	obviously, gestures, nods, that kind of thing.		1	I'm the founding director of, it's a health
2	And lastly, it's important to let me finish		2	promotion program that we set up about twenty
3	asking the question before you start answering,		3	(20) years ago.
4	because the Stenographer can't take down what we		4 Q-	And in terms of your clinical epidemiology
5	both say at the same time.		5	practice, where does that take place?
6	Okay, what is your area of specialty?		6 A-	Most of the work is actually taking place here
7 A-	I'm a general internist by training, and I'm a		7	in these offices now, but it's under the
8	clinical epidemiologist.		8 Q-	"In these offices" would be the McGill
9 Q-	And what does that entail in terms of the first		9	Comprehensive Health
10	general		10 A-	No, the offices we're in right now.
11 A-	Well, internal		11 Q-	Right. And so, which offices, just for the
12 Q-	clinical		12	transcript?
13 A-	Internal medicine		13 A-	This
14 Q-	Yes.		14 Q-	What are we referring to?
15 A-	is basically the sort of diametric opposite		15 A-	Two (2) things, this these offices represent
16	of general surgery. We take care of complex		16	the the offices for Clinemetrica Inc., which
17	diagnostic and therapeutic problems for adults,		17	is a consulting firm we run. It's also a firm
18	and adults only. Typically, we're the guys who		18	that does corporate health and wellness, and on-
19	are in charge of the wards in the hospitals for		19	line health and wellness both for commercial,
20				
	the medical side of the hospital.		20	government and personal use, but also for
21	At McGill University, where I'm a professor		21	research purposes.
22	of medicine, we're the guys who typically teach		22	My clinical epidemiology associates who
23	the medical students, interns and residents, you		23	work under my sources of funding all have their
0.4				
24 25 Q-	know, how to practice internal medicine. Yes.		24 25	offices here because there's inadequate space in the hospitals. And we also run the McGill

AFFIDAVIT

9 1 Comprehensive Health Improvement Program 1 tests 1 Comprehensive Health Improvement Program 2 Q Yes. 3 well, in this space. 3 A approaches to diagnosis and therapy those 4 Q And what does your epidemiology practice entail? 5 Q Okay. And what about the internal medicine 6 research grants from the Federal Government, or 7 from industry, or from some other, you know, 5 Q Okay. And what about the internal medicine 9 What kind of 9 A medicine practice. 1 A 9 What kind of 9 A medicine practice. 9 A medicine practice. 10 Okay. 12 On which topics 11 You know, the full range of gamut of problems 11 14 You know, the full range of gamut of problems 11 14 You know, the full range of gamut of problems 12 14 14 14 14 You know, the full range of gamut of problems 12 14 14 14 14 14 16 Okay. And you've never contributed
2 administrative side of things out of here as 2 Q Yes. 3 well, in this space. 3 A approaches to diagnosis and therapy those 4 A dwhat deso your epidemiology practice entail? A approaches to diagnosis and therapy those 5 A Largely research, it's typically getting 5 Q Okay. And what daso but the internal medicine 6 protion of your practice in that case, in 7 A Largely a general 9 Q What kind of 9 A medicine practice. 10A publishing the results 9 A medicine practice. 10 11Q On which topics 11A You know, the full range of gamut of problems 12A Most of 11Q Osay. And you've never contributed to studies 13C typically? You know, the full range of gamut of problems 14A my research nas typically been around 14A I haven't prescribe and a contraceptives? 14A I haven't prescribe and a study on gall 20 Okay. And you've never contributed to studies related 21 20Q <
3 well, in this space. 3 A- approaches to diagnosis and therapy those sorts of things. 4 Q- And what does your epidemiology practice entail? 4 sorts of things. 5 A. Largely research, it's typically getting 6 portion of your practice in that case, in 7 from industry, or from some other, you know, 6 portion of your practice. 6 9 Q- What kind of 9 A- Largely a general 9 9 Q- What kind of 9 A- Largely a general 9 10A- publishing the results 10A- You know, the full range of gamut of problems 112A- Most of 10A- medicine practice. 10Q- 12A- Most of 11A- You know, the full range of gamut of problems 11A- 13Q- typically? So, you don't prescribe oral contraceptives? 14A- I haven't prescribe oral contraceptives? 14A- inta dults show up with. 13Q- So, you don't prescribe oral contraceptives? 16 15 scription of your practice and research, I So So, Ver ene
4 Q- And what does your epidemiology practice entail? 4 sorts of things. 5 A- Largely research, it's typically getting 5 Q- Okay. And what about the internal medicine portion of your practice in that case, in 6 research grants from the Federal Government, or from industry, or from some other, you know, funding source. Conducting research 5 Q- Okay. And what about the internal medicine portion of your practice in that case, in 7 A- Largely a general 8 Q- General 9 A- medicine practice. 10 O Okay. And what about the internal medicine portion of your practice in that case, in 7 A- Largely a general 8 Q- General 9 A- medicine practice. 10 O O A- Largely a general 8 Q- General 9 A- medicine practice. 10 O O O A- Largely a general 8 Q- General 9 A- I hat adults show up with. 10 Sorts of things. 11 A- I hat adults show up with. 10 A- I hat adults about it fo
5 A. Largely research, it's typically getting 5 Q- Okay. And what about the internal medicine 6 research grants from the Federal Government, or 7 A- Largely a general 8 9 Q. What kind of 8 Q- General 8 Q- Ckay. And what about the internal medicine 6 portion of your practice in that case, in 7 A- Largely a general 8 Q- General 8 Q- General 8 Q- Ckay. And what about the internal medicine 6 portion of your practice. 10 Q- Ckay. And what about the internal medicine 6 portion of your practice. 11 A- Internal medicine 6 portion of your practice. 11 A- Internal medicine 6 And you've never contributed to studies 7
6 research grants from the Federal Government, or from industry, or from some other, you know, 8 6 portion of your practice in that case, in 7 funding source. Conducting research 9 Q What kind of 8 Q 9 Q. What kind of 9 A. medicine practice. 9 10.A. publishing the results 10.Q. Okay. 10.Q. Okay. 11.Q. On which topics 12 that adults show up with. 13.Q. medicine practice. 13.Q. typically? 13.Q. So, you don't prescribe oral contraceptives? 14.A. 14.A. my research has typically been around 15 sure, in thirty (30) years. 16 16 prevention. More recently diabetes, obesity, 16Q. Okay. And you've never contributed to studies 17 we're reaching out into mental health issues 17 we're reaching out into mental health issues 18 Let me think about it for one second. 19 20 Okay. And does that pretty much cover what 20 bladder disease? 23.A. No, not that I can recall. 22 21 A. The clinical epidemiology is r
7 from industry, or from some other, you know, 8 7 A- Largely a general 9 Q- What kind of 9 A- medicine practice. 10A publishing the results 10Q- Okay. 11Q- 11Q- On which topics 11Q- Okay. 11A- You know, the full range of gamut of problems 12A- Most of 12 that adults show up with. 13Q- So, you don't prescribe oral contraceptives? 14A- my research has typically been around 14A- I haven't prescribed an oral contraceptives? 14A- my research ing out into mental health issues 15 Sure, in thirty (30) years. 16 Okay. And does that pretty much cover what 16 Okay. And you've never contributed to studies related 20Q- Okay. And does that pretty much cover what 21 Ohady ou've never contributed to a study on gall 21 you've described, the clinical epidemiology 21 And you've never contributed to studies related 25Q- in terms of 23 And you've never contributed to studies related 25Q- in terms of 24 And you've never contributed to studi
8 funding source. Conducting research 9 Q What kind of 9 A 10A publishing the results 10Q Okay. 10Q Okay. 11Q On which topics 10Q Okay. 11Q On which topics 12A Most of 13Q on which topics 12 that adults show up with. 13Q typically? 11A You know, the full range of gamut of problems 14A my research has typically been around 13Q So, you don't prescribe and contraceptive? 14A my research instead fits around cardiovascular disease 15 sure, in thirty (30) years. 16 prevention. More recently diabetes, obesity, 16Q Okay. And you've never contributed to studies 17 we're reaching out into mental health issues 16Q Okay. And you've never contributed to studies 18 now. But most of it's around cardiovascular 18A Let me think about it for one second. 19 No, I've never published a study on gall 20 bladder disease? 22 portion of your practice and research, I 23A No, not that I can recall. 24A-
9 Q- What kind of 9 A- medicine practice. 10A- publishing the results 10Q- Okay. 11Q- On which topics 11A- You know, the full range of gamut of problems 11A- Most of 11A- You know, the full range of gamut of problems 11A- may research has typically been around 11A- You know, the full range of gamut of problems 15 cardiovascular disease, cardiovascular disease 13Q- So, you don't prescribed an oral contraceptive, I'm 16 prevention. More recently diabetes, obesity, 13Q- Okay. And you've never contributed to studies 17 we're reaching out into mental health issues 16Q- Okay. And does that pretty much cover what 16Q- Okay. And does that pretty much cover what 20Q- Okay. And does that pretty much cover what 20 bladder disease? 23A- No, I've never published a study on gall 21Q- portion of your practice and research, I 23A- No, not that I can recall. 24A- 23A- No, not that I can recall. 24A- Yes in oral contraceptives? 12 1 <a-< td=""> The clinical epidemiology is rea</a-<>
10A- 11Q- On which topics10Q- Okay.0kay.11A- 13Q- 13Q- 13Q- 13Q- 13Q- 13Q-
11 Q- 11 Q- 12 A- 13 Q- 13 Q- 13 Q- 14 A- 15 cardiovascular disease, cardiovascular disease prevention. More recently diabetes, obesity, 17 we're reaching out into mental health issues 18 now. But most of it's around cardiovascular disease.11 A- 10 You know, the full range of gamut of problems 12 that adults show up with. 13 Q- 0 Ckay. And does that pretty much cover what 21 you've described, the clinical epidemiology 22 portion of your practice and research, I 23 should say11 A- 10 You know, the full range of gamut of problems 13 A- 14 A- 14 A- 14 A- 15 sure, in thirty (30) years. 16 Q- 0 Ckay. And does that pretty much cover what 22 portion of your practice and research, I 23 should say 24 A- 25 Q- in terms of11 A- 14 A- 15 sure, in thirty (30) years. 16 Q- 0 Ckay. And does that pretty much cover what 20 bladder disease. 21 Q- 22 portion of your practice and research, I 23 should say 24 A- 25 Q- in terms of11 A- 14 A- 15 sure, in thirty (30) years. 16 D- 16 Okay. And you've never contributed to a study on gall 20 bladder disease? 23 A- 23 A- 24 A- 25 Q- 26 Q- 26 Q- 27 Q- 27 A- 28 A- 28 Q- 29 Right, I meant11 A- 20 D- 20 D- 20 D- 20 D- 20 D- 20 D- 20 D- 20 D- 20 D- 21 D- 22 D- 23 A- 23 A- 24 D- 25 D- 26 D- 27 Q- 27 D- 28 Right, I meant11 A- 20 D- 20 D- <br< td=""></br<>
12 A- Most ofMost of12 that adults show up with.13 Q- 14 A- to research has typically been around to cardiovascular disease, cardiovascular disease, cardiovascular disease, cardiovascular disease, cardiovascular disease, cardiovascular disease, to we're reaching out into mental health issues to we're reaching out into mental health issues disease.12 that adults show up with.17we're reaching out into mental health issues disease.13 Q- sure, in thirty (30) years.16 Q- (Kay. And you've never contributed to studies to regarding gall bladder disease?18now. But most of it's around cardiovascular disease.18 A- Let me think about it for one second.19 No, I've never published a study on gall 20 bladder disease.20 Q- QC Okay. And does that pretty much cover what 21 you've described, the clinical epidemiology 22 portion of your practice and research, I 23 should say10 24 Q- And you or contributed to a study on gall 22 bladder disease?24 A- 25 Q- 2 in terms of10 2 consider myself an oral contraceptive researcher 3 Q- Right, I meant10 2 consider myself an oral contraceptive researcher 3 or expert, but indirectly some of our research 4 studies have been around things like 5 thrombophlebitis, which was indirectly 6 a sesociated in many cases with the prescription 7 Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q-12 P- P- P- P- P- Q-10 Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q- Q-12 P- P- P- P- Q- Q- Q- Q-12 P- P- P- Q- Q-
13 Q- 14 A- my research has typically been around 15 cardiovascular disease, cardiovascular disease 16 prevention. More recently diabetes, obesity, 17 we're reaching out into mental health issues 18 now. But most of it's around cardiovascular disease. 20 Q- Q- Okay. And does that pretty much cover what 21 you've described, the clinical epidemiology 22 portion of your practice and research, I 23 should say13 Q- so, you don't prescribe oral contraceptives? 14 A- I haven't prescribe an oral contraceptive, I'm sue, in thirty (30) years. 16 Q- Okay. And you've never contributed to studies 17 regarding gall bladder disease? 18 A- Let me think about it for one second. 19 No, I've never published a study on gall 20 Let me think about it for one second. 19 No, I've never published a study on gall 21 Q- And you or contributed to a study on gall 22 23 should say 24 A- 25 Q- in terms of10 12 20 A- No, not that I can recall. 24 Q- 25 A- 23 A- No, not that I can recall. 24 Q- 25 A- No, not that I can recall. 24 Q- 25 A- No, not that I can recall. 24 Q- 25 A- 26 might. 27 might. 20 Right. 20 Right, I meant10 12 14 A- 21 A- 26 might, I meant12 14 A- 25 might i meant 26 might, I meant 27 might, I meant12 14 A- 27 might i meant 28 might i meant 29 might, I meant13 Q- 20 might i meant 20 might i meant 20 might, I meant13 Q- 20 might i meant 20 might i meant 21 might i meant 21 might i meant 22 might i meant
14A- 15 my research has typically been around 1514A- cardiovascular disease, cardiovascular disease prevention. More recently diabetes, obesity, 1714A- sure, in thirty (30) years. 16Q- Okay. And you've never contributed to studies regarding gall bladder disease? 18A- Let me think about it for one second. 1916Q- No, I've never published a study on gall 20 Portion of your practice and research, I 2316Q- Sure, in thirty (30) years. 16Q- No, I've never contributed to studies 17 regarding gall bladder disease? 18A- Let me think about it for one second. 19 No, I've never published a study on gall 20 20 21Q- 23 should say 24A- 25Q- 25Q- 25Q- 25Q- 25Q- 25Q- 25Q- 25Q- 2614A- 15 sure, in thirty (30) years. 16Q- No, I've never contributed to a study on gall 22 23A- No, not that I can recall. 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 25 2616Q- No, I've never contributed to studies related 25 25 to oral contraceptives?1012 22 23 A- No, not that I can recall. 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 24Q- 2510 20 22 20 20 20 20 20 21 21 21 21 21 21 22 22 23 24 24 25 25 26 26 27 27 27 28 29 29 2012 24 20 20 20 20 20 20 21 21 21 21 21 22 22 23 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 25 26 26 27 27 28 29 20 20 20 20 20 20 20 20 20 20 20 21 21 21 21 21 <br< td=""></br<>
15cardiovascular disease, cardiovascular disease15sure, in thirty (30) years.16prevention. More recently diabetes, obesity,16Q-Okay. And you've never contributed to studies17we're reaching out into mental health issues17regarding gall bladder disease?18now. But most of it's around cardiovascular18A-Let me think about it for one second.19disease.19No, I've never published a study on gall20 Q-Okay. And does that pretty much cover what20bladder disease.21you've described, the clinical epidemiology21 Q-And you or contributed to a study on gall22portion of your practice and research, I23should say23should say23 A-No, not that I can recall.24A-Yes, it's not24 Q-And you've never contributed to studies related25 Q in terms of25to oral contraceptives?101A-Jesus Well, yes Not I I don't2research3or expert, but indirectly some of our research3 Q-Right.4studies have been around things like5Q-Right, I meant5thrombophlebitis, which was indirectly6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.9oontraceptive researcher.
16prevention. More recently diabetes, obesity, 1716Okay. And you've never contributed to studies17we're reaching out into mental health issues 1816Okay. And you've never contributed to studies18now. But most of it's around cardiovascular 1918A- No, I've never published a study on gall20Okay. And does that pretty much cover what 212021you've described, the clinical epidemiology 222123should say 232124Yes, it's not 25Q- 262324Yes, it's not 262425 in terms of2410111A-2research 3Q-3Q-3Q-4A-4A-4A-5Q-6A-7Q-7Q-9Q-9Q-9Q-9Q-9Q-9Q-9Q-9Q-9Q-9Q-9Q-1011121314141515161616171617171819191010101112 </td
17we're reaching out into mental health issues18now. But most of it's around cardiovascular19disease.20 Q-Okay. And does that pretty much cover what21you've described, the clinical epidemiology22portion of your practice and research, I23should say24 A-Yes, it's not25 Q in terms of10101A-1A-2research3Q-3Q-Right.14A-4A-2Right.4A-4Yes.5Q-6A-7Q-9Q-0-7Q-9Q-0-9Q-0-9Q-0-18-19No, I've never published a study on gall20bladder disease?23Ahou're never contributed to a study on gall24-25-101211A-12-13-14-15-16-17-18-19-10-10-11-12-13-14- <tr< td=""></tr<>
18now. But most of it's around cardiovascular18A-Let me think about it for one second.19disease.19No, I've never published a study on gall20 Q-Okay. And does that pretty much cover what20bladder disease.21you've described, the clinical epidemiology21 Q-And you or contributed to a study on gall22portion of your practice and research, I22bladder disease?23should say23 A-No, no to that I can recall.24 A-Yes, it's not24 Q-And you've never contributed to studies related25 Q in terms of2124 Q-10121A-The clinical epidemiology is really a22research20I3Q-Right.34A profession, as opposed to a practice.15Q-Right. I meant56A-Yes.7Q research instead of78A-Yes.89Q practice, but does that cover what you've99Q practice, but does that cover what you've9
19disease.19No, I've never published a study on gall20 Q-Okay. And does that pretty much cover what20bladder disease.21you've described, the clinical epidemiology21 Q-And you or contributed to a study on gall22portion of your practice and research, I22bladder disease?23should say23 A-No, not that I can recall.24 A-Yes, it's not24 Q-And you've never contributed to studies related25 Q in terms of24 Q-And you've never contributed to studies related25 q-research20I A-3 Q-Right.1A-4 A profession, as opposed to a practice.15 Q-Right, I meant5thrombophlebitis, which was indirectly6 A-Yes.6associated in many cases with the prescription7 Q research instead of7of oral contraceptives. But I'm not suggesting8 A-Yes.8to you that I consider myself an oral9 Q practice, but does that cover what you've9contraceptive researcher.
20 Q- 21 22 22 23Okay. And does that pretty much cover what 21 22 22 23 23 24 A- 25 Q- 25 Q- 25 Q- 2620 21 Q- 21 Q- 21 Q- 21 Q- 21 Q- 21 Q- 21 Q- 21 Q- 22 21 Q- 21 Q- <b< td=""></b<>
21you've described, the clinical epidemiology22portion of your practice and research, I23should say24 A-Yes, it's not25 Q in terms of21Q-24And you've never contributed to a study on gall25 Q in terms of24Q-25 Q in terms of25 Q in terms of26102710281429Presearch302029Right.4A-4A-20Right, I meant4A-5Q-7Q-7Q-7Q-9Q-9Q-9Q-9Q-2021And you or contributed to a study on gall22bladder disease?23A-24Q-24Q-25to oral contraceptives26noral contraceptives?271028to you that I consider myself an oral29Q-20that cover what you've21121122A-23A-24Q-24Q-25to oral contraceptive researcher30130131132133
22 portion of your practice and research, I 22 bladder disease? 23 should say 23 A- No, not that I can recall. 24 A- Yes, it's not 24 Q- And you've never contributed to studies related 25 Q- in terms of 20 And you've never contributed to studies related 25 Q- in terms of 21 A- 1 A- The clinical epidemiology is really a 1 2 research 3 Or expert, but indirectly some of our researcher 3 Q- Right. 3 or expert, but indirectly some of our research 4 A- profession, as opposed to a practice. 5 thrombophlebitis, which was indirectly 6 A- Yes. 6 associated in many cases with the prescription 7 Q- research instead of 7 of oral contraceptives. But I'm not suggesting 8 A- Yes. 9 contraceptive researcher. 9
23should say23 A-No, not that I can recall.24 A-Yes, it's not24 Q-And you've never contributed to studies related25 Q in terms of211A-The clinical epidemiology is really a12research10123Q-Right.14A profession, as opposed to a practice.15Q-Right, I meant3or expert, but indirectly some of our research6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
24 A-Yes, it's not24 Q-And you've never contributed to studies related25 Q in terms of24 Q-25And you've never contributed to studies related1A-The clinical epidemiology is really a1A-Jesus Well, yes Not I I don't2research1A-Jesus Well, yes Not I I don't3Q-Right.1A-Jesus Well, yes Not I I don't4A profession, as opposed to a practice.3or expert, but indirectly some of our research4A profession, as opposed to a practice.4studies have been around things like5Q-Right, I meant5thrombophlebitis, which was indirectly6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
25 Q in terms of25to oral contraceptives?1A-The clinical epidemiology is really a1A-2research1A-Jesus Well, yes Not I I don't2research2consider myself an oral contraceptive researcher3Q-Right.3or expert, but indirectly some of our research4A profession, as opposed to a practice.4studies have been around things like5Q-Right, I meant5thrombophlebitis, which was indirectly6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
1A-The clinical epidemiology is really a1A-Jesus Well, yes Not I I don't12research1A-Jesus Well, yes Not I I don't2consider myself an oral contraceptive researcher3Q-Right.3or expert, but indirectly some of our research44A profession, as opposed to a practice.4studies have been around things like5Q-Right, I meant5thrombophlebitis, which was indirectly6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
1A-The clinical epidemiology is really a1A-Jesus Well, yes Not I I don't2research2consider myself an oral contraceptive researcher3Q-Right.2or expert, but indirectly some of our research4A profession, as opposed to a practice.3or expert, but indirectly some of our research5Q-Right, I meant4studies have been around things like6A-Yes.5thrombophlebitis, which was indirectly7Q research instead of6associated in many cases with the prescription8A-Yes.7of oral contraceptives. But I'm not suggesting9Q practice, but does that cover what you've9contraceptive researcher.
2research2consider myself an oral contraceptive researcher3Q-Right.3or expert, but indirectly some of our research4A profession, as opposed to a practice.4studies have been around things like5Q-Right, I meant5thrombophlebitis, which was indirectly6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
3 Q-Right.3or expert, but indirectly some of our research4 A profession, as opposed to a practice.4studies have been around things like5 Q-Right, I meant5thrombophlebitis, which was indirectly6 A-Yes.6associated in many cases with the prescription7 Q research instead of7of oral contraceptives. But I'm not suggesting8 A-Yes.8to you that I consider myself an oral9 Q practice, but does that cover what you've9contraceptive researcher.
4A profession, as opposed to a practice.4studies have been around things like5Q-Right, I meant5thrombophlebitis, which was indirectly6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
5Q-Right, I meant5thrombophlebitis, which was indirectly6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
6A-Yes.6associated in many cases with the prescription7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
7Q research instead of7of oral contraceptives. But I'm not suggesting8A-Yes.8to you that I consider myself an oral9Q practice, but does that cover what you've9contraceptive researcher.
8 A- Yes.8to you that I consider myself an oral9 Q practice, but does that cover what you've9contraceptive researcher.
9 Q practice, but does that cover what you've 9 contraceptive researcher.
10 said Does that cover that portion of the 100 And when you mentioned that thrombonble bits
To said Does that cover that portion of the To Q- And when you mentioned that thompophies its
11 epidemiological research that you do? 11 effect related to an oral contraceptive, is that
12 A- Well, over the years I've been doing this now 12 a study topic that you addressed specifically,
13 since nineteen You know, my first clinical 13 or was that
14 epidemiology paper was probably published around 14 A- No, it was just something I was peripherally
15 eighty-four ('84), and I came back to McGill in 15 involved in. But that was the focus of the
16 eighty-six ('86), and the range of topics I've 16 study
17 published on over the years is quite extensive, 17 Q- Okay.
18 but I'm giving you the highlights 18 A they were looking at an the benefits of
19 Q- Right. 19 an exercise program for people who have
20 A the things that I 20 developed thrombophlebitis in the past.
21 Q- So, those 21 Q- So, directly speaking, you've never contributed
22 A that I'm known particularly for. 22 to a study on oral contraceptives?
23 Q- Those are the main ones, the topics you 23 A- No. No.
24 mentioned? 24 Q- Or published a paper on
25 A- I would say cardiovascular disease, diagnostic 25 A- No.

AFFIDAVIT

13 13 14 15 14 14 16 CKay. And you mentioned that you wanet to make sure there were no errors, did Professor 16 3 Q. And you haven't contributed to any studies, or public inclus related to Yaz or Yasmin, sepecifically? 3 A. Well, I wanet to see is was there any other 4 way that could that a thoughful statistican 5 could interpret the data differently from the 6 And you don't have specific expertise with 6 or D. Joseph's what was Professor Joseph's 7 A And you don't have specific expertise. 7 A. Myou don't have any specific clinical or 14 resparts right. 7 C. Ald you don't have any specific clinical or 13 14 research expertise regarding call contraceptives? 16 No. 16 15 A. No (Joon't					
2 A. I havent. sure there were no errors, dif yrofessor 3 G. And you havent contributed to any studies, or sure there were no errors, dif yrofessor 4 published any studies related to Yaz or Yasmin, sure there were no errors, dif yrofessor 5 No, In Awent. 6 7 Q. And you don't have specific expertise with 7 expertise, or specific clinical expertise. 7 9 A. Ido not have either specific research 10 - Regarding oral contraceptives? 12 - That's right. 13 - No, I don't. 14 research expertise regarding gall bladder 10. 15 - Incluing gallstones 16 - Incluing gallstones 20 - Gallstones 21 - disease over the years. 22 - in your usual practice? 23 - Yes. 24 - No, No. 25 - No, no. 26 - Okay. Switching gears now, did you prepare for your usual practice? 24 - No, there search studies that the time I did the the pol of a senior statistican to assort were the study you're referring 27 - No, in not.					
3 G. And you havenit contributed to any studies, or 3 A. Well, I wanted to see iswas there any other 9 published any studies related to Yaz or Yasmin, 3 A. Well, I wanted to see iswas there any other 6 A. No, I havenit. could interpret the data differently from the 6 A. No, I havenit. 6 A. No, I havenit. 7 A. Ady ou don't have specific expertise. 7 A. Right. And so, what was Professor Joseph's 8 regards to cal contraceptives? 8 or Dr. Joseph's what were his thoughts on 9 a. I do no have either specific reincal 7 A. Right. And so, what was Professor Joseph's 10 expertise, or specific clinical expertise. 7 A. He agreed with what I had stated. 11 A. Robing out don't have any specific clinical or 13 A. No. 12 A. No, I don't. 13 A. No. 13 A. No. I don't. 14 Tespered with was the stengths and wakenesses, what did 14 A. No, I don't. 16A. No. 15A. No, I don't. 18 Dr. Loseph as yin the strengths of the estrengths of the estrengths and wakenesses. 16A. No, I don't. 18 Dr. Loseph as yin the strengths of the estrengths of the estrengths of the estrengths of the estrengths and wakenesses. 17 A. No, Iron ot. 20 A. No, we were aligned, the agreed with He did 21A. No, no. 21 testhe strengthy foused on the one (1)	1 Q-	oral contraceptives?	1 Q-	Okay. And you mentioned that you wanted to make	
3 G. And you havenit contributed to any studies, or 3 A. Well, I wanted to see iswas there any other 9 published any studies related to Yaz or Yasmin, specifically? and you don't have specific expertise with could interpret the data differently from the 6 A. No, I haven't. between the specific expertise with 7 CR and you don't have specific expertise. 7 D. And you don't have specific expertise. 7 CR and you don't have setter specific related to see itswas the thoughts on 9 A. I do no thave either specific related to see itswas the touchthe thought the stated. 10 10 expertise, or specific clinical cort 11 CR and you don't have any specific clinical cort 13 A. No. I don't. 13 A. No. 14 dessee? 10. Charger ewith any of the 15 A. No. I don't. 13 A. No. 16 A. No, I don't. 13 A. No. 17 A. No, Ion 14 14 14 18 D. Loseph say in the weaknesses? 14 10 14 14 D an expert In in gallstones 24 24 24 21 24 D. But nothing You're not a specialist or 24 14 15 10 A on ic holecystectomies? 24	2 A-	I haven't.	2	sure there were no errors, did Professor	
4 way that could that a thoughful is tatistician 5 And you don't have specific expertise with 5 6 A. No, I haven't. 6 7 C. And you don't have specific expertise with 7 8 regards to oral contraceptives? 8 9 A. I do not have either specific research 9 10 Regarding oral contraceptives? 10A. 12A. That's right. 8 13O- And you don't have any specific clinical or research expertise regarding gall bladder 10A. 14 research expertise regarding gall bladder 10A. 15A. No. 16A- 16A. No. I don't. 16A- 16A. No. I don't. 16D- 16A. No. 16D- 16A. No. 16D- 17 what were the strengths and weaknesses, what did 18A. Nothing outside of what I mean, as a general 19 19 report, and the weaknesses? 20- 20A. Calistones 21 not Hed id not examine the deposition in a 22A. No, no. 22		And you haven't contributed to any studies, or	3 A-		
5 specifically? 5 could interpret the data differently from the 6 A No, I haven't: 6 way I had. 7 A rady out on't have specific expertise with 7 C Right. And so, what was Professor Joseph's 8 regards to oral contraceptives? 8 or Dr. Joseph's what were his thoughts on 9 H id on thave either specific research 9 that? 10 expertise, or specific clinical expertise. 10A He agreed with what I had stated. 110- Okay. Did he disagree with any of the statements you 13A 12A- That's right. 13A No. 13A- No. 16A No. I have and provided? 15 disease? 15A No. 16A- No. I having interms of the strengths and weaknesses. What I id 18 17A- Including galistones in particular? 18 No. 18A- No. Statistician to askeese? 20 19 intermist. you see plenty of gali bladder 21 10 21A- <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
6 A. No. I havenit. 6 way I had. 7 Q. And you don't have specific expertise with negards to oral contraceptives? 7 Q. Right. And so, what was Professor Joseph's 9 A. I do not have either specific research 8 or Dr. Joseph's what were his thoughts on 10 A. Regarding oral contraceptives? 10 A. He agreed with what I had stated. 11 Q. Regarding oral contraceptives? 10 A. He agreed with what I had stated. 13 Q. And you don't have any specific clinical or research expertise regarding gall bladder 10 A. No. 16 A. No. I don't. 13 A. No. 17 Q. Inding outside of what I mean, as a general intemist, you see plenty of gall bladder 20 A. No, we were aligned, he agreed with He did 12 A. disease over the years. 20 A. No, we were aligned, he agreed with He did 23 A. Yes. 20 A. No, we were aligned, he agreed with He did 13 C. or in cholecystectomies? 24 A. Right. 24 D. But nothing You're not a specialist or 24 A. No. 25 A. No, no. Sataistician. Me simply focused on the one (1)					
1 C- And you don't have specific expertise with 8 regards to oral contraceptives? 8 A I do not have either specific research 10 expertise, or specific clinical expertise. 10- Regarding oral contraceptives? 10- 120- And you don't have any specific clinical or 130- And you don't have any specific clinical or 14 10- 130- And you don't have any specific clinical or 15 disease? 10- 130- And you don't have any specific clinical or 14 13A- No. 14 research expertise regarding gall bladder 15 disease? 10- had provided? 132- No. I don't. 130- Including gallstones in particular? 13A- No. 14 in gour sual practice? 20- Gallstones 20- Callstones 20- 230- Callstones 20- Callstones 20- 20- No. 240- But nothing You're not a specialist or 20- 20- No. 20- 25A- No, in not. 14 1 statistician. He simply focused on the one (1) 2 24- No. 3 t					
8 regards to oral contraceptives? 9 9 A I do not have either specific research 9 10 Regarding oral contraceptives? 10 112- That's right. 10- 132- And you don't have any specific clinical or 13.4. 134- Not if arget and inding gall bladder 13.4. 15- disease? 110- 16A- No, I dont. 110- 17- Including gall bladder 10- 17- Including gall bladder 10- 17- Including gall bladder 10- 18- Nothing outside of what Inea, he strengths and weaknesses? 20- Gallstones 20- 21- Law not He disagree with any of the strengths of the disagree with any of the strengths of the s					
9 tdo				•	
10 expertise, or specific clinical expertise. 10.4. He agreed with what I had stated. 11.2. Regarding oral contraceptives? 11.0. Okay. Did k disagree with any of the 13.2. And you don't have any specific clinical or 13.4. No. 13.2. And you don't have any specific clinical or 13.4. No. 14 research expertise regarding gall bladder 13.4. No. 16.3. No. Induding gallstones in particular? 13.4. No. 17.0. Including gallstones in particular? 13.4. No. 20.4. Callstones 20.4. No. weere aligned, here weaknesses? what were the strengths and weaknesses? 21.4. disease over the years. 20.4. No. we were aligned, here weaknesses? 20.4. 22.4. or in cholecystectomies? 21. not He did not examine the deposition in 22.4. or in cholecystectomies? 24.4. No. 3. or in cholecystectomies? 24.4. No. 4. No. 14 14 16 1. Statistician. 4.5.4. or in cholecystectomies?					
110- Regarding oral contraceptives? 11 0- Okay Did he disagree with any of the stargets is statements you 12A- That's right. 11 0- Okay Did he disagree with any of the stargets is statements you 13A- And you don't have any specific clinical or research expertise regarding gall bladder 14 had provided? 14 research expertise regarding gall bladder 14 had provided? 14A- No. I don't. 14 had provided? 17A- Nothing outside of what I mean, as a general internsit, you see plenty of gall bladder 10 had provided? 19 internist, you usel practice? 20 - Gall stones 20 - Right. 21 He did not examine the deposition in the clinical cases that were presented here, he has no 21A- in your usual practice? 21 He did not examine the deposition in the clinical cases that were presented here, he has no 22 - Right. 23A- Yes.					
12A. That's right 12 statements you 13Q- And you don't have any specific clinical or 13A- No. 13Q- And you don't have any specific clinical or 13A- No. 14 research expertise regarding gall bladder 13A- No. 15 disease? 13A- No. 16A- No. (Joon't. 13A- No. 17Q- Including gallstones in particular? 15A- No. 18A- Nothing outside of what Image pertion of the strems o	10	expertise, or specific clinical expertise.	10 A-	He agreed with what I had stated.	
 13Q- And you don't have any specific clinical or research expertise regarding gall bladder is disease? 13A- No. 14Q had provided? 15A- No. 14Q had provided? 15A- No. 16A- No, I don't. 17Q- Including gallstones in particular? 18A- Nothing outside of what I mean, as a general internist, you see plenty of gall bladder 19 report, and the weaknesses, what did 18 Dr. Joseph say in terms of the strengths of the report, and the weaknesses? 20- Gallstones 21A- ves. 22A- Yes. 23A- Yes. 24Q- But nothing You're not a specialist or 25A- No, no. 25A- No, no. 25A- No, no. 25A- No, no. 26- Okay. Switching gears now, did you prepare for 6 your testmony today? 7 A- Only insomuch as I reminded myself what I had 8 written and reviewed, the research studies that 14 deposition was going to happen, I enlisted the help of a senior statistician to. make sure 1 16 hadri made any errors in my in what I had 17 written, and to sort of debate with me what the 18 strengths and weaknesses of my of my of you consulted? 21A- No. 22A- No, we are inclusted the help of a senior statistician to. make sure 1 16 hadri made any errors in my in what I had 17 written, and to sort of debate with me what the 18 strengths and weaknesses of my of my 19 deposition was going to happen, I enlisted the help of a senior statistician to. make sure 1 16 hadri made any errors in my in what I had 17 written, and to sort of debate with me what the 18 strengths and weaknesses of my of my 19 deposition was going to happen, I enlisted the help of a senior statistician that 20 consulted? 23A- Yes. 24A- No, That's right. 24A- That's correct. 24A	11 Q-	Regarding oral contraceptives?	11Q-	Okay. Did he disagree with any of the	
130- And you don't have any specific clinical or 13.4- No. 14 research expertise regarding gall bladder 14.0- had provided? 15 disease? 15.A- No. 16A- No, I don't. 16.A- No. 170- Including gall stones in particular? 17.A- And you also mentioned that you wanted to see 170- Including gall stones 18.A- No. 20- Gallstones 20- Gallstones 20- 21.A- disease over the years. 20- No. were aligned, he agreed with He did 21.A- or in cholexystectomies? 20- Callstones 24- 25.A- No. 0. 25A- No. particular clinical expertise, he's a 1 Q- or in cholexystectomies? 3 the Canadian Medical Association 4 A- No, firn not. 5 A- No, wexamined at the time I did the 3 ustistician to mod specification to make sure I 16 1 statistician to and the weakenesse? 4 A- No, firn not. Satistician to an	12 A-	That's right.	12	statements you	
14 research expertise regarding gall bladder 15 disease? 16A. No, I don't. 17Q- Including gallstones in particular? 18A. Nothing outside of what I mean, as a general 19 internist, you see plenty of gall bladder 20Q- Gallstones 21A. disease over the years. 22Q- in your usual practice? 23A- Yes. 24Q- But nothing You're not a specialist or 25A- No, no. 1 an expert in in gallstones 24 P. But nothing You're not a specialist or 25A- No, no. 1 an expert in in gallstones 2.A- No. 3.Q- in gallstones 4.A- No. (I'm not. 5.Q- Okay. Switching gears now, did you prepare for your testimony today? 7.A- Only insomuch as I reminded myself what I had 8 written and reviewed, the research studies that 9 I had, you know, examined at the time I did the tot the timinant twas a study on different oral 10 constraceptives and the	13 Q-		13 A-	•	
15 disease? 15A- No. 16A- No, I don't. 16A- No, I don't. 17Q- Including gallstones in particular? 16A- And you also mentioned that you wanted to see 18A- Nothing outside of what Image: memory togall bladder 16C- And you also mentioned that you wanted to see 20G- Gallstones 20A- No, we were aligned, he agreed with He did 21A- or isour outsul practice? 20A- No, we were aligned, he agreed with He did 21A- or in your usual practice? 20A- No, we were aligned, he agreed with He did 22A- Yes. 20A- No, we were aligned, he agreed with He did 23A- Yes. 20A- No, we were aligned, he agreed with He did 24- But nothing You're not a specialist or 24- Right. 25 A- or in cholecystectomies? 14 1 statistician. He simply focused on the one (1) 2 A- No, 'Im not. 3 the Canadian Mecical Association 4 3 Yes. 1 statistician to		• • • •			
16A- No, I don't. 16Q- And you also mentioned that you wanted to see 17A- Including galistones in particular? Mathematical and meaking sees, what did 18A- Nothing outside of what I mean, as a general internist, you see plenty of gall bladder 16Q- And you also mentioned that you wanted to see 20Q- Galistones 20A- No, seeph say in terms of the strengths and weaknesses, what did 21A- disease over the years. 20A- No, we were aligned, he agreed with He did 21A- disease over the years. 20A- No, we were aligned, he agreed with He did 22A- in your usual practice? 20A- No, we were aligned, he agreed with He did 23A- Yes. 20A- No, we were aligned, he agreed with He did 23A- Yes. 20A- No, mot. 22 24 O- But nothing You're not a specialist or 24 80A 314 16 1 Q- on in cholecystectomies? 24A No, We meal inpact on align should you prepare for 32A C. journal. 2 Q- Oky insomuch as I reminded myself what I had 34 A- Noh you're referring 5					
17 Q- Including gallstones in particular? 18 A. Nothing outside of what I mean, as a general 17 what were the strengths and weaknesses, what did 19 internist, you see plenty of gall bladder 20 Gallstones 20.4. 20.4. Gallstones 20.4. No, we were aligned, he agreed with He did 21.4. disease over the years. 20.4. No, we were aligned, he agreed with He did 22.4. But nothing You're not a specialist or 24.2. Right. 25.4. No, no. 25.4. or in cholecystectomies? 4 A. No, I'm not. 3 statistician. He simply focused on the one (1) 2 A. No, I'm not. 4 Q- And you're referring 5 Q. Okay. Switching gears now, did you prepare for 6 Q- or the Etimony toda? 7 A. Only insomuch as I reminded myself what I had 8 Well, it wasn't actually a study on the 9 I hadn' made any errors in my in what I had 11 astatistician to					
18A- Nothing outside of what I mean, as a general intermist, you see plenty of gall bladder 18 Dr. Joseph say in terms of the strengths of the report, and the weaknesses? 20G- Gallstones 20A- No, we were aligned, he agreed with He did 21A- in your usual practice? 20A- No, we were aligned, he agreed with He did 22A- Yes. 20A- No, no. 24A- 24A- But nothing You're not a specialist or 24A- Yes. 25A- No, no. 24A- Right. 25A- No, no. 24A- Yes. 2A- No, no. 14 16 1 or in cholecystectomies? 14 16 2 A- No, 'I'm not. 2 statistician. He simply focused on the one (1) 2 A- No, 'I'm not. 2 Satistician to once I knew that this 3 written and reviewed, the research studies that 6 to the Etminan Study? 7 A- Only insomuch as I reminded myself what I had 10A- to the Etminan Study? 7 A- I also enlisted the help of a senior 13A- That's right. 14					
19 internist, you see plenty of gall bladder 20Q. Gallstones 21A. disease over the years. 22Q. in your usual practice? 23A. Yes. 24Q. But nothing You're not a specialist or 22 25A. No. no. 1 Q. an expert in in gallstones 2 A. No. the one (1) statistician. 24 Q. 2 A. No. particular clinical expertise, he's a 1 Q. an expert in in gallstones 24 Q. 2 A. No. 14 16 1 Q. an expert in in gallstones 24 Q. 2 A. No. 14 15 3 Q. or in cholecystectomies? 4 A. 4 A. No. I'm not. 4 Q. And you're referring 5 Q. Okay. Switching gears now, did you prepare for 6 Q. to the Etimian Study? 7 A. Tady you know, examined at the time I did the 9 Etimians, it was a study on different oral 10 testinstician to once I knew that this				U	
20 Q- 21 A- 21 A- 22 Gallstones20 A- disease over the years. 22 Market in your usual practice?20 A- No, we were aligned, he agreed with He did not He did not examine the deposition in 22 terms of the clinical cases that were presented here, he has no22 A- 23 A- 24 Q- 25 A- 25 A- No, no.20 A- No, we were aligned, he agreed with He did not He did not examine the deposition in 22 terms of the clinical cases that were presented here, he has no24 Q- 25 A- 26 A- 3 Q- 2 A- 3 Q- 2 A- 3 Q- 2 A- 3 Q- 2 A- 3 Q- 2 A- 3 Q- 2 A- 3 Q- 		•			
21 A disease over the years.21not He did not examine the deposition in22 Q in your usual practice?2323 A.Yes.2424 Q.But nothing You're not a specialist or2425 A.No, no.2426 M.But nothing You're not a specialist or2427 A.No.2528 Q or in cholecystectomies?144 A.No, I'm not.35 Q.Okay.Switching gears now, did you prepare for your testimony today?37 A.Only insomuch as I reminded myself what I had written and reviewed, the research studies that 91 Ad, you know, examined at the time I did the 910testimony, and specifically focused on the one 111011deposition was going to happen, I enlisted the help of a senior statistician to ore I knew that this 141615help of a senior statistician to make sure I hadn't made any errors in my in what I had trime, and to sort of debate with me what the strengths and weaknesses of my of my deposition were.1620Okay, So who was that senior statistician that you consulted?1621Quespen, he's a professor of 23epidemiology and biostatics at McGill. 24224Okay. And when did you consult him?21234epidemiology and biostatics at McGill. 2422240Okay. And when did you consult him?21					
22 Q in your usual practice? 22 terms of the clinical cases that were presented 23 A- Yes. 24 Q- But nothing You're not a specialist or 24 Q- Right. 25 A- No, no. 24 Q- Right. 25 A particular clinical expertise, he's a 1 Q or in cholecystectomies? 1 statistician. He simply focused on the one (1) 2 A- No. 3 Q or in cholecystectomies? 3 the Canadian Medical Association 4 A- No, I'm not. 5 Q- Okay. Switching gears now, did you prepare for 5 A journal. 6 Q- writes and reviewed, the research studies that 8 Well, it wasn't actually a study on the 9 I had, you know, examined at the time I did the 9 Etrninan, it was a study on different oral 10 contraceptives and their impact on gall bladder 11 disease. 11 also enlisted the help of a senior 13 statistician to once I knew that this 14 the position was going to happen, I enlisted the 14 16 14 deposition was going to happen, I enlisted the 14 16 15 help of a senior statistician to make sure I 16 for that you <					
23 A. Yes. 23 here, he has no 24 Q. Right. 24 Q. But nothing You're not a specialist or 24 Q. Right. 25 A. particular clinical expertise, he's a 1 Q. or in cholecystectomies? 14 1 statistician. He simply focused on the one (1) 2 A. No. 3 the Canadian Medical Association 4 3 Q. or in cholecystectomies? 4 4 4 No. (I'm not. 2 study by the one (1) study that I quoted in 5 A. No, i'm not. 5 A. 6 Q. or the terminan study? 7 7 A. Only insomuch as I reminded myself what I had 6 Q. to the Etminan Study? 7 A. Only insomuch as pecifically focused on the one 10 contraceptives and their impact on gall bladder 11 statistician to once I knew that this 14 deposition was going to happen, I enlisted the 14 deposition was querrors in my in what I had 15A. Tea's correct. 14 deposition were. 16Q. ot that yo		disease over the years.	21	not He did not examine the deposition in	
24 Q- 25 A- No, no.But nothing You're not a specialist or 25 A- No, no.24 Q- 25 A- particular clinical expertise, he's a1Q- 25 A- No, no.14161Q- 25 A- No.14161Q- 25 A- No.14161Q- 25 A- No.1612A- 25 A- No.1612A- 20 And you're referring3the Canadian Medical Association 443Q- 4A- AN oy'm not.4Q- 44A- 20 Okay. Switching gears now, did you prepare for your testimony today?5A- 4 journal.6You testimony today?7A- 7That's right.77A- 1Only insomuch as I reminded myself what I had written and reviewed, the research studies that 9I had, you know, examined at the time I did the 9Nell, it wasn't actually a study on the 910contraceptives and their impact on gall bladder 1010contraceptives and their impact on gall bladder 1111deposition was going to happen, I enlisted the 15help of a senior statistician to make sure I 1615A- No.13statistician to once I knew that this 1515A- NoYes.14deposition was going to happen, I enlisted the thelp of a senior statistician to make sure I 1615A- No16hadn't made any errors in my in what I had 1715A- Yes.Yes.16hadn't made any errors in the	22 Q-	in your usual practice?	22	terms of the clinical cases that were presented	
24 Q- But nothing You're not a specialist or 24 Q- Right. 25 A- No, no. 25 A- particular clinical expertise, he's a 1 Q- an expert in in gallstones 14 16 1 Q- or in cholecystectomies? 1 statistician. He simply focused on the one (1) 2 A- No. 2 study by the one (1) study that I quoted in 3 Q- or in cholecystectomies? 3 the Canadian Medical Association 4 A- No, I'm not. 4 Q- And you're referring 5 Q- Okay. Switching gears now, did you prepare for 6 Q- journal. 6 You're stimony today? 7 A- That's right. 8 9 I had, you know, examined at the time I did the 9 Etminan, it was a study on different oral 10 10 testimony, and specifically focused on the one 11 disease. 12Q- 11 deposition was going to happen, I enlisted the 15A- Yes. 16Q- to that you 14 deposition wasen statistician to make sur	23 A-	Yes.	23	here, he has no	
25ANo, no.25A particular clinical expertise, he's a1Q an expert in in gallstones14161Q an expert in in gallstones1statistician. He simply focused on the one (1)2A-No. I'm not.2study by the one (1) study that I quoted in3Q-Okay. Switching gears now, did you prepare for3the Canadian Medical Association4A-No, I'm not.4Q-5Q-Okay. Switching gears now, did you prepare for5A-6your testimony today?7A-Only insomuch as I reminded myself what I had8written and reviewed, the research studies that6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had7A-That's right.8written and reviewed, the research studies that8Well, it wasn't actually a study on the9I had, you know, examined at the time I did the9Etminan, it was a study on different oral10contraceptices and their impact on gall bladder1111(1) major study that I quoted.13 A-12I also enlisted the help of a senior13 A-13statistician to once I knew that this14 A-14deposition was going to happen, I enlisted the15 A-15help of a senior statistician to make sure I16 Q-16hadn't made any errors in my in what I had17 A-17written, and to	24 Q-	But nothing You're not a specialist or	24 Q-		
1414161Q an expert in in gallstones1statistician. He simply focused on the one (1)2A-No.1statistician. He simply focused on the one (1)3Q or in cholecystectomies?3the Canadian Medical Association4A-No, I'm not.3the Canadian Medical Association5Q-Okay. Switching gears now, did you prepare for5A-6your testimony today?6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had8written and reviewed, the research studies that9I had, you know, examined at the time I did the9Etminan, it was a study on different oral10testimony, and specifically focused on the one10contraceptives and their impact on gall bladder1111major study that I quoted.12But that's the study you're referring13statistician to once I knew that this13A-That's correct.14deposition was going to happen, I enlisted the15A-Yes.16hadn't made any errors in my in what I had17A-Right.18strengths and weaknesses of my of my9Did he mention anything with regards to20Q-Okay, so who was that senior statistician that20weaknesses in your analysis?21A-Lawrence Joseph, he's a professor of21A-No.22epidemiology and biostatics at McGill.22And you mentioned that you had				•	
1Q an expert in in gallstones1statistician. He simply focused on the one (1)2A-No.3Q or in cholecystectomies?3the Canadian Medical Association4A-No, I'm not.3Q-And you're referring55Q-Okay. Switching gears now, did you prepare for6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had7A-That's right.8written and reviewed, the research studies that8Well, it wasn't actually a study on the9I had, you know, examined at the time I did the9Etminan, it was a study on different oral10testimony, and specifically focused on the one10contraceptives and their impact on gall bladder11(1) major study that I quoted.12Q-But that's the study you're referring13statistician to once I knew that this13A-That's correct.14deposition was going to happen, I enlisted the14Q to that you15help of a senior statistician to make sure I16Q discussed with16hadn't made any errors in my in what I had16Q discussed with17written, and to sort of debate with me what the17A-Right.18strengths and weaknesses of my of my18Q Dr. Joseph? Okay.19Did he mention anything with regards to2020Q-Okay, so who was that senior statistician that20<		14		· · · ·	16
2A-No.2study by the one (1) study that I quoted in3Q or in cholecystectomies?3the Canadian Medical Association4A-No, I'm not.4Q-And you're referring5Q-Okay. Switching gears now, did you prepare for5A journal.6your testimony today?6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had6Q to the Etminan Study?8written and reviewed, the research studies that8Well, it wasn't actually a study on the9I had, you know, examined at the time I did the9Etminan, it was a study on different oral10testimony, and specifically focused on the one10contraceptives and their impact on gall bladder11(1) major study that I quoted.12But that's the study you're referring13statistician to once I knew that this13 A-That's correct.14deposition was going to happen, I enlisted the14 Q to that you15help of a senior statistician to make sure I16 Q discussed with16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20Okay, so	1 0		1	statistician. He simply focused on the one (1)	10
3Q or in cholecystectomies?3the Canadian Medical Association4A-No, I'm not.4Q-And you're referring5Q-Okay. Switching gears now, did you prepare for6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had6Q to the Etminan Study?8written and reviewed, the research studies that8Well, it wasn't actually a study on the9I had, you know, examined at the time I did the9Etminan, it was a study on different oral10testimony, and specifically focused on the one10contraceptives and their impact on gall bladder11(1) major study that I quoted.12Q-But that's the study you're referring13statistician to once I knew that this13A-That's correct.14deposition was going to happen, I enlisted the14 Q to that you15help of a senior statistician to make sure I15A-Yes.16hadn't made any errors in my in what I had16Q discussed with17written, and to sort of debate with me what the17A-Right.18strengths and weaknesses of my of my8Q Dr. Joseph? Okay.19deposition were.20Q-Okay, so who was that senior statistician that21A-20Okay, so who was that senior statistician that22Q-And you mentioned that you had reviewed21you consulted?22Q-And you mentioned that yo					
4A-No, I'm not.4Q-And you're referring5Q-Okay. Switching gears now, did you prepare for5A journal.6your testimony today?6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had7A-8written and reviewed, the research studies that8Well, it wasn't actually a study on the9I had, you know, examined at the time I did the9Etminan, it was a study on different oral10testimony, and specifically focused on the one10contraceptives and their impact on gall bladder11(1) major study that I quoted.12I also enlisted the help of a senior12Q-13statistician to once I knew that this13A-That's correct.14deposition was going to happen, I enlisted the14GQ discussed with15help of a senior statistician to make sure I15A-Yes.16hadn't made any errors in my in what I had16Q discussed with17written, and to sort of debate with me what the17A-Right.18strengths and weaknesses of my of my18Q Dr. Joseph? Okay.19Did he mention anything with regards to20Q-Okay, so who was that senior statistician that2021you consulted?21A-22A-Lawrence Joseph, he's a professor of22Q-23epidemiology and biostatics at McGill.2324oru					
5Q-Okay. Switching gears now, did you prepare for your testimony today?5A journal.6you restimony today?6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had 87A-That's right.8written and reviewed, the research studies that 9I had, you know, examined at the time I did the 97A-That's right.9I had, you know, examined at the time I did the 10testimony, and specifically focused on the one 119Etminan, it was a study on different oral 10010testimony, and specifically focused on the one 1110contraceptives and their impact on gall bladder 111111(1) major study that I quoted. 1212 Lalso enlisted the help of a senior 1312 Q-But that's the study you're referring13statistician to once I knew that this 1413 A-That's correct.14deposition was going to happen, I enlisted the 1414 Q to that you15help of a senior statistician to make sure I 1615 A-Yes.16hadn't made any errors in my in what I had 1716 Q discussed with17written, and to sort of debate with me what the 1717 A-Right.18strengths and weaknesses of my of my 1918 Q Dr. Joseph? Okay.19Did he mention anything with regards to 20 Q-Okay, so who was that senior statistician that 21 you consulted?21 A-22 A-					
6your testimony today?6Q to the Etminan Study?7A-Only insomuch as I reminded myself what I had7A-8written and reviewed, the research studies that8Well, it wasn't actually a study on the9I had, you know, examined at the time I did the9Etminan, it was a study on different oral10testimony, and specifically focused on the one10contraceptives and their impact on gall bladder11(1) major study that I quoted.11disease.12I also enlisted the help of a senior12 Q-But that's the study you're referring13statistician to once I knew that this13 A-That's correct.14deposition was going to happen, I enlisted the14 Q to that you15help of a senior statistician to make sure I15 A-Yes.16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20Q-Okay, so who was that senior statistician that22 A-22A-Lawrence Joseph, he's a professor of22 Q-23epidemiology and biostatics at McGill.2324 Q-Okay. And when did you consult him?2424for24					
7A-Only insomuch as I reminded myself what I had 87A-That's right.8written and reviewed, the research studies that 9I had, you know, examined at the time I did the 107A-That's right.9I had, you know, examined at the time I did the 109Etminan, it was a study on different oral 10910testimony, and specifically focused on the one 11(1) major study that I quoted.10contraceptives and their impact on gall bladder 1112I also enlisted the help of a senior 1312 Q-But that's the study you're referring13statistician to once I knew that this 1413 A-That's correct.14deposition was going to happen, I enlisted the 1514 Q to that you15help of a senior statistician to make sure I 1615 A-Yes.16hadn't made any errors in my in what I had 1716 Q discussed with17written, and to sort of debate with me what the 18strengths and weaknesses of my of my 1918 Q-19Did he mention anything with regards to 20 Q-Okay, so who was that senior statistician that you consulted?21 A-22A-Lawrence Joseph, he's a professor of 23epidemiology and biostatics at McGill.22 Mrd you mentioned that you had reviewed 2324 Q-Okay. And when did you consult him?24for24	5 Q-	Okay. Switching gears now, did you prepare for	5 A-	journal.	
8written and reviewed, the research studies that 98Well, it wasn't actually a study on the 99I had, you know, examined at the time I did the 1018Well, it wasn't actually a study on the 910testimony, and specifically focused on the one 111010contraceptives and their impact on gall bladder11(1) major study that I quoted.10contraceptives and their impact on gall bladder12I also enlisted the help of a senior12 Q-But that's the study you're referring13statistician to once I knew that this13 A-That's correct.14deposition was going to happen, I enlisted the 14 deposition was going to happen, I enlisted the 14 deposition was going to happen, I enlisted the 1514 Q to that you15help of a senior statistician to make sure I 1616 Q discussed with17written, and to sort of debate with me what the 1716 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that 202021 A-21 A-No.22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill. 24 Q-24Okay. And when did you consult him?24	6	your testimony today?	6 Q-	to the Etminan Study?	
9I had, you know, examined at the time I did the 109Etminan, it was a study on different oral contraceptives and their impact on gall bladder10testimony, and specifically focused on the one 1110contraceptives and their impact on gall bladder11(1) major study that I quoted.10contraceptives and their impact on gall bladder12I also enlisted the help of a senior 13statistician to once I knew that this thelp of a senior statistician to make sure I 1613.A-16hadn't made any errors in my in what I had 17mitten, and to sort of debate with me what the the deposition were.16.Q- the mention anything with regards to20Okay, so who was that senior statistician that 21 you consulted?19Did he mention anything with regards to22And when did you consult him?22And you mentioned that you had reviewed 231124Okay. And when did you consult him?24for	7 A-	Only insomuch as I reminded myself what I had	7 A-	That's right.	
9I had, you know, examined at the time I did the 109Etminan, it was a study on different oral contraceptives and their impact on gall bladder10testimony, and specifically focused on the one 1110contraceptives and their impact on gall bladder11(1) major study that I quoted.10contraceptives and their impact on gall bladder12I also enlisted the help of a senior 13statistician to once I knew that this thelp of a senior statistician to make sure I 1613.A-16hadn't made any errors in my in what I had 17mitten, and to sort of debate with me what the the deposition were.16.Q- the mention anything with regards to20Okay, so who was that senior statistician that 21 you consulted?19Did he mention anything with regards to22And when did you consult him?22And you mentioned that you had reviewed 231124Okay. And when did you consult him?24for			8	•	
10testimony, and specifically focused on the one10contraceptives and their impact on gall bladder11(1) major study that I quoted.11disease.12I also enlisted the help of a senior12Q-But that's the study you're referring13statistician to once I knew that this13A-That's correct.14deposition was going to happen, I enlisted the14Q to that you15help of a senior statistician to make sure I15A-Yes.16hadn't made any errors in my in what I had16Q discussed with17written, and to sort of debate with me what the17A-Right.18strengths and weaknesses of my of my18Q Dr. Joseph? Okay.19Did he mention anything with regards to20Q-Okay, so who was that senior statistician that2021you consulted?21A-23epidemiology and biostatics at McGill.22Q-24 Q-Okay. And when did you consult him?2424 Q-Okay. And when did you consult him?24					
11(1) major study that I quoted.11disease.12I also enlisted the help of a senior12 Q-But that's the study you're referring13statistician to once I knew that this13 A-That's correct.14deposition was going to happen, I enlisted the14 Q to that you15help of a senior statistician to make sure I16 Q to that you16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that2021you consulted?21 A-22 A-Lawrence Joseph, he's a professor of22 Q-23epidemiology and biostatics at McGill.22 Q-24 Q-Okay. And when did you consult him?2424 Q-Okay. And when did you consult him?24	-		-	•	
12I also enlisted the help of a senior12 Q-But that's the study you're referring13statistician to once I knew that this13 A-That's correct.14deposition was going to happen, I enlisted the14 Q to that you15help of a senior statistician to make sure I14 Q to that you16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that20weaknesses in your analysis?21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for					
13statistician to once I knew that this13 A-That's correct.14deposition was going to happen, I enlisted the14 Q to that you15help of a senior statistician to make sure I14 Q to that you16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that20weaknesses in your analysis?21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for					
14deposition was going to happen, I enlisted the14 Q to that you15help of a senior statistician to make sure I15 A-Yes.16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that20weaknesses in your analysis?21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for		•			
15help of a senior statistician to make sure I15 A-Yes.16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that20weaknesses in your analysis?21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for					
16hadn't made any errors in my in what I had16 Q discussed with17written, and to sort of debate with me what the17 A-Right.18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that20weaknesses in your analysis?21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for				•	
17written, and to sort of debate with me what the strengths and weaknesses of my of my deposition were.17 A-Right.19deposition were.18 Q- Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that you consulted?19Did he mention anything with regards to22 A-Lawrence Joseph, he's a professor of epidemiology and biostatics at McGill.21 A- No.No.24 Q-Okay. And when did you consult him?24for		•			
18strengths and weaknesses of my of my18 Q Dr. Joseph? Okay.19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that you consulted?20weaknesses in your analysis?21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of epidemiology and biostatics at McGill.22 Q-And you mentioned that you had reviewed 2324 Q-Okay.And when did you consult him?24for		• •			
19deposition were.19Did he mention anything with regards to20 Q-Okay, so who was that senior statistician that20weaknesses in your analysis?21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for		written, and to sort of debate with me what the	17 A-	-	
20 Q- you consulted?Okay, so who was that senior statistician that you consulted?20 weaknesses in your analysis?21 you consulted?21 A- No.No.22 A- 23 epidemiology and biostatics at McGill.22 Q- and you mentioned that you had reviewed aliterature in preparation for your Affidavit24 Q- Okay.Okay. And when did you consult him?24 and for	18	strengths and weaknesses of my of my	18 Q-	Dr. Joseph? Okay.	
20 Q- you consulted?Okay, so who was that senior statistician that you consulted?20 weaknesses in your analysis?21 you consulted?21 A- No.No.22 A- 23 epidemiology and biostatics at McGill.22 Q- and you mentioned that you had reviewed aliterature in preparation for your Affidavit24 Q- Okay.Okay. And when did you consult him?24 and for	19	• • •	19	Did he mention anything with regards to	
21you consulted?21 A-No.22 A-Lawrence Joseph, he's a professor of22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for			20		
22 A-Lawrence Joseph, he's a professor of epidemiology and biostatics at McGill.22 Q-And you mentioned that you had reviewed23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for					
23epidemiology and biostatics at McGill.23literature in preparation for your Affidavit24 Q-Okay. And when did you consult him?24for	21		121 A-		
24 Q- Okay. And when did you consult him? 24 for		you consulted?		-	
	22 A-	you consulted? Lawrence Joseph, he's a professor of	22 Q-	And you mentioned that you had reviewed	
20 A- Let's say in the last month. 25 A- Yes.	22 A- 23	you consulted? Lawrence Joseph, he's a professor of epidemiology and biostatics at McGill.	22 Q- 23	And you mentioned that you had reviewed literature in preparation for your Affidavit	
	22 A- 23 24 Q-	you consulted? Lawrence Joseph, he's a professor of epidemiology and biostatics at McGill. Okay. And when did you consult him?	22 Q- 23 24	And you mentioned that you had reviewed literature in preparation for your Affidavit for	

10-And did you review any other studies, other than 17 14 I have spoken to another lawyer who originally approached me 19 3 A - Oh, lots.	· · · · · · · · · · · · · · · · · · ·	
2 than approached me 3 A. Oh, lots. approached me 4 A the Etminan A the Etminan 5 A. Yes. G And 6 Do you recall some A the Etminan 7 A. No, I dorth have the names for you, I you F 9 Sackett's report, you know, but, to be quite 9 0 frank with you, when lwas first approached to 7 11 do this, I said I'm really only interested in 10 10 13 they showed me Dr. Sackett's report, who I 110 10 14 boling on the right side of this argument, and 10 10 15 years, he's one of my mentors. His report 10 10 16 focused primarily on the thromobyhlebitis story, 17 16 10 17 rather	17	19
2 than approached me 3 A. Oh, lots. approached me 4 A the Etminan A the Etminan 5 A. Yes. G And 6 Do you recall some A the Etminan 7 A. No, I dorth have the names for you, I you F 9 Sackett's report, you know, but, to be quite 9 0 frank with you, when lwas first approached to 7 11 do this, I said I'm really only interested in 10 10 13 they showed me Dr. Sackett's report, who I 110 10 14 boling on the right side of this argument, and 10 10 15 years, he's one of my mentors. His report 10 10 16 focused primarily on the thromobyhlebitis story, 17 16 10 17 rather	1 Q- And did you review any other studies, other	1 A- I have spoken to another lawyer who originally
a A Oh, lots. 3 G And 4 O		
4 A. the Etminan		
5 A- Yes. 5 Q- Was he an English speaking lawyer? I mean an aligophone you know what I'm saying, was he 7 A- No, I don't have the names for you, I you 8 8 Know, I initially I had initially seen Dr. 8 9 Sacketti sreport, you know, but, to be quite 9 10 do this, isaid I'm really only interested in 9 11 do this, isaid I'm really only interested in 10 12 being on the right side of this argument, and 13A- Now, you mentioned that you knew Dr. Sackett: 14 who I have personal experience with for many 14 15 years, he's one of my mentors. His report 16A- No. 17 Sockett's report, you with Dr. Sackett: 16A- No. 18A- Mo, I ddin't, he had passed away by the time I 15A- No. 19A than the the gail bladder disease story. 10A. I'm quessing the separt. 10A- So, I reviewed his report, I reviewed a 21 21 number of the papers that he queck os othat I 20A 25A- What's your firm's name? 18 11 Me SAMY ELNEMR, 1 21 Me SAMY ELNEMR, 2 22 Number of the papers that he queck os othat I 2 3 Siskinds. 3 3 Siskinds. 3 4 I had to fits c		
6 O- Doyou recall some 6 anglophone you know what I'm saying, was 7 A- No.1 don't have the names for you, I you 7 he 9 Sackett's report, you know, but, to be quite 9 0 a native anglophone you know what I'm saying, was 9 Sackett's report, you know, but, to be quite 9 0 a native anglophone you know what I'm saying, was 10 fank with you, when I was first approached to 10A I'm guessing to na native anglophone speaker? 11 do this, I said I'm really only interested in 11A I'm guessing he was an English speaking lawyer. 13 they showed me Dr. Sackett's report, who I 12A I'm guessing he was an English speaking lawyer. 14 who I have personal experience with for many 14 Did you speak with Dr. Sackett in the context 15 15 your report? 14A Did you speak with Dr. Sackett in the context 16 16 rocused primarily on the thrombophiebilit story, 17A I'm antine 17A 20 So, Ireviewed his report, I'reviewed a 22 I'm chail wouldn't serve as a 18 21 So. Ireviewed his report, I'reviewed a 22 interestedonly interested in being on the 23 22A So, who provided you with Dr		
7 A. No. ¹ dort have the names for you, Lyou 7 he ¹ . 8 know, InitiallyI had initially seen Dr. 8 A. I would 9 Sackett's report, you know, but, to be quite 9 C. a native anglophone speaker? 10 frank with you, when I was first approached to 10 A. I'm guessing so, yes. 11 O Kay. 110 O Kay. 12 being on the right side of this argument, and 12. Now, you mentioned that you knew Dr. Sackett. 14 who I have personal experience with for many 14 Did you speak with Dr. Sackett. 15 years, he's one of my mentors. His report 16 A. 16 for oused primarily on the thrombophiebits story. 104 No. I didn't, he had passed away by the time I 19.4 than the the gail bladder disease story. 102 You mentioned that you wanted you were 21 So, I reviewed his report, I reviewed a 21 You mentioned that you wanted you were 22.1 So, I reviewed his report, I reviewed a 21 You mentioned that you wanted you were 22.1 So, I reviewed his report. Sakinds. <		
8 know, Lintially I had initially seen Dr. 8 A. I would 9 Sackett's report, you know, but, bo be outie 9 a native anglophone speaker? 10 frank with you, when I was first approached to 10 a native anglophone speaker? 11 do this, I said I'm really only interested in 10 a native anglophone speaker? 13 they showed me Dr. Sackett's report, who I 12 I'm guessing he was an English speaking lawyer. 13 they showed me Dr. Sackett's report, who I 12 I'm guessing he was an English speaking lawyer. 14 they showed me Dr. Sackett's report, i'm or many 12 I'm guessing he was an English speaking lawyer. 15 years, he's one of my mentors. His report 16 drafting your report? 18 drafting your report? 18 drafting your report? 20		
9 Sackett's report, you know, but, to be quite frank with you, when I was first approached to this, I said I'm really only interested in the phowed me Dr. Sackett's report, who I 9 C		8 A- I would
10. frank with you, when I was first approached to 11 do this. I said I'm really only interested in 12 being on the right side of this argument, and 13 they showed me Dr. Sackett's report, who I 14 who I have personal experience with for many 15 years, he's one of my mentors. His report 16 focused primarily on the thrombophlebits story, 17 rather 18Q. Yes. 10A. I'm guessing I'm guessing so, yes. 19W. A thave personal experience with for many 15 years, he's one of my mentors. His report 16 focused primarily on the thrombophlebits story, 17 rather 10A. I'm guessing I'm guessing so, yes. 18Q. Yes. 10A. I'm guessing I'm guessing be was an English speaking lawyer. 13Q. I have personal experience with for many 19A than the the gall bladder disease story. 10A. I'm guessing I'm guessing so, yes. 20 Yes. 10A. I'm guessing I'm guessing be was an English speaking lawyer. 21 So, I reviewed his report, I reviewed a 22 number of the papers that he quoted, so that I 23 could get a handle on that information myself 24 On behair of Petitioners: 3 Siskinds. 10A. I'm guessing I'm guessing as part of 3 siskinds 21 Me SAMY ELNEMR, 22 11 24 that? 23 Siskinds May it Maitre Einemr, or was it 6 Siskinds Was it Maitre Einemr, or was it 6 Siskinds was it Maitre Einemr, or was it 7 Siskinds in Toronto? 10A and what convinced you of that Pare was? 9 A. Yes, I was convinced, you of that? Or were you 8 A. I can't recail. I don't remember who sent me 9 the report. 10A and what convinced you? 11A		
11 do this, I said I'm really only interested in being on the right side of this argument, and the ty showed me Dr. Sackett's report, who I 110-0 Kay. 12 being on the right side of this argument, and the ty showed me Dr. Sackett's report, who I 110-0 Kay. 14 who I have personal experience with for many ty years, he's one of my mentors. 110-0 Kay. 14 Did you speak with Dr. Sackett in the context 10-0 Kay. 15 focused primarily on the thrombophiebilis story, i'r rather 110-0 Kay. 19A than the the gall bladder disease story. 110-0 Kay. 10A-0 Kay. 20 So, I reviewed his report, I reviewed a 20 110-0 Kay. 21 So, I reviewed his report, I reviewed a 20 110-0 Kay. 110-0 Kay. 22 number of the papers that he quoled, so that I 20 120-0 Kay. 120-0 Kay. 24 Do heal of Petitioners: 3 18 20 11 expert witness in this if I feit that that 20 25 A- What's berr ortorad, with any other lawyer that any other lawyer that any other lawyer that 1 110-0 Kay. 110-0 Kay. 110-0 Kay. 24 1 expert witness in this if I feit that that 2 2 25 O- So, whe provided you		8 i i
12 being on the right side of this argument, and 12.4 Im guessing he was an English speaking lawyer. 13 they showed me Dr. Sackett's report, who I 13.0 Now, you mentioned that you knew Dr. Sackett. 14 who I have personal experience with for many 13.0 Now, you speak with Dr. Sackett in the context 15 years, he's one of my mentors. His report 15.0 16 focused primarily on the thrombophlebitis story, 16.4 No., Iddin't, he had passed away by the time I 19.4 than the the gall bladder disease story. 19 saw his report. 20.0 20 than the the gall bladder disease story. 19 saw his report. 20.0 21 So, I reviewed his report, I reviewed a 21 You mentioned that you wanted you were 22 number of the papers that he quoted, so that I 22 interested only interested in being on the 23 right side of the question, what did you mean by that for equestion, what did you mean by that for 24.0 So, whot provided you with Dr. Sackett's report? 24 So. 18 20 1 Me SAMY ELNEMR, 18 19 that?		
13 they showed me Dr. Sackett's report, who I 130- No. ³ , you mentioned that you knew Dr. Sackett. 14 who I have personal experience with for many 14 Did you speak with Dr. Sackett in the context 15 focused primarily on the thrombophlebitis story. 16 no. 18 Yes. 16 than the the gall bladder disease story. 20 than the up of the papers that he quoted, so that I 22 drafting your mentioned that you wanted you were 21 So, I reviewed his report, I reviewed a 21 You mentioned that you wanted you were 22 number of the papers that he quoted, so that I 22 interested only interested in being on the 23 could get a handle on that information myself 23 You mentioned that you wanted you were 24-0 So, who provided you with Dr. Sackett's report? 25A Well, I said I wouldn't serve as a as an 1 Me SAMY ELNEMR, 1 expert witness in this if I felt that that 2 2 So, kinds and it Mair Elnemr, or was it 6 associated with Yasmin. 5 3 Siskinds was it Maire Elnemr, or was it 6 associated with Yasmin. 100-		5
14 who I have personal experience with for many 14 Did you speak with Dr. Sackett in the context 15 years, he's one of my mentors. His report 15 of 16 focused primarily on the thrombophiebitis story, 15 of 17 rather than the the gall bladder disease story. 17.0 drafting your report? 20 So, I reviewed his report, I reviewed a 21 So, I reviewed his report, I reviewed a 21 21 So, who provided you with Dr. Sackett's report? 20.0 Right. 21 23 could get a handle on that information myself 23 25.4 Well, I said I wouldn't serve as a as an 24.0 So, who provided you with Dr. Sackett's report? 24 that? 26.4 25.A What's your firm's name? 26.4 Well, I said I wouldn't serve as a as an 20 Siskinds. 1 expert witness in this if I felt that that 2 the position this firm was taking as part of 3 their Class Action was the wrong position. So, 3 their Class Action was the wrong position. So, 4 I had to first convinced you of that? Or were you 3		
15 years, he's one of my mentors. His report 15 of 16 focused primarily on the thrombophlebitis story, 17 rather 18Q- Yes. 16A No. 16A 19A- than the the gall bladder disease story. 18A No, I didn't, he had passed away by the time I 20 than the the gall bladder disease story. 20Q- Right. 21 So, I reviewed his report, I reviewed a 20Q- Right. 22 number of the papers that he quoted, so that I 23 right side of the question, what did you mean by 24Q- So, who provided you with Dr. Sackett's report? 25A- Well, I said I wouldn't serve as a as an 25A What's your firm's name? 18 20 1 expert witness in this if 1 feit that that 20 2 On behaf of Petitioners: 3 3 3 Siskinds was it Maitre Elnerm, or was it 6 associated with Yasmin. 7 Siskinds was it Maitre Elnerm, or was it 6 associated with Yasmin. 7 7 Siskinds in Toronto? 8 A I can't recall. I don't rememebr who sent me		
16 focused primarily on the thrombophlebits story, rather 16A- No. 17 rather 17Q- drafting your report? 18Q- Yes. 17Q- drafting your report? 18Q- Yes. 18A- No. 20 20 20 20 20 21 So, I reviewed his report, I reviewed a 21 You mentioned that you wanted you were 23 could get a handle on that information myself 22 interested only interested in being on the 23 could get a handle on that information myself 24 25A- Well, I said I wouldn't serve as a as an 1 Me SAMY ELNEMR, 1 expert witness in this if 1 felt that that 20 1 Me GENEVIEVE BERTRAND: 3 their Class Action was the wrong position. So, 4 4 Mad ton't remember who sent me 9 their looki like there was? 9 9 the report. 0 And what convinced you of that? Or were you 8 10- Did you have contact with any other lawyer than 1 Mate convinced, and 110- Maitre Elnemr? 14A-		
17 rather 17 Q- drafting your report? 18 Q- Yes. 18 A- No, I didn't, he had passed away by the time I 19 A- than the the gall bladder disease story. 20 20 So, I reviewed his report, I reviewed a 20 21 So, I reviewed his report, I reviewed a 20 22 number of the papers that he quoted, so that I 20 23 could get a handle on that information myself 20 24 Q- So, who provided you with Dr. Sackett's report? 25 25 A- What's your firm's name? 20 18 20 20 1 Me SAMY ELNEMR, 20 2 On behalf of Petitioners: 3 3 Siskinds was it Matre Elnemr, or was it 6 3 Siskinds was it Matre Elnemr, or was it 7 4 Me GENEVIEVE BERTRAND: 1 5 O, bot aff of Petitioners: 3 6 Siskinds was it Matre Elnemr, or was it 6 7 Siskinds in Toronto? 7 8 A 1 can't recall. I don't remember who sent me 9 the report. 9 10Q- Did you have contact with any other lawyer t		
18Q- Yes. 18A- w. than the the gall bladder disease stoy. 18A- No, I didn't, he had passed away by the time I 19A than the the gall bladder disease stoy. 19 saw his report. 20 number of the papers that he quoted, so that I 19 saw his report. 21 So, I reviewed his report, I reviewed a 21 You mentioned that you wanted you were 22 number of the papers that he quoted, so that I 21 You mentioned that you wanted you were 23 could get a handle on that information myself 24 You mentioned that you wanted you were 24Q- So, who provided you with Dr. Sackett's report? 24 that? 25A- 24A Welf.NEMR, 21 expert witness in this if I felt that that 2 On behalf of Petitioners: 3 the position this firm was taking as part of 3 Siskindswas it Maitre Elnemr, or was it 6 associated with Yasmin. 7 A. I can't recall. I don't remember who sent me 9 A- Yes, I was convinced that there was? 9 the report. 0- And what convinced you? 11 Maitre Elnemr? 10- And what convinced you? 12A- Yes, there were some oth		
19A than the the gall bladder disease story. 19 saw his report. 20 Right. 20Q- 21 So, I reviewed his report, I reviewed a 20Q- 22 number of the papers that he quoted, so that I 20Q- 23 could get a handle on that information myself 20Q- 24Q- So, who provided you with Dr. Sackett's report? 25A- 25A- What's your firm's name? 25A- 18 20 1 Me SAMY ELNEMR, 2 2 On behalf of Petitioners: 3 3 Siskinds was it Maître Elnemr, or was it 4 GenEVIEVE BERTRAND: 5 So, what And when you say "Siskinds," was it 6 Siskinds in Toronto? 8 A L can't recall. I don't remember who sent me 9 the report. 10Q- Did you have contact with any other lawyer than 11 Maître Elnemr? 12A- Yes, there were some others. Was there anybody 13 from Toronto, or were they all 14A- Lixew nothing of this particular birth control 15 You're going to have to answer		3 , 1
20 20 Q- Right. 21 So, I reviewed his report, I reviewed a 20 Q- 22 number of the papers that he quoted, so that I 23 23 could get a handle on that information myself 24 Q- 24 Q- So, who provided you with Dr. Sackett's report? 23 25 A- What's your firm's name? 26 1 Me SAMY ELNEMR, 21 2 On behalf of Petitioners: 21 expert witness in this if 1 felt that that 2 On behalf of Petitioners: 2 the position this firm was taking as part of 3 Siskinds 4 I had to first convince myself that it really 5 Q- So, what And when you say "Siskinds," was it 6 associated with Yasmin. 7 G- And what convinced you of that? Or were you 8 8 A- I can't recall. I don't remember who sent me 9 + Yes, I was convinced, and 10Q- 10 Q- Did you have contact with any other lawyer than 10Q- And what convinced you? 11A- 11 Me SAMY ELNEMR: 14A- I have mothing of this particular birth control 15 You're going to have to answer 10		
21 So, I reviewed his report, I reviewed a 21 You mentioned that you wanted you were 22 number of the papers that he quoted, so that I interested only interested in being on the 23 could get a handle on that information myself interested only interested in being on the 24 So, who provided you with Dr. Sackett's report? 25A What's your firm's name? 25A What's your firm's name? 26 1 Me SAMY ELNEMR, 20 2 On behalf of Petitioners: 3 3 Siskinds. siskinds, was it 4 GenEVIEVE BERTRAND: 4 5 Q. So, what And when you say "Siskinds," was it 6 6 Siskinds was it Maître Elnemr, or was it 7 7 Siskinds in Toronto? 7 8 A - I carl recall. I don't remember who sent me 9 9 the report. 10Q- And what convinced you of that? Or were you 8 A - I carl recall. I don't remember who sent me 9 9 the report. 10Q- And what convinced you? 11 Maître Elnemr? 11A- it was largely that pa	s ,	I I I I I I I I I I I I I I I I I I I
22 number of the papers that he quoted, so that I 22 interested only interested in being on the 23 could get a handle on that information myself 24 So, who provided you with Dr. Sackett's report? 24 25A- What's your firm's name? 25A- Well, I said I wouldn't serve as a as an 20 1 Me SAMY ELNEMR, 21 expert witness in this if I felt that that 20 3 Siskinds. 3 their Class Action was the wrong position. So, 4 4 Me GENEVIEVE BERTRAND: 5 did look like there was an increased risk 6 6 Siskinds. in don't remember who sent me 9 And what convinced you of that? Or were you 8 A- I can't recall. I don't remember who sent me 9 Are report. 10Q- 10Q- Did you have contact with any other lawyer than 11 11		5
23 could get a handle on that information myself 23 right side of the question, what did you mean by 24Q. So, who provided you with Dr. Sackett's report? 25A- Well, I said I wouldn't serve as a as an 25A- What's your firm's name? 25A- Well, I said I wouldn't serve as a as an 1 Me SAMY ELNEMR, 20 2 On behalf of Petitioners: 2 the position this if I felt that that 20 3 Siskinds. 4 He position this firm was taking as part of 3 their Class Action was the wrong position. So, 4 Me GENEVIEVE BERTRAND: 4 I had to first convinced myself that it really 5 5 Q- So, what And when you say "Siskinds," was it 6 associated with Yasmin. 7 7 Siskinds in Toronto? 7 Q- And what convinced you of that? Or were you 8 8 A - I can't recall. I don't remember who sent me 9 A- Yes, I was convinced, and 10Q- 10 Q- Did you have contact with any other lawyer than 10Q- And what convinced you? 11A- 11 Maître Elnemr? 11A- it was largely that paper that I quoted. 12Q- </td <td></td> <td></td>		
24 Q- So, who provided you with Dr. Sackett's report? 24 that? 25A- What's your firm's name? 24 that? 1 Me SAMY ELNEMR, 1 expert witness in this if 1 felt that that 20 1 Me SAMY ELNEMR, 2 the position this firm was taking as part of 3 siskinds. 2 the position this firm was taking as part of 3 their Class Action was the wrong position. So, 4 I had to first convince myself that it really 5 5 5 did look like there was an increased risk 6 associated with Yasmin. 7 Q- And what convinced you of that? Or were you 8 A I can't recall. I don't remember who sent me 9 A Yes, I was convinced, and 10Q- Did you have contact with any other lawyer than 10Q- Did you have contact with any other lawyer than 11A- it was largely that paper that I quoted. 12Q- 12A- Yes, there were some others. Was there anybody 13 before reading it? 14A- I knew nothing of this particular birth control 15 You're going to have to answer 16Q- To the best of your knowledge. 17A- Right. I mean, given that I haven't prescribed 18Q- To the best of your knowledge.		
25A Well, I said I wouldn't serve as a as an 20 1 Me SAMY ELNEMR, 20 2 On behalf of Petitioners: 2 3 Siskinds. 2 4 Me GENEVIEVE BERTRAND: 2 5 Q-So, what And when you say "Siskinds," was it 6 6 Siskinds was it Maître Elnemr, or was it 7 7 Siskinds in Toronto? 7 8 A - I can't recall. I don't remember who sent me 9 9 the report. 7 10Q-Did you have contact with any other lawyer than 10Q And what convinced you? 11A- it was largely that paper that I quoted. 12Q-Okay. Were you familiar with the Etminan Study 13 before reading it? 14A- 14Me SAMY ELNEMR: 16Q-And you're referring to Yaz and Yasmin? 17Me GENEVIEVE BERTRAND: 17A- 18Q-To the best of your knowledge. 17A- 19Me SAMY ELNEMR: 10Q-And what convinced you? 12Q-To the best of your knowledge. 17A- 13Me GENEVIEVE BERTRAND: 16A- 14A- I knew onthing of this particular birth control	· · · · · · · · · · · · · · · · · · ·	
1 Me SAMY ELNEMR, 20 1 Me SAMY ELNEMR, 1 expert witness in this if I felt that that 2 On behalf of Petitioners: 2 the position this firm was taking as part of 3 Siskinds. 3 the cost on this firm was taking as part of 4 Me GENEVIEVE BERTRAND: 4 I had to first convince myself that it really 5 Q- So, what And when you say "Siskinds," was it 6 associated with Yasmin. 7 Siskinds. 7 Q- And what convinced you of that? Or were you 8 A - I can't recall. I don't remember who sent me 9 A. Yes, I was convinced, and 10Q- Did you have contact with any other lawyer than 10Q- And what convinced you? 11.A. 11 Maître Elnemr? 11A. it was largely that paper that I quoted. 12Q- 12A- Yes, there were some others. Was there anybody 13 before reading it? 14Me SAMY ELNEMR: 14A- I knew nothing of this particular birth control pill. 16A- I just 16Q- And you're referring to Yaz and Yasmin? 17A- 17		
1Me SAMY ELNEMR,1expert witness in this if I felt that that2On behalf of Petitioners:2the position this firm was taking as part of3Siskinds3their Class Action was the wrong position. So,4Me GENEVIEVE BERTRAND:4I had to first convince myself that it really5Q-So, what And when you say "Siskinds," was it6associated with Yasmin.7Siskinds in Toronto?7Q-And what convinced you of that? Or were you8A-I can't recall. I don't remember who sent me8convinced that there was?9the report.9A-Yes, I was convinced you?11Maître Elnemr?11.A it was largely that paper that I quoted.12A-Yes, there were some others. Was there anybody13from Toronto, or were they all14Me SAMY ELNEMR:1kew nothing of this particular birth control15You're going to have to answer16Q-16A-I just16Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17A-18Q-To the best of your knowledge1820 to the best of your knowledge.21 to the best of your knowledge.22 to the best of your knowledge.23Do you remember23Do you remember23Do you remember23Do you remember24I had any doubts, I either turned to a colleague25and made sure I understood it correctly, or I		· ·
2On behalf of Petitioners:2the position this firm was taking as part of3Siskinds.3their Class Action was the wrong position. So,4Me GENEVIEVE BERTRAND:4I had to first convince myself that it really5Q-So, what And when you say "Siskinds," was it56Siskinds was it Maître Elnemr, or was it67Siskinds in Toronto?78A-I can't recall. I don't remember who sent me89the report.9A-10Q-Did you have contact with any other lawyer than10Q-11Maître Elnemr?11A-12A-Yes, I here were some others.Was there anybody13from Toronto, or were they all1314 Me SAMY ELNEMR:14A-I knew nothing of this particular birth control15You're going to have to answer1516A-I just16Q-17 Me GENEVIEVE BERTRAND:17A-18Q-To the best of your knowledge20 to the best of your knowledge.20 to the best of your knowledge.20 to the best of your knowledge.20 to the best of your knowledge.21How would you qualify your level of22 Me GENEVIEVE BERTRAND:2123 Q-Do you remember23 Q-Do you remember23 Q-Do you remember23 Q-Do you remember24 A-I hada any doubts, I either turned to a colleague25		
3 Siskinds. 3 their Class Action was the wrong position. So, 4 Me GENEVIEVE BERTRAND: 4 I had to first convince myself that it really 5 Q-So, what And when you say "Siskinds," was it 5 did look like there was an increased risk 6 Siskinds was it Maître Elnemr, or was it 6 associated with Yasmin. 7 Siskinds in Toronto? 7 Q-And what convinced you of that? Or were you 8 A-I can't recall. I don't remember who sent me 9 convinced that there was? 9 the report. 9 A-Yes, I was convinced, and 10Q- Did you have contact with any other lawyer than 10Q-And what convinced you? 11 Maître Elnemr? 11A it was largely that paper that I quoted. 12A-Yes, there were some others. Was there anybody 13 before reading it? 14Me SAMY ELNEMR: 14A- I knew nothing of this particular birth control 15 You're going to have to answer 16Q-And you're referring to Yaz and Yasmin? 17Me GENEVIEVE BERTRAND: 17A- Right. I mean, given that I haven't prescribed 18Q- To the best of your knowledge. 20Q- Right. I wasn't up-to-		
4Me GENEVIEVE BERTRAND:4I had to first convince myself that it really5Q-So, what And when you say "Siskinds," was it5did look like there was an increased risk6Siskinds was it Maître Elnemr, or was it7Q-And what convinced you of that? Or were you8A-I can't recall. I don't remember who sent me8convinced that there was?9the report.9A-Yes, I was convinced you?10Q-Did you have contact with any other lawyer than10Q-And what convinced you?11Maître Elnemr?11A it was largely that paper that I quoted.12 A-Yes, there were some others. Was there anybody13before reading it?14 Me SAMY ELNEMR:14A-I knew nothing of this particular birth control15You're going to have to answer16Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge19date on what's happening in birth control pills.20 to the best of your knowledge.20Right.21 A-I just can't recall. But21How would you qualify your level of22 Me GENEVIEVE BERTRAND:22Understanding when reading French?23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have25and made sure I understood it correctly, or I		
5Q-So, what And when you say "Siskinds," was it5did look like there was an increased risk6Siskinds in Toronto?7Q-And what convinced you of that? Or were you8A-I can't recall. I don't remember who sent me8convinced that there was?9the report.9A-Yes, I was convinced, and10Q-Did you have contact with any other lawyer than10Q-And what convinced you?11Maître Elnemr?11A it was largely that paper that I quoted.12A-Yes, there were some others. Was there anybody12Okay. Were you familiar with the Etminan Study13from Toronto, or were they all14A-I knew nothing of this particular birth control15You're going to have to answer16Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17A-Right. I mean, given that I haven't prescribed18Q-To the best of your knowledge19date on what's happening in birth control pills.20 to the best of your knowledge.20Q-21A-I just can't recall. But21How would you qualify your level of22 Mc GENEVIEVE BERTRAND:21How would you qualify your level of23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have23 A-I think it was pretty good it correctly, or I25 Q any names?25and made sure I understood it correctly, or I		•
6Siskinds was it Maître Elnemr, or was it6associated with Yasmin.7Siskinds in Toronto?7Q-And what convinced you of that? Or were you8A-I can't recall. I don't remember who sent me8convinced that there was?9the report.9A-Yes, I was convinced, and10Q-Did you have contact with any other lawyer than10Q-And what convinced you?11Maître Elnemr?11A it was largely that paper that I quoted.12A-Yes, there were some others. Was there anybody12Q-Okay. Were you familiar with the Etminan Study13from Toronto, or were they all13before reading it?14Me SAMY ELNEMR:14A-I knew nothing of this particular birth control15You're going to have to answer15pill.16A-I just16Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17A-Right. I mean, given that I haven't prescribed18Q-To the best of your knowledge19date on what's happening in birth control pills.20 to the best of your knowledge.20Q-Right.21A-I just can't recall. But21How would you qualify your level of22A-Do you remember23A-I think it was pretty good. Whenever but if24A I have24I had any doubts, I either turned to a colleague25Q any names?25and made sure I understood it correctly, or I		
7Siskinds in Toronto?7Q-And what convinced you of that? Or were you8A-I can't recall. I don't remember who sent me8convinced that there was?9the report.9A-Yes, I was convinced, and10Q-Did you have contact with any other lawyer than10Q-And what convinced you?11Maître Elnemr?11A it was largely that paper that I quoted.12A-Yes, there were some others. Was there anybody12Q-Okay. Were you familiar with the Etminan Study13from Toronto, or were they all14A-I knew nothing of this particular birth control15You're going to have to answer15pill.16A-I just16Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17A-Right.I wasn't up-to-19 Me SAMY ELNEMR:19date on what's happening in birth control pills.20 to the best of your knowledge.20Q-Right.21A-I just can't recall. But21How would you qualify your level of22Me GENEVIEVE BERTRAND:22understanding when reading French?23Q-Do you remember23A-I think it was pretty good. Whenever but if24A I have24I had any doubts, I either turned to a colleague25Q any names?25and made sure I understood it correctly, or I		
8 A- I can't recall. I don't remember who sent me 8 convinced that there was? 9 the report. 9 A- Yes, I was convinced, and 10Q- Did you have contact with any other lawyer than 10Q- And what convinced you? 11 Maître Elnemr? 11A- it was largely that paper that I quoted. 12A- Yes, there were some others. Was there anybody 12Q- Okay. Were you familiar with the Etminan Study 13 from Toronto, or were they all 11A- it was largely that paper that I quoted. 14Me SAMY ELNEMR: 14A- I knew nothing of this particular birth control 15 You're going to have to answer 15pill. 16A- I just 16Q- And you're referring to Yaz and Yasmin? 17 Me GENEVIEVE BERTRAND: 17A- Right. I mean, given that I haven't prescribed 18 them in thirty (30) years, I I wasn't up-to- 19 19Me SAMY ELNEMR: 20 to the best of your knowledge. 20Q- 21A- I just can't recall. But 21 How would you qualify your level of 22Me GENEVIEVE BERTRAND: 22 understanding when reading French?		
9the report.9A-Yes, I was convinced, and10 Q-Did you have contact with any other lawyer than10 Q-And what convinced you?11Maître Elnemr?11 A it was largely that paper that I quoted.12 A-Yes, there were some others. Was there anybody12 Q-Okay. Were you familiar with the Etminan Study13from Toronto, or were they all12 Q-Okay. Were you familiar with the Etminan Study14 Me SAMY ELNEMR:14 A-I knew nothing of this particular birth control15You're going to have to answer15pill.16 A-I just16 Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17 A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge19date on what's happening in birth control pills.20 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of22 A-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		5
10 Q-Did you have contact with any other lawyer than10 Q-And what convinced you?11Maître Elnemr?11 A it was largely that paper that I quoted.12 A-Yes, there were some others. Was there anybody12 Q-Okay. Were you familiar with the Etminan Study13from Toronto, or were they all12 Q-Okay. Were you familiar with the Etminan Study14 Me SAMY ELNEMR:14 A-I knew nothing of this particular birth control15You're going to have to answer15pill.16 A-I just16 Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17 A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge18them in thirty (30) years, I I wasn't up-to-19 Me SAMY ELNEMR:20 Q-Right.2120 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of22 Me GENEVIEVE BERTRAND:22understanding when reading French?23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		
11Maître Elnemr?12 A- Yes, there were some others. Was there anybody13from Toronto, or were they all14 Me SAMY ELNEMR:15You're going to have to answer16 A- I just17 Me GENEVIEVE BERTRAND:18 Q- To the best of your knowledge19 Me SAMY ELNEMR:20 to the best of your knowledge.21 A- I just can't recall. But22 Me GENEVIEVE BERTRAND:23 Q- Do you remember24 A I have25 Q any names?		
12 A-Yes, there were some others. Was there anybody13from Toronto, or were they all14 Me SAMY ELNEMR:15You're going to have to answer16 A-I just17 Me GENEVIEVE BERTRAND:18 Q-To the best of your knowledge19 Me SAMY ELNEMR:20 to the best of your knowledge.21 A-I just can't recall. But22 Me GENEVIEVE BERTRAND:23 Q-Do you remember23 Q-Do you remember24 A I have25 Q any names?		,
13from Toronto, or were they all13before reading it?14 Me SAMY ELNEMR:14 A-I knew nothing of this particular birth control15You're going to have to answer15pill.16 A-I just16 Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17 A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge17 A-Right. I mean, given that I haven't prescribed19 Me SAMY ELNEMR:19date on what's happening in birth control pills.20 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		0, 1, 1
14 Me SAMY ELNEMR:14 A-I knew nothing of this particular birth control15You're going to have to answer15pill.16 A-I just16 Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17 A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge18them in thirty (30) years, I I wasn't up-to-19 Me SAMY ELNEMR:19date on what's happening in birth control pills.20 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of22 Me GENEVIEVE BERTRAND:23 Q-Do you remember23 A-23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have25and made sure I understood it correctly, or I		, , , , , , , , , , , , , , , , , , , ,
15You're going to have to answer15pill.16 A-I just16 Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17 A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge18them in thirty (30) years, I I wasn't up-to-19 Me SAMY ELNEMR:19date on what's happening in birth control pills.20 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		0
16 A-I just16 Q-And you're referring to Yaz and Yasmin?17 Me GENEVIEVE BERTRAND:17 A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge17 A-Right. I mean, given that I haven't prescribed19 Me SAMY ELNEMR:19date on what's happening in birth control pills.20 to the best of your knowledge.19date on what's happening in birth control pills.21 A-I just can't recall. But21How would you qualify your level of23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have23 A-I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		5 1
17 Me GÉNEVIEVE BERTRAND:17 A-Right. I mean, given that I haven't prescribed18 Q-To the best of your knowledge18them in thirty (30) years, I I wasn't up-to-19 Me SAMY ELNEMR:19date on what's happening in birth control pills.20 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of22 Me GENEVIEVE BERTRAND:22understanding when reading French?23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		
18 Q-To the best of your knowledge18them in thirty (30) years, I I wasn't up-to-19 Me SAMY ELNEMR:19date on what's happening in birth control pills.20 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of22 Me GENEVIEVE BERTRAND:22understanding when reading French?23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I	,	, ,
19 Me SAMY ELNEMR:19 date on what's happening in birth control pills.20 to the best of your knowledge.20 Q-21 A-I just can't recall. But22 Me GENEVIEVE BERTRAND:2123 Q-Do you remember24 A I have25 Q any names?25 Q any names?		5 / 5 / I
20 to the best of your knowledge.20 Q-Right.21 A-I just can't recall. But21How would you qualify your level of22 Me GENEVIEVE BERTRAND:22understanding when reading French?23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I	, ,	
21 A-I just can't recall. But21How would you qualify your level of22 Me GENEVIEVE BERTRAND:22understanding when reading French?23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		
22 Me GENEVIEVE BERTRAND:22understanding when reading French?23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I	, , ,	•
23 Q-Do you remember23 A-I think it was pretty good. Whenever but if24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I	,	5 1 5 5
24 A I have24I had any doubts, I either turned to a colleague25 Q any names?25and made sure I understood it correctly, or I		
25 Q any names? 25 and made sure I understood it correctly, or I	23 O- Do vou remember	a b
		23 A- I think it was pretty good. Whenever but if
	24 A I have	23 A- I think it was pretty good. Whenever but ifI had any doubts, I either turned to a colleague

	21			23
1	you know, I used Google Translate if there	1 Q-	Okay, that you can	
2	was	2 A-	I You know, to me it really this	
3 Q-	Okay.	3	case out of the three (3) cases really	
4 A-	a word I couldn't you know, but it was	4	hung on that specific paper, I found nothing	
5	not a very difficult testimony to read, the	5	else that was either on gall bladder disease	
6	obstetrician/gynaecologist who wrote the other	6	that was either confirmatory or contradictory to	
7	report it was fairly straightforward.	7	that specific paper, and you know, the rest of	
8 Q-	So, you're talking about Dr. Masse Dr	8	my reading was on gall bladder and	
9 A-	Right.	9	thrombophlebitis.	
10 Q-	André Masse's	10	And I mean, I could I probably do have	
11 A-	Right.	11	a digital trail, so to speak, because as a	
12 Q-	report?	12	general rule, I would	
13	And in terms of the medical records	13 Q-	Yes.	
14 A-	Right, the medical records were not particularly	14 A-	copy a paper and put it away. But there	
15	complicated either.	15	could be all kinds of stuff	
16 Q-	Okay. Did you review any other documents in the	16 Q-	Okay.	
17	context of We've talked about some of the	17 A-	that I've just I don't really I'd have	
18	literature	18	to spend some time on it	
19 A-	No.	19 Q-	Okay.	
20 Q-		20 A-	if that's what you wanted.	
20 Q-	Dr. Masse's report I			
		21 Q-	Well, if it's easily if you do have a folder	
22 Q-	the medical records.	22	where you've	
23 A-	My review was confined to Dr. Sackett's report,	23 A-	I don't.	
24	my own research around the literature on birth	24 Q-	split everything okay.	
25	control pill and these complications, and Dr.	25	How did you come to be involved in the	
	22			24
1	Masse's report.	1	proceedings in the Class Action as an expert?	
2 Q-	Okay.	2 A-	A member of a lawyer in Siskinds' firm a	
3	Did you In the context of preparing your	3	different lawyer called me up or sent me an	
4	report, did you review the medical records, as	4	e-mail, rather	
5	well?	5 Q-	Okay.	
6 A-	Yes.	6 A-	and asked me would I be interested in doing	
7 Q-	So, Ms. Guindon, Ms. Gladu, and Ms. Bouchard's	7	this, and I sort of responded, "Well, where did	
8	medical records	8	you get my name from, and why are you calling	
9 A-	That's right.	9	me?"	
10 Q-	the three (3) representative Plaintiffs?	10 Q-	Right.	
11 A-	That's right.	11 A-	and that sort of thing.	
12 Q-	Would you be in a position to provide us with a	12 Q-	And was that in the context of the Quebec	
13	list of the literature that you've reviewed	13		
13			action?	
	a list of the research you did? Did you keep a	14 A-	l guess so, yes.	
15	track of any of it, or would you have to redo	15Q-	And do you remember who You said you don't	
16	the research?	16	remember who	
17 A-	I have some reprints of papers that I thought	17 A-	But I	
18	started to look interesting, but certainly I	18 Q-	you specifically spoke to?	
19	have some this would take some work.	19 A-	That's a name I can come up with	
20 Q-	Okay.	20 Q-	Okay.	
21 A-	This would take some work.	21 A-	if I had to.	
22 Q-	So, you don't have something	22 Q-	Well, no, that's fine, actually.	
	In some	23	Well, how many times I'll ask you this,	
23 A-				
24 Q-	ready	24	how many times have you spoken to counsel in the	

Astrida Auza o.c.r.

Steno Exact MAXIN

4 14-		25	4 4		27
	SAMY ELNEMR:		1 A-	I remembered every I have the documents	
2	To the best of your recollection		2 Q-	Right.	
3 A- 4 Q-	Yes, yes, I get it. obviously.		3 A- 4 Q-	in my office, and I remember reviewing Sure.	
5 A-	I'm going to guess, between e-mails, personal		5 A-	absolutely everything that was provided to	
6 7	contact, and telephone calls, we're talking		6 7 Q-	me. Okay In your report you refer to Mc. Guinden	
	about half a dozen (6). GENEVIEVE BERTRAND:		7 Q- 8	Okay. In your report, you refer to Ms. Guindon taking Yasmin instead of Yaz, but you meant to	
9 Q-	Okay. And does that include discussions		9	write Yaz in regard to Ms. Guindon, not Yasmin,	
10	regarding the report?		10	correct?	
11 A-	There was one (1) discussion about the report			SAMY ELNEMR:	
12	before it was submitted.		12	You can refer him to the report?	
13 Q-	And how many drafts of the report did you have?			GENEVIEVE BERTRAND:	
14 A-	For the I can't recall if there were any		14	Sure.	
15	changes, but, you know, if there was, it was		15 A-	l'm sorry	
16	only in, you know, some I refused to change		16 Q-	So, for example, at paragraph 6 of your	
17	the report based on any any outside ideas		17	report	
18	other than my own, but there might have been a		18 A-	Sorry, give me one second.	
19	couple of things where someone said, you know,		19 Q-	Sure, please	
20	"Make sure you put this in at this point here,"		20 A-	Is this	
21	type of thing. But the report is my report.		21 Q-	take your time.	
22 Q-	Okay. Do you recall which of Ms. Guindon's		22 A-	this document here that I have in front of	
23	medical records you reviewed?		23	me?	
24 A-	You're going to have to orient me on which one		24 Q-	Your report, yes Oh, no, that's the Motion,	
25	of		25	I think, and	
		26			28
1 Q-	No, just	20	1 Me	SAMY ELNEMR:	20
2 A-	which one of the patients she is.		2	That's the Motion	
3 Q-	Oh, so she's the main representative Plaintiff			GENEVIEVE BERTRAND:	
4	who took Yaz. Obese smoker			I have a copy here, if you need one.	
5 A-	Yes.			SAMY ELNEMR:	
6 Q-	she was the first one		6	This is your report.	
7 A-	I remember I only loosely remember the three		7 A-	Yes.	
8	(3) patients			GENEVIEVE BERTRAND:	
9 Q-	Okay.			Okay, so if you take, for example, paragraph	
10 A-	without having the document in front		10	6 and it's throughout the section on Ms.	
11 Q-	Sure.		11	Guindon	
12 A-	of me. I remember that one (1) of the		12 A-	Yes.	
13	cases, I didn't think had absolutely anything to		13 Q-	but if you if you look at her section	
14	do with birth control pills, at all.		14	and one (1) example is paragraph 6 You refer	
15 Q-	Yes.		15	to	
16 A-	And the other two (2) were very similar, for the		16 A-	Yes.	
17	most part, the women who had multiple risk		17 Q-	Ms. Guindon as taking Yasmin, but I would	
18	factors for gallstones, and who developed their		18	have assumed you meant Yaz wherever you wrote	
19	thrombophlebitis following their hospitalization		19	Yasmin in terms of Madame Ms. Guindon?	
20	for the gallstones.		20 A-	I guess I was using I'm just guessing that I	
21 Q-	Right, okay, but So, for all three (3) of		21	was using the two (2) terms interchangeably	
22	them, you wouldn't specifically remember which		22	based on whatever I was probably responding	
	medical records you would have reviewed		23	to what I thought was in Dr. Masse's report.	
23					
23 24 A-	I don't remember		24	used Did I use Did I use Yaz or Yasmin	
	I don't remember without having the documents		24 25	used Did I use Did I use Yaz or Yasmin throughout the report?	

AFFIDAVIT

	29		31
1 Q-	I think you used Yasmin throughout the report.	1 Q-	Are you aware that there are two (2) different
2 A-	Right.	2	actions, one (1) in Ontario, and one (1) in
2 A- 3 Q-	And I Perhaps you meant but I understand	3	Quebec?
			Yes, I was told that.
4	your response, perhaps you meant to write Yaz	4 A-	
5	instead of Yasmin	5 Q-	Yes, okay.
6 A-	Oh, yes, I think that would be	6	Did you use Dr. Sackett's as the basis for
7 Q-	for Ms. Guindon	7	your own opinion?
8 A-	I think that	8 A-	No, I didn't. Wall switch seems new to Ma. Guindan
9 Q-	is that	9 Q-	We'll switch gears now to Ms. Guindon
10 A-	would be true.	10	specifically, and we'll start with the
11Q-	Is that true? Okay.	11	gallstones.
12	Also in the report, you refer to the	12 A-	Okay.
13	Etminian E-T-M-I-N-I-A-N	13 Q-	I'll start with general questions, though,
14 A-	Sorry, where are we now?	14	first, regarding gallstones
15 Q-	So, at paragraph 8	15 A-	Yes.
16 A-	Yes.	16 Q-	before getting into Ms. Guindon's specific
17 Q-	of the report, you refer to the Etminian	17	situation.
18 A-	Yes.	18	Now, you're aware that fifteen percent
19 Q-	E-T-M-I-N-I-A-N, at paragraph 8, and the	19	(15%) of Caucasian women in North America are at
20	Etimian	20	risk of developing gallstones?
21 A-	Yes.	21 A-	If you say so, sure.
22 Q-	E-T-I-M-I-A-N Study at paragraph 14.	22 Q-	Okay, so you're not specifically aware of that?
23 A-	Yes.	23 A-	I don't have a number in my own mind
24 Q-	But I think you meant to write the Etminan	24 Q-	Okay.
25	Study, E-T-M-I-N-A-N.	25 A-	as to I mean, I know lots of women
	30		32
1 A-	You're saying there's a spelling mistake?	1	develop gallstones, but I don't have a specific
2 Q-	Yes, I'm just	2	
		14	number in my mind.
3 A-	Okay.	2 3 Q-	•
3 A- 4 Q-	Okay. I want to make sure that that		Okay, are you aware that a family history of
	I want to make sure that that	3 Q-	Okay, are you aware that a family history of gallstones doubles that risk?
4 Q- 5 A-		3 Q- 4	Okay, are you aware that a family history of
4 Q- 5 A-	I want to make sure that that Right.	3 Q- 4 5 A-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk.
4 Q- 5 A- 6 Q- 7	I want to make sure that that Right. was your intention. That's why I'm spelling	3 Q- 4 5 A- 6	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known
4 Q- 5 A- 6 Q-	I want to make sure that that Right. was your intention. That's why I'm spelling them out for you.	3 Q- 4 5 A- 6 7 Q-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk.
4 Q- 5 A- 6 Q- 7 8	I want to make sure that that Right. was your intention. That's why I'm spelling	3 Q- 4 5 A- 6 7 Q- 8	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing
4 Q- 5 A- 6 Q- 7 8 9	I want to make sure that that Right. was your intention. That's why I'm spelling them out for you.	3 Q- 4 5 A- 6 7 Q- 8 9 A-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I
4 Q- 5 A- 6 Q- 7 8 9 10	I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD)	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones?
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes.
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10Q- 11A- 12Q-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q-	I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen?
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz,
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A-	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A- 17 Q-	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. the Etminan Study? 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and progesterone that was in it
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A- 17 Q- 18 A-	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. the Etminan Study? That's right. 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 Q-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and progesterone that was in it Right.
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A- 17 Q- 18 A- 19 Q-	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. the Etminan Study? That's right. Okay. Were you given other any other 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 Q- 19 A-	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and progesterone that was in it Right. but it wasn't an important point in my
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A- 17 Q- 18 A- 19 Q- 20	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. the Etminan Study? That's right. Okay. Were you given other any other documents in regard to the Ontario proceedings, 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 Q- 19 A- 20	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and progesterone that was in it Right. but it wasn't an important point in my consideration, I wasn't I don't fuss about
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A- 17 Q- 18 A- 19 Q- 20 21	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. the Etminan Study? That's right. Okay. Were you given other any other documents in regard to the Ontario proceedings, and other than Dr. Sackett's report? 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 Q- 19 A- 20 21	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and progesterone that was in it Right. but it wasn't an important point in my consideration, I wasn't I don't fuss about the chemical composition. For me, as a clinical
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A- 17 Q- 18 A- 19 Q- 20 21 22 A-	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. the Etminan Study? That's right. Okay. Were you given other any other documents in regard to the Ontario proceedings, and other than Dr. Sackett's report? If I was, I can't remember them. The only 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 Q- 19 A- 20 21 22	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and progesterone that was in it Right. but it wasn't an important point in my consideration, I wasn't I don't fuss about the chemical composition. For me, as a clinical epidemiologist, as opposed to, let's say, a
4 Q- 5 A- 6 Q- 7 8 9 10 11 A- 12 13 Me 14 Q- 15 16 A- 17 Q- 18 A- 19 Q- 20 21 22 A- 23	 I want to make sure that that Right. was your intention. That's why I'm spelling them out for you. (DISCUSSION OFF RECORD) No, there was only one (1) there's only one (1) study. GENEVIEVE BERTRAND: There's only one (1) study, and you meant to refer to Right. the Etminan Study? That's right. Okay. Were you given other any other documents in regard to the Ontario proceedings, and other than Dr. Sackett's report? If I was, I can't remember them. The only things I remember are the things I did the 	3 Q- 4 5 A- 6 7 Q- 8 9 A- 10Q- 11A- 12Q- 13 14 15A- 16 17 18Q- 19A- 20 21 22 23	Okay, are you aware that a family history of gallstones doubles that risk? I wouldn't have known off the top of my head that it doubled the risk. Okay. Are you aware that obesity is a known risk factor of developing That one, I gallstones? That I am aware of, yes. And you're aware or are you aware that Yaz only contains twenty micrograms (20 mcg) of estrogen? I was aware of it at the I read up on Yaz, and I checked out the amount of estrogen and progesterone that was in it Right. but it wasn't an important point in my consideration, I wasn't I don't fuss about the chemical composition. For me, as a clinical epidemiologist, as opposed to, let's say, a pharmacologist, it's not what the ingredients

AFFIDAVIT

	33	3	:	35
1 A-	The clinical research data.	1	quite frank with you, to show that something at	
2 Q-	Okay, that are used in studies, for example?	2	a certain dose does not increase the risk of	
3 A-	Well, it was specifically used in that one (1)	3	something is a very difficult study to do.	
4	study that I quoted.	4 Q-	Yes.	
1				
5 Q-	Okay. Were you aware that Yasmin contains	5 A-	The easiest way to do that is simply have the	
6	thirty micrograms (30 mcg) of estrogen?	6	study underpowered so that you can't prove it.	
7 A-	I know there's different dosing levels of it,	7	So, in those sorts of situations, negative	
8	yes.	8	studies are far less important than positive	
9 Q-	Between You mean different dosing between Yaz	9	studies, particularly if the positive studies	
10	and Yasmin?	10	are positive because they're so much bigger than	
11 A-	Well, that there's different levels there's	11	the negative studies were.	
12	a lower dose estrogen and a higher dose	12 Q-	Yes. So, you haven't seen any studies that	
13	estrogen.	13	that do Did you look for any studies that	
14 Q-	Between the Yaz and Yasmin? I'm just trying	14	mentioned that	
15	to or between oral contraceptives, generally?	15 A-	I looked for everything I could find	
16 A-	Oh, again, I'm thinking primarily of the generic	16 Q-		
			Okay.	
17	name of the drug, and I know it comes in	17 A-	on the drug.	
18	different doses of estrogen	18 Q-	And specifically	
19 Q-	Okay.	19 A-	Around gallstones and thrombophlebitis.	
20 A-	and part of the problem is that the research	20 Q-	Okay, and you You did not come across a study	
21	studies often are going back and forth between	21	that would that	
22	one dose or the other dose, they're not always	22 A-	That would sway my opinion?	
23	looking at the same dose.	23 Q-	No, no, in terms of That oral contraceptives	
24 Q-	Is that because they take into consideration	24	with less than fifty micrograms (50 mcg) of	
25	various	25	estrogen don't contribute significantly to the	
			5 5 ,	
	34			36
1 A-	34 Well, I mean	1	development of gallstones. You haven't	36
1 A- 2 Q-				36
	Well, I mean oral contraceptives?	1	development of gallstones. You haven't	36
2 Q- 3 A-	Well, I mean	1 2 A-	development of gallstones. You haven't I didn't seen that?	36
2 Q- 3 A- 4	Well, I mean oral contraceptives? That's right, women just get prescribed different	1 2 A- 3 Q- 4 A-	development of gallstones. You haven't I didn't seen that? I didn't find a study like that.	36
2 Q- 3 A- 4 5 Q-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right.	1 2 A- 3 Q- 4 A- 5 Q-	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with	36
2 Q- 3 A- 4 5 Q- 6 A-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical.	1 2 A- 3 Q- 4 A- 5 Q- 6	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive	1 2 A- 3 Q- 4 A- 5 Q- 6 7	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure.	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed?	1 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A-	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm.	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q-	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer.	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A-	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q-	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones?	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones?	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay.	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven.	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A-	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q-	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER:	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18	 Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? 	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18 19 Me 0	Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? GENEVIEVE BERTRAND:	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 19	 development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when the gallstone started growing, but when the 	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18 19 Me 0 20	 Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? GENEVIEVE BERTRAND: Fifty (50). Five zero (5-0). 	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 19 20	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when the gallstone started growing, but when the gallstone became of sufficient size that it	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18 19 Me 0 20 21 Q-	 Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? GENEVIEVE BERTRAND: Fifty (50). Five zero (5-0). Did you understand that as being five zero (5-0) 	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 19 20 21	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when the gallstone started growing, but when the gallstone became of sufficient size that it caused the inflammation and the symptoms of gall	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18 19 Me 0 20 21 Q- 22	 Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? GENEVIEVE BERTRAND: Fifty (50). Five zero (5-0). Did you understand that as being five zero (5-0) when I asked the question? 	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 19 20 21 22	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when the gallstone started growing, but when the gallstone became of sufficient size that it caused the inflammation and the symptoms of gall bladder disease, so that somebody actually had	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18 19 Me 0 20 21 Q- 22 23 A-	 Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? GENEVIEVE BERTRAND: Fifty (50). Five zero (5-0). Did you understand that as being five zero (5-0) when I asked the question? When you said fifty (50), yes. 	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 19 20 21 22 23	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when the gallstone started growing, but when the gallstone became of sufficient size that it caused the inflammation and the symptoms of gall bladder disease, so that somebody actually had to do something about it. Because I think we'd	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18 19 Me (20 21 Q- 22 23 A- 24 Q-	 Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? GENEVIEVE BERTRAND: Fifty (50). Five zero (5-0). Did you understand that as being five zero (5-0) when I asked the question? When you said fifty (50), yes. Okay. 	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 19 20 21 22 23 24	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when the gallstone started growing, but when the gallstone became of sufficient size that it caused the inflammation and the symptoms of gall bladder disease, so that somebody actually had to do something about it. Because I think we'd agree that there's lots of asymptomatic	36
2 Q- 3 A- 4 5 Q- 6 A- 7 Q- 8 A- 9 Q- 10 11 12 13 14 A- 15 16 Q- 17 THE 18 19 Me 0 20 21 Q- 22 23 A-	 Well, I mean oral contraceptives? That's right, women just get prescribed different Right. doses, it's typical. Okay, depending on the oral contraceptive Sure. that's prescribed? Are you aware that oral contraceptives with less than fifty micrograms (50 mcg) of estrogen don't significantly contribute to the formation of gallstones? I'm not sure, I don't I'm not aware that that's been proven. Okay. COURT REPORTER: It was fifteen (15)? One five (1-5)? GENEVIEVE BERTRAND: Fifty (50). Five zero (5-0). Did you understand that as being five zero (5-0) when I asked the question? When you said fifty (50), yes. 	1 2 A- 3 Q- 4 A- 5 Q- 6 7 8 9 A- 10 Q- 11 A- 12 Q- 13 14 15 A- 16 17 18 19 20 21 22 23	development of gallstones. You haven't I didn't seen that? I didn't find a study like that. You're aware that Ms. Guindon was diagnosed with a gallstone that measured three point two centimetres (3.2 cm) two (2) months after she started taking Yaz? M'hm. It has to be a verbal answer. Oh, yes. I'm sorry, yes. Okay. And you agree that a gallstone that size would have started forming before Ms. Guindon started taking Yaz? I couldn't say with certainty, because I really don't know how fast gallstones grow, but what's important is not at least as a clinician, I would argue that what's important is not when the gallstone started growing, but when the gallstone became of sufficient size that it caused the inflammation and the symptoms of gall bladder disease, so that somebody actually had to do something about it. Because I think we'd	36

		37			39
1	cause anybody any trouble	0,	1	the Yaz.	00
2 Q-	Right.		2 Q-	Okay. Switching gears now, still on Ms.	
3 A-	nobody fusses about them.		3	Guindon, but with regard to the	
4 Q-	Would you agree that it's likely more likely		4	thromboembolism	
5	than not that it's likely that a gallstone		5 A-	Yes.	
6	that size would have started forming before she		6 Q-	you're aware that without any risk factors,	
7	had started taking the Yaz before two (2)		7	just generally speaking, the risk of developing	
8	months, basically, it would		8	thrombophlebitis is four (4) out of ten thousand	
9 A-	Yes, I really couldn't say, I have no I have		9	(10,000) persons a year? Are you aware of that?	
10	no knowledge of exactly what the speed that		10 A-	I wouldn't know that	
11	gallstones can grow.		11Q-	Okay.	
12 Q-	Okay. But you agree with Dr. Masse that Ms.		12 A-	number off the top of my head.	
13	Guindon had many important risk factors		13 Q-	And that using any oral contraceptive, no matter	
14 A-	Yes.		13 Q-		
				the brand, would increase that risk by two to $(2, 2)$ times?	
15Q-	associated with gallstones?		15	three (2 - 3) times?	
16 A-	Yes, I do.		16 A-	I know that most oral contraceptives will	
17 Q-	And you also agree that Ms. Guindon's most		17	increase the risk of developing	
18	important risk factors were associated Well,		18	thrombophlebitis.	
19	were regarding the gallstone, were the		19 Q-	Okay. Regardless of the oral contraceptive,	
20	obesity and the fact that she smoked?		20	regardless of	
21 A-	I would argue her most important risk factor was		21 A-	Right.	
22	the fact that she was hospitalized for a		22 Q-	the brand? And the risk of developing	
23	cholecystectomy up until she was hospitalized		23	thrombophlebitis when taking an oral	
24	for a cholecystectomy I'm sorry, you're		24	contraceptive decreases with the dose of	
25	talking about the gallstones. Yes		25	estrogen are you aware of that?	
		38			40
1 Q-	Yes.	38	1 A-	Yes.	40
1 Q- 2 A-	Yes. I would argue Yes, you're right, the	38	1 A- 2 Q-	Yes. And you're aware that the Institut national de	40
		38			40
2 A-	I would argue Yes, you're right, the	38	2 Q-	And you're aware that the Institut national de	40
2 A- 3	I would argue Yes, you're right, the smoking and the obesity would be the most	38	2 Q- 3	And you're aware that the Institut national de santé publique du Québec so the INSPQ	40
2 A- 3 4	I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the	38	2 Q- 3 4 A-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes.	40
2 A- 3 4 5	I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones.	38	2 Q- 3 4 A- 5 Q-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the	40
2 A- 3 4 5 6 Q-	I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon	38	2 Q- 3 4 A- 5 Q- 6	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives?	40
2 A- 3 4 5 6 Q- 7 A-	I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes.	38	2 Q- 3 4 A- 5 Q- 6 7 A-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes.	40
2 A- 3 4 5 6 Q- 7 A- 8 Q-	I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that?	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that?	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews.	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A-	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q-	I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that?	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A-	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A- 17	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more important. 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A- 17	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but I've you know, I've served as I've served	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A- 17 18 Q-	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more important. Okay. And you agree that Ms. Guindon's use of Yaz is not the cause of the gallstone? 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A- 17 18	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but I've you know, I've served as I've served on these committees over the years, and I've also been an expert advisor to these committees,	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A- 17 18 Q- 19 20 A-	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more important. Okay. And you agree that Ms. Guindon's use of Yaz is not the cause of the gallstone? No, I wouldn't agree to that. 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A- 17 18 19	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but I've you know, I've served as I've served on these committees over the years, and I've	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A- 17 18 Q- 19 20 A- 21 Q-	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more important. Okay. And you agree that Ms. Guindon's use of Yaz is not the cause of the gallstone? No, I wouldn't agree to that. Okay, but it's not It's not the main cause of 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A- 17 18 19 20	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but I've you know, I've served as I've served on these committees over the years, and I've also been an expert advisor to these committees, and I wouldn't let any committee report Yes.	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A- 17 18 Q- 19 20 A- 21 Q- 22	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more important. Okay. And you agree that Ms. Guindon's use of Yaz is not the cause of the gallstone? No, I wouldn't agree to that. Okay, but it's not It's not the main cause of the gallstone, there are, as we mentioned, the 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A- 17 18 19 20 21 Q- 22 A-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but I've you know, I've served as I've served on these committees over the years, and I've also been an expert advisor to these committees, and I wouldn't let any committee report Yes. in Quebec, or Canada for that matter, change	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A- 17 18 Q- 19 20 A- 21 Q- 22 23	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more important. Okay. And you agree that Ms. Guindon's use of Yaz is not the cause of the gallstone? No, I wouldn't agree to that. Okay, but it's not It's not the main cause of the gallstone, there are, as we mentioned, the other factors that are more important than 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A- 17 18 19 20 21 Q- 22 A- 23	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but I've you know, I've served as I've served on these committees over the years, and I've also been an expert advisor to these committees, and I wouldn't let any committee report Yes. in Quebec, or Canada for that matter, change my opinion, because	40
2 A- 3 4 5 6 Q- 7 A- 8 Q- 9 10 11 12 13 14 A- 15 Q- 16 A- 17 18 Q- 19 20 A- 21 Q- 22	 I would argue Yes, you're right, the smoking and the obesity would be the most important reason that she developed the gallstones. Right. So, for Ms. Guindon Yes. you agree with that? And you agree that the risks associated with any oral contraceptive for developing gallstones is small compared to other risk factors? So, we're talking about the risk factors of obesity, smoking, immobility Yes, I I would surgery I would agree that obesity and smoking are more important. Okay. And you agree that Ms. Guindon's use of Yaz is not the cause of the gallstone? No, I wouldn't agree to that. Okay, but it's not It's not the main cause of the gallstone, there are, as we mentioned, the 	38	2 Q- 3 4 A- 5 Q- 6 7 A- 8 Q- 9 A- 10 11 12 13 Q- 14 15 16 A- 17 18 19 20 21 Q- 22 A-	And you're aware that the Institut national de santé publique du Québec so the INSPQ Yes. reviewed the available studies regarding the risk of progesterone in oral contraceptives? Yes. Were you aware of that? Yes, I don't know that they did that study, but I wouldn't be put off by any provincial or national body that comes up with these sorts of reviews. Okay. And Dr. Masse referred to this review in his expert report, do you have a recollection of that that he mentioned that? I didn't recall that he mentioned it, but I've you know, I've served as I've served on these committees over the years, and I've also been an expert advisor to these committees, and I wouldn't let any committee report Yes. in Quebec, or Canada for that matter, change	40

1mean, without looking at the report1A-2personally3Q-3Q-Yes.3cited?4A they're not all necessarily of particularly5high standards.6Q-Okay. But in this case, you haven't reviewed7the national the7the national the5Q-Okay, and the study you cited, just for the8A-No, I didn't I didn't9Q INSPQ's report?10A-I didn't review the national report.10A-I didn't review the national report.11Q-So, you don't know the quality of the INSPQ's10A-Right.12A-No, I don't.12A-CMAJ, yes.13Q report?Okay.13Q-14Were you aware that the Institute concluded14We were talking about the fact that obe15that all the available15on its own increases the risk of16A-No,16A-Yes.17Q studies had methodological flaws?17Q-18A-No, I didn't read the report.17Q-19Q-Were you aware that the Institute concluded that2020if there were there was, sorry, a difference20Q-20Q-Verbally?	
2personally2Institute's report did they cite the study I3Q-Yes.3cited?4A they're not all necessarily of particularly5high standards.6Q-Okay. But in this case, you haven't reviewed5Q-7the national the5Q-Okay, and the study you cited, just for the8A-No, I didn't I didn't6record, is9Q INSPQ's report?9(2011), it's the Etminan Study10A-I didn't review the national report.10A-Right.11Q-So, you don't know the quality of the INSPQ's10A-Right.12A-No, I don't.10A-Right.13Q report? Okay.11Q published in this CMAJ14Were you aware that the Institute concluded14We were talking about the fact that obe15that all the available16A-Yes.16A-No, I didn't read the report.17Q developing thrombophlebitis by two to the18A-No, I didn't read the report.17Q developing thrombophlebitis by two to the18A-No, I didn't read the report.19A-M'hm.20if there were there was, sorry, a difference20Q-Verbally?	
2personally2Institute's report did they cite the study I3Q-Yes.3cited?4A they're not all necessarily of particularly5high standards.5high standards.6Q-Okay. But in this case, you haven't reviewed56Q-Okay. But in this case, you haven't reviewed5Q-Okay, and the study you cited, just for the7the national the7A-Is the8A-No, I didn't I didn't8Q dated May seventeen (17), twenty elever9Q INSPQ's report?9(2011), it's the Etminan Study10A-I didn't review the national report.11Q published in this CMAJ11Q-So, you don't know the quality of the INSPQ's11Q published in this CMAJ12A-No, I don't.13Q-Okay. Okay. so back to the thrombophlebit14Were you aware that the Institute concluded14We were talking about the fact that obe15that all the available16A-Yes.16A-No, I didn't read the report.17Q developing thrombophlebitis by two to the18A-No, I didn't read the report.19A-M'hm.19Q-Were you aware that the Institute concluded that20Q-Verbally?	
 3 Q- Yes. 4 A they're not all necessarily of particularly 5 high standards. 6 Q- Okay. But in this case, you haven't reviewed 7 the national the 8 A- No, I didn't I didn't 9 Q INSPQ's report? 10 A- I didn't review the national report. 11 Q- So, you don't know the quality of the INSPQ's 12 A- No, I don't. 13 Q report? Okay. 14 Were you aware that the Institute concluded 15 that all the available 16 A- No. 17 Q studies had methodological flaws? 17 Q- Were you aware that the Institute concluded that 20 if there were there was, sorry, a difference 3 cited? 4 Me GENEVIEVE BERTRAND: 5 Q- Okay, and the study you cited, just for the 6 - record, is 7 A- Is the 8 Q dated May seventeen (17), twenty elever 9 (2011), it's the Etminan Study 10 A- Right. 11 Q published in this CMAJ 12 A- CMAJ, yes. 13 Q- Okay. Okay, so back to the thrombophlebiti 14 We were talking about the fact that obe 15 on its own increases the risk of 16 A- Yes. 17 Q developing thrombophlebitis by two to the 18 (2 - 3) times you agree with that? 19 A- M'hm. 20 Q- Verbally? 	
 4 A they're not all necessarily of particularly 5 high standards. 6 Q- Okay. But in this case, you haven't reviewed 7 the national the 8 A- No, I didn't I didn't 9 Q INSPQ's report? 10 A- I didn't review the national report. 11 Q- So, you don't know the quality of the INSPQ's 12 A- No, I don't. 13 Q report? Okay. 14 Were you aware that the Institute concluded 15 that all the available 16 A- No. 17 Q studies had methodological flaws? 17 Q- Were you aware that the Institute concluded that 20 if there were there was, sorry, a difference 4 Me GENEVIEVE BERTRAND: 5 Q- Okay, and the study you cited, just for the 6 record, is 7 A- Is the 8 Q dated May seventeen (17), twenty elever 9 (2011), it's the Etminan Study 10 A- Right. 11 Q published in this CMAJ 12 A- CMAJ, yes. 13 Q- Okay. Okay, so back to the thrombophlebitis by two to the 16 A- Yes. 17 Q developing thrombophlebitis by two to the 18 (2 - 3) times you agree with that? 19 A- M'hm. 20 Q- Verbally? 	
 5 high standards. 6 Q- Okay. But in this case, you haven't reviewed 7 the national the 8 A- No, I didn't I didn't 9 Q INSPQ's report? 10 A- I didn't review the national report. 11 Q- So, you don't know the quality of the INSPQ's 12 A- No, I don't. 13 Q report? Okay. 14 Were you aware that the Institute concluded 15 that all the available 16 A- No. 17 Q studies had methodological flaws? 17 Q- Were you aware that the Institute concluded that 20 if there were there was, sorry, a difference 5 Q- Okay, and the study you cited, just for the record, is 5 Q- Okay, and the study you cited, just for the 6 record, is 7 A- Is the 8 Q dated May seventeen (17), twenty elever 9 (2011), it's the Etminan Study 10 A- Right. 11 Q published in this CMAJ 12 A- CMAJ, yes. 13 Q- Okay. Okay, so back to the thrombophlebiti 14 We were talking about the fact that obe 15 on its own increases the risk of 16 A- No. 17 Q developing thrombophlebitis by two to the 18 (2 - 3) times you agree with that? 19 A- M'hm. 20 Q- Verbally? 	
 6 Q- Okay. But in this case, you haven't reviewed the national the 8 A- No, I didn't I didn't 9 Q INSPQ's report? 10 A- I didn't review the national report. 11 Q- So, you don't know the quality of the INSPQ's 12 A- No, I don't. 13 Q report? Okay. 14 Were you aware that the Institute concluded 15 that all the available 16 A- No. 17 Q studies had methodological flaws? 17 Q- Were you aware that the Institute concluded that 20 if there were there was, sorry, a difference 6 record, is 7 A- Is the 8 Q dated May seventeen (17), twenty elever 9 (2011), it's the Etminan Study 10 A- Right. 11 Q published in this CMAJ 12 A- CMAJ, yes. 13 Q- Okay. Okay, so back to the thrombophlebiti 14 We were talking about the fact that obe 15 on its own increases the risk of 16 A- Yes. 17 Q developing thrombophlebitis by two to the 18 A- No, I didn't read the report. 19 A- M'hm. 20 Q- Verbally? 	
 7 the national the 8 A- No, I didn't I didn't 9 Q INSPQ's report? 10 A- I didn't review the national report. 11 Q- So, you don't know the quality of the INSPQ's 12 A- No, I don't. 13 Q report? Okay. 14 Were you aware that the Institute concluded 15 that all the available 16 A- No. 17 Q studies had methodological flaws? 18 A- No, I didn't read the report. 19 Q- Were you aware that the Institute concluded that 20 if there were there was, sorry, a difference 7 A- Is the 7 A- Is the 8 Q dated May seventeen (17), twenty elever 9 (2011), it's the Etminan Study 10 A- Right. 11 Q published in this CMAJ 12 A- CMAJ, yes. 13 Q- Okay. Okay, so back to the thrombophlebiti 14 We were talking about the fact that obe 15 on its own increases the risk of 16 A- Yes. 17 Q developing thrombophlebitis by two to the 18 (2 - 3) times you agree with that? 19 A- M'hm. 20 Q- Verbally? 	
 8 A- No, I didn't I didn't 9 Q INSPQ's report? 10 A- I didn't review the national report. 11 Q- So, you don't know the quality of the INSPQ's 12 A- No, I don't. 13 Q report? Okay. 14 Were you aware that the Institute concluded 15 that all the available 16 A- No. 17 Q studies had methodological flaws? 17 Q studies had methodological flaws? 18 A- No, I didn't read the report. 19 Q- Were you aware that the Institute concluded that if there were there was, sorry, a difference 8 Q dated May seventeen (17), twenty elever 9 (2011), it's the Etminan Study 10 A- Right. 11 Q published in this CMAJ 12 A- CMAJ, yes. 13 Q- Okay. Okay, so back to the thrombophlebiting about the fact that obe 15 on its own increases the risk of 16 A- No. 17 Q studies had methodological flaws? 18 A- No, I didn't read the report. 19 A- M'hm. 20 Q- Verbally? 	
9Q INSPQ's report?10 A-I didn't review the national report.11 Q-So, you don't know the quality of the INSPQ's12 A-No, I don't.13 Q report? Okay.14Were you aware that the Institute concluded15that all the available16 A-No.17 Q studies had methodological flaws?18 A-No, I didn't read the report.19 Q-Were you aware that the Institute concluded that20if there were there was, sorry, a difference	
10 A-I didn't review the national report.11 Q-So, you don't know the quality of the INSPQ's12 A-No, I don't.13 Q report? Okay.14Were you aware that the Institute concluded15that all the available16 A-No.17 Q studies had methodological flaws?18 A-No, I didn't read the report.19 Q-Were you aware that the Institute concluded that20if there were there was, sorry, a difference	
11 Q-So, you don't know the quality of the INSPQ's11 Q published in this CMAJ12 A-No, I don't.12 A-CMAJ, yes.13 Q report? Okay.13 Q-Okay. Okay, so back to the thrombophlebit14Were you aware that the Institute concluded14We were talking about the fact that obe15that all the available16 A-No.16 A-No.16 A-Yes.17 Q studies had methodological flaws?17 Q developing thrombophlebitis by two to the18 A-No, I didn't read the report.18(2 - 3) times you agree with that?19 Q-Were you aware that the Institute concluded that19 A-M'hm.20if there were there was, sorry, a difference20 Q-Verbally?	
12 A-No, I don't.13 Q report? Okay.14Were you aware that the Institute concluded15that all the available16 A-No.17 Q studies had methodological flaws?18 A-No, I didn't read the report.19 Q-Were you aware that the Institute concluded that20if there were there was, sorry, a difference	
 13 Q report? Okay. 14 Were you aware that the Institute concluded 15 that all the available 16 A- No. 17 Q studies had methodological flaws? 18 A- No, I didn't read the report. 19 Q- Were you aware that the Institute concluded that 20 if there were there was, sorry, a difference 13 Q- Okay. Okay, so back to the thrombophlebitis 13 Q- Okay. Okay, so back to the thrombophlebitis 14 We were talking about the fact that obe 15 on its own increases the risk of 16 A- Yes. 17 Q developing thrombophlebitis by two to the 18 (2 - 3) times you agree with that? 19 A- M'hm. 20 Q- Verbally? 	
14Were you aware that the Institute concluded14We were talking about the fact that obe15that all the available14We were talking about the fact that obe16 A-No.15on its own increases the risk of17 Q studies had methodological flaws?16 A-Yes.18 A-No, I didn't read the report.17 Q developing thrombophlebitis by two to the19 Q-Were you aware that the Institute concluded that19 A-M'hm.20if there were there was, sorry, a difference20 Q-Verbally?	
14Were you aware that the Institute concluded14We were talking about the fact that obe15that all the available14We were talking about the fact that obe16 A-No.15on its own increases the risk of17 Q studies had methodological flaws?16 A-Yes.18 A-No, I didn't read the report.17 Q developing thrombophlebitis by two to the19 Q-Were you aware that the Institute concluded that19 A-M'hm.20if there were there was, sorry, a difference20 Q-Verbally?	IS.
15that all the available15on its own increases the risk of16 A-No.16 A-Yes.17 Q studies had methodological flaws?17 Q developing thrombophlebitis by two to the18 A-No, I didn't read the report.18(2 - 3) times you agree with that?19 Q-Were you aware that the Institute concluded that19 A-M'hm.20if there were there was, sorry, a difference20 Q-Verbally?	sity
16 A-No.16 A-Yes.17 Q studies had methodological flaws?17 Q developing thrombophlebitis by two to the18 A-No, I didn't read the report.18(2 - 3) times you agree with that?19 Q-Were you aware that the Institute concluded that19 A-M'hm.20if there were there was, sorry, a difference20 Q-Verbally?	,
17 Q- 18 A- No, I didn't read the report.17 Q- 18 A- 	
18 A-No, I didn't read the report.18(2 - 3) times you agree with that?19 Q-Were you aware that the Institute concluded that19 A-M'hm.20if there were there was, sorry, a difference20 Q-Verbally?	ee
19 Q-Were you aware that the Institute concluded that19 A-M'hm.20if there were there was, sorry, a difference20 Q-Verbally?	00
20 if there were there was, sorry, a difference 20 Q- Verbally?	
21 in the rick between a fourth generation and 21.4 Veg. I do Corry	
21 in the risk between a fourth generation oral 21 A-Yes, I do. Sorry.	
22 contraceptive and a second generation oral 22 Q- Okay, you do.	
23contraceptive, the difference would be very low,23And that the risk that risk increases	
24 representing one to two (1 - 2) cases per ten 24 two to twenty-four (2 - 24) times in obese w	omen
25thousand (10,000) women years?25who take an oral contraceptive?	
42	44
1 A- Yes, I don't know the report, so I don't know 1 A- There's no question that obesity is a major	risk
2 what they concluded. 2 factor for	
3 Q- Okay. So, you're not aware of the Institute's 3 Q- Okay.	
4 conclusion that, given that result, there is no 4 A for for that complication, yes.	
5 need to change the clinical practise? 5 Q- For thrombophlebitis?	
6 A- I don't know that conclusion, either. 6 A- Yes.	
7 Q- Okay. You agree, however, that obesity, on its 7 Q- Okay. And you also agree that smoking	
8 own, increases the risk of developing 8 increases	
9 thrombophlebitis by two to three (2 - 3) times? 10 A Serry	
10 A- Sorry 10 Q the risk of developing thrombophlebitis?	
11Q- So 12A Ves, I do.	
12 A- I'm not allowed I'm not allowed to ask a 12 Q- And that a post-operative period and	
13 question, am I? 13 immobilization can also increase the risk of	
14 Q- No, you don't want to ask me any questions. 14 developing thrombophlebitis?	
15 A- No, no, just I'm trying to get at this 15 A- Yes, I agree.	
16 Institute report 16 Q- And you agree with Dr. Masse that the prime	
17 Q- We can Do we go off the record? 17 cause of Ms. Guindon's thrombophlebitis w	as the
18 Me SAMY ELNEMR: 18 immobility and the surgery during the previo	ous
19 We can go off the record. 19 month for the removal of her gall bladder?	
20 Me GENEVIEVE BERTRAND: 20 A- That would be my best guess, too.	
21 We'll go off the record. 21 Q- And that a high cholesterol is also a vascula	ar
22 A- Just for my own information.	
23 Q- Yes. 23 A- For thrombophlebitis?	
2424 Q-Yes.25(DISCUSSION OFF RECORD)25 A-I'm not aware of that.	

AFFIDAVIT

		45			47
2 3 4 5 A- 6 7 Q- 8 A- 9 10 Q- 11 12 13 14 A- 15 Q- 16 A- 17 Q- 18 A- 19 Q- 20 A- 21 Q- 22 23	You're not aware of that, okay. Do you know that a Factor V Leiden on its own increases seven (7) times the risk of developing a thromboembolic event? If she had a If she had a thrombotic tendency, yes, that would increase her risk. Including a Factor V Leiden, you mean? I have to check Factor V Leiden, but I'm sure you're right. Okay. Now, you testified earlier that you reviewed Ms. Guindon's medical records. You're aware that Ms. Guindon presented all those risks? Yes. That she presented with Had multiple risks, yes. Right. She had obesity? Correct. She was a smoker? Right. She had surgery in November two thousand and nine (2009), two (2) months before presenting a thromboembolic event? Yes.		1 Q- 2 3 4 - 5 Q- 6 7 4 - 9 Q- 10 11 12 A- 13 Q- 14 15 16 A- 17 Q- 18 19 20 21 22 A- 23 Q- 24 A-	Okay. So, you agree that smoking, obesity, the surgery, immobilization, the Factor V Leiden likely all contributed to the thrombophlebitis? Yes. And you agree that patients presenting thromboembolic events generally present with many different risk factors? Yes. And that the risk factors presented by Ms. Guindon collectively and individually influenced an increase for a thromboembolic risk? I'd agree with that. And that this could have been the case, no matter what oral contraceptive she would have taken? I would agree with that. And you'd agree that the use of an oral contraceptive containing drospirenone does not significantly increase the risk of a thromboembolic event, compared to other oral contraceptives? It's not clear to me, I don't agree with that. Okay. But it's a complicated issue, I will agree to	
	That she travelled long distances? She		25	that.	
2 3 4 A- 5 6 7 Q- 8 A- 9 Q- 10 11 A- 12 13 Q- 14 A- 15 Q- 16 A- 17 Q- 18 A- 19 20 Q- 21 A- 22 23 Q-	travelled between Gatineau and Quebec in that time before her thromboembolic event in December of two thousand and nine (2009)? I'm not sure I would have thought that was a major issue, but but it could it could have played a role. And that she had a Factor V Leiden? Okay. And Okay, or were you aware of that in your review of the record? I remember one (1) of them, I just didn't remember whether she was the one. Okay. But you remember seeing that Yes, I do. and you agreed that that would be a factor? Yes, yes. Yes. And she also had high cholesterol even Yes, I'm not aware of high cholesterol being a major risk factor for thrombophlebitis. Okay. It is a major risk factor for vascular disease Okay. but that's arterial vascular disease, not	46	1 Q- 2 A- 5 6 Q- 7 8 9 10 11 12 13 14 15 16 17 18 9 21 Q- 21 Q- 22 Q- 23 Q- 23 Q- 23 Q- 24 A-	Okay. But it's not clear to you is what you would say I wouldn't to that? agree that it doesn't increase risk. And but would you say that it does, or is that unclear to you? I didn't You know, once it was clear to Once it was clear to me what the clinical cases were, that were being presented, I didn't focus most of my research on the thrombophlebitis risk. There were conflicting papers, that was clear, and it became increasingly clear to me that the If the surgical admission was the primary cause of the thrombophlebitis which I felt it was then the question I asked, well, was the surgical admission due to the use of one or other oral contraceptives? So, I I didn't think I could get to the bottom of this very easily. Okay, so And I went the easier route, if you would. Which is the gall bladder The gall bladder story.	48

			_
	49	51	L
1 A-	Yes.	1 since we're going to	
2 Q-	So, you didn't You're saying you didn't focus	2 Me GENEVIEVE BERTRAND:	
3	much of your research and what you put in your	3 Well, we'll	
4	report with regard to the thromboembolic	4 Me SAMY ELNEMR:	
5	event		
		5 remove her?	
6 A-	No.	6 Me GENEVIEVE BERTRAND:	
7 Q-	you you didn't, okay.	7 We'll cover it just	
8	Would you say that for Ms. Gladu it's the	8 A- Sure, that's fine.	
9	same, that no matter what oral contraceptive she	9 Q- I only have three (3) more questions.	
10	would have taken, Ms. Gladu would likely have	10 Me SAMY ELNEMR:	
11	developed a thromboembolic event, as well?	11 Do we need to address the Mrs. Bouchard's	
12 A-	No, relatively speaking, a thromboembolic event,	12 case, since she will be removed from the case,	
13	for most women coming into the hospital with	13 most likely?	
14	for a cholecystectomy, even with multiple risk	14 Me SYLVIE RODRIGUE,	
15			
	factors, the majority of them don't develop a	15 On behalf of Respondent:	
16	thromboembolic event.	16 Well, we don't know that yet, that's the	
17 Q-	But in terms So, let me go back, we'll talk	17 problem.	
18	more specifically about Ms. Gladu.	18 Me GENEVIEVE BERTRAND:	
19	So, you testified that you reviewed her	19 That's why we'll just ask for	
20	medical records, as well?	20 Me SAMY ELNEMR:	
21 A-	Yes.	21 Most likely, but I'll I won't stand in the	
22 Q-	And you're aware that Ms. Gladu presented with	22 way	
23	many of the risks that we just discussed?	23 Me GENEVIEVE BERTRAND:	
24 A-	Yes.	24 Yes.	
25 Q-		25	
25 Q-	Right, that she was obese	25	
	50	52	2
1 A-	M'hm. Yes, I'm sorry sorry.	1 Me SAMY ELNEMR:	
2 Q-	And that she was hospitalized	2 of a few questions, so	
3 A-	Yes.	3 Me SYLVIE RODRIGUE:	
4 Q-	for a period of time? And she was	4 It will be	
5	immobilized, as well, for a period	5 A- Sure, go ahead.	
		-	
6 A-	Yes.	6 Q- It will be brief, just to avoid having him	
7 Q-	of time?	7 coming back.	
8	And that she presented with an infection,	8 Me SAMY ELNEMR:	
9	which is also a risk factor for a thromboembolic	9 Okay, no problem.	
10	event?	10 Me GENEVIEVE BERTRAND:	
11 A-	M'hm. Yes, sorry.	11 Q- Just before we get to Ms. Bouchard, regarding	
12 Q-	Thank you.	12 Ms. Gladu, since we talked about the fact that	
13	And so, you would agree that the risk	13 she had all of those the same risk factors,	
14	factors presented by Ms. Gladu influenced and	14 the obesity, the hospitalization, the	
15	also increased her thromboembolic risk?	15 immobilization It would have been the same	
16 A-	Yes, I would.	16 result in terms of her thromboembolic, no matter	
17 Q-	And that her thrombophlebitis was likely due to	17 which oral contraceptive she would have taken?	
18	her immobilization following the surgery?	18 A- No, I don't agree with that.	
19 A-	That was the most important risk factor, yes.	19 Q- And why is that different for Ms. Gladu?	
20 Q-	Okay. And with regard to Ms. Bouchard, you	20 A- I I didn't I don't agree with that for	
21	testified that you reviewed her medical records,	21 either of those people for either patient.	
		22 Q- And why is that?	
22	as well?		
22 23 A-	as well? That was	,	
23 A-	That was	23 A- Because of that paper that I've cited	
23 A- 24 Me	That was SAMY ELNEMR:	23 A- Because of that paper that I've cited 24 Q- Okay.	
23 A-	That was	23 A- Because of that paper that I've cited	

AFFIDAVIT

	5	3	diaguagiag	55
1 Q-	Okay, we'll get to the paper, let's cover Ms.	1	discussion.	
2	Bouchard.	2 Q-	Okay.	
3	You testified that you reviewed her medical	3 A-	And that, to me, was the critical issue. You	
4	records?	4	know, in the absence of a randomized trial where	
5 A-	Yes.	5	they randomly give women one oral contraceptive	
6 Q-	And you agree with Dr. Masse that Ms. Bouchard's	6	versus the other, and then follow them for many	
7	strokes were the result of a vasculitis	7	years to see who develops	
8	affecting the arterial circulation of the brain?	8 Q-	Right.	
9 A-	Correct.	9 A-	either thrombophlebitis or gall stones,	
10 Q-	And that this has nothing to do with oral	10	you're really stuck with trying to come up with	
11	contraceptives?	11	comparables.	
12 A-	I'm not aware of I couldn't find any data to	12 Q-	Yes.	
13	support that.	13 A-	And you really need a big study to pull that one	
14 Q-	So, it has nothing to do with oral	14	off, and this was the only one that I could find	
15 A-	l don't	15	that I thought was sufficiently powered.	
16 Q-	contraceptives?	16 Q-	Okay. Were you aware that there were only two	
17 A-	think so.	17	(2) studies or that there are two (2) studies	
18 Q-	And you agree that it's unlikely that Yasmin was	18	concerning the use of drospirenone containing	
19	the cause of Ms. Bouchard's vasculitic strokes?	19	oral contraceptives? So, you found one (1),	
20 A-	Correct.	20	which was the Etminan one	
21 Q-	Okay. So, when you looked at the literature in	21 A-	No, I found more	
22	preparation for your report We talked about	21 Q-		
23		22 Q- 23 A-	were you aware	
	this a bit, but I want to ask you specifically,		I found more than	
24	did you look at all of the available studies, or	24 Q-	Okay.	
25	only the studies that supported your position?	25 A-	one (1), but I focused on what I	
	5			56
1 A-	No, no, I looked at all the available studies I	1 Q-	Okay.	
2	could. I was interested in trying to get to the	2 A-	thought was the best study.	
3	bottom of the question.	3 Q-	Were you aware that there is only one (1) study	
4 Q-	Right. And as part of your analysis, did you	4	concerning the use of drospirenone compared to	
5	identify any studies that concluded that	5	women who are not taking any oral	
6	drospirenone use was not related to an increased	6	contraceptives?	
7	risk of gall bladder disease compared to women	7 A-	Yes, that wasn't the critical issue to me	
8	that were not taking an oral contraceptive?	8 Q-	Okay.	
9 A-	I don't recall finding a study like that.	9 A-	though. The critical issue was what if	
	• •	U 10		
1 1111 1-	Did you identify any studies that concluded that	10	vou're taking oral. You see in an	
10 Q-	Did you identify any studies that concluded that	10	you're taking oral You see, in an	
11	drospirenone wasn't associated with a higher	11	epidemiologic in an epidemiologic type study	
11 12	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the	11 12	epidemiologic in an epidemiologic type study like this, women who are taking oral	
11 12 13	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel?	11 12 13	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more	
11 12 13 14 A-	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't?	11 12 13 14	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women	
11 12 13 14 A- 15 Q-	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not.	11 12 13 14 15	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to	
11 12 13 14 A- 15 Q- 16 A-	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I	11 12 13 14 15 16	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive.	
11 12 13 14 A- 15 Q- 16 A- 17	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to	11 12 13 14 15 16 17	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was,	
11 12 13 14 A- 15 Q- 16 A- 17 18	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to me was the study I cited was, in my opinion,	11 12 13 14 15 16 17 18	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users	
11 12 13 14 A- 15 Q- 16 A- 17 18 19	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to	11 12 13 14 15 16 17	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users and looking for a signal that one (1) or more	
11 12 13 14 A- 15 Q- 16 A- 17 18	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to me was the study I cited was, in my opinion,	11 12 13 14 15 16 17 18	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users	
11 12 13 14 A- 15 Q- 16 A- 17 18 19	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to me was the study I cited was, in my opinion, the best study.	11 12 13 14 15 16 17 18 19	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users and looking for a signal that one (1) or more	
11 12 13 14 A- 15 Q- 16 A- 17 18 19 20 Q-	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to me was the study I cited was, in my opinion, the best study. Okay.	11 12 13 14 15 16 17 18 19 20	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users and looking for a signal that one (1) or more oral contraceptives were worse than the others. And that's a very difficult thing to do, you	
11 12 13 14 A- 15 Q- 16 A- 17 18 19 20 Q- 21 A- 22	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to me was the study I cited was, in my opinion, the best study. Okay. The one that had the greatest number of observations, the one that had sufficient	11 12 13 14 15 16 17 18 19 20 21 22	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users and looking for a signal that one (1) or more oral contraceptives were worse than the others. And that's a very difficult thing to do, you need a very big study for that.	
11 12 13 14 A- 15 Q- 16 A- 17 18 19 20 Q- 21 A- 22 23	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to me was the study I cited was, in my opinion, the best study. Okay. The one that had the greatest number of observations, the one that had sufficient statistical power to adjust for all of the other	11 12 13 14 15 16 17 18 19 20 21 22 23 Q-	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users and looking for a signal that one (1) or more oral contraceptives were worse than the others. And that's a very difficult thing to do, you need a very big study for that. Okay.	
11 12 13 14 A- 15 Q- 16 A- 17 18 19 20 Q- 21 A- 22	drospirenone wasn't associated with a higher risk of gall bladder disease, compared to the use of Levonorgestrel? Wasn't? Was not. You know, I don't recall that either, that I found one. The thing that was most important to me was the study I cited was, in my opinion, the best study. Okay. The one that had the greatest number of observations, the one that had sufficient	11 12 13 14 15 16 17 18 19 20 21 22	epidemiologic in an epidemiologic type study like this, women who are taking oral contraceptives, for whatever reason, are more likely to be similar, than comparing a women who's not taking an oral contraceptive, to someone who is taking an oral contraceptive. So, the great strength of this study was, they were comparing all oral contraceptive users and looking for a signal that one (1) or more oral contraceptives were worse than the others. And that's a very difficult thing to do, you need a very big study for that.	

	•			
	57			59
1 Q-	Okay. And did you come across a study that	1	with a copy of the Jick Study, which we will	
2	it's the Jick Study J-I-C-K	2	'coter' as Exhibit I-1 to the examination, and	
3 A-	I'd have to go over my notes	3	I'll let Dr. Grover take a look at the the	
4 Q-	Okay.	4	study, it's a short one, it's only four (4)	
5 A-	I can't tell you.	5	pages three (3) pages.	
-	SAMY ELNEMR:	6	p-3	
7	G J-I	7	EXHIBIT I-1: A copy of the Jick Study -	
8 Me	GENEVIEVE BERTRAND:	8	three pages.	
9	J J J-I-C-K.	9		
-	SAMY ELNEMR:	-	SAMY ELNEMR:	
11	C-K.	11	Do you plan on asking questions on this	
1	GENEVIEVE BERTRAND:	1	GENEVIEVE BERTRAND:	
13	Jick Study.	13	No.	
-	SAMY ELNEMR:		SAMY ELNEMR:	
15	Jick.	15	Okay.	
-	GENEVIEVE BERTRAND:	-	GENEVIEVE BERTRAND:	
17 Q-		17 18	Just Well, one (1) or two (2) follow-up, just	
18 A-	I couldn't say.			
19Q-	Okay.		SAMY ELNEMR:	
20 A-	I just don't remember.	20	Because we might need some time to read it.	
21 Q-	Okay, if So, I'll ask on the record for the	21 A-		
22	undertaking, if you can find it, if you can draw		GENEVIEVE BERTRAND:	
23	up a list of the studies that you did consult,	23	No, no	
24	going back you know, whatever is 'dans la	24 A-	So	
25	mésure du possible' what's possible, if you	25 Q-	But go ahead, if you want to read the	
	58			60
1	could draw up that list We'll ask for it	1	abstract	
2	as	2 Me	SAMY ELNEMR:	
3 A-	Sure.	3	Just look at this	
4 Q-	an undertaking.	4 Me	GENEVIEVE BERTRAND:	
5 A-	Sure, sure.		take your time, and	
6		6 A-	Could I have a copy of the other study	
7	UNDERTAKING #U-1: Prepare a list of the	7 Q-	Yes.	
8	studies that Dr. Grover consulted. And if	8 A-	that you have right in front of you?	
9	he cannot come up with a complete list of	9 Q-	Well, I'll actually Well, I can provide you	
10	the literature reviewed, then confirm	10	with a copy now, we'll	
11	whether or not he the Jick Study in the	11	We can be off record right now.	
12	course of his literature review (page 61).	12	We can be on record right new.	
13		13	(DISCUSSION OFF RECORD)	
	GENEVIEVE BERTRAND:	14		
15Q-	Now, the Jick Study stands for the proposition		GENEVIEVE BERTRAND:	
16	that there is no increased risk of gall bladder	16 Q-	So, Dr. Grover, now that you've had an	
17	disease with the use of drospirenone compared to	17	opportunity to review the study the Jick	
18	women who don't take oral contraceptives, and			
	· · ·	18	Study, do you recall having read this study	
19	compared to Levonorgestrel, okay? Were you	19	and in your literature review?	
20	aware of that?	20 A-	I might well have, but I could certainly confirm	
21 A-	I don't recall whether I read the study and	21	it.	
22	dismissed it as being inferior to this study, or	22 Q-	Okay. And so, maybe we'll 'précisez' We'll	
23	did I never find the study. I just can't tell	23	particularize the undertaking that we ask for,	
24	you off the top of my head.	24	Undertaking 1	
25 Q-	Okay. So, we So, I'm providing Dr. Grover	25 A-	Sure.	
			Stono Exact	7.6

AFFIDAVIT

	61			63
1 Q if you can't come up with a complete list of		1 Me	GENEVIEVE BERTRAND:	
2 the literature review, then also confirm that		2 Q-	Okay, go ahead.	
3 whether or not Dr. Grover reviewed the Jick		3 A-	Yes. So, when you say it didn't show anything,	
4 Study in the course of his literature review.		4	well, the first thing that comes to mind is,	
5 Me SAMY ELNEMR:		5	it's vastly underpowered compared to the	
6 Okay.		6	'Etminian' Study, which has a lot more	
7 Me GENEVIEVE BERTRAND:		7	statistical clout to identify an association.	
8 Q- Now, for the purposes of the transcript, I'll		8	The other thing is, the study design is an	
9 read the conclusions that are part of the		9	inferior study design to the 'Etminian' Study.	
10 abstract. And the conclusions read:		10	The 'Etminian' Study is a retrospective cohort	
11 "There is no evidence in these		11	study where they're following the women forward	
12 data that drospirenone or		12	in time, looking for the development of this	
13 Levonorgestrel containing oral		13	disease, whereas this was a case control study	
14 contraceptive use confers an		14	where they're comparing cases, women who have	
15 increased risk of gall bladder		15	developed the disease, to woman who haven't, in	
16 disease compared to women not		16	a retrospective fashion.	
17 currently exposed to an oral		17	They also have very limited data to adjust	
18 contraceptive, nor is use of		18	for potential confounders. In this particular	
19 drospirenone oral contraceptives		19	case	
20 associated with a higher risk of		20 Q-	In which study?	
21 gall bladder disease than use of		21 A-	In your Jick Study.	
22 Levonorgestrel containing oral		22 Q-	Okay.	
23 contraceptives."		23 A-	In the Jick Study, they were able to adjust for	
24 Does the conclusion contained in the Jick Study		24	basically only body mass index. Let me just be	
25 change your opinion, at all?		25	absolutely certain about that.	
		25	absolutely certain about that.	
	62			64
1 A- No. No, it doesn't.		1	So, they only adjusted They only	
2 Q- And why is that?		2	adjusted for BMI, which is one (1) risk factor	
3 A- Well, first of all, it's a vastly inferior study		3	for gall bladder disease, whereas the 'Etminian'	
4 to the study by Etminan.		4	Study adjusted for multiple potential	
5 Q- Why is that?		5	confounders, including weight, smoking, presence	
6 A- One, the simple numbers that they have here		6	of diabetes, inflammatory bowel disease,	
7 they have all of basically, twenty-nine		7	pancreatitis, sickle cell anemia, statin use,	
8 hundred (2,900) cases of gall bladder disease,		8	and fibrate use. So	
9 compared to fifty-eight hundred and some odd		9 Q-	And where do you see that? I see you're	
			, , ,	
10 individuals who don't have gall bladder disease.		10	referring to the Etminan Study, which	
11 So, the number of cases is far inferior to the		11 A-	Yes, that's in the results section on page 901.	
12 study by 'Etminian'.		12 Q-	And where does it say in that report on page 901	
13The other thing is, the study designs		13	that they okay, they adjusted I think	
14 vastly		14	you're referring to the second paragraph of the	
15 Q- So, wouldn't the results still		15	results?	
16 Me SAMY ELNEMR:		16 A-	Right. So, they used a multivariate model that	
17 Oh, just let him		17	adjusted not only for body mass index, but for	
18 Me GENEVIEVE BERTRAND:		18	all these other things that we know are	
19 Sorry.		19	important as risk factors for the development of	
20 Me SAMY ELNEMR:		20	gall bladder disease. It's just It's just it	
21 Let him finish the answer		21	completely	
22 Me GENEVIEVE BERTRAND:		22 Q-	So	
23 Yes, before		23 A-	It completely trumps the Jick Study, in my	
24 Me SAMY ELNEMR:		24	opinion.	
25 please.		25 Q-	So, you're saying that, to your mind, this	

Astrida Auza o.c.r.

Steno Exact MAXIN

	65			67
1	study you wouldn't rely on the results of	1	significant does not mean that an observed	
2	this study?	2	association is valid?	
3 A-	I would say that, given the two (2) studies	3 A-	It cannot prove causality, correct.	
4	together If I had to choose between the	4 Q-	Right. And so, statistically significant	
5	results of these two (2) studies, I'd go with	5	associations can be observed as a result of	
6	the Etminan Study because it's a vastly superior	6	chance alone?	
7	study to the Jick Study.	7 A-	Correct.	
8 Q-	But not having to choose between the two (2) in	8 Q-	And statistically significant associations may	
9	terms of the conclusions of the Jick Study, do	9	be affected by various types of bias?	
10	you Do you dispute the results of the Jick	10 A-	By various types of bias, correct.	
11	Study?	11Q-	And types of bias or biases can sorry,	
12 A-	The Jick Study didn't show any association, but	12	biases and various types of biases can	
13	the simplest explanation for the absence of the	13	include bias in the study design?	
14	association would be the weak study design and	14 A-	Right.	
15	their inability to adjust for more than just	15 Q-	Bias in conduct?	
16	weight in their analysis.	16 A-	Correct.	
17 Q-	Is that something that you know, or something	17 Q-	Bias in the analysis?	
18	that you're you suspect? Or and what	18 A-	Correct.	
19	would you be	19 Q-	And in your report, you refer to the results of	
20 A-	It makes it	20	the Etminan Study, but you don't discuss its	
21 Q-	basing that on?	21	methodological limitations?	
22 A-	It makes it a weak study, that I know for	22 A-	I didn't see any of those biases in the study	
23	certain. Is that the reason they didn't find	23	design.	
24	the association? I can never be sure of that.	24 Q-	Okay, you don't mention that to be eligible for	
25 Q-	Okay, in your report now, you refer to the	25	the study, for example, the women had to have	
	66			68
1		1	been taking the oral contraceptive for at least	68
	Etminan Study, you mention that the Etminan	1	been taking the oral contraceptive for at least six (6) months?	68
2	Etminan Study, you mention that the Etminan Study is a retrospective cohort study?	1 2	six (6) months?	68
2 3 A-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right.	1 2 3 A-	six (6) months? No, I didn't mention that.	68
2 3 A- 4 Q-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have	1 2 3 A- 4 Q-	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz	68
2 3 A- 4 Q- 5	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations?	1 2 3 A- 4 Q- 5	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months?	68
2 3 A- 4 Q- 5 6 A-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes.	1 2 3 A- 4 Q- 5 6 A-	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included	68
2 3 A- 4 Q- 5 6 A- 7 Q-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not	1 2 3 A- 4 Q- 5 6 A- 7	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available?	1 2 3 A- 4 Q- 5 6 A- 7 8	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct.	1 2 3 A- 4 Q- 5 6 A- 7 8 9	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can	1 2 3 A- 4 Q- 5 6 A- 7 8	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct.	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct.	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk.	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12 13	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12 13 14 Q- 15	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship?	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'll I can repeat the question.	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study?	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17 18 Me	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'll I can repeat the question. SAMY ELNEMR:	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17 18 A-	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study? That's correct.	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17 18 Me 5 19	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'll I can repeat the question. SAMY ELNEMR: Could you repeat the question, please?	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17 18 A- 19 Q-	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study? That's correct. And you omitted in your study to discuss in	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17 18 Me 19 20 Me	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'll I can repeat the question. SAMY ELNEMR: Could you repeat the question, please? GENEVIEVE BERTRAND:	1 2 3 4 4 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17 18 A- 19 Q- 20	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study? That's correct. And you omitted in your study to discuss in your report, sorry, to discuss the impact of the	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17 18 Me 19 20 Me 21 Q-	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'll I can repeat the question. SAMY ELNEMR: Could you repeat the question, please? GENEVIEVE BERTRAND: You would agree that in epidemiology a valid	1 2 3 4 4 2 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17 18 A- 19 Q- 20 21	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study? That's correct. And you omitted in your study to discuss in your report, sorry, to discuss the impact of the study's design features on the results of the	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17 18 Me 20 Me 21 Q- 22	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'II I can repeat the question. SAMY ELNEMR: Could you repeat the question, please? GENEVIEVE BERTRAND: You would agree that in epidemiology a valid statistically significant association is not	1 2 3 4 4 2 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17 18 A- 19 Q- 20 21 22	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study? That's correct. And you omitted in your study to discuss in your report, sorry, to discuss the impact of the study's design features on the results of the study?	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17 18 Me 20 Me 21 Q- 22 23	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'II I can repeat the question. SAMY ELNEMR: Could you repeat the question, please? GENEVIEVE BERTRAND: You would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship?	1 2 3 A- 4 Q- 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17 18 A- 19 Q- 20 21 22 23 A-	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study? That's correct. And you omitted in your study to discuss in your report, sorry, to discuss the impact of the study's design features on the results of the study? I'm sorry, say that	68
2 3 A- 4 Q- 5 6 A- 7 Q- 8 9 A- 10 Q- 11 12 13 A- 14 Q- 15 16 17 18 Me 20 Me 21 Q- 22	Etminan Study, you mention that the Etminan Study is a retrospective cohort study? Right. And a retrospective cohort studies also have their limitations? Yes. In retrospective studies, important data may not be available? Correct. And not having important data available can limit the ability to control for factors that can influence the outcome? Correct. And you would agree that in epidemiology a valid statistically significant association is not sufficient to establish a causal relationship? I'II I can repeat the question. SAMY ELNEMR: Could you repeat the question, please? GENEVIEVE BERTRAND: You would agree that in epidemiology a valid statistically significant association is not	1 2 3 4 4 2 5 6 A- 7 8 9 10 11 12 13 14 Q- 15 16 17 18 A- 19 Q- 20 21 22	six (6) months? No, I didn't mention that. And Ms. Guindon, herself, had been taking Yaz for less than six (6) months? Right, but just because this study only included women who'd been taking oral contraceptives for six (6) months or more If you believe, on the basis of this study's results, that there was an increased risk associated with taking Yaz for six (6) months or more, that doesn't mean that taking Yaz for less than six (6) months is associated with no risk. But in this case, Ms. Guindon's group, the group of women taking an oral contraceptive for less than six (6) months, would not have been part of the study? That's correct. And you omitted in your study to discuss in your report, sorry, to discuss the impact of the study's design features on the results of the study?	68

· · · · · · · · · · · · · · · · · · ·	
	71 to the other. So, all of these errors
	dy design just reduce the likelihood
	an association. The fact that you sociation despite all those
	ings strengthens your conclusion that
v l	n association.
7cessation, or switching oral contraceptives was7Q-At Table	3
8extremely common, and that only twenty percent8A-Yes.9(20%) of the original cohort was continuously9Q of So	we'll We'll 'ester' this
	, we'll We'll 'coter' this Study as I-2 to the to the
11 years? 11 examinat	
12 A- Right, but that would only be important if you 12	
	I-2: A copy of the Etminan Study.
14 taking the contraceptives than another group, 14	
15and I didn't see that as being a bias in this15 Me GENEVIE16study.16 Q- And I've	/E BERTRAND: provided you with a copy, Doctor, and
17 Q- Okay. 17 so l'm	source you with a copy, bootor, and
18 A-In fact, those sorts of issues really add what18 A-Yes.	
19 we call background noise to a study, they reduce 19 Q referrir	g you to Table 3 of
20the likelihood that we'll see an association.20 A-Yes.	
	dy at page 903, and more particularly
	ng you to the Levonorgestrel, which one, and the Norgestrel, which is
	ne mentioned on the list
25 Q- Yes, I understand. 25 A- Yes.	
70	72
	the adjusted for propensity score
2 Q- Right. 2 A- Yes.	
3 A and those issues would only weaken the 3 Q column	l.
4 likelihood of finding an association. 4 A- Yes.	
	you understand If I'm talking to you
	Levonorgestrel and the Norgestrel, do rstand that two (2) these two (2)
,	
9 Q- Body mass index 9 A- That they	ds that they're comparing?
10 A- They did adjust 10 Q- Do you u	ds that they're comparing? 're nderstand, if I'm talking to you about
10 A- They did adjust 10 Q- Do you u 11 Q- diet 11 the If w	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and
10 A- They did adjust 10 Q- Do you u 11 Q- diet 11 the If w 12 A- for obesity. 12 Norgestre	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2)
10 A-They did adjust10 Q-Do you u11 Q diet11the If w12 A for obesity.12Norgestree13 Q family history or ethnicity.13compound	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds?
10 A-They did adjust10 Q-Do you u11 Q diet11the If w12 A for obesity.12Norgestre13 Q family history or ethnicity.13compound14 A-There's things that are missing, I absolutely14 A-No, I don	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds?
10 A-They did adjust10 Q-Do you u11 Q diet11the If w12 A for obesity.12Norgestra13 Q family history or ethnicity.13compound14 A-There's things that are missing, I absolutely14 A-No, I don15agree with you on that, I mean But no no15 Q-Okay. D16data set I've never seen a study that could16between	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? t.
10 A-They did adjust10 Q-Do you u11 Q diet11the If w12 A for obesity.12Norgestre13 Q family history or ethnicity.13compound14 A-There's things that are missing, I absolutely14 A-No, I don15agree with you on that, I mean But no no15 Q-Okay. D16data set I've never seen a study that could16between17adjust for absolutely every known potential17 A-No, I don	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? t. b you understand the relationship Norgestrel and Levonorgestrel? t.
10 A-They did adjust10 Q-Do you u11 Q diet11the If w12 A for obesity.12Norgestre13 Q family history or ethnicity.13compound14 A-There's things that are missing, I absolutely14 A-No, I don15agree with you on that, I mean But no no15 Q-Okay. D16data set I've never seen a study that could16between17adjust for absolutely every known potential17 A-No, I don18confounder.18 Q-So, if I te	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? t. b you understand the relationship Norgestrel and Levonorgestrel? t. I you there's only The only
10 A-They did adjust10 Q-Do you u11 Q diet11 the If w12 A for obesity.12 Norgestre13 Q family history or ethnicity.13 compound14 A-There's things that are missing, I absolutely14 A-15agree with you on that, I mean But no no15 Q-16data set I've never seen a study that could16 between17adjust for absolutely every known potential17 A-18confounder.18 Q-19 Q-Okay, and you didn't mention in your report that19	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? t. b you understand the relationship Norgestrel and Levonorgestrel? t. I you there's only The only redient in Norgestrel is
10 A-They did adjust10 Q-Do you u11 Q diet11 the If w12 A for obesity.12 Norgestre13 Q family history or ethnicity.13 compound14 A-There's things that are missing, I absolutely14 A-15agree with you on that, I mean But no no15 Q-16data set I've never seen a study that could1617adjust for absolutely every known potential17 A-18confounder.18 Q-20no medical records were reviewed to confirm the20	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? t. o you understand the relationship Norgestrel and Levonorgestrel? t. I you there's only The only redient in Norgestrel is estrel, from a scientific perspective,
10 A-They did adjust10 Q-Do you u11 Q diet11 the If w12 A for obesity.12 Norgestre13 Q family history or ethnicity.13 compound14 A-There's things that are missing, I absolutely14 A-15agree with you on that, I mean But no no15 Q-16data set I've never seen a study that could1617adjust for absolutely every known potential17 A-18confounder.18 Q-20no medical records were reviewed to confirm the20	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? t. b you understand the relationship Norgestrel and Levonorgestrel? t. I you there's only The only redient in Norgestrel is
10 A-They did adjust10 Q-Do you u11 Q diet11 the If w12 A for obesity.12 Norgestre13 Q family history or ethnicity.12 Norgestre14 A-There's things that are missing, I absolutely14 A-15 agree with you on that, I mean But no no15 Q-16 data set I've never seen a study that could16 between17 adjust for absolutely every known potential17 A-18 confounder.18 Q-20 no medical records were reviewed to confirm the20 Levonorg21 diagnosis of a gall bladder event?21 if you S22 A-No, but again, if that's the case, it would only22 I'm23 add background noise to reduce the chance of23 A-	ds that they're comparing? 're Inderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? it. b you understand the relationship Norgestrel and Levonorgestrel? it. I you there's only The only redient in Norgestrel is estrel, from a scientific perspective, o, if that is the case and it is,
10 A-They did adjust10 Q-Do you u11 Q diet11 the If w12 A for obesity.12 Norgestre13 Q family history or ethnicity.12 Norgestre14 A-There's things that are missing, I absolutely14 A-15 agree with you on that, I mean But no no15 Q-16 data set I've never seen a study that could16 between17 adjust for absolutely every known potential17 A-18 confounder.18 Q-20 no medical records were reviewed to confirm the20 Levonorg21 diagnosis of a gall bladder event?21 if you S22 A-No, but again, if that's the case, it would only22 I'm23 add background noise to reduce the chance of23 A-24 finding an association, unless you believe one24 Q-	ds that they're comparing? 're nderstand, if I'm talking to you about e're comparing Levonorgestrel and el, do you understand these two (2) ds? t. o you understand the relationship Norgestrel and Levonorgestrel? t. I you there's only The only redient in Norgestrel is estrel, from a scientific perspective,

AFFIDAVIT

73 75 1 from a scientific perspective, if you compare a chemical compound to itself, you wouldn't expect 1 the Levnorgestrel and Norgestrel In that 2 3 to find a statistically different result, would 3 nature, you would not expect to find a 3 4 you? 4 statistically different result in that case 6 5 Me SAMY ELNEMR: 6 normally, would you? 6 file took 6 No, you wouldn't. 7 GENEVIEVE BERTRAND: 70 You wouldn't. 8 So 70 You wouldn't. 9 Me SAMY ELNEMR: 9 hit is same. thing, it's 10 10 I'm sorry, you're going to have to repeat 100 hit dist the same thing, 100 13 GENEVIEVE BERTRAND: 14 Okay, so I'l statt over. 144 14 Okay, so I'l statt over. 144 I doen for propensity score in that table. 16 16 m referring Dr. Grover to Table 3, the 16 m analysis where you're looking at whet on adjusted for comparison being positive just on chance alone. 200 14 Okay. Counde statt whet anust tabl	-,		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
2 chemical compound to itself, you wouldn't expect to find a statistically different result, would you? 2 case, comparing two (2) things of the same statistically different result in that case normally, would you? 5 Me SAMY ELNEMR: 5 normally, would you? 6 A. No, you wouldn't. 6 A. No, you wouldn't. 7 Me GENEVIEVE BERTRAND: 7 Q. You wouldn't. 8 So	73	3		75
2 chemical compound to itself, you wouldn't expect to find a statistically different result, would you? 2 case, comparing two (2) things of the same statistically different result in that case normally, would you? 5 Me SAMY ELNEMR: 5 normally, would you? 6 A. No, you wouldn't. 6 A. No, you wouldn't. 7 Me GENEVIEVE BERTRAND: 7 Q. You wouldn't. 8 So	1 from a scientific perspective, if you compare a	1	the Levonorgestrel and Norgestrel In that	
4 you? statistically different result in that case 5 Me SAMY ELNEMR: 6 6 If we look 7 7 Me GOREVIEVE BERTRAND: 7 9 Me SAMY ELNEMR: 7 9 Me SAMY ELNEMR: 7 10 I'm sorry, you're going to have to repeat 11 11 that 8 12A- Yes. 100- And the fact that they looked at the same 13Me GENEVIEVE BERTRAND: 13 14 Okay, so I'll start over. 14 15 So, we're comparing here, in this table 15 16 I'm referring Dr. Grover to Table 3, the 16 17 Levonogestrel and the Norgestrel, and the 18 18 adjusted for propensity score is? 200- As we So, it could be chance 21A- Yes. 220- Okay. 220- Okay. 220 or it could be the 220- Okay. 220 though, the adjusted propensity score biom 23A Could be bias. 220 though, the adjusted propensity score biom 24A - Yes. 23A - User mask, we'll move on. 5 So, we're comparing these two (2) <t< td=""><td>2 chemical compound to itself, you wouldn't expect</td><td>2</td><td>case, comparing two (2) things of the same</td><td></td></t<>	2 chemical compound to itself, you wouldn't expect	2	case, comparing two (2) things of the same	
4 you? statistically different result in that case 5 Me SAMY ELNEMR: 6 6 If we look 7 7 Me GOREVIEVE BERTRAND: 7 9 Me SAMY ELNEMR: 7 9 Me SAMY ELNEMR: 7 10 I'm sorry, you're going to have to repeat 11 11 that 8 12A- Yes. 100- And the fact that they looked at the same 13Me GENEVIEVE BERTRAND: 13 14 Okay, so I'll start over. 14 15 So, we're comparing here, in this table 15 16 I'm referring Dr. Grover to Table 3, the 16 17 Levonogestrel and the Norgestrel, and the 18 18 adjusted for propensity score is? 200- As we So, it could be chance 21A- Yes. 220- Okay. 220- Okay. 220 or it could be the 220- Okay. 220 though, the adjusted propensity score biom 23A Could be bias. 220 though, the adjusted propensity score biom 24A - Yes. 23A - User mask, we'll move on. 5 So, we're comparing these two (2) <t< td=""><td></td><td>3</td><td></td><td></td></t<>		3		
5 Me SAMY ELNEMR: 5 normali, would you? 6 Me SAMY ELNEMR: 6 A. No. you wouldn't. 7 Me GENEVIEVE BERTRAND: 7 Q. You wouldn't. 8 So 8 A. If it's the same thing, it's the same thing. 10 I'm sorry, you're going to have to repeat 10 Q. And the fact that they looked at the same 11 that 8 A. If it's the same thing. 12A- Yes. 12 13Me GENEVIEVE BERTRAND: 14 A. 14 Okay, so I'l start over. 14 A. 15 So, we're comparing here, in this table 15 16 I'm refering Dr. Grover to Table 3, the 16 17 Levonorgestrel and the Norgestrel, and the 17 18 adjusted for propensity score is? 21A- Yes. 220- Doyou understand what an adjusted for 20 As we So, it could be the 23A- I don't consider 23A- 24A- Yes. 22A- 25A though, the adjusted propensity score being 25A- 25A though, the adjusted propensity score being 25A- 2 C- Lat me ask you the question, and and then 3 3 A Yes. 9 4 3 A Yes. 9 <td>4 you?</td> <td>4</td> <td>statistically different result in that case</td> <td></td>	4 you?	4	statistically different result in that case	
if twe look 6 A. No, you'wouldn't. 7 Me GENEVIEVE BERTRAND: 6 A. No, you'wouldn't. 9 Me SAMY ELNEMR: 7 Q. You wouldn't. 10 Im sorry, you're going to have to repeat 11 if the same		5	•	
7 Me GENEVIEVE ERERTRAND: 7 O. You'wouldnt. 8 So 8 A. Hift's the same thing, it's the same thing, it's the same thing. 9 Me SAMY ELNEMR: 9 the same thing. 10 If m sorry, you're going to have to repeat 100. 11 that 110. 12A - Yes. 12 13Me GENEVIEVE BERTRAND: 12 14 Okay, so Ifi start over. 12 15 So, we're comparing here, in this table 13 16 If mefering Dr. Grover to Table 3, the 16 17 Levonorgestrel and the Norgestrel, and the 17 18 adjusted for propensity score is? 200. A sew				
8 So				
9 Me SAMY ELNENR: 9 the same thing. 10 I'm sorry, you're going to have to repeat 100- 11 that Compound and they found a statistical difference 12A- Yes. 12 shows in this case that there must have been 13Me GENEVIEVE BERTRAND: 13 bias, correct? 14 Okay, so I'll start over. 13 bias, correct? 14 Cokay, so I'll start over. 14A- It deson't mean there's bias, it could also 17 Levonorgestrel and the Norgestrel, and the 16 m analysisWhen you do an analysisWhen you do 18 adjusted for propensity score in that table. 16 na analysis where you're looking at multiple 10 propensity score in that table. 18 risk of a comparison being positive just on 19 chance alone. 200- As we So, it could be chance 21A- Yes. 21A- Yes. 21A- Yes. 21A- Yes. 23A- I doin toonsider 23A- 23A- 24Q- So 24A- Yes. 24A- Yes. So So. Here is a sociation or there is a sociation or there is a risk of 3 well				
10 Im sorry, you're going to have to repeat that 100- And the fact that they looked at the same compound and they found a statistical difference shows in this case that there must have been bias, correct? 11 Charge SC ERTRAND: 12 Shows in this case that there must have been bias, correct? 14 Charge SC ERTRAND: 14 Charge SC ERTRAND: 14 15 So, we're comparing here, in this table 15 shows in this case that there must have been 16 I'm referring Dr. Grover to Table 3, the 16 an analysis where you're looking at multiple 16 Do you understand what an adjusted for propensity score is? 20- As we So, it could be chance 21A- Yes. 220- Okay. 21A- Yes. 220- 220- Okay. 21A- Yes. 220- 221A- I don't consider 224A- I don't consider 23A- Could be thas 24A- Yes. 225A			-	
11 that 11 compound and they found a statistical difference 12A. Yes. shows in this case that there must have been bias, correct? 14 Okay, so III start over. 14. It doesn't mean there's bias, it could also 15 So, we're comparing here, in this table 14. It doesn't mean there's bias, it could also 16 I'm referring Dr. Grover to Table 3, the 16 an analysis where you're looking at multiple 17 Levonorgestrel and the Norgestrel, and the 18 risk of a comparison being positive just on 19. Do you understand what an adjusted for 19 chance alone. 20- 21A. Yes. 220- Okay. 220- As we So, it could be chance 224. 23A. I don't consider 23A. Could be bias. 240- fact that there are bias? 25A though, the adjusted propensity score being 25A. But the salso You have to be clear here that, 4 A Yes. 5 So. we're comparing these two (2) 6 The adjusted 7 10. in Ark Yes. 10. Norgestrel and Levonorgestrel. 10. 8 A Yes. 8		-		
12A- Yes. 12 shows in this case that there must have been 13Me GENEVIEVE BERTRAND: 13 bias, correct? 14 Okay, so I'll start over. 13 bias, correct? 15 So, we're comparing here, in this table 15 mean When you do an analysis. When you do an analysis. When you do an analysis where you're looking at multiple 16 Im referring Dr. Grover to Table 3, the 15 mean When you do an analysis. When you do an analysis where you're looking at multiple 17 Levonorgestrel and the Norgestrel, and the 17 comparisons, there is a risk of there is a 18 risk of a comparison being positive just on 19 charce alone. 20- Okay. 21A- Yes. 21A- Yes. 21A- Yes. 21A- Yes. 22A- Could be tha 23A- Could be thas 23A- Could be thas 22A- Okay. 22A- Could be tabas. 24O for it could be thas 24A- Yes. 21 the most important column in that table. 2 Correct, sir? 24A- Yes. 3 we'll 3A- But it's also You have to be clear here that, refatively speaking, the comparison between than				
13Me GENEVIEVE BERTRAND: 13 bias, correct? 14 Okay, so I'll start over. 14.A tt doesn't mean there's bias, it could also 15 So, we're comparing here, in this table 14.A tt doesn't mean there's bias, it could also 16 I'm referring Dr. Grover to Table 3, the 16 an analysis where you're looking at multiple 17 Levonorgestrel and the Norgestrel, and the 18 organisons, there is a risk of a comparison being positive just on 190- Do you understand what an adjusted for 20 As we So, it could be chance 21.A 21A Yes. 21.A Yes. 22.Q- or it could be the 23.A 23A- I don't consider 23.A Could be bias. 24.Q- or it could be the 24Q- So 24.Q- So 24.Q- or it could be bias. 24 So 24.P So 25.A But there's no obvious bias to me, here. 25 Q- Let me ask you the question, and and then 3 A. But it's also You have to be clear here that, the treat is an association or there is not association or there is an association or there is it's aso You have to be clear here that, the treat is abo				
14 Okay, so I'll start over. 14 A- It doesn't mean there's bias, it could also 15 So, we're comparing here, in this table 15 mean When you do an analysis When you do 16 I'm referring Dr. Grover to Table 3, the 15 mean When you do an analysis When you do 17 Levonorgestrel and the Norgestrel, and the 17 comparisons, there is a risk of there is a 18 adjusted for propensity score is? 200- As weSo, it could be chance 21A- Yes. 22Q- Okay. 22Q- or it could be the 23A- I don't consider 23A- Could be the 23A- 24D- So 24D- So 24D- So 25A though, the adjusted propensity score being 74 74 76 1 the most important column in that table. 1 0- Okay, so it's chance or bias. But if Is that 2 0- okay, we'll move on. 5 Norgestrel and Levonorgestrel, whether you agree 6 So, we're comparing these two (2) 7 we'll 3 7 comparison between you do an analysis you 8 Norgestrel and Levonorgestrel, whethe				
15 Šo, we're comparing here, in this table 15 mean When you do an analysis When you do 16 I'm referring Dr. Grover to Table 3, the 16 an analysis where you're looking at multiple 17 Levonorgestrel and the Norgestrel, and the 16 an analysis where you're looking at multiple 18 adjusted for propensity score in that table. 18 risk of a comparisons, there is a fisk of there is a 19. Do you understand what an adjusted for 19 chance alone. 20 20. Okay. 21A. Yes. 21A. Yes. 22A. I don't consider 23A. Could be thas 24. O. So 25A though, the adjusted propensity score being 25A. But there's no obvious bias to me, here. 76 74 The most important column in that table. 1 0- Okay, so it's chance or bias. But if Is that 2 Q- Let me ask you the question, and and then 3 A- But it's also You have to be clear here that, trelatively speaking, the comparison between 5 Q- okay, we'll move on. 5 Norgestrel al-twoorgestrel. 7 8 A- Yes. 7 weak one, and it depends on which analysis you we a statistically 6 So, we're				
16 I'm referring Dr. Grover to Table 3, the 16 an analysis where you're looking at multiple 17 Levnorgestrel and the Norgestrel, and the 17 comparisons, there is a risk of there is a 18 adjusted for propensity score in that table. 19 chance alone. 20Q- 20 Do you understand what an adjusted for 19 chance alone. 20Q- 21A- Yes. 22Q- Okay. 22Q- or it could be the 23A- 23A- I don't consider 23A- Could be the ask. 22Q- or it could be the 23A- I don't consider 24Q- So 24Q- So 24Q- So 2 G- Let me ask you the question, and and then 3 A- But there's no obvious bias to me, here. 76 1 the most important column in that table. 2 correct, sir? 74 76 1 the most important column in that table. 2 Norgestrel and Levnorgestrel, whether you agree 6 there is an association or there isn', it's a 3 A - Yes. So, we're comparing these two (2) 6 there is an association or there isn', it's a 10 in Norgestrel is Le	5.			
17 Levonorgestrel and the Norgestrel, and the adjusted for propensity score in that table. 17 comparisons, there is a risk of t				
18 adjusted for propensity score in that table. 18 risk of a comparison being positive just on chance alone. 19 De you understand what an adjusted for propensity score is? 20 A see So, it could be chance 21A Yes. 21A Yes. 21A Yes. 21A Yes. 21A Yes. 23A I don't consider 22 Q As we So, it could be the 23A Could be bias. 24D So 25A though, the adjusted propensity score being 74 Yes. 25 A though, the adjusted propensity score being 74 O kay, so it's chance or bias. The most important column in that table. 2 O Let me ask you the question, and and then 74 O kay, so it's chance or bias. But if Is that 3 we'll 3 A- Yes. But it's also You have to be clear here that, relatively speaking, the comparison between 5 O okay, we'll move on. 50, we're comparing these two (2) 7 weak one, and it depends on which analysis you 8 A Yes. 9 shows a very marginally significant result, the 10 adjusted 11 Ar Yes. 12 - Yes. 12 - Yes. 12 - Yes. 12 Me SAMY ELNEMR: 12 - Yes. 12 - Yes. 12 - Yes. 13 Is that a fact? 12 - Yes. 12 - Yes. 13 significant res				
19Q- Do you understand what an adjusted for propensity score is? 19 chance alone. 21A- Yes. 20Q- As weSo, it could be chance 22Q- Okay. 21A- Yes. 23A- I don't consider 22Q- or it could be the 23A- I don't consider 22Q- or it could be the 23A- I don't consider 22Q- fact that there are bias? 25A- though, the adjusted propensity score being 74 1 the most important column in that table. 2Q- Let me ask you the question, and and then 3 well 3A- But it's also You have to be clear here that, 4 A Yes. 3A- But it's also You have to be clear here that, 4 A Yes. 74 76 7 correct, sir? 3A- But it's also You have to be clear here that, 4 Yes. 74 74 74 1 Q- okay, we'll move on. 74 74 1 A Yes. 74 74 1 Noro				
20 propensity score is? 20 Q- As we So, it could be chance 21 A- Yes. 21 A- Yes. 22 Q- Okay. 23 A- I don't consider 22 Q- Okay. 22 Q- 23 A- I don't consider 23 A- Could be bias. 24 Q- So though, the adjusted propensity score being 25 A- But there's no obvious bias to me, here. 25 A though, the adjusted propensity score being 74 76 1 the most important column in that table. 2 O- As we So, it could be the 2 Q- Let me ask you the question, and and then 3 A- But it's also You have to be clear here that, 3 we'll 3 A- But it's also You have to be clear here that, 4 Yes. 5 Q- okay, we'll move on. 5 6 So, we're comparing these two (2) 7 weak one, and it depends on which analysis you 8 A Yes. 9 Q- and Norgestrel. The only active ingredient 10 adjusted 11A- Yes. 12A Yes. 9 shows a very marginally significant result, the 12A He GE				
21A. Yes. 21A. Yes. 22Q. Okay. 22Q or it could be the 23A. I don't consider 22A. Could be bias. 24Q. So 23A though, the adjusted propensity score being 24Q. So 25A though, the adjusted propensity score being 24Q. So 2 Q. Let me ask you the question, and and then 3 3. we'll 4 4 A. Yes. 3 5 Q okay, we'll move on. 5 6. So, we're comparing these two (2) 7 7 compounds, Levonorgestrel 7 8 A. Yes. 8 9 Q and Norgestrel is Levonorgestrel. 7 11A. Yes. 10 12Me GENEVIEVE BERTRAND: 10 13 Is that a fact? 14 14Me GENEVIEVE BERTRAND: 17 15 It is a fact, and I'm putting it to Dr. Grover, 16 16 but what's important is the next question. 17 17Me SAMY ELNEMR: 17 18 Go ahead. 17 19Me GENEVIEVE BERTRAND: 17 120Q. You would understand from a scientific 17 21 perspective and Dr. Grover, tell me if you				
22 Q- Okay. 22 Q- or it could be the 23 A- I don't consider 23 A- Could be bias. 24 Q- So 25 A- But there's no obvious bias to me, here. 74 76 74 76 74 76 74 76 75 90 76 1 Q- 77 74 78 74 79 74 74 74 74 74 74 74 75 84 74 74 74 74 74 74 74 74 75 84 74 74 74 74 75 74 74 74 75 74 74 74 75 74 75 74 75 74 75 74 75 75 75 75 <				
23 A. I don't consider 23 A. Could be bias. 24 Q. So 24 Q. fact that there are bias? 25 A. though, the adjusted propensity score being 74 76 1 the most important column in that table. 1 Q. Okay, so it's chance or bias. But if Is that 2 Q. Let me ask you the question, and and then 3 A. Yes. 3 we'll 3 A. But it's also You have to be clear here that, 4 A. Yes. So, we're comparing these two (2) 6 there is an association or there isn't, it's a 7 compounds, Levonorgestrel. 7 weak one, and it depends on which analysis you 8 A. Yes. 10. adjusted 11A- Yes. 12A- rate score doesn't show a statistically 13 Is that a fact? 13 significant result, and the crude rate shows a 14Me GENEVIEVE BERTRAND: 12A- rate score doesn't show a statistically 13 Go ahead. 17 Levonorgestrel, I would have said it's more 18 Go ahead. 17 Levonorgestrel, I would have				
24 Q- So 24 Q- fact that there are bias? 25A though, the adjusted propensity score being 25A- But there's no obvious bias to me, here. 74 74 76 1 the most important column in that table. 1 Q- 2 Q- Let me ask you the question, and and then 3 A- 3 we'll 3 A- 4 Yes. 3 A- 5 Q- okay, we'll move on. 5 Norgestrel and Levonorgestrel, whether you agree 6 So, we're comparing these two (2) 6 there is an association or there isn't, it's a 7 weak one, and it depends on which analysis you 8 look at. The adjusted for propensity score 9 Q- and Norgestrel. 10 adjusted 11A- Yes. 11Q- Yes. 12Me SAMY ELNEMR: 12A- rate score doesn't show a statistically 13 Is that a fact? 13 significant result, and the crude rate shows a 14Me GENEVIEVE BERTRAND: 15 So, if you'd asked me to comment on the 16 but what's important is the next	,			
25A-25A-But there's no obvious bias to me, here.74761the most important column in that table.12Q-Let me ask you the question, and and then13we'll34A-Yes.5Q okay, we'll move on.56So, we're comparing these two (2)6there is an association or there isn't, it's a7compounds, Levonorgestrel78A-Yes.9Q and Norgestrel. The only active ingredient710in Norgestrel is Levonorgestrel.11Q-11A-Yes.11Q-12Me GENEVIEVE BERTRAND:12A-15It is a fact?1316but what's important is the next question.11Q-17Me SAMY ELNEMR:12A-18Go ahead.19Me GENEVIEVE BERTRAND:1410marginally statistically significant result.16but what's important is the next question.17Me SAMY ELNEMR:18Go ahead.19Me GENEVIEVE BERTRAND:20Q-20Q-20Q-212223A-24Q-24Q-24Q-25A-24Q-24Q-24Q-24Q-24Q-24Q-24Q-24Q-24Q-24Q-24Q-24Q-25A-25A-26A-<				
74741the most important column in that table.2Q-2Let me ask you the question, and and then3we'll4A-4Yes.5Q-6So, we're comparing these two (2)7compounds, Levonorgestrel8A-9Q-9Q-9Q-11A-12Morgestrel is Levonorgestrel8A-9Q-9Q-9Q-14Morgestrel is Levonorgestrel.11A-Yes.12Morgestrel is Levonorgestrel.11A-Yes.12Me GENEVIEVE BERTRAND:15It is a fact?16but what's important is the next question.17Me GENEVIEVE BERTRAND:18Go ahead.19Me GENEVIEVE BERTRAND:10perspective and Dr. Grover, tell me if you20You would understand from a scientific21perspective and Dr. Grover, tell me if you22don't agree23A-Okay.24Q-If you compare a chemical compound to itself24Q-If you compare a chemical compound to itself </td <td></td> <td></td> <td></td> <td></td>				
1the most important column in that table.1Q-Okay, so it's chance or bias. But if Is that2Q-Let me ask you the question, and and then3A-3we'll3A-But it's also You have to be clear here that,4A-Yes.3A-5Q okay, we'll move on.5Norgestrel and Levonorgestrel, whether you agree6So, we're comparing these two (2)6there is an association or there isn't, it's a7compounds, Levonorgestrel.7weak one, and it depends on which analysis you8A-Yes.8look at. The adjusted for propensity score9Q and Norgestrel. The only active ingredient10adjusted11A-Yes.11Q-Yes.12Me GENEVIEVE BERTRAND:11Q-Yes.13Is that a fact?13significant result, and the crude rate shows a14Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.16comparison between Norgestrel and17Levonorgestrel.19Q-Okay, and other than chance or bias, are there20Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two	25 A though, the adjusted propensity score being	25 A-	But there's no obvious bias to me, here.	
2Q-Let me ask you the question, and and then2correct, sir?3we'll3A-But it's also You have to be clear here that,4A-Yes.3A-5Q okay, we'll move on.5Norgestrel and Levonorgestrel, whether you agree6So, we're comparing these two (2)6there is an association or there isn', it's a7compounds, Levonorgestrel7weak one, and it depends on which analysis you8A-Yes.8look at. The adjusted for propensity score9Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.10adjusted11A-Yes.12A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.17Levonorgestrel, I would have said it's more18Go ahead.19Okay, and other than chance or bias, are there20You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22compounds that are the same?23	74	L I		76
3we'll3A-But it's also You have to be clear here that,4A-Yes.4relatively speaking, the comparison between5Q okay, we'll move on.5Norgestrel and Levonorgestrel, whether you agree6So, we're comparing these two (2)6there is an association or there isn't, it's a7compounds, Levonorgestrel7weak one, and it depends on which analysis you8A-Yes.89Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.11Q-11A-Yes.11Yes.12 Me SAMY ELNEMR:12 A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,16comparison between Norgestrel and17 Me SAMY ELNEMR:17Levonorgestrel, I would have said it's more18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23 A-Okay.23 A- <td>1 the most important column in that table.</td> <td>1 Q-</td> <td>Okay, so it's chance or bias. But if Is that</td> <td></td>	1 the most important column in that table.	1 Q-	Okay, so it's chance or bias. But if Is that	
3we'll3A-But it's also You have to be clear here that,4A-Yes.4relatively speaking, the comparison between5Q okay, we'll move on.5Norgestrel and Levonorgestrel, whether you agree6So, we're comparing these two (2)6there is an association or there isn't, it's a7compounds, Levonorgestrel7weak one, and it depends on which analysis you8A-Yes.89Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.11Q-11A-Yes.11Yes.12 Me SAMY ELNEMR:12 A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,16comparison between Norgestrel and17 Me SAMY ELNEMR:17Levonorgestrel, I would have said it's more18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23 A-Okay.23 A- <td>2 Q- Let me ask you the question, and and then</td> <td>2</td> <td>correct, sir?</td> <td></td>	2 Q- Let me ask you the question, and and then	2	correct, sir?	
4A-Yes.4relatively speaking, the comparison between5Q okay, we'll move on.5Norgestrel and Levonorgestrel, whether you agree6So, we're comparing these two (2)6there is an association or there isn't, it's a7compounds, Levonorgestrel7weak one, and it depends on which analysis you8A-Yes.8look at. The adjusted for propensity score9Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.10adjusted11A-Yes.11Q-Yes.12Me SAMY ELNEMR:12A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,16comparison between Norgestrel and17Levonorgestrel, I would have said it's more18borderline more unclear.19Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23 A-Okay.23 A-24 Q-If you compare a chemical compound to itself24 Q-Okay. <td></td> <td>3 A-</td> <td>But it's also You have to be clear here that,</td> <td></td>		3 A-	But it's also You have to be clear here that,	
5Q okay, we'll move on.5Norgestrel and Levonorgestrel, whether you agree6So, we're comparing these two (2)6there is an association or there isn't, it's a7compounds, Levonorgestrel7weak one, and it depends on which analysis you8A-Yes.79Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.10adjusted11A-Yes.11Q-Yes.12 Me SAMY ELNEMR:12A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,16comparison between Norgestrel and17 Me SAMY ELNEMR:17Levonorgestrel, I would have said it's more18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22compounds that are the same?23A-Okay.24 Q-If you compare a chemical compound to itself24 Q-24 Q-Okay.24 Q-				
6So, we're comparing these two (2)6there is an association or there isn't, it's a7compounds, Levonorgestrel7weak one, and it depends on which analysis you8A-Yes.9Oadjusted for propensity score9Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.10adjusted11 A-Yes.11Q-Yes.12 Me SAMY ELNEMR:12A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.16comparison between Norgestrel and17 Me SAMY ELNEMR:18borderline more unclear.19 Me GENEVIEVE BERTRAND:19Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20Other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22compounds that are the same?23A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24Q-Okay.				
7compounds, Levonorgestrel7weak one, and it depends on which analysis you8A- Yes.8look at. The adjusted for propensity score9Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.10adjusted11A- Yes.11Q-Yes.11Q-12 Me SAMY ELNEMR:12A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.16comparison between Norgestrel and17Levonorgestrel, I would have said it's more18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q- You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23 A-Okay.24 Q-24 Q-If you compare a chemical compound to itself24 Q-Okay.				
8A-Yes.8look at. The adjusted for propensity score9Q and Norgestrel. The only active ingredient9shows a very marginally significant result, the10in Norgestrel is Levonorgestrel.10adjusted11A-Yes.11Q-Yes.12 Me SAMY ELNEMR:12A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.16comparison between Norgestrel and17 Me SAMY ELNEMR:17Levonorgestrel, I would have said it's more18Go ahead.19Q-Okay, and other than chance or bias, are there20Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23A-Okay.23A-23A-Okay.23A-That's the only two (2) that I24Q-If you compare a chemical compound to itself24Q-Okay.				
9Q and Norgestrel. The only active ingredient10in Norgestrel is Levonorgestrel.11 A-Yes.12 Me SAMY ELNEMR:11 Q-13Is that a fact?14 Me GENEVIEVE BERTRAND:12 A-15It is a fact, and I'm putting it to Dr. Grover,16but what's important is the next question.17 Me SAMY ELNEMR:1418Go ahead.19 Me GENEVIEVE BERTRAND:18Go ahead.19 Me GENEVIEVE BERTRAND:1019 Q-20 Q-You would understand from a scientific20 Q-You would understand from a scientific21perspective and Dr. Grover, tell me if you22don't agree23 A-Okay.24 Q-If you compare a chemical compound to itself				
10in Norgestrel is Levonorgestrel.11 A-Yes.12 Me SAMY ELNEMR:11 Q-13Is that a fact?14 Me GENEVIEVE BERTRAND:12 A-15It is a fact, and I'm putting it to Dr. Grover,16but what's important is the next question.17 Me SAMY ELNEMR:1618Go ahead.19 Me GENEVIEVE BERTRAND:18Go ahead.19 Me GENEVIEVE BERTRAND:20 Q-You would understand from a scientific20 Q-You would understand from a scientific21perspective and Dr. Grover, tell me if you22don't agree23 A-Okay.24 Q-If you compare a chemical compound to itself				
11 A-Yes.12 Me SAMY ELNEMR:11 Q-Yes.13 Is that a fact?12 A rate score doesn't show a statistically14 Me GENEVIEVE BERTRAND:13 significant result, and the crude rate shows a15 It is a fact, and I'm putting it to Dr. Grover,15 So, if you'd asked me to comment on the16 but what's important is the next question.16 comparison between Norgestrel and17 Me SAMY ELNEMR:17 Levonorgestrel, I would have said it's more18 Go ahead.18 borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-20 Q-You would understand from a scientific21 perspective and Dr. Grover, tell me if you21 statistically different result for these two (2)22 don't agree22 compounds that are the same?23 A-Okay.24 Q-If you compare a chemical compound to itself	, , , , , , , , , , , , , , , , , , ,			
12 Me SAMY ELNEMR:12 A rate score doesn't show a statistically13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.16comparison between Norgestrel and17 Me SAMY ELNEMR:17Levonorgestrel, I would have said it's more18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23 A-Okay.23 A-23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.			-	
13Is that a fact?13significant result, and the crude rate shows a14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.15So, if you'd asked me to comment on the17Me SAMY ELNEMR:16comparison between Norgestrel and18Go ahead.17Levonorgestrel, I would have said it's more18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23 A-Okay.23 A-23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.				
14 Me GENEVIEVE BERTRAND:14marginally statistically significant result.15It is a fact, and I'm putting it to Dr. Grover,15So, if you'd asked me to comment on the16but what's important is the next question.15So, if you'd asked me to comment on the17Me SAMY ELNEMR:16comparison between Norgestrel and18Go ahead.17Levonorgestrel, I would have said it's more18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree22compounds that are the same?23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.				
15It is a fact, and I'm putting it to Dr. Grover, but what's important is the next question.15So, if you'd asked me to comment on the 1616but what's important is the next question.15So, if you'd asked me to comment on the 1617 Me SAMY ELNEMR:16comparison between Norgestrel and 1718Go ahead.17Levonorgestrel, I would have said it's more borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there 20 other reasons the there would be a 2120 Q-You would understand from a scientific 2220other reasons the there would be a 2121perspective and Dr. Grover, tell me if you 2221statistically different result for these two (2) 2223 A-Okay.23 A-That's the only two (2) that 1 24 Q-24 Q-If you compare a chemical compound to itself24 Q-			-	
16but what's important is the next question.16comparison between Norgestrel and17 Me SAMY ELNEMR:17Levonorgestrel, I would have said it's more18Go ahead.17Levonorgestrel, I would have said it's more19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree22compounds that are the same?23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.				
17 Me SAMY ELNEMR:17Levonorgestrel, I would have said it's more18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree22compounds that are the same?23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.			•	
18Go ahead.18borderline more unclear.19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree23 A-Okay.23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-		110		
19 Me GENEVIEVE BERTRAND:19 Q-Okay, and other than chance or bias, are there20 Q-You would understand from a scientific20other reasons the there would be a21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree22compounds that are the same?23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.		17		
20 Q- 21You would understand from a scientific perspective and Dr. Grover, tell me if you20other reasons the there would be a 2122don't agree21statistically different result for these two (2) 2223 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-	17 Me SAMY ELNEMR:			
21perspective and Dr. Grover, tell me if you21statistically different result for these two (2)22don't agree22compounds that are the same?23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-	17 Me SAMY ELNEMR: 18 Go ahead.	18	borderline more unclear.	
22don't agree22compounds that are the same?23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.	17 Me SAMY ELNEMR: 18 Go ahead. 19 Me GENEVIEVE BERTRAND:	18 19 Q-	borderline more unclear. Okay, and other than chance or bias, are there	
23 A-Okay.23 A-That's the only two (2) that I24 Q-If you compare a chemical compound to itself24 Q-Okay.	 17 Me SAMY ELNEMR: 18 Go ahead. 19 Me GENEVIEVE BERTRAND: 20 Q- You would understand from a scientific 	18 19 Q- 20	borderline more unclear. Okay, and other than chance or bias, are there other reasons the there would be a	
24 Q- If you compare a chemical compound to itself 24 Q- Okay.	 17 Me SAMY ELNEMR: 18 Go ahead. 19 Me GENEVIEVE BERTRAND: 20 Q- You would understand from a scientific 21 perspective and Dr. Grover, tell me if you 	18 19 Q- 20 21	borderline more unclear. Okay, and other than chance or bias, are there other reasons the there would be a statistically different result for these two (2)	
	 17 Me SAMY ELNEMR: 18 Go ahead. 19 Me GENEVIEVE BERTRAND: 20 Q- You would understand from a scientific 21 perspective and Dr. Grover, tell me if you 22 don't agree 	18 19 Q- 20 21 22	borderline more unclear. Okay, and other than chance or bias, are there other reasons the there would be a statistically different result for these two (2) compounds that are the same?	
1.25 So wo're comparing two (2) of the same thing 1.25 A guess I can think of off the ten of my head	 17 Me SAMY ELNEMR: 18 Go ahead. 19 Me GENEVIEVE BERTRAND: 20 Q- You would understand from a scientific 21 perspective and Dr. Grover, tell me if you 22 don't agree 23 A- Okay. 	18 19 Q- 20 21 22 23 A-	borderline more unclear. Okay, and other than chance or bias, are there other reasons the there would be a statistically different result for these two (2) compounds that are the same? That's the only two (2) that I	
25 So, were companing two (2) of the same timing, 25A guess i can timit of on the top of my near	 17 Me SAMY ELNEMR: 18 Go ahead. 19 Me GENEVIEVE BERTRAND: 20 Q- You would understand from a scientific 21 perspective and Dr. Grover, tell me if you 22 don't agree 23 A- Okay. 24 Q- If you compare a chemical compound to itself 	18 19 Q- 20 21 22 23 A- 24 Q-	borderline more unclear. Okay, and other than chance or bias, are there other reasons the there would be a statistically different result for these two (2) compounds that are the same? That's the only two (2) that I Okay.	

Astrida Auza o.c.r.

Steno Exact MAXIN

			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	7	7		79
1	as chance or bias.	1	not support	
2 Q-	And isn't it true that	2 A-	Yes, I didn't review that issue.	
3 A-	Well, misclassification, of course, but yes.	3 Q-	Okay.	
4 Q-	And isn't it true that the authors of the study	4 A-	I couldn't say.	
5	conclude that the small amount of increased	5 Q-	•	
6	risk, together with possible biases in the	6	And there are no studies that demonstrate	
7	study, make the differences in the incidents of	7	an association between Yaz or Yasmin	
8	gall bladder disease unlikely to be clinically	8	specifically, and functional gall bladder	
9	significant?	9	disorder, correct?	
10 A-	That is their conclusion, that's correct.	10 A-		
11Q-	So, they candidly admitted that there are biases		SAMY ELNEMR:	
12	in their study, and that could have affected the	12	Could you specify which one you're talking	
13	results of the study?	13	about?	
14 A-	I didn't they said "compounded with the	14 A-	I'm sorry, say that again.	
15	possibility of residual biases."		e GENEVIEVE BERTRAND:	
16 Q-		16 Q-		
17 A-	Right. But the possibility of residual biases are	17	association between Yaz and Yasmin and	
		18		
18	always there in any study, other than a		functional gall bladder disorder?	
19	perfectly	19 A-	, ,	
20 Q-	Yes.	20 Q-	5	
21 A-	done randomized control trial. So	21	cholecystectomy, the	
22 Q-	Right.	22 A-	, , , , , , , , , , , , , , , , , , ,	
23 A-	all they're saying is that this isn't a	23	defined as a cholecystectomy.	
24	perfect study.	24 Q-	, ,	
25 Q-	Right.	25	LifeLink Health Plan Claims Database?	
	7	8		80
1	And you would agree with that, that it's	1 A-	M'hm.	
2	not a it's not a perfect study?	2 Q-	And Well, just maybe verbally, if you could	
3 A-	Not Not a perfect study to prove causality.	3	say "yes"?	
4 Q-	Okay. So, there The existing literature does	4 A-	Yes.	
5	not support that low doses of estrogen we're	5 Q-	Yes.	
6	talking about estrogen this time used in	6 A-	Sorry.	
7	modern oral contraceptives, including Yaz or	7 Q-	5	
8	Yasmin, are associated with an increased risk of	8	the past, correct? Do you recall that?	
9	gall bladder disease, compared to non-use of	9 A-		
10	oral contraceptives?	10 Q-		
11 A-	Well, I wouldn't say that, because	11 A-		
12 Q-	Okay.	12 Q-		
13 A-	this study actually found an association,	13 A-		
14	and	14 Q-	0	
15 Q-	But we're talking about estrogen, not progestin.	15 A-	5	
16	but were taiking about estrogen, not progestill.	16Q-	,	
17 A-	Oh, I'm sorry. Sorry, say that	17 A-	whatsoever.	
17 A-				
	So, I'll repeat	18Q-	Okay.	
19 A-	Repeat it again?	19		
20 Q-	the question.	20	(DISCUSSION OFF RECORD)	
21 A-	Yes.	21		
		1.22 1.42	e GENEVIEVE BERTRAND:	
22 Q-	So, in terms of the literature So, we're			
23	switching from progestin which is the Etminan	23 Q-	So, Dr. Grover, just to come back to your	

AFFIDAVIT

		01			0.0
2immob3to have4of an o5A-6Q-7An8compa9contration10similar11sugges12contration13have til14 A-No.15 Q or C16 A-I mean17decide18 Q-Right.19An20the Etr21proper22duratio23said th24that it o	s, the obesity, the surgery, the bilization, the infection, were more likely e caused a thrombotic event than her use oral contraceptive? gree with that, okay. Ind in discussing the Jick Study, and not aring the women that were on or off oral iceptives, you said that all the women are r Surely, you didn't mean or didn't st that all of the women taking an oral iceptive are all obese, or all smokers, or he same risk factors as Ms. Gladu Suindon? That's not what you meant? In more similar in the sense that they all ed to take oral contraceptives. Okay. Ind when you said that all of the flaws in minan Study, including the dose, the r diagnosis of gall bladder disease, the on of taking the oral contraceptive You hat all of this was background noise and only strengthened the association in the an Study.		12	Yes. At very least, you wouldn't expect that the gall bladder would be taken out in the absence of gall stones. At very least they would have known they had gall stones. So, we will suspend the examination and 'sujet' subject to the the undertaking to be provided. We thank you for your time today, Dr. Grover SYLVIE RODRIGUE: Thank you. SENEVIEVE BERTRAND: we appreciate it. AND FURTHER DEPONENT SAITH NOT 	83
2examp3associ4gall bla5study?6A-7diagno8of chol9of thes10fact, di11 Q-Becau12 A-Yes.13 Q-That w14 A-I mear15bladde16cholec17 Q-Yes.18 A I can19here in20Now, I21her ga23nothing24cholec	ow, if there's no proper diagnosis, for ble, doesn't it tell you that there's a weak iation because it could be someone without adder disease that was included in the		3 Judi 4 the f 5 trans 6 best 7 8 And 9 10 11 AST	ATRIDA AUZA, Official Court Reporter in the cial District of Montreal, hereby certify that oregoing pages are a true and accurate scription of the mechanical recording, to the of my skill, ability, and understanding. I have signed, TRIDA AUZA train the porter	84

Astrida Auza o.c.r.

No.: 500-06-000484-093 DECEMBER 13, 2016

	4 [2] 39:8 59:4
-and- [2] 1:11,15	
-vs- [1] 1:20	- 5 -
	5 [1] 2:14
- 1 -	5-0 [2] 34:20,21
<i>1</i> [21] 14:11 16:1,2 25:11	50 [4] 34:11,20,2
26:12 28:14 30:11,12,14	500-06-000484-0
31:2 33:3 41:24 46:11 55:	59 [1] 4:14
19,25 56:3,19 59:17 60:	
24 64:2	- 6 -
1-5 [1] 34:18	6 [10] 25:7 27:16
10,000 [2] 39:9 41:25	68:2,5,8,11,12,1
13 [1] 1:42	61 [3] 3:19 58:12
13th [1] 5:2	644 [1] 5:8
14 [1] 29:22	
15 [2] 31:19 34:18	- 7 -
17 [1] 43:8	7 [1] 45:3
1953 [1] 5:7	71 [1] 4:16
	75 [1] 7:19
- 2 -	
2 [29] 7:5 8:15 26:16 28:	- 8 -
21 31:1 36:7 37:7 39:15	8 [2] 29:15,19
41:24 42:9 43:18,24 45:	84 [1] 10:15
22 55:17 59:17 65:3,5,8	86 [1] 10:16
69:10,22 72:7,12 74:6,25	
75:2 76:21,23	-9-
2,900 [1] 62:8	901 [2] 64:11,12
20 [3] 8:3 32:13 69:9	903 [1] 71:21
2009 [2] 45:22 46:3 2011 [1] 43:9	
2016 [2] 1:42 5:2	- A -
2010 [2] 1.42 5.2 24 [1] 43:24	ability [2] 66:11
25 [1] 7:20	absence [3] 55:4 3
29th [1] 5:6	
2307 [1] 0.0	absolutely [5] 2 63:25 70:14,17
- 3 -	<i>abstract</i> [2] 60:1
3 [12] 22:10 23:3 26:8,21	accurate [1] 84:
39:15 42:9 43:18 51:9 59:	across [2] 35:20
5 71:7,19 73:16	Action [5] 1:5 5:
3.2 [1] 36:7	24:1,13
	,

4 [2] 39:8 59:4	36:22 60:9 78:13 80:11	I
4 [2] 39.0 39.4	add [2] 69:18 70:23	ľ
- 5 -	address [2] 50:25 51:11	<u>ן</u>
5 [1] 2:14	addressed [1] 12:12	<u>ן</u>
5-0 [2] 34:20,21	adjust [6] 54:23 63:17,23	<u>ן</u>
50 [4] 34:11,20,23 35:24	65:15 70:10,17	<u>ן</u>
500-06-000484-093 [1] 1:4	<i>adjusted</i> [11] 64:1,2,4,13,	'
59 [1] 4:14	17 72:1 73:18,19,25 76:8,	
55 [1] 4.14	10	
- 6 -	adjustment [1] 70:6	
6 [10] 25:7 27:16 28:10,14	administrative [1] 9:2	
68:2,5,8,11,12,16	admission [2] 48:14,17	
61 [3] 3:19 58:12	admitted [1] 77:11	
644 [1] 5:8	<i>adults</i> [3] 6:17,18 11:12	
	advisor [1] 40:19	
- 7 -	<i>affected</i> [2] 67:9 77:12	
7 [1] 45:3	affecting [1] 53:8	
71 [1] 4:16	Affidavit [1] 16:23	
75 [1] 7:19	affiliations [1] 80:14	
	Affirmation [1] 5:11	
- 8 -	after [2] 5:11 36:7	
8 [2] 29:15,19	again [4] 33:16 70:22 78:	
84 [1] 10:15	19 79:14	
86 [1] 10:16	ago [1] 8:3	
	agree [37] 36:12,24 37:4,	.
- 9 -	12,17 38:8,9,16,18,20,24	
901 [2] 64:11,12	42:7 43:18 44:7,15,16 47:	
903 [1] 71:21	1,5,12,16,17,22,24 48:5	
	50:13 52:18,20 53:6,18	
- A -	66:14,21 70:15 74:22 76:	
ability [2] 66:11 84:6	5 78:1 80:25 81:6	
absence [3] 55:4 65:13 83:	agreed [3] 15:10,20 46:15	
3	ahead [4] 52:5 59:25 63:2	
absolutely [5] 26:13 27:5	74:18	
63:25 70:14,17	aligned [1] 15:20	
abstract [2] 60:1 61:10	allowed [2] 42:12	4
accurate [1] 84:4	alone [2] 67:6 75:19	
across [2] 35:20 57:1	always [2] 33:22 77:18	
Action [5] 1:5 5:18 20:3	am [2] 32:11 42:13	
24:1,13	America [1] 31:19	
actions [1] 31:2	amount [2] 32:16 77:5	ľ
active [3] 72:19,25 74:9	analysis [7] 16:20 54:4 65:	ľ
actually [7] 8:6 16:8 24:22	16 67:17 75:15,16 76:7	ľ
		1

André [1] 21:10 anemia [1] 64:7 *anglophone* [2] 19:6,9 another [2] 19:1 69:14 answering [1] 6:3 any [34] 13:3,4,13 14:16 15:3,11 17:1 18:10,25 20: 24 21:16 22:15 25:14,17 30:19 35:12,13 37:1 38: 10 39:6,13 40:10,20 42: 14 53:12 54:5,10 56:5 65: 12 67:22 70:6 77:18 80:14 anybody [2] 18:12 37:1 anything [4] 16:19 22:25 26:13 63:3 APPEARANCES [1] 1:34 **APPEARED** [1] 5:4 appreciate [1] 83:14 *approached* [2] 17:10 19:2 approaches [1] 11:3 *area* [1] 6:6 *argue* [4] 36:18 37:21 38:2 79:10 argument [1] 17:12 Argyle [1] 5:8 around [6] 9:14,18 10:14 12:4 21:24 35:19 arterial [2] 46:24 53:8 asked [4] 24:6 34:22 48: 16 76:15 asking [2] 6:3 59:11 associated [10] 12:6 20:6 37:15,18 38:9 54:11 61: 20 68:10,13 78:8 associates [1] 8:22 **Association** [21] 16:3 63: 7 65:12,14,24 66:15,22 67:2 69:20 70:1,4,24 71:3, 4,6 76:6 78:13 79:7,17 81: 24 82:3 associations [2] 67:5,8 assume [1] 82:14 assumed [1] 28:18 ASTRIDA [3] 1:45 84:2,11

Astrida Auza o.c.r.

- 4 -

30 [3] 11:15 20:18 33:6

asymptomatic [1] 36:24 authors [1] 77:4 AUZA [3] 1:45 84:2,11 *available* [6] 40:5 41:15 53:24 54:1 66:8,10 Avenue [1] 5:9 avoid [1] 52:6 award [1] 80:7 aware [32] 31:1,18,22 32: 3,7,11,12,15 33:5 34:10, 14 36:5 39:6,9,25 40:2,8 41:14,19 42:3 44:25 45:1, 12 46:9,18 49:22 53:12 55:16,22 56:3 58:20 away [2] 19:18 23:14 AZ161213 [1] 1:45

- B -

back [7] 10:15 33:21 43: 13 49:17 52:7 57:24 80:23 background [3] 69:19 70: 23 81:23 based [2] 25:17 28:22 basically [5] 6:15 7:4 37:8 62:7 63:24 basing [1] 65:21 basis [3] 31:6 68:9 82:7 **BAYER** [2] 1:23 5:17 became [2] 36:20 48:13 **because** [18] 5:24 6:4 8: 24 23:11 33:24 35:10 36: 15,23 40:23 52:23 59:20 65:6 66:25 68:6 69:24 78: 11 82:3.11 **become** [1] 7:6 **before** [11] 6:3 20:13 25: 12 31:16 36:13 37:6,7 45: 22 46:2 52:11 62:23 behalf [3] 5:15 18:2 51:15 being [9] 17:12 19:22 34: 21 46:18 48:10 58:22 69: 15 73:25 75:18 believe [3] 68:8 70:24 82:8 believed [1] 69:13 bell [1] 57:17 benefits [1] 12:18 **BERTRAND** [42] 1:38 2: 14 5:14,17 18:4,17,22 25: 8 27:13 28:3,8 30:13 34: 19 42:20 43:4 51:2,6,18, 23 52:10 57:8,12,16 58: 14 59:12,16,22 60:4,15 61:7 62:18,22 63:1 66:20 71:15 73:7,13 74:14,19 79:15 80:22 83:13 **best** [7] 18:18,20 25:2 44: 20 54:19 56:2 84:6 better [1] 56:24 bias [15] 67:9,10,11,13,15, 17 69:15 75:13,14,23,24, 25 76:1,19 77:1 *biases* [8] 67:11,12,22 77: 6,11,15,17 big [2] 55:13 56:22 bigger [1] 35:10 *biostatics* [1] 14:23 biostatistics [1] 7:9 birth [4] 20:14,19 21:24 26:14 *bit* [1] 53:23 bladder [37] 11:17,20,22 13:14,19 16:10 17:19 23: 5,8 36:22 44:19 48:23,24 54:7,12 58:16 61:15,21 62:8,10 64:3,20 70:21 77: 8 78:9 79:8,18,19,22 81: 21 82:4,10,19,21,23,25 83:3 bladders [1] 82:15 **BMI** [1] 64:2 **body** [4] 40:11 63:24 64: 17 70:9 borderline [1] 76:18 born [1] 5:6 **both** [2] 6:5 8:19 **bottom** [2] 48:20 54:3

BOUCHARD [5] 1:17 50:

20,25 52:11 53:2 **Bouchard's** [4] 22:7 51:11 53:6,19 **bowel** [1] 64:6 **brain** [1] 53:8 **brand** [2] 39:14,22 **brief** [1] 52:6

- C -C [3] 1:1,4,45 C-K [1] 57:11 call [1] 69:19 called [1] 24:3 calling [1] 24:8 calls [1] 25:6 **CAME** [2] 5:4 10:15 Canada [2] 40:22 80:7 Canadian [1] 16:3 candidly [1] 77:11 *cannot* [3] 3:14 58:9 67:3 cardiovascular [4] 9:15, 18 10:25 care [1] 6:16 case [15] 11:6 23:3 41:6 47:13 51:12 63:13,19 68: 14 70:1,22 72:21 75:2,4, 12 cases [10] 12:6 15:22 23: 3 26:13 41:24 48:9 62:8, 11 63:14 82:20 *Caucasian* [1] 31:19 causal [2] 66:16,23 causality [2] 67:3 78:3 cause [6] 37:1 38:19,21 44:17 48:15 53:19 caused [2] 36:21 81:3 causes [1] 38:24 cell [1] 64:7 *censoring* [1] 69:6 centimetres [1] 36:7 certain [3] 35:2 63:25 65: 23 *certainly* [2] 22:18 60:20

certainty [1] 36:15 certify [1] 84:3 cessation [2] 69:7,22 *chance* [7] 67:6 70:23 75: 19,20 76:1,19 77:1 change [4] 25:16 40:22 42: 5 61:25 changes [1] 25:15 charge [1] 6:19 check [1] 45:8 *checked* [1] 32:16 *chemical* [3] 32:21 73:2 74:24 cholecystectomies [1] 14: 3 cholecystectomy [9] 37: 23,24 49:14 79:21,23 82: 8,9,16,24 cholesterol [3] 44:21 46: 17,18 *choose* [2] 65:4,8 circulation [1] 53:8 *cite* [1] 43:2 *cited* [4] 43:3,5 52:23 54: 18 Claims [1] 79:25 clarify [1] 80:25 *Class* [4] 1:5 5:17 20:3 24: 1 *clear* [8] 47:22 48:1,8,9,13 76:3 79:16 Clinemetrica [1] 8:16 *clinical* [23] 6:8,12 7:3,4,6, 7,13,15,17,20 8:4,22 9:21 10:1,13 13:10,13 15:22, 25 32:21 33:1 42:5 48:9 *clinically* [2] 70:6 77:8 clinician [1] 36:17 clout [1] 63:7 *cm* [1] 36:7 **CMAJ** [2] 43:11,12 *cohort* [4] 63:10 66:2,4 69: 9

Astrida Auza o.c.r.

colleague [2] 5:19 20:24 collectively [1] 47:10 column [2] 72:3 74:1 combination [1] 7:8 come [9] 3:14 23:25 24:19 35:20 55:10 57:1 58:9 61: 1 80:23 comes [3] 33:17 40:11 63: 4 coming [2] 49:13 52:7 commercial [1] 8:19 *committee* [1] 40:20 committees [2] 40:18,19 *common* [1] 69:8 comparables [1] 55:11 compare [2] 73:1 74:24 compared [12] 38:11 47: 20 54:7,12 56:4 58:17,19 61:16 62:9 63:5 71:1 78:9 comparing [11] 56:14,18, 24 63:14 72:8,11 73:15 74:6,25 75:2 81:8 *comparison* [4] 56:24 75: 18 76:4,16 comparisons [1] 75:17 *complete* [3] 3:15 58:9 61: 1 completely [2] 64:21,23 complex [1] 6:16 *complicated* [2] 21:15 47: 24 complication [1] 44:4 complications [1] 21:25 composition [1] 32:21 compound [3] 73:2 74:24 75:11 compounded [1] 77:14 compounds [4] 72:8,13 74:7 76:22 Comprehensive [3] 7:25 8:9 9:1 concerning [3] 5:18 55:18 56:4

conclude [1] 77:5 concluded [5] 41:14,19 42:2 54:5,10 *conclusion* [6] 42:4,6 61: 24 71:5 77:10 80:24 *conclusions* [3] 61:9,10 65:9 conduct [1] 67:15 Conducting [1] 9:8 confers [1] 61:14 confined [1] 21:23 confirm [5] 3:16 58:10 60: 20 61:2 70:20 confirmatory [1] 23:6 *conflicting* [1] 48:12 confounder [1] 70:18 confounders [3] 63:18 64: 5 70:7 consider [3] 12:2,8 73:23 consideration [2] 32:20 33:24 *consult* [2] 14:24 57:23 consulted [3] 3:14 14:21 58:8 consulting [1] 8:17 contact [2] 18:10 25:6 contained [1] 61:24 *containing* [4] 47:18 55: 18 61:13,22 contains [2] 32:13 33:5 *context* [4] 19:14 21:17 22: 3 24:12 continuously [1] 69:9 contraceptive [30] 11:14 12:2,9,11 34:7 38:10 39: 13, 19, 24 41: 22, 23 43: 25 47:14,18 49:9 52:17 54:8 55:5 56:15,16,18,25 61: 14,18 68:1,15 69:10 81:4, 12.22 contraceptives [33] 11:13, 25 12:7,22 13:1,8,11 16: 10 33:15 34:2,10 35:23 39:16 40:6 47:21 48:18

53:11,16 55:19 56:6,13, 20 58:18 61:19,23 68:7 69:7, 14,23 78:7,10 81:9,17 contradictory [1] 23:6 contribute [2] 34:12 35:25 *contributed* [6] 11:16,21, 24 12:21 13:3 47:3 control [7] 20:14,19 21:25 26:14 63:13 66:11 77:21 convince [1] 20:4 *convinced* [4] 20:7,8,9,10 corporate [1] 8:18 correct [19] 16:13 27:10 45:18 53:9,20 66:9,13,24 67:3,7,10,16,18 68:18 75: 13 76:2 77:10 79:9 80:8 correctly [1] 20:25 coter [2] 59:2 71:9 counsel [1] 24:24 couple [1] 25:19 COURT [3] 34:17 84:2,12 *cover* [5] 9:20 10:9,10 51: 7 53:1 critical [4] 43:1 55:3 56:7,9 crude [1] 76:13 currently [1] 61:17 - D -**D** [2] 1:1 2:5 dans [1] 57:24 data [12] 7:14 15:5 32:24, 25 33:1 53:12 61:12 63: 17 66:7,10 70:16 79:24 Database [1] 79:25 date [1] 20:19 dated [1] 43:8 day [2] 5:2,6 debate [1] 14:17

DECEMBER [3] 1:42 5:2

decided [1] 81:17

decreases [1] 39:24

46:2

define [1] 79:19 defined [1] 79:23 *demonstrate* [2] 79:6,16 depending [1] 34:7 depends [1] 76:7 **DEPONENT** [1] 83:16 **depose** [1] 5:12 deposition [3] 14:14,19 15:21 described [1] 9:21 description [1] 7:1 design [9] 7:10 63:8,9 65: 14 67:13,23 68:21 69:2 71:2 designs [1] 62:13 despite [1] 71:4 *develop* [2] 32:1 49:15 developed [6] 7:15 12:20 26:18 38:4 49:11 63:15 developing [13] 7:10,13 31:20 32:8 38:10 39:7,17, 22 42:8 43:17 44:10,14 45:4 development [3] 36:1 63: 12 64:19 develops [1] 55:7 *diabetes* [2] 9:16 64:6 diagnosed [1] 36:5 *diagnosis* [7] 11:3 70:21 81:21 82:1,7,19 *diagnostic* [2] 6:17 10:25 diametric [1] 6:15 diet [1] 70:11 difference [3] 41:20,23 75: 11 differences [1] 77:7 *different* [13] 16:9 24:3 31: 1 33:7,9,11,18 34:4 47:7 52:19 73:3 75:4 76:21 differently [1] 15:5 *difficult* [3] 21:5 35:3 56: 21 digital [1] 23:11

Astrida Auza o.c.r.

directly [1] 12:21 director [1] 8:1 disagree [1] 15:11 discuss [5] 67:20 68:19, 20 69:1,4 discussed [2] 16:16 49:23 discussing [1] 81:7 discussion [6] 25:11 30:9 42:25 55:1 60:13 80:20 discussions [1] 25:9 disease [36] 9:15,19 10: 25 11:17,20,22 13:15,21 16:11 17:19 23:5 36:22 46:22,24,25 54:7,12 58: 17 61:16,21 62:8,10 63: 13,15 64:3,6,20 77:8 78:9 79:22 81:21 82:4,10,19,25 dismissed [1] 58:22 disorder [3] 79:9,18,20 dispute [1] 65:10 distances [1] 45:25 **DISTRICT** [2] 1:3 84:3 **Doctor** [1] 71:16 *document* [2] 26:10 27:22 *documents* [4] 21:16 26: 25 27:1 30:20 dose [8] 33:12,22,23 35:2 39:24 81:20 doses [3] 33:18 34:6 78:5 dosing [2] 33:7,9 dossiers [1] 30:25 doth [1] 5:11 doubled [1] 32:6 doubles [1] 32:4 doubts [1] 20:24 *down* [1] 6:4 dozen [1] 25:7 Dr [33] 3:13 5:16 15:8,18 16:18 17:8,13,24 19:13, 14 21:8,20,23,25 28:23 30:21,24 31:6 37:12 40: 13 44:16 53:6 58:8,25 59: 3 60:16 61:3 73:16 74:15, 21 80:23 83:9

drafting [1] 19:17 drafts [1] 25:13 draw [2] 57:22 58:1 drospirenone [8] 47:18 54:6,11 55:18 56:4 58:17 61:12,19 *drug* [2] 33:17 35:17 *due* [2] 48:17 50:17 duration [1] 81:22 *during* [1] 44:18

- E -E [2] 1:4 2:5 e-mail [1] 24:4 e-mails [1] 25:5 *E-T-I-M-I-A-N* [1] 29:22 *E-T-M-I-N-A-N* [1] 29:25 *E-T-M-I-N-I-A-N* [2] 29:13, 19 earlier [2] 45:10 80:24 easier [1] 48:22 easiest [1] 35:5 easily [2] 23:21 48:20 effect [1] 12:11 eighty-four [1] 10:15 eighty-six [1] 10:16 either [10] 13:9 20:24 21: 15 23:5,6 42:6 52:21 54: 16 55:9 eleven [1] 43:8 eligible [1] 67:24 **ELNEMR** [34] 1:35 18:1,6, 11,14,19 25:1 27:11 28:1, 5 42:18 50:24 51:4,10,20 52:1.8 57:6,10,14 59:10, 14,19 60:2 61:5 62:16,20, 24 66:18 73:5,9 74:12,17 79:11 English [2] 19:5,12 enlisted [2] 14:12,14 entail [2] 6:9 9:4 epidemiologic [2] 56:11

epidemiological [1] 10:11 epidemiologist [3] 6:8 7:7 32:22 epidemiology [15] 7:3,4,7, 13,17,20 8:4,22 9:4,21 10: 1,14 14:23 66:14,21 errors [3] 14:16 15:2 71:1 establish [2] 66:16,23 estrogen [13] 32:14,16 33: 6,12,13,18 34:11 35:25 39:25 78:5,6,15,24 ethnicity [1] 70:13 Etimian [1] 29:20 *Etminan* [21] 4:16 16:6,9 17:4 20:12 29:24 30:17 43:9 55:20 62:4 64:10 65: 6 66:1 67:20 71:10,13 78: 23 79:24 81:20,25 *Etminian* [7] 29:13,17 62: 12 63:6,9,10 64:3 even [2] 46:17 49:14 event [11] 45:4,23 46:2 47: 20 49:5,11,12,16 50:10 70:21 81:3 events [1] 47:6 every [2] 27:1 70:17 everything [3] 23:24 27:5 35:15 evidence [1] 61:11 exactly [1] 37:10 **EXAMINATION** [6] 1:29 2: 14 5:14 59:2 71:11 83:6 examine [1] 15:21 **examined** [1] 14:9 example [6] 27:16 28:9,14 33:2 67:25 82:2 exercise [1] 12:19 *Exhibit* [3] 59:2,7 71:13 **EXHIBITS** [1] 4:5 existing [2] 78:4,25 expect [3] 73:2 75:3 83:2 experience [1] 17:14 expert [6] 12:3 14:1 20:1 24:1 40:14,19

expertise [6] 7:10 13:7, 10,14 15:25 explanation [1] 65:13 exposed [2] 61:17 69:10 extensive [1] 10:17 extremely [1] 69:8

- F -

fact [11] 37:20,22 43:14 52:12 69:18 71:3 74:13, 15 75:10,24 82:10 factor [14] 32:8 37:21 44: 2 45:2,7,8 46:7,15,19,21 47:2 50:9,19 64:2 factors [18] 26:18 37:13, 18 38:12,13,23 39:6 47:7, 9 49:15 50:14 52:13 54: 24,25 64:19 66:11 81:1,13 fairly [1] 21:7 familiar [1] 20:12 familiarity [1] 7:9 family [2] 32:3 70:13 far [3] 35:8 62:11 78:25 fashion [1] 63:16 fast [1] 36:16 features [2] 68:21 69:2 Federal [1] 9:6 felt [2] 20:1 48:16 few [1] 52:2 *fibrate* [1] 64:8 fifteen [2] 31:18 34:18 *fifty* [4] 34:11,20,23 35:24 fifty-eight [1] 62:9 fifty-three [1] 5:7 *filed* [1] 5:18 find [10] 35:15 36:4 53:12 55:14 57:22 58:23 65:23 71:4 73:3 75:3 *finding* [4] 54:9 70:4,24 71:3 fine [2] 24:22 51:8 finish [2] 6:2 62:21

Astrida Auza o.c.r.

5

firm [4] 8:17 20:2 24:28 78:9 79:8,18,19,20,2270:2520firm's [1] 17:2581:21 82:4,10,14,19,21,GROVER [15] 1:29 2:13 3:highlights [1] 10:18first [9] 6:9 10:13 17:10 20:23,25 83:2,4,514 5:6,16 58:8,25 59:3 60:him [5] 14:24 27:12 52:64 26:6 31:14 62:3 63:4 71:gallstone [8] 36:6,12,19,16 61:3 73:16 74:15,2162:17,212320 37:5,19 38:19,2280:23 83:10history [2] 32:3 70:13five [3] 34:18,20,21gallstones [21] 13:17,20grow [2] 36:16 37:11hom [5] 36:9 43:19 50:1,11flaws [2] 41:17 81:1914:1 26:18,20 31:11,14,growing [1] 36:1980:1focused [4] 14:10 16:1 17:36:1,16,25 37:11,15,2528:20 44:20 76:2513folder [1] 23:21gamut [1] 11:112052:14
first [9] 6:9 10:13 17:10 20: 4 26:6 31:14 62:3 63:4 71: 2323,25 83:2,4,5 gallstone [8] 36:6,12,19, 20 37:5,19 38:19,2214 5:6,16 58:8,25 59:3 60: 16 61:3 73:16 74:15,21 80:23 83:10him [5] 14:24 27:12 52:6 62:17,212320 37:5,19 38:19,22 gallstones [21] 13:17,20 focus [3] 12:15 48:10 49:2 focused [4] 14:10 16:1 17: 16 55:25 folder [1] 23:2120 32:1,4,10 34:13 35:19 38:5,1114 5:6,16 58:8,25 59:3 60: 16 61:3 73:16 74:15,21 80:23 83:10him [5] 14:24 27:12 52:6 62:17,21 history [2] 32:3 70:13 history [2] 32:3 70:13 history [2] 32:3 70:13five [3] 34:18,20,21 flaws [2] 41:17 81:19 focus [3] 12:15 48:10 49:2 focused [4] 14:10 16:1 17: 16 55:25 16 55:2520 32:1,4,10 34:13 35:19 38:5,11 gamut [1] 11:11growing [1] 36:19 guessing [4] 19:10,12 28: 20hospital [3] 6:20 7:24 49: 13 hospitalization [2] 26:19 52:14
4 26:6 31:14 62:3 63:4 71: 23gallstone [8] 36:6,12,19, 20 37:5,19 38:19,2216 61:3 73:16 74:15,21 80:23 83:1062:17,21 history [2] 32:3 70:13 history [2] 32:3 70:13five [3] 34:18,20,21 flaws [2] 41:17 81:19 focus [3] 12:15 48:10 49:2 16 55:25gallstones [21] 13:17,20 14:1 26:18,20 31:11,14, 20 32:1,4,10 34:13 35:19 36:1,16,25 37:11,15,25 38:5,1116 61:3 73:16 74:15,21 80:23 83:1062:17,21 history [2] 32:3 70:13 hm [5] 36:9 43:19 50:1,11focus [3] 12:15 48:10 49:2 focused [4] 14:10 16:1 17: 16 55:2520 32:1,4,10 34:13 35:19 36:1,16,25 37:11,15,25 38:5,11guess [6] 7:1 24:14 25:5 28:20 44:20 76:2562:17,21 history [2] 32:3 70:13 hm [5] 36:9 43:19 50:1,11 80:1folder [1] 23:21gamut [1] 11:112052:14
2320 37:5,19 38:19,2280:23 83:10history [2] 32:3 70:13five [3] 34:18,20,21gallstones [21] 13:17,20grow [2] 36:16 37:11hm [5] 36:9 43:19 50:1,11flaws [2] 41:17 81:1914:1 26:18,20 31:11,14,growing [1] 36:1980:1focuse [3] 12:15 48:10 49:220 32:1,4,10 34:13 35:19guess [6] 7:1 24:14 25:5hospital [3] 6:20 7:24 49:focused [4] 14:10 16:1 17:36:1,16,25 37:11,15,2528:20 44:20 76:2513folder [1] 23:21gamut [1] 11:112052:14
five [3] 34:18,20,21gallstones [21] 13:17,20grow [2] 36:16 37:11hm [5] 36:9 43:19 50:1,11flaws [2] 41:17 81:1914:1 26:18,20 31:11,14,growing [1] 36:1980:1focus [3] 12:15 48:10 49:220 32:1,4,10 34:13 35:19guess [6] 7:1 24:14 25:5hospital [3] 6:20 7:24 49:focused [4] 14:10 16:1 17:36:1,16,25 37:11,15,2528:20 44:20 76:251316 55:2538:5,11guessing [4] 19:10,12 28:hospitalization [2] 26:19folder [1] 23:21gamut [1] 11:112052:14
flaws [2] 41:17 81:19 14:1 26:18,20 31:11,14, growing [1] 36:19 80:1 focuse [3] 12:15 48:10 49:2 20 32:1,4,10 34:13 35:19 guess [6] 7:1 24:14 25:5 hospital [3] 6:20 7:24 49: focused [4] 14:10 16:1 17: 36:1,16,25 37:11,15,25 28:20 44:20 76:25 13 folder [1] 23:21 gamut [1] 11:11 20 52:14
focus[3] 12:15 48:10 49:220 32:1,4,10 34:13 35:19guess[6] 7:1 24:14 25:5hospital[3] 6:20 7:24 49:focused[4] 14:10 16:1 17:36:1,16,25 37:11,15,2538:5,1128:20 44:20 76:251316 55:2538:5,11gamut[1] 11:112052:14
focused[4] 14:10 16:1 17: 16 55:2536:1,16,25 37:11,15,25 38:5,1128:20 44:20 76:25 guessing13 hospitalizationfolder[1] 23:21gamut[1] 11:112052:14
16 55:25 38:5,11 guessing [4] 19:10,12 28: hospitalization [2] 26:19 folder [1] 23:21 gamut [1] 11:11 20 52:14
folder [1] 23:21 gamut [1] 11:11 20 52:14
follow-up [1] 59:17 Gatineau [1] 46:1 GUINDON [18] 1:9 22:7 hospitalized [3] 37:22,23
following [3] 26:19 50:18 gears [3] 14:5 31:9 39:2 27:7,9 28:11,17,19 29:7 50:2
63:11general [9] 6:7,10,16 7:2431:9 36:5,13 37:13 38:6hospitals [2] 6:19 8:25
follows [1] 5:12 11:7,8 13:18 23:12 31:13 39:3 45:12 47:10 68:4 81: however [1] 42:7
foregoing [1] 84:4 generally [3] 33:15 39:7 15 hundred [3] 5:7 62:8,9
formation [1] 34:12 47:6 Guindon's [7] 25:22 31:16 hung [1] 23:4
forming [2] 36:13 37:6 generation [2] 41:21,22 37:17 38:18 44:17 45:11
forth [1] 33:21 generic [1] 33:16 68:14 - I -
forward [1] 63:11 GENEVIEVE [41] 1:13,38 gun [1] 82:22 I-1 [3] 4:13 59:2,7
found [8] 23:4 54:17 55: 5:14 18:4,17,22 25:8 27: guys [2] 6:18,22 I-2 [3] 4:16 71:10,13
19,21,23 70:1 75:11 78:13 13 28:3,8 30:13 34:19 42: gynaecologist [1] 21:6 ideas [1] 25:17
founding [1] 8:1 20 43:4 51:2,6,18,23 52: identify [3] 54:5,10 63:7
four [4] 5:8 39:8 59:4 10 57:8,12,16 58:14 59: - H - immobility [2] 38:13 44:18
fourth [1] 41:21 12,16,22 60:4,15 61:7 62: hadn't [1] 14:16 immobilization [5] 44:13
frank [2] 17:10 35:1 18,22 63:1 66:20 71:15 half [1] 25:7 47:2 50:18 52:15 81:2
frankly [1] 40:25 73:7,13 74:14,19 79:15 handle [1] 17:23 immobilized [1] 50:5
French [1] 20:22 80:22 83:13 happen [1] 14:14 impact [3] 16:10 68:20 69:
front [3] 26:10 27:22 60:8 Geneviève [2] 2:14 5:16 happening [1] 20:19 1
full [1] fill haven't [9] 11:14 13:2,3,6 important [22] 5:24 6:2 32
functional[3] 79:8,18,19give[2] 27:18 55:520:17 35:12 36:1 41:6 63:19 35:8 36:17,18 37:13,
funding[2] 8:23 9:8given[4] 20:17 30:19 42:41518,21 38:4,17,23,25 50:
FURTHER [1] 83:16 65:3 he's [3] 14:22 15:25 17:15 19 54:17 64:19 66:7,10
fuss [1] 32:20 giving [1] 10:18 head [4] 32:5 39:12 58:24 69:12 70:6 74:1,16
fusses [1] 37:3 GLADU [12] 1:13 22:7 49: 76:25 Improvement [2] 7:25 9:1
8,10,18,22 50:14 52:12, <i>Health</i> [9] 7:25 8:1,9,18, <i>IMS</i> [3] 79:24 80:7,16
- G - 19 80:24,25 81:13 19 9:1,17 79:25 80:7 inability [1] 65:15
G [1] 57:7 good [3] 7:1 20:23 82:24 Hello [1] 5:16 inadequate [1] 8:24
gall [42] 11:17,19,21 13: Google [1] 21:1 help [2] 14:12,15 incidents [1] 77:7
14,19 16:10 17:19 23:5,8 government [2] 8:20 9:6 hereby [1] 84:3 include [2] 25:9 67:13
36:21 44:19 48:23,24 54: grants [1] 9:6 herself [1] 68:4 included [2] 68:6 82:4
7,12 55:9 58:16 61:15,21 great [1] 56:17 high [4] 41:5 44:21 46:17, Including [5] 13:17 45:7
62:8,10 64:3,20 70:21 77: greatest [1] 54:21 18 64:5 78:7 81:20
<i>group</i> [5] 68:14 69:13,14 <i>higher</i> [3] 33:12 54:11 61:

Astrida Auza o.c.r.

Index

		1.	6
<i>increase</i> [8] 35:2 39:14,17	interns [1] 6:23	-L-	<i>lot</i> [1] 63:6
44:13 45:6 47:11,19 48:5	<i>interpret</i> [1] 15:5	largely [4] 7:8 9:5 11:7 20:	<i>lots</i> [3] 17:3 31:25 36:24
increased [8] 20:5 50:15	into [4] 9:17 31:16 33:24	11	<i>low</i> [2] 41:23 78:5
54:6 58:16 61:15 68:10	49:13	lastly [1] 6:2	<i>lower</i> [1] 33:12
77:5 78:8	<i>involved</i> [2] 12:15 23:25	Lawrence [1] 14:22	
increases [5] 42:8 43:15,	<i>isn't</i> [4] 76:6 77:2,4,23	lawyer [6] 18:10 19:1,5,12	- M -
23 44:8 45:3	<i>issue</i> [7] 43:1 46:5 47:24	24:2,3	<i>main</i> [3] 10:23 26:3 38:21
increasingly [1] 48:13	55:3 56:7,9 79:2	layman's [1] 7:12	<i>major</i> [5] 14:11 44:1 46:5,
index [3] 63:24 64:17 70:9	<i>issues</i> [3] 9:17 69:18 70:3	<i>least</i> [4] 36:17 68:1 83:2,4	19,21
indicator [1] 82:24	<i>it's</i> [43] 5:24 6:2 7:8,9 8:1,	Leiden [5] 45:2,7,8 46:7	majority [1] 49:15
indirectly [2] 12:3,5	7,17 9:5,18,24 23:21 28:	47:2	<i>makes</i> [2] 65:20,22
individually [1] 47:10	10 32:23,24 34:6 37:4,5	<i>level</i> [1] 20:21	mandate [1] 24:25
<i>individuals</i> [1] 62:10	38:21 43:9 47:22,24 48:1	<i>levels</i> [2] 33:7,11	marginally [3] 40:25 76:9,
industry [1] 9:7	49:8 53:18 56:24 57:2 59:	Levonorgestrel [16] 54:	14
infection [2] 50:8 81:2	4 62:3 63:5 64:20 65:6 75:	13 58:19 61:13,22 71:22	<i>mass</i> [3] 63:24 64:17 70:9
inferior [4] 58:22 62:3,11	8 76:1,3,6,17 78:1,2	72:6,11,16,20,25 73:17	Masse [5] 21:8 37:12 40:
63:9	<i>its</i> [4] 42:7 43:15 45:2 67:	74:7,10 75:1 76:5,17	13 44:16 53:6
inflammation [1] 36:21	20	LifeLink [1] 79:25	<i>Masse's</i> [4] 21:10,20 22:1
inflammatory [1] 64:6	itself [2] 73:2 74:24	<i>likelihood</i> [3] 69:20 70:4	28:23
<i>influence</i> [1] 66:12		71:2	<i>matter</i> [5] 39:13 40:22 47:
<i>influenced</i> [2] 47:10 50:14	- J -	<i>likely</i> [12] 37:4,5 38:25 47:	14 49:9 52:16
information [2] 17:23 42:	J [2] 57:9	3 49:10 50:17 51:13,21	<i>maybe</i> [2] 60:22 80:2
22	J-I [1] 57:7	56:14 69:13 81:2	<i>mcg</i> [4] 32:13 33:6 34:11
ingredient [3] 72:19,25 74:	J-I-C-K [2] 57:2,9	<i>limit</i> [1] 66:11	35:24
9	JANINE [1] 1:9	<i>limitations</i> [2] 66:5 67:21	<i>McGill</i> [6] 6:21 7:24 8:8,25
ingredients [1] 32:23	Jesus [1] 12:1	<i>limited</i> [1] 63:17	10:15 14:23
initially [2] 17:8	<i>Jick</i> [20] 3:17 4:13 57:2,	<i>line</i> [1] 8:19	<i>mean</i> [18] 13:18 19:5,23
insomuch [1] 14:7	13,15 58:11,15 59:1,7 60:	<i>LIST</i> [12] 3:5,13,15 4:5 22:	20:17 23:10 31:25 33:9
INSPQ [1] 40:3	17 61:3,24 63:21,23 64:	13,14 57:23 58:1,7,9 61:1	34:1,25 41:1 45:7 67:1 68:
INSPQ's [2] 41:9,11	23 65:7,9,10,12 81:7	71:24	11 70:15 75:14,15 81:10
instead [3] 10:7 27:8 29:5	Joseph [3] 14:22 15:18 16:	<i>literature</i> [15] 3:16,18 16:	82:14
Institut [1] 40:2	18	23 21:18,24 22:13 53:21	<i>meant</i> [9] 10:5 27:8 28:18
Institute [3] 41:14,19 42:	Joseph's [2] 15:7,8	58:10,12 60:19 61:2,4 78:	29:3,4,24 30:14 81:15,16
16	journal [1] 16:5	4,22,25	<i>measured</i> [1] 36:6
Institute's [2] 42:3 43:2	Judicial [1] 84:3	long [2] 36:25 45:25	mechanical [1] 84:5
intention [1] 30:6		look [10] 20:5 22:18 28:13	medical [16] 6:20,23 16:3
interchangeably [1] 28:21	- K -	35:13 53:24 59:3 60:3 73:	21:13,14,22 22:4,8 25:23
interested [5] 17:11 19:22	keep [1] 22:14	6 76:8 82:22	26:23 30:25 45:11 49:20
24:6 54:2	kind [2] 6:1 9:9	looked [4] 35:15 53:21 54:	50:21 53:3 70:20
interesting [1] 22:18	kinds [1] 23:15	1 75:10	<i>medicine</i> [9] 6:13,22,24 7:
internal [7] 6:11,13,24 7:	knowledge [3] 18:18,20	looking [6] 12:18 33:23 41:	15,18,21,22 11:5,9
18,21,22 11:5	37:10	1 56:19 63:12 75:16	<i>member</i> [1] 24:2
internist [2] 6:7 13:19	known [5] 10:22 32:5,7 70:	loosely [1] 26:7	mental [1] 9:17
	17 83:5	Lord [1] 5:1	<i>mention</i> [8] 16:19 66:1 67:

Astrida Auza o.c.r.

STEVEN GROVER AFFIDAVIT Index

24 68:3 69:6,21 70:5,19 *mentioned* [13] 10:24 12: 10 15:1,16 16:22 19:13, 21 35:14 38:22 40:15,16 54:25 71:24 *mentors* [1] 17:15 *mésure* [1] 57:25 methodological [2] 41:17 67:21 *micrograms* [4] 32:13 33: 6 34:11 35:24 *might* [3] 25:18 59:20 60: 20 *mind* [5] 31:23 32:2 48:25 63:4 64:25 misclassification [1] 77:3 *missing* [1] 70:14 mistake [1] 30:1 *mistakes* [1] 82:18 *model* [1] 64:16 *modern* [1] 78:7 *month* [2] 14:25 44:19 *months* [9] 36:7 37:8 45: 22 68:2,5,8,11,12,16 **MONTREAL** [3] 1:3 7:24 84:3 more [23] 7:5 9:16 37:4 38: 16,23,25 49:18 51:9 55: 21,23 56:13,19 63:6 65: 15 68:8,11 69:13 71:21 76:17,18 81:2,16 *Motion* [2] 27:24 28:2 *move* [1] 74:5 Mrs [2] 50:25 51:11 **Ms** [40] 22:7 25:22 27:7,9 28:10,17,19 29:7 31:9,16 36:5,13 37:12,17 38:6,18 39:2 44:17 45:11,12 47:9 49:8,10,18,22 50:14,20 52:11,12,19 53:1,6,19 68: 4,14 80:24,25 81:13 *multiple* [5] 26:17 45:16 49:14 64:4 75:16 *multivariate* [1] 64:16

must [1] 75:12 *myself* [5] 12:2,8 14:7 17: 23 20:4

- N -

N [3] 1:1,4 2:5 name [6] 5:16 17:25 19:4 24:8,19 33:17 names [2] 17:7 18:25 national [4] 40:2,11 41:7, 10 native [1] 19:9 nature [1] 75:3 necessarily [1] 41:4 need [7] 28:4 42:5 50:25 51:11 55:13 56:22 59:20 negative [2] 35:7,11 *never* [7] 11:16,19,24 12: 21 58:23 65:24 70:16 next [1] 74:16 *nine* [2] 45:22 46:3 *nineteen* [2] 5:7 10:13 *nobody* [1] 37:3 nods [1] 6:1 noise [3] 69:19 70:23 81: 23 non-use [1] 78:9 non-users [1] 56:25 none [1] 80:15 nor [1] 61:18 Norgestrel [12] 71:23 72: 6,12,16,19,24 73:17 74:9, 10 75:1 76:5,16 normally [1] 75:5 North [1] 31:19 notes [1] 57:3 Nothing [7] 13:18,24 20: 14 23:4 53:10,14 82:23 November [2] 5:7 45:21 number [6] 17:22 31:23 32:2 39:12 54:21 62:11 numbers [1] 62:6

- 0 -**Obese** [4] 26:4 43:24 49: 25 81:12 obesity [14] 9:16 32:7 37: 20 38:3,13,16 42:7 43:14 44:1 45:17 47:1 52:14 70: 12 81:1 observations [1] 54:22 observed [2] 67:1,5 obstetrician [1] 21:6 obvious [1] 75:25 obviously [2] 6:1 25:4 odd [1] 62:9 OFF [15] 30:9 32:5 39:12 40:10 42:17,19,21,25 55: 14 58:24 60:11,13 76:25 80:20 81:8 office [1] 27:3 offices [7] 8:7,8,10,11,15, 16,24 Official [2] 84:2,12 often [1] 33:21 *omitted* [2] 68:19 69:6 on- [1] 8:18 once [3] 14:13 48:8,9 one [48] 11:18 14:10 16:1, 2 17:15 25:11,24 26:2,6, 12 27:18 28:4,14 30:11, 14 31:2 32:9 33:3,22 34: 18 41:24 46:11,12 48:18 54:17,21,22 55:5,13,14, 19,20,25 56:3,19 59:4,17 62:6 64:2 69:13 70:24 71: 23,24 76:7 79:10,12 ones [1] 10:23 **Ontario** [2] 30:20 31:2 opinion [6] 31:7 35:22 40: 23 54:18 61:25 64:24 **opportunity** [1] 60:17 opposed [2] 10:4 32:22 opposite [1] 6:15 oral [63] 11:13,14,25 12:2, 7,8,11,22 13:1,8,11 16:9 33:15 34:2,7,10 35:23 38:

10 39:13,16,19,23 40:6 41: 21,22 43:25 47:14,17,20 48:18 49:9 52:17 53:10, 14 54:8 55:5,19 56:5,10, 12,15,16,18,20,25 58:18 61:13,17,19,22 68:1,7,15 69:7,10,23 78:7,10 81:4,8, 11,17,22 orient [1] 25:24 original [1] 69:9 originally [1] 19:1 outcome [1] 66:12 outside [2] 13:18 25:17 over [6] 10:12,17 13:21 40: 18 57:3 73:14 over-reported [1] 70:25 own [8] 21:24 25:18 31:7, 23 42:8,22 43:15 45:3 - P -**P** [1] 1:4 **PAGE** [8] 2:9 3:9,18 4:9 58:12 64:11,12 71:21 pages [5] 4:14 59:5,8 84:4 pancreatitis [1] 64:7 paper [8] 10:14 12:24 20: 11 23:4,7,14 52:23 53:1 papers [3] 17:22 22:17 48: 12 *paragraph* [7] 27:16 28:9, 14 29:15,19,22 64:14 part [6] 20:2 26:17 33:20 54:4 61:9 68:16 particularize [1] 60:23 particularly [5] 10:22 21: 14 35:9 41:4 71:21 passed [1] 19:18 *past* [2] 12:20 80:8 patient [1] 52:21

Astrida Auza o.c.r.

Steno Exact MAXIN

patients [3] 26:2,8 47:5

82:15

per [1] 41:24

people [4] 7:5 12:19 52:21

ſ

STEVEN GROVER AFFIDAVIT Index

8

percent [4] 7:19,20 31:18	22 10:4,9 11:6,9 13:22	provide [2] 22:12 60:9	<i>recall</i> [14] 11:23 17:6 18:8,
69:8	<i>practise</i> [3] 7:16,23 42:5	provided [5] 15:14 17:24	21 24:25 25:14,22 40:16
<i>perfect</i> [3] 77:24 78:2,3	<i>précisez</i> [1] 60:22	27:5 71:16 83:8	54:9,16 58:21 60:18 80:8,
<i>perfectly</i> [1] 77:19	preparation [2] 16:23 53:	providing [1] 58:25	10
Perhaps [2] 29:3,4	22	PROVINCE [2] 1:2 5:9	recently [1] 9:16
period [3] 44:12 50:4,5	<i>Prepare</i> [3] 3:13 14:5 58:7	provincial [1] 40:10	<i>recollection</i> [2] 25:2 40:14
peripherally [1] 12:14	preparing [1] 22:3	<i>publique</i> [1] 40:3	RECORD [11] 30:9 42:17,
personal [3] 8:20 17:14	prescribe [1] 11:13	<i>published</i> [7] 7:15 10:14,	19,21,25 43:6 46:10 57:
25:5	prescribed [4] 11:14 20:	17 11:19 12:24 13:4 43:11	21 60:11,13 80:20
PERSONALLY [2] 5:4 41:2	17 34:3,9	publishing [1] 9:10	recording [1] 84:5
persons [1] 39:9	prescription [1] 12:6	<i>pull</i> [1] 55:13	records [12] 21:13,14,22
perspective [3] 72:20 73:	presence [1] 64:5	purposes [2] 8:21 61:8	22:4,8 25:23 26:23 45:11
1 74:21	present [2] 5:20 47:6	<i>putting</i> [2] 72:24 74:15	49:20 50:21 53:4 70:20
Petitioners [3] 1:18,36 18:	presented [8] 15:22 45:12,		redo [1] 22:15
2	15 47:9 48:10 49:22 50:8,	- Q -	<i>reduce</i> [3] 69:19 70:23 71:
pharmacologist [1] 32:23	14	qualify [1] 20:21	2
Physician [1] 5:8	presenting [2] 45:22 47:5	quality [1] 41:11	<i>refer</i> [8] 27:7,12 28:14 29:
<i>pill</i> [2] 20:15 21:25	pretty [3] 9:20 20:23 82:24	QUEBEC [7] 1:2 5:9,19 24:	12,17 30:15 65:25 67:19
<i>pills</i> [2] 20:19 26:14	<i>prevention</i> [1] 9:16	12 31:3 40:22 46:1	<i>referred</i> [1] 40:13
<i>place</i> [2] 8:5,6	previous [1] 44:18	Québec [1] 40:3	referring [9] 8:14 16:4,12
Plaintiff [1] 26:3	primarily [2] 17:16 33:16	quite [3] 10:17 17:9 35:1	20:16 64:10,14 71:19,22
Plaintiffs [1] 22:10	primary [2] 44:16 48:15	<i>quoted</i> [5] 14:11 16:2 17:	73:16
<i>plan</i> [2] 59:11 79:25	problem [3] 33:20 51:17	22 20:11 33:4	reformulate [1] 5:23
<i>played</i> [1] 46:6	52:9		refused [1] 25:16
<i>please</i> [3] 27:19 62:25 66:	problems [2] 6:17 11:11	- R -	regard [5] 27:9 30:20 39:3
19	proceedings [2] 24:1 30:	<i>randomized</i> [2] 55:4 77:21	49:4 50:20
<i>plenty</i> [1] 13:19	20	randomly [1] 55:5	<i>regarding</i> [8] 11:17 13:11,
point [3] 25:20 32:19 36:6	profession [1] 10:4	<i>range</i> [2] 10:16 11:11	14 25:10 31:14 37:19 40:
poor [1] 82:6	professor [4] 6:21 14:22	rate [2] 76:12,13	5 52:11
portion [4] 7:17 9:22 10:	15:2,7	rather [2] 17:17 24:4	Regardless [2] 39:19,20
10 11:6	progesterone [2] 32:17	reaching [1] 9:17	regards [2] 13:8 16:19
position [4] 20:2,3 22:12	40:6	<i>read</i> [9] 21:5 32:15 41:18	<i>related</i> [4] 11:24 12:11 13:
53:25	progestin [2] 78:15,23	58:21 59:20,25 60:18 61:	4 54:6
<i>positive</i> [4] 35:8,9,10 75:	Program [4] 7:25 8:2 9:1	9,10	<i>relationship</i> [3] 66:16,23
18	12:19	reading [4] 20:13,22 23:8	72:15
possibility [2] 77:15,17	promotion [1] 8:2	30:25	<i>relatively</i> [2] 49:12 76:4
possible [3] 57:25 77:6	propensity [5] 72:1 73:18,	ready [1] 22:24	rely [1] 65:1
post-operative [1] 44:12	20,25 76:8	<i>really</i> [12] 7:7 10:1 17:11	<i>remember</i> [16] 18:8,23 24:
potential [3] 63:18 64:4	<i>proper</i> [2] 81:21 82:1	20:4 23:2,3,17 36:15 37:9	15,16 26:7,12,22,24 27:3
70:17	proportion [1] 7:16	55:10,13 69:18	30:22,23 46:11,12,13 57:
power [1] 54:23	proposition [1] 58:15	reason [3] 38:4 56:13 65:	20
powered [1] 55:15	<i>prove</i> [3] 35:6 67:3 78:3	23	remembered [1] 27:1 reminded [1] 14:7

Astrida Auza o.c.r.

Γ

9

removal [1] 44:19 review [14] 3:18 17:1 remove [1] 51:5 16,23 22:4 40:13 41:1 removed [1] 51:12 46:10 58:12 60:17,19 repeat [6] 66:17,19 68:24 2,4 79:2 73:10 78:18,19 reviewed [17] 3:16 14 report [51] 15:19 17:9,13, 16:22 17:21 22:13 25 15,21,24 18:9 19:17,19 26:23 40:5 41:6 45:11 21 2 2 2 2 5 2 5 2 10 6 10 5 0:21 5 2:2 5 2:10 6	0 Sackett [2] 19:13,14 show [5] 11:12 35:1 63 61: Sackett's [7] 17:9,13,24 65:12 76:12 21:23 30:21,24 31:6 showed [1] 17:13 8:8 SAITH [1] 83:16 shows [4] 32:24 75:12 :23 SAMY [32] 1:35 18:1,14, 9,13 :49: 19 25:1 27:11 28:1,5 42: sickle [1] 64:7	
removed[1] 51:1246:10 58:12 60:17,19repeat[6] 66:17,19 68:242,4 79:273:10 78:18,19reviewed[17] 3:16 14report[51] 15:19 17:9,13,16:22 17:21 22:13 2515,21,24 18:9 19:17,1926:23 40:5 41:6 45:11	61: Sackett's [7] 17:9,13,24 65:12 76:12 21:23 30:21,24 31:6 showed [1] 17:13 8:8 SAITH [1] 83:16 shows [4] 32:24 75:12 8:23 SAMY [32] 1:35 18:1,14, 9,13 9,13 49: 19 25:1 27:11 28:1,5 42: sickle [1] 64:7 51:3 18 50:24 51:4,10,20 52:1, side [4] 62:20 9:2 17:12	
repeat [6]66:17,1968:242,479:273:1078:18,19reviewed [17]3:1614report [51]15:1917:9,13,16:2217:2122:132515,21,2418:919:17,1926:2340:541:645:11	21:23 30:21,24 31:6 showed [1] 17:13 8:8 SAITH [1] 83:16 shows [4] 32:24 75:12 9:23 SAMY [32] 1:35 18:1,14, 9,13 49: 19 25:1 27:11 28:1,5 42: sickle [1] 64:7 11:3 18 50:24 51:4,10,20 52:1, side [4] 6:20 9:2 17:12	76:
73:10 78:18,19reviewed [17] 3:16 14report [51] 15:19 17:9,13,16:22 17:21 22:13 2515,21,24 18:9 19:17,1926:23 40:5 41:6 45:11	SAITH [1] 83:16 shows [4] 32:24 75:12 23 SAMY [32] 1:35 18:1,14, 9,13 49: 19 25:1 27:11 28:1,5 42: sickle [1] 64:7 51:3 18 50:24 51:4,10,20 52:1, side [4] 6:20 9:2 17:12	76:
report[51]15:1917:9,13,16:2217:2122:132515,21,2418:919:17,1926:2340:541:645:11	SAMY [32] 1:35 18:1,14, 9,13 49: 19 25:1 27:11 28:1,5 42: sickle [1] 64:7 51:3 18 50:24 51:4,10,20 52:1, side [4] 6:20 9:2 17:12	76:
15,21,24 18:9 19:17,19 26:23 40:5 41:6 45:11	49:19 25:1 27:11 28:1,5 42:sickle [1] 64:751:318 50:24 51:4,10,20 52:1,side [4] 6:20 9:2 17:12	
-, , , -	51:3 18 50:24 51:4,10,20 52:1, side [4] 6:20 9:2 17:12	
21:7,12,20,23 22:1,4 25: 19 50:21 53:3 58:10 6	8 57:6.10.14 59:10.14.19 23	19:
10,11,13,17,21 27:7,12, 70:20	, -,,	
17,24 28:6,23,25 29:1,12, <i>reviewing</i> [1] 27:3	60:2 61:5 62:16,20,24 66: signal [1] 56:19	
17 30:21,24 40:14,20 41: reviews [1] 40:12	18 73:5,9 74:12,17 79:11 signed [1] 84:8	
1,9,10,13,18 42:1,16 43:2 <i>right</i> [56] 8:10,11 10:3		2
49:4 53:22 64:12 65:25 19 13:12 15:7,24 16:7		:9
67:19 68:20 69:1 70:19 17:12 19:20,23 20:17		35:
REPORTER [3] 34:17 84: 21:9,11,14 22:9,11 24		
2,12 26:21 27:2 29:2 30:5,	, , , , , , , , , , , , , , , , , , , ,	81:
represent [2] 5:17 8:15 18 32:18 34:3,5 37:2	- , -	
representative [2] 22:10 6 39:21 43:10 45:9,17		
26:3 49:25 54:4 55:8 60:8,		
representing [1] 41:24 64:16 66:3 67:4,14 68		5:5
reprints [1] 22:17 69:12 70:2 77:16,22,2	25 64:25 77:23 sir [1] 76:2	
<i>research</i> [23] 7:4,14 8:21 80:9,13 81:18	scientific [3] 72:20 73:1 Siskinds [5] 18:3,5,6,7	' 24:
9:5,6,8,14,22 10:2,7,11 <i>ring</i> [1] 57:17	74:20 2	
12:3 13:9,14 14:8 21:24 <i>risk</i> [59] 20:5 26:17 3		
22:14,16 30:24 33:1,20 32:4,6,8 35:2 37:13,1		
48:11 49:3 38:11,12 39:6,7,14,17		12,
researcher [2] 12:2,9 40:6 41:21 42:8 43:15		
residents [1] 6:23 44:1,10,13,22 45:3,6		
residing [1] 5:8 19,21 47:7,9,11,19 48		
residual [2] 77:15,17 12 49:14 50:9,13,15,1		
responded [1] 24:7 52:13 54:7,12,24 58:1 04:45 20 04:0 40 00:4 04:45 20 04:0 40 00:4		
Respondent [4] 1:24,40 5: 61:15,20 64:2,19 68:1 40 75:47	Sinai [2] 10.0 24.0	
15 51:15 13 75:17,18 77:6 78:8		
responding [1] 28:22 13	series [1] 5:21 smoker [2] 26:4 45:19	
response [1] 29:4 risks [4] 38:9 45:13,10		
rest [1] 23:7 23	served [2] 40:17 smoking [6] 38:3,13,16	6 44:
result [10] 42:4 52:16 53:7 RODRIGUE [5] 1:39 5		
67:5 73:3 75:4 76:9,13,14, 51:14 52:3 83:11	seven [1] 45:3 Solemn [1] 5:11	
21 role [1] 46:6	seventeen [1] 43:8 some [16] 9:7 12:3 17:6	6
results [13] 9:10 62:15 64: route [1] 48:22	seventy-five [1] 7:19 18:12 21:17 22:17,19,2	21,
11,15 65:1,5,10 66:25 67: <i>rule</i> [1] 23:12	she's [1] 26:3 23,25 23:18 25:16 59:2	20
19 68:9,21 69:2 77:13 run [2] 8:17,25	short [1] 59:4 62:9 82:8	
retrospective [5] 63:10,16	<i>shortcomings</i> [1] 71:5 <i>somebody</i> [1] 36:22	
66:2,4,7 - S -	should [1] 9:23	

Astrida Auza o.c.r.

AFFIDAVIT Index

			10
someone [3] 25:19 56:16	statin [1] 64:7	19 70:16 71:2,10,13,21	take [14] 6:4,16 8:5 22:19,
82:3	statistical [3] 54:23 63:7	77:	21 27:21 28:9 33:24 43:
something [7] 12:14 22:	75:11	4,7,12,13,18,24 78:2,3,13,	25 58:18 59:3 60:5 81:17
22 35:1,3 36:23 65:17	<i>statistically</i> [10] 66:15,22,	24 79:22,24 81:7,20,25	82:14
sorry [21] 27:15,18 29:14	25 67:4,8 73:3 75:4 76:12,	82:5	<i>taken</i> [5] 47:15 49:10 52:
36:11 37:24 41:20 42:10	14,21	study's [3] 68:9,21 69:2	17 82:21 83:3
43:21 50:1,11 62:19 67:	statistician [5] 14:13,15,	<i>stuff</i> [1] 23:15	taking [23] 8:6 20:2 27:8
11 68:20,23 73:10 78:17	20 15:4 16:1	subject [1] 83:7	28:17 36:8,14 37:7 39:23
79:14 80:6 82:6	Stenographer [2] 5:25 6:4	submitted [1] 25:12	54:8 56:5,10,12,15,16 68:
<i>sort</i> [5] 6:15 7:12 14:17 24:	STEVEN [3] 1:29 2:13 5:6	subsequently [1] 82:22	1,4,7,10,12,15 69:14 81:
7,11	still [2] 39:2 62:15	Such [1] 70:8	11,22
<i>sorts</i> [4] 11:4 35:7 40:11	stones [4] 55:9 79:20 83:4,	sufficient [4] 36:20 54:22	<i>talk</i> [1] 49:17
69:18	5	66:16,23	<i>talked</i> [3] 21:17 52:12 53:
source [1] 9:8	<i>stop</i> [1] 69:13	sufficiently [1] 55:15	22
sources [1] 8:23	story [3] 17:16,19 48:24	suggest [1] 81:11	talking [10] 21:8 25:6 37:
space [2] 8:24 9:3	straightforward [1] 21:7	suggesting [1] 12:7	25 38:12 43:14 72:5,10
speak [2] 19:14 23:11	strength [1] 56:17	sujet [1] 83:7	78:6,15 79:12
speaker [1] 19:9	strengthened [1] 81:24	superior [1] 65:6	<i>teach</i> [1] 6:22
speaking [6] 12:21 19:5,	strengthens [1] 71:5	<i>support</i> [3] 53:13 78:5 79:	telephone [1] 25:6
12 39:7 49:12 76:4	strengths [5] 7:11 14:18	1	<i>ten</i> [2] 39:8 41:24
specialist [1] 13:24	15:17,18 69:5	supported [1] 53:25	tendency [1] 45:6
specialty [1] 6:6	strokes [2] 53:7,19	<i>sure</i> [23] 11:15 14:15 15:2	<i>terms</i> [16] 6:9 7:12,22 8:4
specific [8] 13:7,9,10,13	<i>stuck</i> [1] 55:10	20:25 25:20 26:11 27:4,	9:25 15:18,22 21:13 28:
23:4,7 31:16 32:1	students [1] 6:23	14,19 30:4 31:21 34:8,14	19,21 35:23 49:17 52:16
specifically [12] 12:12 13:	studies [33] 3:13 11:16,24	45:8 46:4 51:8 52:5 58:3,	65:9 78:22 79:20
5 14:10 24:18 26:22 31:	12:4 13:3,4 14:8 17:1 33:	5 60:25 65:24 82:20	testified [4] 45:10 49:19
10,22 33:3 35:18 49:18	2,21 35:8,9,11,12,13 40:5	Surely [1] 81:10	50:21 53:3
53:23 79:8	41:17 53:24,25 54:1,5,10	surgery [7] 6:16 38:15 44:	testimony [3] 14:6,10 21:5
specify [1] 79:12	55:17 57:23 58:8 65:3,5	18 45:21 47:2 50:18 81:1	tests [1] 11:1
speed [1] 37:10	66:4,7 79:6,16	surgical [2] 48:14,17	Thank [3] 50:12 83:9,12
spelling [2] 30:1,6	Study [121] 3:17 4:13,16	suspect [1] 65:18	that's [29] 7:1,14 13:12 16:
spend [2] 7:5 23:18	7:10,11 11:19,21 12:12,	suspend [1] 83:6	7,12,13 22:9,11 23:20 24:
<i>split</i> [1] 23:24	16,22 14:11 16:2,6,8,9,12	sway [1] 35:22	19,22 27:24 28:2 30:6,18
spoke [1] 24:18	20:12 29:22,25 30:12,14,	switch [1] 31:9	34:3,9,15 46:24 51:8,16,
spoken [2] 19:1 24:24	17 33:4 35:3,6,20 36:4 40:	Switching [5] 14:5 39:2	19 56:21 64:11 68:18 70:
stand [1] 51:21	9 43:2,5,9 54:9,18,19 55:	69:7,22 78:23	22 76:23 77:10 81:15
standards [1] 41:5	13 56:2,3,11,17,22 57:1,2,	SYLVIE [5] 1:39 5:19 51:	<i>their</i> [11] 8:23 16:10 20:3
stands [1] 58:15	13 58:11,15,21,22,23 59:	14 52:3 83:11	26:18,19 65:15,16 66:5
start [4] 6:3 31:10,13 73:14	1,4,7 60:6,17,18 61:4,24	symptoms [1] 36:21	77:10,12 82:7
started [7] 22:18 36:8,13,	62:3,4,12,13 63:6,8,9,10,		therapeutic [1] 6:17
14,19 37:6,7	11,13,20,21,23 64:4,10,	- T -	therapy [1] 11:3
stated [1] 15:10	23 65:1,2,6,7,9,11,12,14,	T [1] 1:4	<i>there</i> [43] 15:2,3 18:12 20:
statements [1] 15:12	22 66:1,2 67:13,20,22,25	<i>Table</i> [6] 71:7,19 73:15,16,	5,8 21:1 23:14 25:11,14,
	68:6,17,19,22 69:3,5,16,	18 74:1	15,18 30:11 31:1 36:25

Astrida Auza o.c.r.

Index

38:22,24 41:20 42:4 48:12 55:16,17 56:3 58:16 61:11 68:9 70:5 71:6 75:12,17, 24 76:6,19,20 77:11,18 78: 4 79:6 82:11,20 *there's* [16] 8:24 30:1,11, 14 33:7,11 36:24 44:1 70: 14 72:18 75:14,25 82:1,2, 22 *they're* [9] 33:22 35:10 40: 25 41:4 63:11,14 72:8,9 77:23 thing [11] 6:1 24:11 25:21 54:17 56:21 62:13 63:4,8 74:25 75:8,9 things [13] 8:15 9:2 10:20 11:4 12:4 25:19 30:23 64: 18 69:21,22 70:14 75:2 thinking [1] 33:16 thirteenth [1] 5:2 thirty [3] 11:15 20:18 33:6 *though* [3] 31:13 56:9 73: 25 thoughtful [1] 15:4 *thoughts* [1] 15:8 *thousand* [5] 5:1 39:8 41: 25 45:21 46:3 three [12] 4:13 22:10 23:3 26:7,21 36:6 39:15 42:9 43:17 51:9 59:5,8 thromboembolic [13] 45: 4,23 46:2 47:6,11,20 49:4, 11,12,16 50:9,15 52:16 thromboembolism [1] 39: 4 thrombophlebitis [24] 12: 5,10,20 17:16 23:9 26:19 35:19 39:8,18,23 42:9 43: 13,17 44:5,10,14,17,23 46:19 47:3 48:11,15 50: 17 55:9 *thrombotic* [2] 45:5 81:3 through [1] 30:25

29:1 *time* [14] 6:5 7:19 14:9 19: 18 23:18 27:21 46:2 50:4, 7 59:20 60:5 63:12 78:6 83:9 times [7] 24:23,24 39:15 42:9 43:18,24 45:3 today [3] 5:20 14:6 83:9 together [2] 65:4 77:6 too [1] 44:20 took [1] 26:4 top [4] 32:5 39:12 58:24 76:25 *topic* [1] 12:12 *topics* [3] 9:11 10:16,23 Toronto [2] 18:7,13 track [1] 22:15 trail [1] 23:11 *training* [3] 6:7 7:5,6 transcribe [1] 5:25 *transcript* [2] 8:12 61:8 transcription [1] 84:5 Translate [1] 21:1 travelled [2] 45:25 46:1 trial [2] 55:4 77:21 trouble [1] 37:1 *true* [5] 29:10,11 77:2,4 84: 4 trumps [1] 64:23 *trying* [4] 33:14 42:15 54: 2 55:10 *turned* [1] 20:24 *twenty* [4] 8:2 32:13 43:8 69:8 twenty-five [1] 7:20 *twenty-four* [1] 43:24 twenty-nine [1] 62:7 twenty-ninth [1] 5:6 *two* [33] 5:1 7:5 8:15 26: 16 28:21 31:1 36:6,7 37:7 39:14 41:24 42:9 43:17, 24 45:21,22 46:3 55:16, 17 59:17 65:3,5,8 69:10,

21 72:7,12 74:6,25 75:2 76:21,23 type [2] 25:21 56:11 types [4] 67:9,10,11,12 typical [1] 34:6 Typically [5] 6:18,22 9:5, 13,14

- U -U [2] 1:4 *U-1* [2] 3:

U-1 [2] 3:13 58:7 unclear [2] 48:7 76:18 under [2] 8:7,23 under-reported [1] 70:25 *underpowered* [2] 35:6 63: 5 understand [12] 5:22 7:14 29:3 34:21 69:25 72:5,7, 10,12,15 73:19 74:20 understanding [2] 20:22 84:6 understood [1] 20:25 undertaking [6] 57:22 58: 4,7 60:23,24 83:7 UNDERTAKINGS [1] 3:5 University [1] 6:21 unless [2] 70:24 82:8 unlikely [2] 53:18 77:8 **up** [13] 3:15 8:2 11:12 24: 3.19 32:15 37:23 40:11 55:10 57:23 58:1,9 61:1 up-to- [1] 20:18 users [2] 56:18,25 using [3] 28:20,21 39:13 usual [1] 13:22 **Usually** [1] 7:5

- V -

V [5] 45:2,7,8 46:7 47:2 valid [3] 66:14,21 67:2 various [4] 33:25 67:9,10, 12 vascular [4] 44:21 46:21,

24.25 vasculitic [1] 53:19 vasculitis [1] 53:7 vastly [4] 62:3,14 63:5 65: 6 venous [1] 46:25 verbal [1] 36:10 verbally [3] 5:24 43:20 80: 2 versus [2] 7:17 55:6 very [11] 21:5 26:16 35:3 41:23 48:20 56:21,22 63: 17 76:9 83:2,4 - W want [5] 30:4 42:14 53:23 59:25 80:24 wanted [5] 15:1,3,16 19: 21 23:20 wards [1] 6:19 way [4] 15:4,6 35:5 51:22 we'd [1] 36:23 weak [5] 65:14,22 76:7 82: 2,6 weaken [1] 70:3 weaknesses [6] 7:11 14: 18 15:17,19 16:20 69:5 weight [2] 64:5 65:16 wellness [2] 8:18,19 Westmount [1] 5:9 *What's* [6] 17:25 20:19 36:

 what's
 [6] 17:25 20:19 36:

 16,18 57:25 74:16

 whatever
 [3] 28:22 56:13

 57:24

 whatsoever
 [1] 80:17

 when
 [17] 12:10 14:24 17:

 10 18:5 20:22 34:22,23

 36:18,19 39:23 53:21 63:

 3 75:15 81:19 82:6

 Whenever
 [1] 20:23

 whereas
 [2] 63:13 64:3

wherever [1] 28:18

who'd [1] 68:7

Astrida Auza o.c.r.

throughout [3] 28:10,25

No.: 500-06-000484-093 DECEMBER 13, 2016

Index

[12
who's [1] 56:15	zero [2] 34:20,21	I	
<i>why</i> [7] 24:8 30:6 51:19			
52:19,22 62:2,5			
<i>without</i> [5] 26:10,25 39:6			
41:1 82:3			
witness [1] 20:1			
woman [2] 63:15 82:20			
women [23] 26:17 31:19,			
25 34:3 41:25 43:24 49:			
13 54:7 55:5 56:5,12,14			
58:18 61:16 63:11,14 67:			
25 68:7,15 81:8,9,11 82:9			
<i>won</i> [1] 80:7			
word [1] 21:4			
work [4] 8:6,23 22:19,21			
worse [1] 56:20			
wouldn't [15] 19:25 26:22			
32:5 38:20 39:10 40:10,			
20 48:3 62:15 65:1 73:2			
75:6,7 78:11 83:2			
write [3] 27:9 29:4,24			
written [2] 14:8,17			
wrong [2] 20:3 82:23			
wrote [2] 21:6 28:18			
- X -			
X [1] 2:5			
- Y -			
Yasmin [18] 5:18 13:4 20:			
6,16 27:8,9 28:17,19,24			
29:1,5 33:5,10,14 53:18			
78:8 79:7,17			
Yaz [24] 5:18 13:4 20:16			
26:4 27:8,9 28:18,24 29:4			
32:12,15 33:9,14 36:8,14			
37:7 38:19 39:1 68:4,10,			
12 78:7 79:7,17			
years [12] 7:6 8:3 10:12,			
17 11:15 13:21 17:15 20:			
18 40:18 41:25 55:7 69:11			
yet [1] 51:16			
- Z -			
- 2 -			

Astrida Auza o.c.r.

No.: 500-06-000484-093 DECEMBER 13, 2016

			1
- A -	.L.	wouldn't [15]	
agree [37]	Levonorgestrel [16]		
any [34]	literature [15]	- Y -	
Association [21]		Yasmin [18]	
aware [32]	- M -	Yaz [24]	
	mean [18]		
- B -	medical [16]		
because [18]	more [23]		
Bertrand [41]	Ms [40]		
bias [15]			
bladder [37]	- 0 -		
	OFF [15]		
- C -	one [48]		
case [15]	oral [63]		
clinical [23]			
contraceptive [30]	- R -		
contraceptives [33]	remember [16]		
correct [19]	report [51]		
	research [23]		
- D -	reviewed [17]		
disease [36]	right [56]		
Dr [33]	risk [59]		
- E -	- S -		
ELNEMR [33]	SAMY [31]		
epidemiology [15]	say [28]		
Etminan [21]	some [16]		
	sorry [21]		
-F-	studies [33]		
factors [18]	Study [121]		
	sure [23]		
- G -			
gall [42]	- T -		
gallstones [21]	taking [23]		
GENEVIEVE [39]	terms [16] that's [29]		
Guindon [17]	there [43]		
-1-	there's [16]		
important [22]	thrombophlebitis [24]		
it's [43]	two [33]		
1 I I I I I I I I I I I I I I I I I I I			
- J -	- W -		
Jick [20]	when [17]		
	women [23]		

Astrida Auza o.c.r.

EXHIBIT P-12

Research paper published in the Canadian Medical Association Journal, dated May 17, 2011



Oral contraceptives and the risk of gallbladder disease: a comparative safety study

Mahyar Etminan PharmD MSc, Joseph A.C. Delaney PhD, Brian Bressler MD MSc, James M. Brophy MD PhD

Abstract

CMAI

Background: Recent concerns have been raised about the risk of gallbladder disease associated with the use of drospirenone, a fourthgeneration progestin used in oral contraceptives. We conducted a study to determine the magnitude of this risk compared with other formulations of oral contraceptives.

Methods: We conducted a retrospective cohort study using the IMS LifeLink Health Plan Claims Database. We included women who were using an oral contraceptive containing ethinyl estradiol combined with a progestin during 1997–2009. To be eligible, women had to have been taking the oral contraceptive continuously for at least six months. We computed adjusted rate ratios (RRs) for gallbladder disease using a Cox proportional hazards model. In the primary analysis, gallbladder disease was defined as cholecystectomy; in a secondary analysis, it was defined as hospital admission secondary to gallbladder disease.

Results: We included 2 721 014 women in the cohort, 27 087 of whom underwent surgical or

laparoscopic cholecystectomy during the follow-up period. Compared with levonorgestrel, an older second-generation progestin, a small, statistically significant increase in the risk of gallbladder disease was associated with desogestrel (adjusted RR 1.05, 95% confidence interval [CI] 1.01–1.09), drospirenone (adjusted RR 1.20, 95% CI 1.16–1.26) and norethindrone (adjusted RR 1.10, 95% CI 1.06–1.14). No statistically significant increase in risk was associated with the other formulations of oral contraceptive (ethynodiol diacetate, norgestrel and norgestimate).

Interpretation: In a large cohort of women using oral contraceptives, we found a small, statistically significant increase in the risk of gallbladder disease associated with desogestrel, drospirenone and norethindrone compared with levonorgestrel. However, the small effect sizes compounded with the possibility of residual biases in this observational study make it unlikely that these differences are clinically significant.

ral contraceptives are the most popular mode of birth control among women and are used by about 100 million women worldwide.⁴ Long-term use of these drugs has been associated with a variety of serious adverse events, including deep vein thrombosis, stroke and pulmonary embolism.⁴ In addition, both estrogen and progesterone have been shown to play an important role in the formation of gallstones.⁴ However, the relative risk of gallbladder disease associated with different formulations of oral contraceptives, including newer formulations, is unknown.

Recently, there have been concerns expressed in the media about reports of gallbladder disease necessitating cholecystectomy associated with the use of drospirenone, a fourth-generation progestin." Drospirenone combined with ethinyl estradiol is primarily marketed as Yaz and Yasmin in Canada and the United States and is one of the most prescribed oral contraceptives in North America, with worldwide sales of \$2 billion in 2009. The scientific evidence on the risk of gallbladder disease associated with drospirenone consists of only anecdotal or spontaneous reports in databases of adverse drug events.

A possible link between drospirenone and gallbladder disease may lead to cholecystectomy and possible surgical complications.⁸ If there were a substantial risk of gallbladder disease with drospirenone, this might influence its overall risk-benefit ratio and could prompt physicians to prescribe safer alternatives. Given that women using oral contraceptives have been found to be at increased risk of gallbladder disease compared with women not using oral contraceptives,⁴ any excess risk associated with the use of drospirenone merits quantification within the context of a comparative safety study. Competing interests: None declared.

This article has been peer reviewed.

Correspondence to: Mahyar Etmínan. mahyar etmínan *a* veh ea. metmínan *a* shaw ea

CMAJ 2011, DOI:10.1503 /cmaj.110161

Methods

Data sources

We obtained data from the IMS LifeLink Health Plan Claims Database. This database is the largest of its kind in the United States and captures health information on about 78 million residents representing all geographic areas in the country (midwest, 35%; northeast, 21%; south, 31° o; west, 13° o)." Data are captured longitudinally, with an average enrolment period of two years. Data fields include demographic characteristics (age, sex, geographic location), prescription drugs (drug name, quantity, day supply), diagnoses (using the International Classification of Diseases, ninth revision [ICD-9]) and hospital admissions (including visits to an emergency department and surgical procedures). The database is subject to routine quality checks to ensure the validity and completeness of the data. and it has been used in numerous pharmacoepidemiologic and health outcome studies.10 In addition, because the data come from more than 104 managed care organizations, they go through rigorous quality checks before they are incorporated in the main database."

Study cohort and exposure definition

We conducted a retrospective cohort study. We included all women who were using an oral contraceptive containing ethinyl estradiol combined with a progestin during 1997–2009. The progestins studied were norethindrone, ethynodiol diacetate, norgestrel, levonorgestrel, norgestimate, desogestrel and drospirenone.

Cohort entry was defined as the index date (baseline), which occurred after 180 days of continuous exposure to a study drug. We excluded women who had lesser amounts of exposure. To avoid misclassification bias, exposed persontime was computed from the index date. This approach allowed for a sustained exposure period without interruptions.

Cohort members were followed to the end of the study period: to the date they switched to another study drug; to discontinuation of a study drug; to the diagnosis of gallbladder disease: or to the termination of health coverage. Because gallbladder disease has a slow onset, we extended follow-up for an additional six months after cohort members had been censored, to observe any new diagnoses of gallbladder disease that may have developed after a study drug was stopped.

Outcome measures

For the primary analysis, the outcome of gallbladder disease was defined as having had a cholecystectomy. Information on cholecystectomies was ascertained using Current Procedural Terminology (CPT) codes for both surgical and laparoscopic cholecystectomies (CPT codes 47600, 47605, 47610, 47612, 47620, 47562, 47563, 47564, 49310, 56340 and 56341). These procedure codes are used by surgeons to be reimbursed for their services. They have been

Characteristic	Desogestrel n = 351 322	Drospirenone n = 448 287	ETD n = 53 244	Levonorgestrel n = 495 748	Norethindrone n = 546 621	Norgestimate n = 722 667	Norgestrel n = 103 125
Age, yr, mean (SD)	28 (6.0)	28 (6.1)	29 (5.9)	29 (6.1)	30 (5.8)	27 (5.6)	29 (6.3)
Length of follow-up, d, mean (SD)	363 (479)	314 (396)	377 (492)	357 (471)	287 (431)	338 (433)	351 (470)
No. with gallbladder disease	3 911	4 974	632	5 201	4 789	6 432	1 148
Drug use, %							
Statin	0.39	0.39	0.59	0.50	0.44	0.29	0.64
Fibrate	0.06	0.08	0.07	0.06	0.06	0.04	0.06
Medical history, %							an ann an tha an tao
Sickle-cell anemia	0.04	0.03	0.02	0.04	0.05	0.03	0.04
Diabetes mellitus	3.13	3.18	3.07	3.01	3.11	2.33	3.55
Inflammatory bowel disease	0.47	0.50	0.55	0.46	0.42	0.36	0.47
Pancreatitis	0.35	0.35	0.36	0.36	0.33	0.26	0.40
Smoking	5.00	4.60	5.65	5.29	5.01	4.65	5.91
Obesity	0.36	0.42	0.37	0.34	0.34	0.23	0.36

shown to be well correlated with gallbladder disease and have been used as a marker in previous epidemiologic studies.¹¹

For the secondary analysis, we considered the outcome as all hospital admissions secondary to gallbladder disease (ICD-9 codes 574 and 575).

Statistical analysis

We used the Cox proportional hazards model to estimate hazard ratios for gallbladder disease (cholecystectomy or hospital admission secondary to gallbladder disease). We hypothesized that a possible risk of gallbladder disease with use of oral contraceptives would require at least six months of continuous use of these drugs. Thus, exposure was defined at baseline (after 180 days of exposure). To avoid misclassification bias, we excluded participants who either had an event or left the cohort before 180 days of exposure.

Models were adjusted for available covariates to control for confounding: the covariates were age, calendar time, sickle-cell anemia, diabetes mellitus, inflammatory bowel disease, obesity, pancreatitis, smoking and use of statins and fibrates. Levonorgestrel was used as the reference group because it is the most common progestin used in oral contraceptives."

As a sensitivity analysis, we repeated the study to include women who had two years of continuous use of oral contraceptives. We adjusted all analyses for known contounders.

As an alternative analysis, we developed a propensity score model based on the probability of a participant being exposed to drospirenone or another oral contraceptive. We then used this propensity score as an alternate means of adjusting the Cox model.

Proportionality of hazards were examined graphically by means of log 4og survival curves.

and no meaningful deviations from proportionality were observed after baseline.

As a final sensitivity analysis, we considered a short time window in case the association between oral contraceptives and gallbladder disease was due to acute exposure to the study drug. For this analysis, we defined exposure as the first day of exposure to a study drug, and we followed participants for 180 days (until censoring, the end of the study period or cholecystectomy).

Results

The cohort included 2 721 014 women, with 2 460 094 person-years of follow-up. A total of 27 087 women underwent surgical or laparoscopic cholecystectomy. The mean time to cholecvstectomy was 330 days (median 166, interquartile range 29-445 days). The baseline characteristics of the women were comparable across the different types of progestins (Table 1). Except for fibrate use, the covariates used in the multivariable model were associated with an increased risk of gallbladder disease (age, rate ratio [RR] 1.01, 95% confidence interval [CI] 1.01-1.02; reported smoking, RR 2.06, 95% C1 1.99 2.14; reported obesity, RR 2.63, 95% CI 2.41-2.87: diabetes. RR 1.67, 95% CI 1.59-1.74; inflammatory bowel disease, RR 1.26, 95% CI 1.13 1.40; pancreatitis, RR 9.56, 95% CI 9.10 10.10; sickle-cell anemia, RR 2.20, 95% CI 1.36 3.43): statin use, RR 1.19, 95% CI 1.07 1.33; and fibrate use, RR 1.01, 95% CI 0.78-1.32).

The adjusted RRs for gallbladder disease in the primary analysis, involving women continuously exposed to a study drug for six months, are shown in Table 2 and Figure 1. Compared with the use of levonorgestrel, a small, statistically significant increase in the risk of gallbladder disease

Progestin	Crude rate ratio (95% CI)	Adjusted rate ratio† (95% CI)	Adjusted for propensity score	
Levonorgestrel	1.00 (ref)	1.00 (ref)	1.00 (ref)	
Desogestrel	1.03 (0.99-1.08)	1.05 (1.01-1.09)	1.03 (0.98-1.07)	
Drospirenone	1.39 (1.34-1.44)	1.20 (1.16-1.26)	1.13 (1.09-1.18)	
Ethynodiol diacetate	1.03 (0.95-1.12)	1.08 (0.99-1.25)	1.08 (0.99-1.17)	
Norethindrone	1.12 (1.07-1.19)	1.10 (1.06-1.14)	1.10 (1.06-1.15)	
Norgestimate	0.97 (0.93-1.00)	1.00 (0.96-1.04)	0.92 (0.890.95)	
Norgestrel	1.07 (1.01-1.15)	1.06 (0.99-1.12)	1.07 (1.01-1.48)	

Note: CI = confidence interval, ref = reference group.

*Patients with gailbladder disease were defined as those who underwent cholecystectomy.

rAdjusted for age, calendar time, sickle cell anemia, diabetes mellitus, inflammatory bowel disease, obesity, pancreatitis, smoking, and use of statins and fibrates.

was associated with the use of desogestrel, drospirenone and norethindrone.

A total of 567 447 women continuously took an oral contraceptive for two years, with 792 871 person-years of follow-up. The mean time to cholecystectomy in this group was 510 days. In this sensitivity analysis, a small, statistically significant increase in the risk of gallbladder disease was associated with the use of drospirenone and ethynodiol diacetate (Table 3).

The association between drospirenone use and gallbladder disease was reduced in both the adjusted and propensity score models, with a number needed to harm of 550 compared with levonorgestrel. There was no clinically meaningful difference in the risk of gallbladder disease with different oral contraceptives in the propensity score analysis (Tables 2 and 3).

The results were also consistent in the secondary analysis, in which the outcome was defined as hospital admission secondary to gallbladder disease (Table 4).

A one-sided test of interaction did not show interactions between participants' age and oral contraceptive type.

Finally, the adjusted RRs in the sensitivity analysis for acute exposure showed no association between type of oral contraceptive and gallbladder disease aside from drospirenone, for which a protective effect was observed (desogestrel, RR 0.93, 95% CI 0.86–1.00; drospirenone, RR 0.87, 95% CI 0.81-0.93; ethynodiol diacetate, RR 0.92, 95% CI 0.78-1.01; norethindrone, RR 1.10, 95% CI 1.04–1.18; norgestimate, RR 0.78, 95% CI 0.73-0.83; and norgestrel, RR 0.95, 95% CI 0.87-1.07).

Progestin	Adjusted rate ratio (95% CI)	Decreased risk	Increased risk
Levonorgestrel	1.00 (ref)		
Desogestrel	1.05 (1.01-1.09)		•
Drospirenone	1.20 (1.16-1.26)		•
Ethynodiol diacetate	1.08 (0.99-1.25)		
Norethindrone	1.10 (1.06-1.14)		-
Norgestimate	1.00 (0.96-1.04)	-	÷
Norgestrel	1.06 (0.99-1.12)		-
	0	-	.0 2.0 ratio (95% CI)

Figure 1: Risk of gallbladder disease (as defined by occurrence of cholecystectomy) associated with six months of continuous use of oral contraceptives containing different progestins. Women using levonorgestrel served as the reference group. Rate ratios were adjusted for age, calendar time, sickle-cell anemia, diabetes mellitus, inflammatory bowel disease, obesity, pancreatitis, smoking, and use of statins and fibrates. A rate ratio greater than 1.0 indicates an increased risk of gallbladder disease. CI = confidence interval, ref = reference group.

902 CMAJ, May 17, 2011, 183(8)

Interpretation

In this large cohort of women using oral contraceptives, we found a small, statistically significant increase in the risk of gallbladder disease associated with desogestrel, drospirenone and norethindrone compared with levonorgestrel. However, this difference is unlikely to be clinically important. Moreover, given the observational nature of this study and the fact that adjusting for covariates leads to estimates being closer to the null suggests that residual confounding may explain, at least in part, these small differences.

Studies have shown that long-term use of an oral contraceptive is associated with an increased risk of gallbladder disease compared with no use. A cohort study using data from the Nurse's Health Study found a slight increase in the risk of gallstones among women who had used oral contraceptives for 15 years or longer (RR 1.5. 95% CI 1.10-2.20)." Similarly, a meta-analysis of 26 observational studies found a 36% increase in the development of gallbladder disease among women who were using oral contraceptives compared with those not taking these drugs.4 Both estrogen and progesterone have been shown to increase the risk of gallstones." Estrogen has been shown to increase cholesterol production in the liver, with excess amounts precipitating in bile and leading to the formation of gallstones." Progesterone has been shown to decrease gallbladder motility, which impedes bile flow and leads to gallstone formation."

In our study, there was a high discontinuation rate in the primary cohort, such that only 20% of the original cohort was continuously exposed to an oral contraceptive for two years. Given the likelihood of adverse events and availability of a wide range of oral contraceptives, women are increasingly unlikely to continue with only one type of oral contraceptive.¹⁵ In one study, up to 46% of women who started taking an oral contraceptive stopped the drug after six months.¹⁵

Our data do not show that the increased risk of gallbladder disease associated with drospirenone is clinically meaningful compared with other formulations of oral contraceptives. Drospirenone had worldwide sales of \$2 billion in 2009, making it one of the most prescribed oral contraceptives in North America. The surge in the number of reported cases of gallbladder disease facilitated through the media may have contributed in making drospirenone appear to be associated with a higher risk of gallbladder disease compared with older contraceptives.

Strengths and limitations

Use of the IMS LifeLink Health Plan Claims Database allowed us to examine the risk of gallbladder disease among close to 2.5 million women continuously exposed to different formulations of oral contraceptives, including the newer drospirenone. This attribute of the database, crucial in a study comparing the safety of oral contraceptives, is difficult or impossible to achieve with other equally valid databases owing to sample size limitations. In addition, the increase in the risk of gallbladder disease associated with covariates such as reported smoking and obesity is consistent with findings in the literature and adds face validity to our study.¹⁶

We also took several steps to control for confounding bias that may threaten the validity of pharmacoepidemiologic cohort studies." By design, this study was restricted to all women using oral contraceptives, allowing study participants to share similar characteristics (Table 1). This type of restriction has been used to reduce the risk of confounding by indication in pharmacoepidemiologic studies.11 The use of an active comparator will ensure that any confounding by indication or contraindication is minimized. We also conducted sensitivity analyses in which we examined the risk of gallbladder disease with different exposure periods. The slight protective effect observed with only one prescription of drospirenone may have been due to random error or possible channeling bias, including the possibility that clinicians may have been less likely to prescribe drospirenone to women who may have been more prone to gallbladder disease.

Immortal time bias is another bias that has been noted in various pharmacoepidemiologic studies.¹ This is a bias whereby users of a drug may have a specious survival advantage over nonusers by study design owing to misclassification of exposure time, which makes the intervention seem protective.^{15,17} In our study, misclassification was avoided by defining exposure to six months of continuous use as well as computing exposed person-time at the index date.

The prescribing of oral contraceptives may be influenced by heavy marketing from manufacturers. By controlling for calendar time, we were able to control for secular trends in prescribing of oral contraceptives that may usually favour the prescribing of one oral contraceptive over another.

As with all pharmacoepidemiologic studies that use claims data, our study has limitations. The ICD-9 codes for gallbladder disease in most administrative databases, including the IMS LifeLink Health Plan Claims Database, have not been validated. This is primarily the reason why we used CPT (Common Procedures and Terminology) codes for the primary analysis; CPT codes have been shown to be well correlated with gallbladder disease.¹¹

Body mass index and ethnicity are two variables that we could not control for in this study. Body mass index is a possible confounder because drospirenone was marketed for having the least effect on weight, which may have prompted clinicians to prescribe it to heavier women. Such a bias, if present, would have made drospirenone appear more harmful with respect to gallbladder disease.

Residual confounding with other known and unknown variables may also have affected our results. For example, our data lacked information on diet, which is a potential confounder in this study. Also, we only had data on reported smoking and obesity.

Despite these limitations, given the small magnitude of the relative risks in this large co-

Progestin	Crude rate ratio (95% CI)	Adjusted rate ratiot (95% CI)	Adjusted for propensity score
Levonorgestrel	1.00 (ref)	1.00 (ref)	1.00 (ref)
Desogestrel	0.99 (0.94-1.04)	1.02 (0.96-1.07)	0.99 (0.93-1.04)
Drospirenone	1.50 (1.45-1.60)	1.30 (1.23–1.37)	1.19 (1.14-1.26)
Ethynodiol diacetate	1.11 (1.00-1.23)	1.17 (1.06–1.30)	1.17 (1.06-1.30)
Norethindrone	1.02 (0.97-1.07)	1.04 (0.99-1.10)	1.06 (1.00-1.11)
Norgestimate	0.95 (0.91-0.99)	0.98 (0.93-1.03)	0.87 (0.83-0.91)
Norgestrel	1.09 (1.00-1.18)	1.06 (0.98-1.15)	1.10 (1.01-1.91)

Note: CI = confidence interval, ref = reference group.

*Patients with gallbladder disease were defined as those who underwent cholecystectomy. †Adjusted for age, calendar time, sickle-cell anemia, diabetes mellitus, inflammatory bewel disease, obesity, pancreatitis, smoking, and use of statins and fibrates.

Table 4: Risk of hospital admission secondary to gallbladder disease

Progestin	Crude rate ratio (95% CI)	Adjusted rate ratio* (95% CI)
Levonorgestrel	1.00 (ref)	1.00 (ref)
Desogestrel	0.95 (0.94-0.97)	0.99 (0.98-1.00)
Drospirenone	1.45 (1.43-1.46)	1.10 (1.09-1.12)
Ethynodiol diacetate	0.95 (0.93-0.97)	1.04 (1.01-1.06)
Norethindrone	1.07 (1.06-1.08)	1.09 (1.08-1.10)
Norgestimate	1.00 (0.99-1.01)	0.99 (0.98-1.00)
Norgestrel	1.08 (1.06-1.10)	1.06 (1.05-1.08)

Note: CI = confidence interval, ref = reference group.

*Adjusted for age, calendar time, sickle-cell anemia, diabetes mellitus, inflammatory bowel

disease, obesity, pancreatitis, smoking, and use of statins and fibrates.

hort study, it would require a large and prevalent confounder to alter the interpretation of the study data.

Conclusion

In a large cohort of women using oral contraceptives, we found a small, statistically significant increase in the risk of gallbladder disease associated with the use of desogestrel, drospirenone and norethindrone compared with levonorgestrel. However, the small effect sizes compounded with the possibility of residual biases in this observational study make it unlikely that these differences are clinically significant.

References

- The World Health Organization. *Condensiscular discose and sciencid harmonic contraception*. Lechnical Report Series 877. Geneva: The Organization, 1998.
- van Hylekama Xheg A. Helmerhorst FM. Vandenbroneke JP, et al. Efficies of oestrogen dose and progestogen type on venous thrombotic risk associated with oral contraceptives results of the MEGA case control study. *BMJ* 2009;339:b2221.
- 3 Lavde PM, Vessey MP, Yeares D, Risk factors for gall-bladder disease: a cohort study of young wonien attending family planing chines. *J. Epidemiol Community Health* 1982;36:274-8.
- Hujs C, Koupschild P. Oral contraceptives and the risk of gallbladder disease: a meta-analysis. *Im J Public Health* 1993;83:1113-20.
- 5 Grodstein F, Colditz GA, Hunter DJ, et al. A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors. *Obstet Gynecol* 1994;81:207-14.
- 6 CTV News Fashin Faz high control pill users hands lowshit. Scarbosongh (ON) CTV Inc. 2010 Available www.etv.ca (CTVNews1.dnontenfloric 20100310 birth control. 100310 raecessed 2010 Dec. 241.
- 7 Barer annual report, 2007 Leverkusen (Germany) Baver, 2010 Available, www.annualreport2009 bayer com en Baver-Annual-Report-2009 pdfx (accessed 2010 Dec. 24)
- Fletcher DR, Hobbs MS, Tan P, et al. Complications of cholecystectomy risks of the faparoscopic approach and protective effects of operative cholangrography: a population-based study biol Sing 1999, 229–149, 57
- 9 DNS Health 1967 ark health plan chains database overview and such dasaga issues. The American Medical Association, 2010 vvailable http://nams.edu/ecti/hsrcore/Lifelink/Health Plan/Chains/Data/DesignIssues/wcost/Apul2010%05B1%35D pdf/faceessed/2011/Eeb/29)


nostic, and cost information as predictors of high-risk patients in need of care management. *Am.J.M.mag.Care* 2009;15:41-8

- 11 Simon JA, Hunninghake DB, Aparwal SK, et al. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease the Heart and Estrogen Progestin Replacement Study. *Jun Intern Med* 2001;133:1935-501.
- 12 George ED, Schluger J K. Special women's health issues in hepatobiliary diseases. *Clin Linn Pract* 2000;2:155-69.
- Donovan JM. Physical and metabolic factors in gallstone pathogenesis. *Castrocurerol C In North Am* 1999;28:75-97.
- 14 George ED, Schluger UK, Special women's health issues in hepatobihary diseases. *Chin Frant Pract* 2006;2:155-69.
- 15 Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation a prospective evaluation of frequency and reasons. *Am.J. Obstet. Gynecol* 1998,179:577-82.
- Stroin BL, Tamragouri RN, Morse ML, et al. Oral contraceptives and other risk factors for gallbladder disease. *Clin Pharma*col ther 1986 39:335-41.
- 17 Suissa S, Garbe L. Primer administrative health databases in observational studies of drug effects — advantages and disadvantages. *Nat Clin Proc. Richmonol* 2007;3:725-32.
- 18 Psaty BM, Siscovick DS, Minimizing bias due to confounding by indication in comparative effectiveness research, the importance of restriction. J. W. J 2010, 304 897-8.
- Suissa S. Immortal time bias in pharmaco-epidemiology im F Prokindol 2008 15 49259

Affiliations: From the Department of Medicine (Etminan, Bressler), Faculty of Medicine, University of British Columbia, Vancouver, BC; the Centre for Clinical Epidemiology and Evaluation (Etminan), Vancouver Coastal Health Institute, Vancouver, BC, the College of Pharmacy (Delaney), University of Florida, Gainesville, Fla.; and the Department of Medicine (Brophy), Faculty of Medicine, MeGill University, Montréal, Que

Contributors: Mahyar Etminan, Joseph Delaney and James Brophy contributed to the study concept and design, the acquisition of data and the drafting of the manuscript. All of the authors contributed to the analysis and interpretation of the data and the critical revision of the manuscript for important intellectual content. All of the authors approved the final version of the manuscript submitted for publication. Joseph Delaney was responsible for the statistical analysis and is the study eutarantor.

Funding: The study was funded by an operating grant provided in part by the Fonds de la recherche en sante du Québec (FRSQ), the Ministere de la Santé et des Services sociaux and the McGill University Health Center, James Brophy is the recipient of a career award from the LRSQ.



¹⁰ Forrest CB. Lemke KW, Bodycombe DP, et al. Medication, diag-

No: 500-06-000484-093

SUPERIOR COURT (Class Action) DISTRICT OF MONTREAL

ALEXANDRA PATON

ET ALS.

PETITIONERS

VS.

BAYER INC.

ET ALS.

RESPONDENTS

EXHIBIT P-12

Research paper published in the Canadian Medical Association Journal, dated May 17, 2011

Me Samy Elnemr

BS2497

N/dossier: 67-095

SISKINDS DESMEULES S.E.N.C.R.L.

480 Saint Laurent, Suite 501 Montréal (Québec) H2Y 3Y7 Tél. : (514) 849-1970 Fax : (514) 849-7934 C.A. N° :

C.S. N° : 500-06-000484-093

COUR D'APPEL DU QUÉBEC DISTRICT DE MONTRÉAL

BAYER INC.

APPELANTE - Défenderesse

C.

JANIE GUINDON -et-GENEVIÈVE GLADU -et-JULIEN LEBŒUF

INTIMÉS - Demandeurs

DEMANDE POUR PERMISSION D'APPELER D'UN JUGEMENT QUI AUTORISE L'EXERCICE D'UNE ACTION COLLECTIVE (articles 357 et 358 C.p.c.) Partie appelante Datée du 5 septembre 2018

ORIGINAL

SOCIÉTÉ D'AVOCATS TORYS S.E.N.C.R.L. Avocats de l'Appelante Bayer Inc. Me Sylvie Rodrigue <u>srodrigue@torys.com</u> Tél. : 514.868.5601 | Fax: 514.868-5700 1 Place Ville Marie, Suite 2880 Montréal, Québec H3B 4R4 <u>notifications-mtl@torys.com</u>

BS-2554 Notre référence : 34506-2039